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Abstract 
 
Aims: to optimise linear accelerator-based prostate stereotactic ablative radiotherapy 
(SABR) through planning studies, tumour control probability (TCP) and normal tissue 
complication probability (NTCP) calculations and radiation-induced second primary 
cancer (RISPC) risk assessment. 
 
Methods: A planning study was performed to develop a class solution for prostate 
SABR. A second planning study delivered boosts to dominant intra-prostatic lesions 
(DILs) and TCP and NTCP were calculated. A third planning study compared prostate 
SABR planning using flattened and flattening filter free (FFF) beams. A systematic 
review examined RISPC risk following prostate radiotherapy. A final study estimated 
RISPC risks following prostate SABR in comparison to other contemporary radiation 
techniques. 
 
Results: Prostate SABR was optimal using a single anterior arc which resulted in highly 
conformal plans, lower rectal doses and improved delivery times and monitor unit 
requirements for most patients. Boosting DILs resulted in small TCP increases, but the 
benefit was offset by increases in NTCP. SABR to the whole prostate without DIL 
boosting resulted in high TCP and low NTCP. Plans using flattened and FFF beams 
were dosimetrically similar but FFF resulted in reduced delivery times. Clinical 
evidence, largely based on older radiation techniques, suggests that prostate 
radiotherapy increases RISPC risk. Clinical evidence concerning risk following modern 
techniques is too immature to draw firm conclusions. The final study demonstrated that 
SABR techniques resulted in lower estimated RISPC risks in all organs compared to 
conventionally fractionated techniques, while FFF techniques reduced RISPC risks in 
out-of-field organs. 
 
Conclusions: Linear accelerator-based prostate SABR delivered with a single partial 
arc is optimal and high levels of TCP and low levels of NTCP are predicted from whole 
prostate SABR. FFF allows faster treatment delivery. Second malignancy risk is lower 
using SABR, particularly with FFF, compared to conventionally fractionated techniques. 
Phase III trials are required to investigate prostate SABR in practice. 
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Chapter 1 : Introduction 
 
1.1 Prostate cancer 
 
Prostate cancer (PCa) is the most common cancer in males in the United Kingdom 
(UK), accounting for one-quarter of male cancer diagnoses [1]. In 2011,  41,736 new 
diagnoses of prostate cancer were made, equivalent to a one in eight lifetime risk in 
males with the peak incidence in the 75 to 79 year age group [1]. There has been a 
marked increase in the incidence of prostate cancer over the past thirty years which is 
at least in part attributable to increased detection, initially as a result of increased rates 
of transurethral resection of the prostate (TURP), and laterly to increased Prostate 
Specific Antigen (PSA) testing [2-4]. The majority of patients present with localised 
disease (i.e. disease that has not breached the prostate capsule) [5,6]. These patients 
have a variety of treatment options influenced by disease characteristics (i.e. tumour 
(T) stage, Gleason Score (GS) and PSA at presentation as well as prostate volume 
and severity of urinary symptoms) and patient choice. Current standard treatment 
options for patients with localised prostate cancer include prostatectomy, external 
beam radiotherapy (EBRT), brachytherapy (BT) and combination EBRT with a BT 
boost (EBRT-BT). 
 
1.2 Conventional EBRT 
 
Conventional EBRT delivered doses of up to 70 Gray (Gy), often in 2Gy fractions, but 
long term follow-up showed biochemical control to be sub-optimal, with 5-year and 10-
year biochemical failure rates in the region of 60% (defined at that time as: i) PSA 
increasing or nadir above 1.5ng/ml, or ii) failure to achieve or maintain PSA below a 
specified level (4ng/ml or 1ng/ml) two or more years after radiotherapy, or iii) two 
sequential increases in PSA or iv) development of radiological or symptomatic 
metastases or palpable local recurrence) [7,8]. Delivering a higher radiation dose in an 
effort to improve outcomes, however, was technically difficult without causing an 
unacceptable increase in normal tissue damage.  
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1.3 3D-Conformal EBRT and dose escalation 
 
The introduction of 3-dimensional conformal radiotherapy (3D-CRT), employing 3D 
contouring and planning techniques together with accurate beam shaping around 
target volumes, resulted in significant reductions in acute and late gastrointestinal (GI) 
toxicities at conventional doses, with no significant change in urological side-effects [9-
11]. This provided the opportunity to evaluate dose escalation and several randomised 
trials demonstrated that escalation to 74-79.2Gy in 1.8-2Gy fractions delivered using 
3D-CRT, compared to 64-70Gy, resulted in a 10-20% improvement in biochemical 
control at five years, with 5-year freedom from biochemical failure rates of 64-80% [12-
15]. The data suggest a dose-response relationship with increasing biochemical control 
with increasing dose. Increased doses were, however, accompanied by increased 
acute GI and genitourinary (GU) toxicity together with increased late rectal 
toxicity [12,13,15-19]. For example, long term follow-up (median 8.7 years) from the 
MD Anderson dose escalation trial (comparing 78Gy with 70Gy) revealed that RTOG 
(Radiation Therapy Oncology Group) grade 2 and 3 late rectal toxicity following dose 
escalation was more than double that with non-escalated treatment (78Gy:26% vs. 
70Gy:12%, p=0.014) [18,19].  
 
1.4 IMRT 
 
Intensity-modulated radiotherapy (IMRT) delivers radiotherapy which conforms closely 
to the shape of a target. Typically multiple (i.e. 5-9) beams are angled around a patient 
and multileaf collimators (MLCs) move across each beam, thus altering the intensity of 
treatment over multiple small regions (or beamlets) within the beam. This allows 
complex shapes to be treated precisely and improves organ at risk shielding. IMRT is 
often inversely planned where acceptable plan parameters are specified prior to plan 
creation and the treatment planning system performs a series of iterations to try to 
meet these.  
 
The advent of IMRT has therefore facilitated further improvements in conformity. Trials 
comparing IMRT with 3D-CRT in prostate cancer demonstrated significant reductions 
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in acute and late GI toxicity using IMRT [20,21]. This has facilitated further dose 
escalation. One series of 478 men demonstrated that dose escalation up to 86.4Gy in 
48 fractions using IMRT was feasible with excellent biochemical control: 5-year PSA 
relapse free survival using the Phoenix definition (see Appendix A) was 98%, 85% and 
70% in low, intermediate and high risk patients respectively (see Appendix B for 
definitions of risk group). Acute and late toxicities were lower than what would be 
expected with conformal radiotherapy (Common Terminology Criteria version 3 
(CTCAEv3) late grade 2 and 3 GU toxicity in 13% and <3% of patients and CTCAEv3 
late grade 2 and 3 GI toxicity reported in 3% and <1% of patients respectively) [22]. 
Ten-year biochemical relapse free survival rates (Phoenix definition) of 81%, 78% and 
62% for low, intermediate and high risk patients were recently reported for a series of 
170 patients treated with IMRT to a dose of 81Gy in 45 fractions [23]. Toxicity was 
acceptable: the 10-year likelihoods of CTCAEv3 grade 2 and 3 late GU toxicity were 
9% and 5%. The 10-year likelihoods of CTCAEv3 grade 2 and 3 late GI toxicity were 
2% and 1% respectively [23].  
 
1.5 Volumetric modulated arc therapy 
 
Volumetric modulated arc therapy (VMAT) is a form of IMRT that uses a standard 
linear accelerator to deliver radiotherapy in one or more arcs. Gantry rotation speed, 
dose rate and MLC positions are altered to create highly conformal plans [24]. VMAT 
encompasses the terms IMAT (intensity-modulated arc therapy), RapidArc® (a VMAT 
delivery system made by Varian (United States of America (USA))) and the Elekta 
(Sweden) VMAT system named VMAT. VMAT produces highly conformal plans 
compared to 3D-CRT as a result of the multiple angles of dose delivery, the dose rate 
variability and the modulation which are achievable using this technique [25]. 
Compared to IMRT, VMAT prostate planning studies have demonstrated at least 
equivalent conformity, improved monitor unit (MU) efficiency and faster delivery 
times [25-33] (e.g. average delivery time for one 2Gy fraction using VMAT vs. IMRT: 
90s vs. 292s [31]). 
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1.6 The rationale for hypofractionation 
 
As discussed above, dose escalation can be achieved by increasing the number of 1.8 
to 2Gy fractions and results in improved biochemical control. An alternative means of 
delivering a higher total dose (i.e. a higher biological effective dose; BED) is through 
hypofractionation (i.e. delivering higher doses per fraction). There is a good rationale 
for hypofractionation in PCa. Prostate cancer exhibits slow growth kinetics and so 
responds to changes in fractionation in a manner similar to late responding 
tissues [34,35]. Tissue sensitivities to changes in fractionation are mathematically 
modelled by the linear-quadratic (LQ) equation and quantified by the α/β ratio. In 
general, late responding tissues have low α/β ratios (~3Gy) and are highly sensitive to 
changes in fraction size while early responding tissues and tumours typically have high 
α/β ratios (~8-10Gy). Conventional radiotherapy, delivered with 1.8 to 2Gy fractions, 
aims to cause a degree of tumour kill but at the same time spare late responding 
tissues. Delivering higher doses per fraction, as in hypofractionation, will theoretically 
have a larger impact on tissues with low α/β ratios. Although debated, evidence 
suggests PCa has a low α/β ratio making it theoretically more sensitive to large dose 
per fraction treatments [34-37]. A recent retrospective study including 5969 irradiated 
PCa patients concluded that the α/β ratio of PCa was 1.4Gy (95% confidence interval 
(CI):0.9-2.2Gy) [37], in-keeping with that previously reported by Fowler (1.5Gy 
(95%CI:1.3-1.8Gy) and Brenner (1.2Gy (95%CI:0.03-4.1Gy) [34,35].  
 
Importantly, there is also evidence that the neighbouring late responding rectal and 
bladder tissues have higher α/β ratios than PCa (~3-6Gy) [35,36,38-41]. This allows 
exploitation of the potential biological advantage of the low prostate α/β in one of two 
ways: i) delivering larger hypofractionated doses to the prostate for equivalent late 
normal tissue toxicity, or ii) delivering iso-effective hypofractionated doses to the 
prostate aiming for reduced normal tissue toxicity. This is illustrated further below and 
in Chapter 2. 
 
Calculating the BED and equivalent dose in 2Gy (EQD2) fractions can be helpful when 
comparing alternative dose-fractionation schedules. These can be calculated according 
to: 
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where D is the total dose, d is the dose per fraction and α/β for the prostate is 
considered to be 1.5Gy. When considering toxicities, the BED and EQD2 received by 
acute and late responding tissues can be calculated using α/β ratios of 10Gy and 3Gy 
respectively. These calculations assume no ongoing tumour cell repopulation or 
repopulation delay time, which is acceptable in this setting [42,43].  
 
For example, standard UK radiotherapy delivers 74Gy in 37 fractions. This is 
equivalent to a BED of 173Gy to the prostate (i.e. BED1.5) and 88Gy and 123Gy to the 
acute (BED10) and late (BED3) responding tissues respectively. Because the dose is 
delivered in 2Gy fractions, the EQD2 to the prostate, early and late responding tissues 
is 74Gy. 
 
1.7 Moderate hypofractionation 
 
Several studies have examined moderate hypofractionation using fraction sizes of 2.5 
to 4Gy [44-50]. One randomised trial comparing hypofractionation (55Gy in 20 
fractions; BED1.5:156Gy, EQD21.5:67Gy) with conventional fractionation (64Gy in 32 
fractions; BED1.5:149Gy, EQD21.5:64Gy) in 217 patients showed equivalent biochemical 
control [46]. Another trial, comparing 52.5Gy in 20 fractions (BED1.5:144Gy, 
EQD21.5:62Gy) with 66Gy in 33 fractions (BED1.5:154Gy, EQD21.5:66Gy) in 936 patients 
showed hypofractionation to be inferior [45], perhaps the result of the lower BED in the 
hypofractionated regimen. As the control arms in both trials used non-escalated doses, 
it is not possible to draw conclusions about hypofractionation in comparison to current 
dose-escalated treatments. 
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The CHHiP (Conventional versus Hypofractionated High-dose intensity-modulated 
radiotherapy for Prostate cancer) trial was a recent phase III randomised trial 
comparing 74Gy in 34 fractions (BED1.5:173Gy, BED3:123Gy), 60Gy in 20 fractions 
(BED1.5:180Gy, EQD21.5:77Gy, BED3:120Gy, EQD23:72Gy) and 57Gy in 19 fractions 
(BED1.5:171Gy, EQD21.5:73Gy, BED3:114Gy, EQD23:68Gy), delivered using IMRT [51].  
A planned phase II analysis revealed similar low levels of 2-year grade 2+ bladder and 
bowel toxicity amongst conventionally and hypofractionated regimens [52]. Mature 
outcome data are awaited. 
 
1.8 SABR and ultra-hypofractionation 
 
There has been recent interest in trying to exploit the low α/β of PCa further with 
stereotactic ablative body radiotherapy (SABR), also referred to as stereotactic body 
radiotherapy (SBRT) [53]. The Stereotactic Working Group define SABR as: “the 
precise irradiation of an image-defined extra-cranial lesion associated with the use of 
high radiation dose in a small number of fractions” [54]. To avoid excessive normal 
tissue toxicity as a result of the high BED delivered, Clinical Target Volume (CTV) to 
Planning Target Volume (PTV) margins are generally tighter (i.e. only  few millimetres) 
than with conventionally fractionated radiotherapy. High quality image guidance is 
therefore essential so that the target is not missed and surrounding normal tissues are 
not inappropriately irradiated. Strategies such as daily online imaging of fiducial 
markers or intra-fraction motion tracking facilitate the accurate delivery of SABR with 
tighter CTV-PTV margins. Dose distributions are often more heterogeneous than the 
traditional -5% to +7% considered acceptable by ICRU (International Commission on 
Radiation Units and Measurements) Report 50 [55] and hotspots greater than 110% of 
the prescription dose are also common [56]. This is often achieved by prescribing to a 
peripheral isodose, thus facilitating marked dose escalation within the target and rapid 
dose fall-off beyond [56]. It is not known, however, if, in the context of prostate SABR, 
such heterogeneity is more or less desirable than more homogenous dose 
distributions [57]. 
 
A range of dose-fractionation schedules have been used in localised PCa, including 
35-36.25Gy in 5 fractions, 40Gy in 5 fractions and 38Gy in 4 fractions [58-61]. 
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Treatment is delivered over consecutive or alternate days. As well as theoretically 
offering increased tumour control, SABR is convenient for patients and economically 
attractive.  Using the BED and EQD2 equations above, Table 1.1 compares the doses 
received by the prostate tumour, early responding and late responding tissues between 
SABR schedules and conventionally fractionated regimens. It can be seen that 
compared to conventionally fractionated dose-escalated regimens, SABR doses of 35-
36.25Gy in 5 fractions deliver a higher dose to the prostate for lower doses to the early 
responding tissues and similar or slightly lower doses to the late responding tissues.  
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Table 1.1 Comparison of conventionally fractionated and SABR regimens used for the treatment of prostate cancer 
BED: Biologically equivalent dose, CHHiP: Conventional versus Hypofractionated High-dose intensity-modulated radiotherapy for Prostate 
cancer, EQD2: equivalent dose in 2Gy fractions, EBRT: external beam radiotherapy, SABR: stereotactic ablative radiotherapy 
Treatment EBRT 
dose 
No. 
fractions 
Dose per 
fraction 
BED to 
prostate 
tumour  
(α/β=1.5Gy) 
EQD2 to 
prostate 
tumour 
(α/β=1.5Gy) 
 
BED to 
early 
responding 
tissues 
(α/β=10Gy) 
EQD2 
to early 
responding 
tissues 
(α/β=10Gy) 
 
BED to late 
responding 
tissues 
(α/β=3Gy) 
EQD2 
to late 
responding 
tissues 
(α/β=3Gy) 
 
 
European standard 
fractionation 
78Gy 39 2Gy 182.0Gy 78.0Gy 93.6Gy 78.0Gy 130.0Gy 78.0Gy 
CHHiP trial 
standard arm 
fractionation 
74Gy 37 2Gy 172.7Gy 74.0Gy 88.8Gy 74.0Gy 123.3Gy 74.0Gy 
SABR fractionation 
1 
35Gy 5 7Gy 198.3Gy 85.0Gy 59.5Gy 49.6Gy 116.7Gy 70.0Gy 
SABR fractionation 
2 
36.25 5 7.25 211.5Gy 90.6Gy 62.5Gy 52.1Gy 123.9Gy 74.3Gy 
SABR fractionation 
3 
40Gy 5 8Gy 253.3Gy 108.6Gy 72.0Gy 60Gy 146.7Gy 88.0Gy 
SABR fractionation 
4 
38Gy 4 9.5Gy 278.7Gy 119.4Gy 74.1Gy 61.8Gy 158.3Gy 95.0Gy 
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Thus, the lower α/β of PCa can be exploited by SABR in order to deliver a higher BED 
to the prostate but a dose to the late responding tissues that is biologically similar to 
that received from conventional fractionation. Doses of 40Gy in 5 fractions or 38Gy in 4 
fractions, compared to conventionally fractionated regimens, deliver a much higher 
BED to the prostate as well as a higher dose to the late responding tissues. 
 
SABR can be delivered using standard linear accelerators and the Cyberknife™ 
(Accuray®, USA). The Cyberknife™ is a miniature 6MV linear accelerator mounted on 
a robotic arm which allows multiple small radiation beams to be focused at a target 
from multiple directions thus producing highly conformal plans. Gold fiducials are 
implanted in the prostate and are detected by two in-room stereoscopically mounted 
kilovoltage (kV) imagers. This allows accurate localisation prior to each fraction and 
intra-fraction tracking [62]: real-time images are compared with reconstructed images 
from the planning CT and any intra-fraction prostate motion is automatically corrected. 
The high precision of the system allows small CTV-PTV margins. Delivery time is 
around 40 minutes per fraction [63] thus intra-fraction motion is potentially of concern, 
although real-time tracking is used to correct for this. The Cyberknife™ is not widely 
available in the UK: there are four Cyberknife™ centres within the National Health 
Service and two in the private sector. 
 
Of note, evidence to support ultra-hypofractionation using EBRT in the treatment of 
prostate cancer exists from several years ago. In 1991, Collins et al reported 
encouraging outcomes from a series of 232 patients treated between 1964 and 1984 
with 36Gy in 6 fractions (BED1.5:180Gy, EQD21.5:77Gy) using either a linear accelerator 
or cobalt-60 [64]. Urinary and rectal catheters were used for localisation. Rates of long 
term morbidity were low (two patients (1%) developed rectal strictures) and survival 
was similar to other dose and fractionation schedules in use at that time [64]. The 
promise of ultra-hypofractionation has also been successfully applied in phase II trials 
using high dose rate (HDR) brachytherapy monotherapy [65-67]. Typical schedules 
include 36Gy in 4 fractions over three days (BED1.5:252Gy, EQD21.5:108Gy) and 54Gy 
in 9 fractions over five days (BED1.5:270Gy, EQD21.5:116Gy). HDR brachytherapy, 
however, is invasive, involving anaesthetics, in-patient care and strong analgesics. If 
SABR were shown to be an effective and well tolerated means of delivering ultra-
hypofractionation, then it may become an attractive alternative. 
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1.9 Clinical evidence regarding SABR in prostate cancer 
 
The current evidence regarding SABR in localised PCa is in the form of non- 
randomised trials or series, generally involving small numbers of patients. Considering 
SABR according to the Stereotactic Working Group definition above, and schedules 
that deliver more than 5Gy per fraction, a literature search, last updated September 
2014, identified 23 individual clinical studies from 21 groups which used SABR as the 
sole radiation therapy in localised PCa in the first line setting, 15 using 
Cyberknife™ [57,59-61,68-78] and 8 using linear accelerators [58,79-85]. Based on 
these studies, SABR, as the sole radiation therapy, has been delivered to over 1800 
patients using the Cyberknife™ and over 300 patients using a linear accelerator. SABR 
has also been used as a boost in addition to conventional fractionation in three 
additional studies, two using the Cyberknife™ and one using a linear accelerator [86-
88], and two Cyberknife™ studies have delivered SABR as either the sole radiation 
treatment or as a boost following conventional fractionation [71,72]. The use of prostate 
SABR as a boost is reported in over 170 patients. Most of these studies present 
prospective data. Details of treatment, efficacy and toxicity for individual studies are 
provided in tables in Appendix C. Some groups have published multiple papers 
concerning different patient populations within the same study, as illustrated in 
Appendix C. The following discussion focuses on the 23 prostate SABR studies which 
deliver SABR as the sole radiation modality (and not as a boost following 
conventionally fractionated radiotherapy). Where SABR boost studies are mentioned, 
these are highlighted as such. 
 
1.9.1 Patient selection 
 
Most studies have examined SABR in organ-confined PCa, particularly low and 
intermediate risk disease. A small number of Cyberknife™ studies have included 
patients with T3 disease, or other higher risk features (GS≥8, PSA>20) and although 
outcomes in this group appear encouraging [59,68,70,71,74-76,78], data are too 
immature and too few in number to draw firm conclusions. 
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Part of the concern about the treatment of non-low risk PCa using SABR is that 
intermediate and high risk patients are at higher risk of extra-capsular extension and 
microscopic seminal vesicle (SV) invasion, and so very localised treatments such as 
SABR could be inadequate. To investigate this further, Ju et al examined outcomes 
and dose distributions in 41 patients with intermediate risk prostate cancer treated 
using SABR [89]. The group specifically examined areas around the prostate 
considered at highest risk of extra-capsular spread. Based on the CTV used in this 
study (which included the proximal SV until the point where the left and right SV split), it 
was found that areas of expected extra-capsular extension received adequate doses 
for microscopic tumour cell kill. Given this observation, and positive early clinical 
outcomes, the group concluded that prostate SABR appeared a suitable treatment 
option for intermediate risk patients, but acknowledged that further clinical outcomes 
were required [89]. 
 
Further clinical data has since been provided by Katz and Kang who compared clinical 
outcomes between patients treated for prostate SABR using 35-36.25Gy in 5 fractions 
with low-intermediate risk (GS 6 with PSA>10 or GS 3+4 with PSA<10) and high-
intermediate risk (GS 3+4 with PSA 10-20 or GS 4+3) disease [90]. The CTV contained 
the prostate alone for all patients. Biochemical disease free survival at seven years 
was inferior in the high-intermediate risk group (79.3% vs 93.5%), perhaps suggesting 
that some caution is required when treating higher risk patients, particularly when not 
including any SV within the CTV [90]. 
 
Some studies have excluded patients with large prostate volumes, marked urinary 
symptoms or a previous history of TURP [60,73,79,82,83,85,91], factors which are at 
least relative contra-indications to brachytherapy [92,93].  
 
1.9.2 Use of androgen deprivation 
 
The use of androgen suppression has an uncertain role in the setting of intermediate 
risk PCa patients treated with dose-escalated conventionally fractionated 
radiotherapy [94]. Its use in the setting of SABR is therefore variable between and 
within studies making it difficult to draw conclusions about its role with SABR.  Where 
used, it tends to be in the short term (i.e. a few months to one year) and in the setting 
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of intermediate or high risk disease [91]. In a pooled analysis of 1100 SABR patients 
reported by King et al, the use of androgen suppression had no impact on 5-year 
biochemical relapse free survival [91]. It should be noted, however, that this was a non-
randomised, non-matched comparison and so case selection may introduce bias into 
this comparison. 
 
1.9.3 Dose and fractionation 
 
SABR has been delivered using various dose-fractionation schedules. As the sole 
radiation treatment, fraction sizes have ranged from 6.7-10Gy, equivalent to total 
prostate BED of 183-383Gy or EQD21.5 of 78-164Gy. Doses of 35-36.25Gy in 5 
fractions are most commonly used in Cyberknife™ and linear accelerator-based 
platforms (BED1.5:198-211Gy, EQD21.5 of 85-90Gy), although doses up to 50Gy have 
been delivered in a 5 fraction schedule (BED1.5:383Gy, EQD21.5:164Gy) [83]. In 
addition, four Cyberknife™ studies have delivered 32-38Gy in 4 fractions (BED1.5:203-
279Gy, EQD21.5:87-119Gy) [57,60,70,72], schedules which are similar to those used in 
HDR brachytherapy monotherapy. As a boost, fractions have varied from 5-8Gy (total 
BED1.5 including conventional fractionated treatment: 189-268Gy, EQD21.5:81-115Gy). 
Most studies have delivered treatment over consecutive days although King et al found 
alternate day schedules to cause less low grade (i.e. grade 1 or 2) late urinary and 
rectal toxicity [61]. 
 
1.9.4 Treatment platform 
 
The majority of evidence comes from studies using the Cyberknife™ although eight 
studies from six centres delivered SABR using linear accelerators (Appendix C), which 
are widely available in the UK.  
 
 
 
 
 
13 
 
1.9.5 Data acquisition 
 
Magnetic resonance imaging (MRI) fusion with planning computer tomography (CT) 
scans has often been performed to assist with target delineation [57,59,60,68,69,71-
73,75,76,78,84]. 
 
1.9.6 Patient preparation 
 
Low fibre diets, bowel preparation and enemas have often been used to ensure an 
empty rectum. Vacuum bags, endorectal balloons, rectal-prostate spacers, drinking 
protocols and urinary catheters have been employed in some studies (see Appendix 
C). 
 
1.9.7 CTV contents 
 
All studies encompass the whole prostate within the CTV. The inclusion of some or all 
of the SV within the CTV has differed between and within studies. Of the studies which 
provide sufficient information, nine consider the prostate alone as the CTV, without 
inclusion of the SV, even in the setting of intermediate or high risk 
disease [60,61,71,73,74,79,81-83]. In addition, four studies include a proximal portion 
of the SV in all patients [57,59,68,76] and seven studies include some or all of the SV 
in higher risk or selected cases [69,70,72,75,78,84,85]. Of the five studies which deliver 
SABR as a boost, two boost the prostate alone [71,86], one includes the proximal SV in 
the boost CTV in all patients [88] and two include some or all of the SV within the boost 
CTV in selected cases [72,87]. 
 
1.9.8 CTV-PTV margins and image-guidance 
 
CTV-PTV margins have been variable but generally no more than 5mm margins have 
been employed. Often the posterior CTV-PTV margin is smaller than that in other 
directions. The most commonly adopted margin ‘recipe’ is 5mm in all directions, except 
3mm posteriorly. The small size of CTV-PTV margin is generally considered 
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acceptable in the setting of Cyberknife™ based treatments where intra-fraction motion 
tracking of implanted fiducials is possible. Two linear accelerator-based studies used 
implanted electro-magnetic beacons in some or all patients in order to allow intra-
fraction motion tracking and accompanying small CTV-PTV margins [58,83]. In four of 
the remaining linear accelerator-based studies, fiducial markers (or intra-prostatic 
calcifications) have been employed to allow pre-treatment localisation using cone beam 
computer tomography (CBCT) or portal images (without intra-fraction motion 
tracking [81,82,84,95]).  Only two small studies have used CBCT soft tissue matching 
alone (i.e. without fiducials) for daily online IGRT, also without intra-fraction motion 
tracking [79,85]. Image guidance is discussed in greater detail below. 
 
1.9.9 Target coverage, prescription and dose distribution 
 
In most studies the volume of PTV receiving the prescribed dose was at least 95%. As 
stated before, prescription doses of 35-36.25Gy in 5 fractions are most commonly used 
for both Cyberknife™ and linear accelerator-based prescriptions, while 32-38Gy in 4 
fractions is also used in four Cyberknife™ studies [57,60,70,72]. In the setting of 
Cyberknife™ delivery, the prescription dose is frequently prescribed to a peripheral 
isodose (e.g.75-90% isodose), thereby facilitating rapid dose fall-off beyond the PTV 
and marked dose escalation towards the centre of the PTV. Prescription strategies in 
the setting of linear accelerator-based treatments are more variable. Mantz et al 
adopted a similar strategy to the Cyberknife™ by prescribing to 36.25Gy in 5 fractions 
to a peripheral isodose [79], while Pham et al prescribed 33.5Gy in 5 fractions to the 
isocentre [80]. Importantly, the doses received by the prostate will vary depending on 
whether an isocentric or peripheral isodose prescription strategy is adopted. 
 
SABR dose distributions, particularly in the setting of Cyberknife™ prescribing, are 
often considered ‘homogeneous’, when doses of 35-36.25Gy in 5 fractions are used, 
as in the majority of Cyberknife™ studies, or ‘heterogeneous’, when doses of 32-38Gy 
in 4 fractions are prescribed, and in this situation the dose distribution is designed to 
reflect that achieved by HDR brachytherapy, with large proportions of the PTV 
receiving 125% and 150% of the prescription dose, and with a dose maximum of 200% 
of the prescription dose [57]. Despite being considered a ‘homogenous’ dose 
distribution, because the prescription dose is prescribed to a peripheral isodose, the 
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homogeneity within a ‘homogenous’ plan, is far more heterogeneous than the 
traditional 95 to 107% coverage that is considered homogenous in the setting of 
conventionally fractionated, linear accelerator-based treatments [55]. For example, if a 
dose of 35Gy in 5 fractions is prescribed to the 80% isodose (the strategy adopted by 
Bolzicco et al [59]), then the dose in the centre of the PTV can escalate to 43.75Gy, 
which is 125% of the prescription dose. The relative merits of applying a ‘homogenous’ 
dose distribution, or mimicking the very heterogeneous distribution of HDR 
brachytherapy is uncertain [57,72]. Figure 1-1 illustrates the impact of different 
prescribing strategies on the dose received by the target and normal tissues. 
 
In the setting of linear accelerator-based prostate SABR dose distributions, differing 
approaches are reported. Loblaw et al specified that the maximum PTV dose should be 
no more than 105% of the prescription dose and that the volume of PTV receiving 95% 
of the prescription dose should be at least 99% [82]. Such a strategy would achieve a 
much more homogeneous, and traditional, dose distribution as compared to those 
achieved with the Cyberknife™. Similarly, Alongi et al adopted a homogenous 
prescribing strategy, aiming for a mean dose equal to the prescription dose and aiming 
to limit the maximum dose to 105% of the prescription dose [84]. Boike et al, however, 
also using a linear accelerator-based platform, specified that rapid dose fall-off beyond 
the PTV was prioritised over target homogeneity, resulting in considerable dose 
heterogeneity, more similar to that achieved using the Cyberknife™ [83]. As above, 
Mantz et al prescribed to a peripheral isodose to limit doses to organs at risk, and by 
doing so would also achieve heterogeneous dose distributions [79]. 
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Figure 1-1 Impact of different prescribing strategies on the does received by the 
target and by the surrounding normal tissues  
a) dose is prescribed to the isocentre as in some of the prostate SABR linear 
accelerator based studies, b) dose is prescribed to the 80% isodose, a similar strategy 
as used in some linear accelerator SABR studies and also when delivering a 
‘homogenous’ dose using the Cyberknife™ and c) dose is prescribed to the 50% 
isodose resulting in a very heterogeneous dose distribution, a strategy similar to that 
used when using the Cyberknife™ to deliver a heterogeneous dose 
 
 
 
1.9.10 Organ at risk constraints 
 
The most appropriate organ at risk constraints remain to be defined [96] and a variety 
have been employed. King et al recently reported outcomes for a pooled analysis of 
1100 patients from 8 institutions treated with 35-40Gy in 5 fractions [91]. For the 
majority of patients, the following constraints were adopted: 
 
 
Target Target Target
100%
80%
50%
5%
95%
36.25Gy prescribed 
to isocentre (*)
95% (34.4Gy) covers 
target
36.25Gy prescribed 
to 80% isodose: 
36.25Gy covers target
100%  is maximum 
(45.3Gy= 125% of 
prescription dose)
Rapid dose fall off in 
normal tissues
38Gy prescribed to 
50% isodose: 38Gy 
covers target
100%  is maximum 
(76Gy=200% of 
prescription dose)
Very rapid dose fall 
off in normal tissues
=normal tissue receiving 
doses between that at 
edge of target and 5% 
isodose
*
a) b) c)
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Rectum: 
volume receiving ≥50% of prescription dose (PD): <50%,  
volume receiving ≥80% of PD: <20%,  
volume receiving ≥90% of PD: <10% 
volume receiving ≥100% of PD: <5%.   
 
Bladder: 
volume receiving ≥50% of PD: <40%,  
volume receiving ≥100% of PD: <10% 
 
Femoral head: 
volume receiving ≥40% of PD: <5% 
 
1.9.11 Efficacy 
 
Drawing conclusions about the efficacy of prostate SABR is partly challenging because 
of the different definitions of PSA failure and different outcome measures used in 
different studies. Where figures for efficacy are quoted below, these are accompanied 
by the definition of PSA failure used in that particular study (i.e. ASTRO (American 
Society for Radiation Oncology) definition or Phoenix definition). In terms of 
biochemical outcome measures (e.g. freedom from biochemical failure, biochemical 
relapse free survival, biochemical control, biochemical progression free survival etc.), 
these are considered equivalent when the same definition of PSA failure has been 
used. Where clinically detected failure (in the absence of biochemical failure) is 
included in the measure of efficacy, this has been stated. 
 
Most studies are limited in that they have too few patients and too short follow-up to 
draw firm conclusions regarding treatment efficacy. Some early conclusions can be 
drawn from those studies with the longest durations of follow-up. King et al recently 
pooled and updated data from eight institutions which used the Cyberknife™ to deliver 
doses of 35 to 40Gy in 5 fractions to the prostate with a 5mm margin (and 3mm 
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posteriorly) [91]. In total 1100 patients were included in the analysis, of whom 14% 
received four months of neoadjuvant and concurrent androgen deprivation. Median 
follow-up was 36 months. The 5-year biochemical relapse free survival rate was 
excellent at 93% for all patients, 95% for low risk patients, 84% for intermediate risk 
patients and 81% for high risk patients (Phoenix definition). For 135 patients who had a 
minimum of five years follow-up in this study, the 5-year biochemical relapse free 
survival rate was 99% and 93% for low and intermediate risk patients respectively [91]. 
Similarly, Katz et al reported outcomes for a series of 477 patients treated using the 
Cyberknife™ using doses of 35 to 36.35Gy in 5 fractions [90]. After a median follow-up 
of 72.1 months, 7-year freedom from biochemical relapse (Phoenix definition) was 
95.6% and 89.3% for patients with low and intermediate risk disease [90]. 
 
In terms of linear accelerator-based treatments with longer follow-up, Pham et al 
reported outcomes after 60 months median follow-up for 45 low risk patients prescribed 
33.5Gy in 5 fractions [80]. Biochemical relapse free survival was excellent at 93% 
(Phoenix definition)  [80]. Loblaw et al also reported encouraging 5-year biochemical 
relapse free survival rates of 98% (Phoenix definition) for 83 low risk patients 
prescribed 35Gy in 5 fractions after median follow-up of 55 months [82]. 
 
Of the trials delivering SABR as a boost, after 63 months median follow-up, one study 
reported 5-year biochemical relapse free survival (Phoenix definition) at 98% [87].  
 
In the pooled analysis, King et al considered any treatment that achieved 5-year 
biochemical relapse free survival of greater than 90% equivalent [91]. As such, the 
outcomes achieved for prostate SABR were similar to those predicted using 
nomograms for radical prostatectomy and EBRT delivering 78Gy [91]. Examples of 
efficacy outcomes reported for other prostate cancer treatment modalities are shown in 
Table 1.2. Based on limited follow-up, it appears that the outcomes from SABR 
compare favourably with existing radiation modalities and surgical treatment. 
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Table 1.2 Efficacy outcomes for different prostate cancer treatment modalities 
Continued overleaf. 
Study 
Median 
follow-up 
Efficacy measure* Efficacy 
Dose-escalated (≥74Gy) external beam radiotherapy 
RT01 trial      
(Dearnaley et al; 
n=422; 74Gy, 3- 
and 6-field 
conformal [15]) 
5.3 years 
5-year biochemical 
progression free 
survival (increase in 
PSA of ≥50% and to 
>2ng/ml) 
Low risk: 85%              
Intermediate risk: 79%                  
High risk: 57% 
MD Anderson trial 
(Kuban et al; 
n=151; 78Gy, 4-
field box and 6-field 
conformal [19]) 
8.7 years 
8-year biochemical 
(Phoenix)/ clinical 
freedom from failure 
Low risk: 88%              
Intermediate risk: 86%                 
High risk: 63% 
Dutch trial           
(Al-Mamgani et al; 
n=333; 78Gy, 
conformal [97]) 
5.8 years 
7-year biochemical 
(ASTRO and Phoenix)/ 
clinical freedom from 
failure 
ASTRO: 54%               
Phoenix: 56%                     
(>50% high risk patients) 
Zietman et al  
(n=195;79.2Gy, 
conformal [13]) 
5.5 years 
5-year biochemical 
freedom from failure 
(ASTRO) 
Low risk: 81%                        
Intermediate and high risk: 
80% 
Zelefsky et al         
(n=772; 81Gy, 
IMRT [20]) 
7 years 
8-year biochemical 
relapse free survival 
(ASTRO) 
Low risk: 85%                      
Intermediate risk: 76%                   
High risk: 72% 
Cahlon et al 
(n=478; 86.4Gy, 
IMRT [22]) 
4.4 years 
5-year biochemical 
relapse free survival 
(Phoenix) 
Low risk: 98%               
Intermediate risk: 85%                   
High risk: 70% 
Radical prostatectomy 
Kupelian et al 
(n=1034 [98]) 
5.5 years 
5-year biochemical 
relapse free survival 
(PSA ≤0.2ng/ml) 
T1/T2 disease: 81% 
Potters et al 
(n=746 [99]) 
4.7 years 
5-year freedom from 
biochemical recurrence 
(detectable PSA) 
T1/T2 disease: 83% 
Martinez et al 
(n=157 [100]) 
5.5 years 
5-year biochemical 
control (PSA 
≤0.2ng/ml) 
Low risk: 84% 
Aizer et al 
(n=204 [101]) 
3.8 years 
5-year biochemical 
disease free survival 
(PSA ≤0.2ng/ml) 
Low risk: 93%               
Intermediate risk: 87%              
High risk: 38% 
Low dose rate brachytherapy 
Kupelian et al 
(n=950 [98]) 
3.9 years 
5-year biochemical 
relapse free survival 
(ASTRO) 
T1/T2 disease: 83% 
Potters et al 
(n=733 [99]) 
4.3 years 
5-year freedom from 
biochemical recurrence 
(ASTRO) 
T1/T2 disease: 84% 
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Table 1.2 cont. Efficacy outcomes for different prostate cancer treatment 
modalities 
Study 
Median 
follow-up 
Efficacy measure* Efficacy 
Low dose rate brachytherapy cont. 
Grimm et al 
(n=125 [102]) 
6.8 years 
10-year PSA 
progression free survival 
Low risk: 87% 
Zelefsky et al 
(n=248 [103]) 
4.0 years 
5-year PSA relapse free 
survival (ASTRO) 
Low risk: 88%               
Intermediate risk: 77%               
High risk: 38% 
External beam radiotherapy plus high dose rate (HDR) brachytherapy boost 
Hoskin et al 
(n=110 [104]) 
7.1 years 
5-year biochemical 
(phoenix)/ clinical 
relapse free survival 
75% (Mainly intermediate 
and high risk patients) 
Galalae et al 
(n=611 [105]) 
5 years 
5-year biochemical 
control (ASTRO) 
Low risk: 96%                
Intermediate risk: 88%               
High risk: 69% 
High dose rate (HDR) brachytherapy monotherapy 
Tselis et al 
(n=351 [106]) 
4.9 years 
5-year biochemical 
control (Phoenix) 
Low risk: 94%                    
Intermediate risk: 92%        
High risk: 92% 
Demanes et al 
(n=298 [67]) 
5.2 years 
8-year biochemical 
control (Phoenix) 
97% (Mainly low and 
intermediate risk patients) 
Yoshioka et al 
(n=112 [66]) 
5.4 years 
5-year biochemical 
freedom from failure 
(Phoenix) 
Low risk: 85% (95% CI: 66-
100%),                             
Intermediate risk: 93% (95% 
CI: 83-100)                                            
High risk: 79% (95% CI: 69-
89%) 
Prostate SABR (trials with longest follow-up) 
King et al 
(pooled results, 
n=135 [91]) 
Minimum of 
5 years 
follow-up 
5-year biochemical 
relapse free survival 
(Phoenix) 
Low risk: 99%                    
Intermediate risk: 93%        
High risk: 81%**  
Katz et al 
(n=477 [90]) 
6 years 
7-year freedom from 
biochemical failure 
(Phoenix) 
Low risk: 96%                    
Intermediate risk: 90% 
Pham et al 
(n=40 [80]) 
5 years 
5-year biochemical 
relapse free survival 
(Phoenix) 
Low risk: 93% 
Loblaw et al 
(n=84 [82]) 
4.6 years 
5-year biochemical 
relapse free survival 
(Phoenix) 
Low risk: 98% 
CI: confidence interval, MSK: Memorial Sloan Kettering, *See Appendix A and B for PSA failure 
and risk group definitions, **For high risk patients, 5-year biochemical relapse free survival 
based on all patients, and not just patients with >5 years follow-up, median follow-up 36 months 
here. 
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Following SABR, delivered using the Cyberknife™ or a linear accelerator, PSA is 
reported to fall from baseline levels in all patients, frequently reaching nadirs of less 
than 1ng/ml at 12 to 24 months post treatment [58-60,68-70,72-74,76,80,82,107]. 
 
Initial efficacy results, for both Cyberknife™ and linear accelerator-based platforms, are 
encouraging. Given the long natural history of PCa, particularly low risk PCa, longer 
term follow-up and larger patient numbers are required before the efficacy of SABR in 
localised PCa can be fully determined. In addition, follow-up is too immature to 
determine if the much more homogenous dose distributions adopted in some of the 
linear accelerator-based studies, are equally as efficacious as the more heterogeneous 
dose distributions used in Cyberknife™ based treatments, or whether HDR 
brachytherapy-like dose distributions are preferable to the ‘homogenous’ dose 
distributions which can be achieved when using the Cyberknife™. 
 
Three groups have investigated if there is evidence of a dose-response for prostate 
SABR doses [78,90,91,108]. Katz et al demonstrated no difference in biochemical 
relapse free survival in 430 low and low-intermediate risk patients treated with 35Gy in 
5 fractions and 36.25Gy in 5 fractions [90]. The same group performed a matched-pair 
analysis of 41 patients treated with 35Gy and 41 patients treated with 36.25Gy [108]. 
Low and intermediate risk patients were included. After a median follow-up of 51 
months, 4-year freedom from biochemical relapse was 97.5% in both groups (Phoenix 
definition) [108]. There was, however, a non-significant suggestion of increased urinary 
toxicity with the higher dose [108]. Similarly, in the pooled analysis of data from 1100 
patients from eight institutions, King et al found no dose-response in terms of 
biochemical relapse free survival when comparing doses of 35-40Gy delivered in 5 
fractions [91]. This group suggested that prostate SABR doses which achieve 
biochemical control in excess of 90% lie on the upper plateau portion of the dose-
response curve. The group therefore concluded that since the doses examined were 
effective and well tolerated, then further dose escalation was not justified [91]. When 
examining a small series of intermediate and high risk patients (n=34) with shorter 
follow-up (median 31 months), Oliai et al demonstrated a significant dose-response in 
patients receiving low (35-36.25Gy) and high (37.5Gy) doses [78]. The 3-year actuarial 
freedom from biochemical failure (Phoenix definition) was 72% in intermediate and high 
risk patients receiving low dose SABR and 100% in intermediate and high risk patients 
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receiving high dose SABR (p=0.0363). When low risk patients were also included in the 
analysis (total n=70), however, statistical significance was lost (p=0.0775) [78]. 
Definitive evidence regarding a dose-response for this range of SABR doses has, 
therefore, not yet been demonstrated, although the relatively small number of patients 
involved in the existing studies may mean these studies were underpowered to detect 
a true dose-response relationship. 
 
1.9.12 PSA bounce 
 
This phenomena, mainly defined as a transient rise in PSA of greater than 0.2ng/ml or 
0.4ng/ml, is reported in between 9% and 42% of patients, with the median time to 
bounce occurring between 9 and 36 months post SABR [59,60,73-76,78,80,82,90]. 
Similarly, the pooled analysis of 1100 patients from eight institutions recorded bounces 
in 16% of patients after a median of 18 months [91]. The magnitude of bounce is 
generally small, with median values of 0.5 to 0.7ng/ml reported [74-76,91]. PSA bounce 
was specifically examined in a recent paper produced by Vu et al, as part of the 
Flushing Group [109]. In keeping with the bounce observed in other studies, in a series 
of 120 patients (none of whom received androgen deprivation during the follow-up 
period) with a median follow-up of 24 months, 28% of patients experienced a bounce 
(defined as a rise of at least 0.2ng/ml) after a median of nine months with a median 
bounce magnitude of 0.5ng/ml [109]. On univariate analysis, only age was a significant 
predictor of bounce, with younger men being more likely to experience a bounce. 
Patient race, family history, prior hormone therapy, prostate size, T stage, GS, pre-
radiotherapy PSA and risk group had no impact on the development of a bounce. 
Similarly, on multivariate analysis, only younger age was predictive of developing a 
PSA bounce [109]. Mcbride et al also noted that patients who experienced a bounce 
were younger than those who did not, although the impact of other factors on PSA 
bounce was not examined [73]. Younger age has previously been found to be 
predictive of PSA bounce in patients treated with seed brachytherapy [110].  
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1.9.13 Acute toxicity 
 
SABR is reported to be well tolerated. Toxicity outcomes for individual trials are 
included in Appendix C (Tables C4 to C6) and summarised in Table 1.3. Acute 
toxicities are usually reported as those which occur within three or six months of 
treatment. Based on available evidence, acute grade 4 toxicities are not reported and 
acute grade 3 toxicities are uncommon. Of the 12 Cyberknife™, 7 linear accelerator 
and 5 SABR boost studies which provide sufficient detail, 16 studies (8 
Cyberknife™,  [59,69,70,72-76] 5 linear accelerator [79,81,83-85] and 3 boost 
studies [72,86,88]) report no acute grade 3 urinary toxicities. The remaining eight 
studies report acute grade 3 urinary toxicity in 1 to 8% of patients receiving 
Cyberknife™ treatment (8%=4 patients)  [60,68,71,78], 1 to 3% of patients receiving 
linear accelerator treatment [82,95] and 4 to 9% of patients receiving a SABR boost 
(9%=1 patient) [71,87]. In some cases grade 3 acute urinary toxicity occurred in 
patients with a history of urethral instrumentation, or large volume prostates and 
marked pre-treatment urinary symptoms, both of which are known to predict increased 
acute urinary toxicity [59,60,76,95,111,112]. Of the studies which provide sufficient 
detail, grade 2 acute GU toxicity is reported in 4 to 45% of patients treated using the 
Cyberknife™, 0 to 40% of patients treated using a linear accelerator and 4 to 46% of 
patients receiving SABR as a boost (Table 1.3). The most frequent acute GU toxicities 
appear to be urinary frequency, urgency, dysuria and obstructive symptoms. 
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Table 1.3 Summarised toxicity rates reported in prostate SABR studies (median (and range))  
     See Appendix C for results from individual studies 
Treatment modality 
BED (and EQD2) 
received by normal 
tissue based on SABR 
prescription dose (Gy) 
(acute tissue α/β=10Gy,  
late tissue α/β=3Gy) 
Genitourinary/ urinary toxicity (%) 
 
 
 
Grade: 
Gastrointestinal/ rectal toxicity (%) 
 
 
 
Grade: 
  1 2 3 4 1 2 3 4 
Acute toxicity 
Cyberknife™ studies 
58-74 
(48-62) 
56 
(10-75) 
15 
(4-45) 
0 
(0-8) 
0 
27  
(14-76) 
6 
(0-24) 
0 
(0-2) 
0 
Linear accelerator 
studies 
56-100 
(47-83) 
33 
(20-71) 
19 
(0-40) 
0 
(0-3) 
0 
40 
(0-67) 
7 
(0-27) 
0 0 
Studies delivering 
SABR boost 
82-106 
(68-88) 
59 
(34-75) 
27 
(4-46) 
0 
(0-9) 
0 
39 
(0-75) 
5 
(0-17) 
0 0 
Late toxicity 
Cyberknife™ studies 
117-158 
(70-95) 
9 
(3-48) 
8 
(3-32) 
2 
(0-7*) 
0 
5 
(2-14) 
3 
(0-11) 
0 
(0-5) 
0 
Linear accelerator 
studies 
108-217 
(65-130) 
16 
(0-23) 
5 
(0-13) 
0 
(0-7**) 
0 
25 
(0-35) 
7 
(0-8) 
0 
(0-7) 
0                       
(0-3)
†
 
SABR boost studies 
126-179 
(76-108) 
15 
(3-46) 
8 
(5-12) 
0 
(0-5) 
0 
19 
(3-38) 
3 
(0-10) 
0 
(0-10) 
0 
Note: where more than one publication exists concerning overlapping subsets of patients within the same study (e.g. toxicities in all patients and toxicities                    
in intermediate risk patients only), then the study containing all patients, as opposed to one particular subset of patients, was used to create this summary                    
data in order to avoid double-counting of toxicity and provide a better overall view.                                                                                                                                                                                                                                                           
BED: biologically equivalent dose, EQD2: equivalent dose in 2Gy fractions                                                                                                                                               
*7% represents two patients in series of 29, **7% represents one patient in series of 15, 
†
3% represents two patients in series of 61 and one of these episodes 
may not have been attributable to the radiotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                       
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Of studies reporting acute GI toxicities in detail, 13 of 14 Cyberknife™ 
studies  [57,59,68-78], 7 of 7 linear accelerator studies [79,81-85,95] and 5 of 5 SABR 
boost studies [71,72,86-88] report no grade 3 or greater acute GI toxicities. The one 
remaining study reported grade 3 toxicity in 2% of patients and no grade 4 events [60]. 
Grade 1 and 2 acute rectal toxicity are more common and grade 2 acute rectal toxicity 
is reported in 0 to 24% of patients treated using the Cyberknife™, 0 to 27% of patients 
treated using a linear accelerator and 0 to 17% of patients receiving SABR as a boost 
(Table 1.3 and Appendix C). The most commonly reported acute GI symptoms were 
diarrhoea, rectal frequency and rectal discomfort. 
 
The evidence suggests acute symptoms are worst during and within the first few weeks 
of treatment but largely settle over the following few months. In comparison to other 
radiation modalities used for the treatment of PCa, acute toxicities compare favourably 
(Table 1.4). 
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Table 1.4 Acute toxicities following alternative radiotherapy techniques for 
prostate cancer 
 Acute GU toxicity (%) Acute GI toxicity (%) 
Grade: 1 2 3 4 1 2 3 4 
External beam radiotherapy 
RT01 trial            
(Dearnaley et al; 
n=422; 74Gy, 
conformal [15])* 
52 24 7 1 52 20 2 0 
Dutch trial (Peeters et 
al; n=333;78Gy, 
conformal [113]) 
NR 42 13 0 NR 47 4 0 
Zietman et al (n=195; 
79.2Gy, 
conformal [13]) 
39 45 1 1 54 33 12 0 
Zelefsky et al (n=772; 
81Gy, IMRT [20]) 
46 36 0.5 0 25 57 0 0 
Cahlon et al (n=478; 
86.4Gy, IMRT [22]) 
59 22 0.6 0 34 8 0 0 
Low dose rate (LDR) brachytherapy 
Zelefsky et al    
(n=248 [103]) 
40 55 3 0 61 33 6 0 
Tanaka et al        
(n=155 [114]) 
72 4 2 0 7 0.5 0 0 
External beam radiotherapy with high dose rate (HDR) brachytherapy boost 
Viani et al 
(n=131 [115]) 
40
†
 2 0 13
†
 0 0 
High dose rate (HDR) brachytherapy 
Tselis et al 
(n=351 [106]) 
48 17 5 0 16 2 0 0 
Yoshioka et al 
(n=112 [66]) 
52 17 5 0 52 17 5 0 
Prostate SABR (selected studies with larger patient numbers and sufficient detail) 
Bolzicco et al 
(n=100 [59]) 
34 12 0 0 27 18 0 0 
Katz et al (35Gy 
patients; n=50 [75]) 
72 4 0 0 76 4 0 0 
Katz et al (36.25Gy 
patients; n=254 [75]) 
75 5 0 0 74 4 0 0 
Boike et al (all dose 
groups combined; 
n=45 [83]) 
29 22 0 0 33 11 0 0 
Loblaw et al 
(n=84 [82]) 
71 19 1 0 67 10 0 0 
*acute toxicities read from graph, † rate of most frequent acute toxicity 
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1.9.14 Late toxicity 
 
With regard to late toxicity (which is usually reported as developing or persisting 
beyond three or six months of SABR completion), grade 3 toxicities are uncommon and 
grade 4 toxicities are rare. Late grade 3 urinary toxicity is not reported in 2 of the 12 
Cyberknife™ studies [68,70], 3 of the 5 linear accelerator studies [58,82,84] and 2 of 
the 4 SABR boost studies [87,88] where sufficient detail is available (Appendix C 
Tables C4, C5 and C6). The remaining studies which provide sufficient detail mostly 
report grade 3 late urinary toxicity in one or two cases in each, usually (where reported) 
the result of obstructive symptoms [59-61,69,72-76,78,83,86,95]. This is often 
equivalent less than 5% of cases, although in some smaller series, where only one 
patient is affected, the percentage of patients affected can appear higher [78,83]. 
Specifically, grade 3 late GU toxicity is reported in 0 to 7% of patients treated using the 
Cyberknife™ (7%=2 patients), 0 to 7% of patients treating using a linear accelerator 
(7%=1 patient) and 0 to 5% of patients receiving a SABR boost (Table 1.3 and 
Appendix C). Grade 4 late urinary toxicity has not been reported. Grade 2 late GU 
toxicity is reported in 3 to 32% of patients treated using the Cyberknife™, 0 to 13% of 
patients treated using a linear accelerator and 5 to 12% of patients receiving SABR as 
a boost (Table 1.3 and Appendix C). Low grade symptoms often included urinary 
frequency, urgency, dysuria and nocturia. 
 
As opposed to urinary toxicity as a whole, Arscott et al specifically examined urinary 
retention in a series of 269 patients with low, intermediate and high risk prostate cancer 
treated with 35-36.25Gy in 5 fractions using the Cyberknife™ [116]. After median 
follow-up of three years, the 2-year actuarial incidence of CTCAEv3 grade 2 or greater 
late (defined as occurring beyond six months of SABR) urinary retention was 
41.4% [116]. In total 4 of the 269 patients (1.5%) required catheterisation and/ or 
TURP [116].   
 
Of the studies which provide sufficient detail, late grade 3 or worse rectal toxicity is not 
reported in 11 of 13 Cyberknife™ studies [59-61,69,70,72,74-78], 3 of 5 linear 
accelerator-based studies [58,84,95] and 3 of 4 SABR boost studies [72,86,88]. Of the 
two remaining Cyberknife™ studies, late grade 3 GI toxicity is reported in one or two 
patients, equivalent to 1% or 5% of the study population respectively, largely the result 
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of rectal bleeding/proctitis [68,73]. Of the two remaining linear accelerator studies, one 
reported late grade 3 rectal toxicity necessitating colostomy formation in four patients 
(7%), all of whom received the highest prescription dose of all studies at 50Gy in 5 
fractions (BED1.5:383Gy, EQD21.5:164Gy BED3:217Gy, EQD23:130Gy) [117]. Although 
these toxicities were considered grade 3 events according to CTCAEv3 scoring, 
surgery that results in a colostomy is such a dramatic and life-changing event, that it 
could be argued that these events should be considered grade 4. In addition, two 
patients (3%) in this study (who also received 50Gy in 5 fractions) experienced late 
grade 4 rectal toxicity according to CTCAEv3 scoring [117]. One episode occurred in a 
patient who developed a grade 4 bleeding rectal ulcer but who had significant co-
morbidities which may have contributed to this episode [83]. The patient required 
surgery with colostomy formation and treatment with hyperbaric oxygen. The second 
episode of late grade 4 rectal toxicity occurred in a patient who developed rectal 
bleeding from a Dieulafoy lesion situated on the posterior rectal wall which was not 
contained within the high dose region and may, therefore, not be attributable to the 
radiotherapy [117]. The bleeding was treated with argon plasma laser cauterisation and 
symptoms resolved fully within 24 hours. The other linear accelerator-based study 
which reported high grade (i.e. grade 3 or greater) late rectal toxicity reported no grade 
3 events and one grade 4 event in a patient with a history of diverticulitis who 
developed an anal fistula which required surgery [82]. Although this event was not life 
threatening, it was considered grade 4 given its severity and consequences [82]. The 
one SABR boost study to report high grade late GI toxicity reported grade 3 late rectal 
toxicity in five patients, equivalent to 10% of the study population, and no grade 4 
events [87]. Grade 2 late GI toxicity was reported in 0 to 11% of patients treated using 
the Cyberknife™, 0 to 8% of patients treated using a linear accelerator and 0 to 10% of 
patients receiving SABR as a boost (Table 1.3 and Appendix C). Low grade late rectal 
symptoms mainly included proctitis, diarrhoea and occasional bleeding. As mentioned 
above, one group found grade 1 and 2 late urinary and rectal toxicity to be less 
frequent with alternate day as opposed to consecutive daily treatments [61].  
 
Although a more comprehensive understanding of the frequency and severity of 
toxicities will only be gained once larger trials with longer follow-up are available, crude 
numerical comparisons between late toxicity rates reported for prostate SABR and 
other radiation treatments for prostate cancer are favourable when considering 
schedules other than 50Gy in 5 fractions (Table 1.5).  
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Table 1.5 Late toxicities following alternative radiotherapy techniques for 
prostate cancer 
 Late GU toxicity (%) Late GI toxicity (%) 
Grade: 1 2 3 4 1 2 3 4 
External beam radiotherapy 
RT01 trial (Dearnaley et 
al; n=422; 74Gy, 
conformal [15]) 
15 7 4 27 23 10 
MD Anderson trial 
(Kuban et al; n=151; 
78Gy;4-and 6-field [19]) 
21 11 5 0 42 28 10 0 
Dutch trial (Al-Mamgani 
et al; n=333; 78Gy, 
conformal [97]) 
NR 27 12 1 NR 29 5 1 
Zietman et al  (n=195, 
79.2Gy, conformal [13]) 
43 20 1 0 43 17 1 0 
Zelefsky et al (n=772, 
81Gy, IMRT [20]) 
23 9 5 0 19 2 1 0 
Cahlon et al (n=478; 
86.4Gy, IMRT [22]) 
16 13 2.5 0 13 3 0.4 0 
Low dose rate (LDR) brachytherapy 
Zelefsky et al 
(n=248 [103]) 
NR 41 9 0.4 NR 9 0 0.4 
Tanaka et al 
(n=155 [114]) 
54 8 1 0 12 1 0 0 
External beam radiotherapy with high dose rate (HDR) brachytherapy boost 
Hoskin et al 
(n=110 [104]) 
NR NR 26 0 NR NR 7 0 
High dose rate (HDR) brachytherapy 
Tselis et al 
(n=351 [106]) 
30* 5* 3 0 2 1 1 0 
Yoshioka et al 
(n=112 [66]) 
NR 6 1 0 NR 5 2 0 
Prostate SABR (trials with longest follow-up) 
Freeman and King 
(pooled data; n=41, 5-
year follow-up [118]) 
25 7 3 0 13 3 0 0 
Katz et al (35Gy 
patients; n=50 [75]) 
6 4 0 0 4 2 0 0 
Katz et al (36.25Gy 
patients; n=254 [75]) 
8 9 2 0 5 5 0 0 
Pham et al (n=40 [80]) 23 13 3 0 23 8 0 0 
Loblaw et al (n=84 [82]) 2 5 0 0 35 7 0 1 
MSK: Memorial Sloan Kettering, NR: not reported, *represents rate of most common GU toxicity 
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Some concern, however, was raised following a recent publication by Yu et al who 
compared toxicity at 6, 12 and 24 months post-radiation in a 1:2 matched analysis 
comparing patients treated with SABR and patients treated with conventionally 
fractionated IMRT [119]. The group used claims within the Medicare database to 
indicate toxicity and to determine costs. At 6, 12 and 24 months post-treatment, SABR 
patients experienced more GU toxicity compared to patients treated with IMRT (SABR 
vs. IMRT, toxicity at 6 months: 15.6% vs. 12.6%, odds ratio (OR):1.29 (95%CI:1.05-
1.53, p=0.009), at 12 months: 27.1% vs. 23.2%, OR:1.23, (95%CI:1.03-1.43, p=0.01) 
and at 24 months: 43.9% vs. 36.3%, OR: 1.38 (95%CI:1.12-1.63). The increase in 
claims in the SABR group was due to urinary incontinence, obstruction and urethritis. 
There was also an increase in GI toxicity in SABR patients compared to IMRT patients 
at six months (toxicity at six months SABR vs IMRT: 5.8% vs 4.1% OR:1.42 
(95%CI:1.00-1.85, p=0.02). No specific symptom subgroup within GI toxicity was more 
frequent in SABR patients compared to patients treated with IMRT [119]. The group 
acknowledged, however, that there were limitations in their findings, particularly since 
none of the toxicities could be graded and, additional, potentially confounding factors, 
such as baseline GU and GI function, prostate gland volume, stage and histology, 
radiation dose and radiation fields, could not be adjusted for [119]. Concern was also 
raised that the absolute rates of GU toxicity reported for SABR in this analysis were 
higher than what has been observed clinically [120].  Despite these limitations, this 
study has led others to conclude that SABR should not be considered a routine 
treatment for PCa until the results of ongoing randomised trials which compare SABR 
with conventionally fractionated IMRT are available [120]. 
 
A very recent paper by Kim et al is the first to try to determine predictors of severe 
rectal toxicity (grade 3 or greater) in prostate SABR patients [117]. The evaluated 
patients were the 45 patients treated in the phase I dose escalation trial reported by 
Boike et al [83], as well as an additional 46 patients who were treated within the phase 
II component of the trial and received the highest dose level, 50Gy in 5 fractions. The 
timing of acute and late toxicity were categorised differently for this analysis [117] 
compared to the phase I trial [83] such that acute toxicity was considered as that which 
occurred within 270 days of the start of SABR and late toxicity was considered as that 
which occurred or persisted beyond 270 days from the start of SABR. After median 
follow-up of 24.5 months, of the 61 patients in the highest dose arm, one patient (1.6%) 
experienced grade 3 acute rectal toxicity and one patient (1.6%) developed grade 4 
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acute rectal toxicity. In addition, three patients (4.9%) experienced grade 3 late rectal 
toxicity and two patients (3.3%) experienced grade 4 late rectal toxicity. No patients in 
the 45Gy or 47.5Gy arms experienced grade 3 or 4 rectal toxicity [117]. On multivariate 
analysis, the volume of rectum receiving more that 50Gy and the percent of rectal 
circumference receiving 39Gy were predictive of grade 3 or greater delayed rectal 
toxicity while the percent of rectal circumference receiving 24Gy was predictive of 
grade 2 or greater acute rectal toxicity. The group went on to define thresholds for each 
of these parameters and concluded that for a five fraction schedule, less than 3cm3 of 
rectum should receive 50Gy, less than 35% of the rectal circumference should receive 
39Gy and less than 50% of the rectal circumference should receive 24Gy [117]. This is 
a relatively small study and the prescription dose used was much higher than that used 
in other SABR studies, making the 50Gy and 39Gy constraints less relevant for the 
more commonly used five fraction schedules. In addition, the timing of acute and late 
toxicity is categorised differently to what would be considered routine. Further data is 
therefore required before definitive conclusions can be drawn about the dose-volume 
parameters required for safe SABR delivery. 
 
1.9.15 Quality of life outcomes 
 
Several studies have evaluated quality of life outcomes. The Expanded Prostate 
Cancer Index Composite (EPIC) questionnaire has frequently been used to assess 
urological, rectal and sexual domains and the American Urological Association (AUA)/ 
International Prostatic Symptom Score (IPSS) has often been used to assess urinary 
symptoms. It appears that urinary and bowel quality of life tends to decline in the first 
few months following treatment but frequently returns to baseline by one year, if not 
earlier [58,68,69,75,76,83,121].  
 
The Georgetown group have examined patient reported outcomes and quality of life in 
several papers [76,116,122-124]. A biphasic decline in urinary and bowel scores was 
noted: a transient decline in urinary and bowel summary scores, as well as urinary and 
bowel bother scores, was observed at one month post treatment, which recovered at 
three months [123]. This was followed by a second longer-lasting decline in scores 
between 9 and 18 months, although scores returned to baseline at 24 months [123]. 
The group went on to further characterise the second deterioration in urinary symptoms 
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as a ‘urinary symptom flare’ which was observed in 13% of patients at 6 to 18 months 
following SABR [124]. Symptoms consisted of a transient increase dysuria, frequency, 
urgency and retention. Symptoms returned to close to baseline by 24 months [124]. In 
a paper examining patient reported urinary incontinence specifically, urinary bother and 
incontinence scores worsened at one month (but the statistically significant change 
was not considered clinically relevant), then improved rapidly. A second worsening in 
bother and incontinence scores occurred over the next three years but these were of 
borderline clinical relevance only [122]. The same group specifically reported outcomes 
in terms of obstructive urinary symptoms [116]. As was observed in terms of urinary 
symptoms overall, and in terms of incontinence specifically, a worsening of obstructive 
symptoms was observed at one month, which resolved by three months [116]. Further 
late declines in obstructive symptoms were also noted which were transient [116]. Poor 
correlations were noted between doctor and patient reported outcomes [116]. The 
Georgetown group also examined fatigue scores in prostate SABR patients [125]. 
There was a statistically significant decline in fatigue scores at one month (which was 
only considered clinically relevant in African Americans) [125]. Beyond one month, 
fatigue scores returned to baseline.  
 
Studies examining sexual function and quality of life frequently report a gradual 
worsening in scores over time, which does not recover [73,75,121,123,126,127]. 
Outcomes are usually only assessed in hormone naïve patients. Of patients who were 
potent at the start of SABR, it is reported that between 62% and 82% maintain potency 
at one year [68,69,107,126,127] and further declines in potency occur beyond this time 
point [126,127]. The observed declines in erectile function are not considered to be 
solely attributable to normal ageing [123,127]. Declines in potency following prostate 
SABR are considered comparable to those reported following treatment with other 
radiation modalities [126,127]. No correlation between erectile dysfunction and penile 
bulb dose has been identified in prostate SABR studies [126,127].  
 
Quon et al examined the impact of dose on quality of life by comparing outcomes from 
two prospective trials, one delivering 35Gy in 5 fractions and one delivering 40Gy in 5 
fractions [128]. The CTV-PTV margin size was slightly larger in the higher dose trial 
(5mm) than in the lower dose trial (4mm) and in both trials the CTV was the prostate 
alone. Most quality of life scores remained high (i.e. reflecting a good quality of life) in 
both dose groups, although, at 12 months, a higher proportion of patients treated with 
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40Gy experienced clinically relevant reductions in bowel bother scores [128]. There 
was, however, no significant difference in the proportions of patients reporting 
moderate to severe bowel problems [128]. 
 
Katz et al compared quality of life outcomes in patients treated with prostate SABR and 
patients undergoing radical prostatectomy [129]. As observed above, in SABR patients, 
bowel and urinary quality of life declined in the first few months, but scores returned to 
baseline at one year [129]. Surgical patients displayed larger declines in urinary and 
sexual quality of life in the first six months after treatment while SABR patients 
experienced worse bowel quality of life over the first six months [129]. Longer term, 
declines in urinary and sexual quality of life scores remained significantly lower than 
baseline in surgical patients, but recovered to baseline levels in SABR patients [129]. 
Compared with other prostate cancer treatment modalities, in addition to radical 
prostatectomy, the quality of life outcomes that have so far been reported for prostate 
SABR patients appear comparable [130]. 
 
1.9.16 Cost effectiveness 
 
Loblaw et al estimated that a patient receiving five fraction SABR would save on 
average 1928 Canadian dollars (C$, £1050 approximately, range: C$170 to C$13,937 
(~£92 to ~£7720)) in terms of travel, accommodation and time away from work  
compared to attending for a 39 fraction schedule [82]. 
 
Two groups have performed Markov modelling to compare prostate SABR cost-
effectiveness with conventionally fractionated IMRT [131,132]. SABR was found to be 
the more cost-effective modality, although it was acknowledged that the size of the 
benefit would be influenced by efficacy, toxicity and quality of life outcomes, which, for 
prostate SABR, are not currently mature enough to draw definitive 
conclusions [131,132]. Yu et al, who assessed toxicity following SABR and IMRT 
(above) based on Medicare claims, also calculated the cost of both treatments based 
on the Medicare database. Despite the finding of increased GU toxicity in SABR 
patients, overall SABR costs (which included cancer-related, radiation-related, non-
cancer-related and complication costs), were less than overall costs for IMRT [119]. 
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1.9.17 Conclusions about SABR in prostate cancer 
 
Overall SABR in PCa is well tolerated with most acute and late toxicities being grade 1 
or 2. Acute rectal and urinary symptoms peak during and within the first few weeks of 
treatment but largely settle after a few months. Overall, toxicity rates appear broadly 
comparable with those reported for other routinely used forms of prostate radiation. 
The highest dose delivered (50Gy in 5 fractions) has, however, been associated with a 
greater number of high grade toxicities than any of the other lower dose schedules, 
urging some caution in the use of such marked ultra-hypofractionation.  In terms of 
PSA control, outcomes are promising and comparable with other modalities of prostate 
cancer treatment for low and intermediate risk patients. Clarification regarding optimal 
dose-fractionation, target volume definition, margin definition, dose-volume constraints, 
dose distribution and the addition of androgen deprivation are still required. Longer 
term follow-up from large randomised trials are required to clarify these matters. One 
such trial is the ongoing HYPO-RT-PC phase III randomised Scandinavian trial 
comparing conventional IMRT, 78Gy in 39 fractions (BED1.5:182Gy, BED3:130Gy) with 
linear accelerator delivered SABR, 42.7Gy in 7 fractions (BED1.5:216Gy, EDQ21.5:93Gy, 
BED3:130Gy, EDQ23:78Gy) in patients with intermediate risk prostate cancer [133]. 
Initially this trial aimed to demonstrate a 10% improvement in 5-year freedom from 
failure in the SABR group, but has recently changed to a non-inferiority trial. Another 
phase III trial is the recently opened non-inferiority PACE (Prostate Advances in 
Comparative Evidence) trial. Originally this trial aimed to compare outcomes in low and 
intermediate risk prostate cancer patients treated with robotic prostatectomy, 
conventionally fractionated IMRT (78Gy in 39 fractions) and SABR delivered using the 
Cyberknife™ (delivering either 36.25Gy in 5 fractions (‘homogeneous’ dose 
distribution) or 38Gy in 4 fractions (HDR-brachytherapy like dose distribution) [134]. 
More recently the protocol has been amended to also allow SABR delivery using a 
linear accelerator, delivering a dose of 36.25Gy in 5 fractions. In addition, the 38Gy in 4 
fraction Cyberknife™ schedule has been removed, and so all SABR patients receive 
36.25Gy in 5 fractions [135]. 
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1.10   The influence of overall treatment time 
 
It was previously thought that overall treatment time did not have an impact on 
outcomes following prostate radiotherapy [136]. Recently, however, a large analysis 
has demonstrated that prolonged overall treatment time has a significant negative 
effect on biochemical control in low and intermediate risk PCa patients receiving at 
least 70Gy  [137]. This analysis also confirmed dose as another significant predictor of 
biochemical outcome. The group therefore suggested that that optimisation of 
biochemical outcomes could potentially be achieved by increases in total dose and 
reductions in overall treatment time [137]. Hypofractionation, and in particular the ultra-
hypofractionation used to deliver SABR, meets both these requirements. In terms of 
acute toxicity, however, it has been suggested that shortening treatment times too 
dramatically could result in increased acute side effects, and as such reductions in 
overall treatment times to less than five weeks should be avoided [38]. In practice, 
however, reductions in treatment times to 4 or 5 fractions delivered over consecutive 
days have not been shown to have detrimental effects on acute tissue reactions (see 
above). 
 
1.11   Image guided radiotherapy (IGRT) and associated 
interventions for SABR 
 
One of the challenges in treating PCa is the fact that the prostate and SV do not remain 
in the same position and can change shape (deformation) [138-144]. The prostate and 
SV may move or deform between treatments (inter-fraction motion/ deformation) and 
during treatment (intra-fraction motion/ deformation). Movement may be translational 
(i.e. superior-inferior, anterior-posterior, left-right) or rotational, and both position and 
deformation are influenced by rectal and, to a lesser extent, bladder filling [145,146]. 
The degree of intra-fraction and inter-fraction motion is variable from one individual to 
another. Furthermore, changes in rectal and bladder position can result in variable and, 
at times, excessive doses being delivered to these structures [147-149]. It is preferable, 
therefore, to plan and deliver treatment with an empty rectum, in order to minimise the 
dose delivered here, and with a constant level of bladder filling [145,148,149].  Not only 
has rectal volume been shown to influence the dose received by the rectum, clinical 
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practice has shown that a distended rectum, resulting in a change in prostate position 
or shape, and thus increasing geographical miss, is associated with increased 
biochemical failure [150-152]. 
 
As interest grows in the use of higher dose per fraction treatments, as adopted in 
SABR, it becomes increasingly important to be certain that the desired treatment is 
being delivered to the target volume and not to the surrounding normal tissues. 
Improved image guidance techniques allow reduced PTV margins, thus increased 
normal tissue sparing and, in turn, the potential for further dose escalation. There is no 
gold standard technique to ensure optimal IGRT for the prostate. A variety of 
techniques exists, all of which have strengths and weaknesses. Methods of the more 
commonly used image-guidance strategies are discussed briefly below, with particular 
reference to their use in SABR. 
 
1.11.1 Portal imaging matching to bony anatomy 
 
Traditionally electronic portal images have been used to match treatment fields to 
pelvic bony anatomy. It has been demonstrated, however, that there is significant inter-
fraction prostate motion and that this is independent of the bony anatomy and, as such, 
bony anatomy should not be considered a reliable surrogate for prostate position [153]. 
In the situation where electronic portal imaging is the only technique available, then 
large PTV margins are required to take account of uncertainties in target position. 
Portal imaging with matching to bony anatomy has not been used for image guidance 
in any of the prostate SABR studies discussed above. Portal imaging can be used, 
however, to visualise fiducial markers [82,95] (see below). 
 
1.11.2 Fiducial markers 
 
The implantation of gold fiducial markers (usually three) into the prostate using a rectal 
or transperineal approach provides radio-opaque markers which should move with the 
prostate and so provide an accurate surrogate for prostate position. These can be 
identified on kV or megavoltage (MV) portal images or cone beam images and so 
changes in prostate position can be corrected. Fiducials have been shown to allow 
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highly accurate verification of the prostate and have facilitated reductions in 
conventional CTV-PTV margins and lower rectal wall doses [154-157]. The technique, 
despite being invasive, has been shown to be feasible, safe and acceptable and 
without a negative impact on patient quality of life [158,159]. Potential clinical 
complications include pain, infection and bleeding. There is also a risk of seed 
migration although migration distances tend to be small [154,158-160]. Other concerns 
related to fiducial marker use include the production of artefact on treatment planning 
scans and the inability to fully visualise changes in the surrounding soft tissues and SV 
movement or deformation which may be independent of prostate movement (unless 
fiducial marks are aligned using CBCT to provide additional soft tissue 
information)  [139,161]. Furthermore, the use of fiducial markers for online daily set up 
does not correct for prostate intra-fraction deformation or rotation [141,162].  
 
As well as being one potential method for the correction of inter-fraction motion, fiducial 
markers are also used with the Cyberknife™ for intra-fraction motion monitoring and 
tracking [62]. As mentioned above, the Cyberknife™ system has two in room 
stereoscopically mounted kV x-ray cameras which are capable of real-time fiducial 
marker tracking, and so intra-fraction changes in prostate position can be automatically 
and precisely corrected [62]. Similarly the Calypso® system (Varian, USA) uses an 
electromagnetic tracking system whereby transponders are implanted into the prostate 
and detected externally. Prostate motion can therefore be tracked and movements 
accurately corrected in real time [163]. In either case, ‘live’ intra-fraction motion 
correction means that CTV-PTV margins can be further reduced. The frequency of 
fiducial marker imaging during intra-fraction monitoring must, however, be appropriate 
for the CTV-PTV margin size used [164]. 
 
All of the Cyberknife™ SABR studies have utilised fiducial markers and kV imaging for 
daily online set up as well as for intra-fraction motion tracking. Of the linear accelerator-
based studies, three have utilised fiducial markers for daily online set up [81,82,95], 
one has used the Calypso® electromagnetic beacon system to facilitate online set up 
and intra-fraction motion tracking [58]) and one has used either fiducials or Calypso® 
beacons [83]. One of the remaining studies [84] used intra-prostatic calcifications as 
markers for online daily set up as these have been shown to be adequate surrogates 
for prostate localisation [165]. The remaining two studies did not use any fiducial 
markers, but used CBCT alone [79,85] (see below). Of the five linear accelerator SABR 
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studies which used fiducials for online set up (be those simple fiducials, beacons or 
calcifications) and which provide sufficient details, two have localised fiducials using 
portal images [82,95] and three have localised fiducial markers (or intra-prostatic 
calcifications) using CBCT [58,83,84]. 
 
1.11.3 Cone Beam CT 
 
Cone beam CT (kV or MV) is one means of assessing prostate position and correcting 
for movement. CBCT allows alignment of soft tissue to soft tissue on planning and 
treatment scans, and/ or it can be used to match to fiducial markers. CBCT allows 
visualisation of the prostate as well as the bladder and rectum, and has been shown to 
allow a reduction in CTV-PTV margins and has demonstrated a reduction in acute GU 
toxicity compared to the use of electronic portal imaging with matching to bony 
anatomy [166,167]. CBCT has the advantage of being non-invasive but image quality 
can be poor making accurate soft tissue matching difficult, and considerable inter-
observer variability has been demonstrated in defining the prostate and surrounding 
soft tissue boundaries [168-170]. In addition, performing CBCT prolongs the time that 
the patient is in the treatment room and exposes the patient to further radiation. 
Comparisons of the shifts made as a result of CBCT soft tissue matching to with those 
made in response to imaging of fiducial markers have shown variable 
correlation [168,171,172]. The evidence demonstrates that when using CBCT for soft 
tissue matching (i.e. without fiducials in situ), discrepancies of greater than 5mm 
between CBCT soft tissue matching and marker guided matching are relatively 
uncommon, while alignment within 3mm is more prone to discrepancies between 
techniques. It has been suggested, therefore, that margins of 5 to 7 mm are adequate 
to account for misalignments as a result of interobserver variation in the interpretation 
of where the edges of the prostate lie in relation to the surrounding normal structures 
on CBCT images [141,168]. In most of the linear accelerator SABR studies discussed 
above, CBCT is used in conjunction with fiducial markers, and so smaller CTV-PTV 
margins are considered acceptable [58,83,84]. Only two small studies have used 
CBCT without fiducials, although the CTV-PTV margins adopted were not necessarily 
larger than those used for fiducial based IGRT [79,85]. 
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Despite appropriate PTV margins, and regardless of the image guidance technique, 
marked prostate or organ at risk deformation cannot be adequately corrected unless 
the treatment is re-planned. Adaptive radiotherapy is a relatively new addition to the 
field of radiotherapy whereby image guidance is used not only for localisation but also 
to facilitate re-planning. This approach has not yet been reported in the context of 
prostate SABR. There is also recent interest in performing simultaneous CBCT while 
rotational radiotherapy is being delivered (termed kilovoltage intra-fraction motion 
monitoring) in order to assess prostate intra-fraction motion [173]. Again, this is a very 
recent area and has not yet been used in the context of prostate SABR. 
 
1.11.4 Endorectal Balloons 
 
Endorectal balloons have been used in an effort to immobilise the rectum in one of the 
prostate SABR studies discussed above [83]. Their use in the setting of more 
conventional fractionation has been shown to reduce prostate motion and improve 
rectal sparing when delivering IMRT and conformal RT, and reduce late rectal toxicity 
following conformal RT [174-177]. In the context of prostate SABR, it has been 
demonstrated that endorectal balloons can cause prostate deformation which can 
result in reduced target coverage [178,179]. Careful positioning and diligent correction 
of positioning errors are required to ensure optimal target coverage [178,179]. 
 
1.11.5 Prostate-rectal spacers 
 
A temporary biodegradable gel or biodegradable balloon filled with biodegradable gel 
can be injected transperineally under transrectal ultrasound guidance to act as a 
spacer between the prostate and rectum. Insertion of the gel or balloon has been 
shown to be feasible and well tolerated [180,181]. These interventions have been 
shown to increase rectal-prostate distance by about 1 to 2.5cm and result in reduced 
rectal doses on plans [180,181]. Longer follow-up and larger patient numbers are 
required to establish the clinical impact of these products on long term rectal toxicity. 
One of the SABR studies used spacers in 20% of patients [84]. 
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1.12   SABR delivered using VMAT 
 
One potentially attractive option in PCa is to deliver SABR with VMAT thus drawing on 
the potential radiobiological benefits of ultra-hypofractionation, the efficiency and 
convenience of a few fraction treatment, and the high conformity, MU efficiency and 
rapid delivery speed achievable with VMAT. At the time of project set up, the delivery of 
prostate SABR using VMAT had not been widely documented, and details were only 
available as abstracts with corresponding conference posters [182,183] (discussed in 
Chapter 2). 
 
1.13   Aims…………………………………………………….                                                             
 
The aims of this thesis are: 
 
 To develop a class solution for prostate SABR delivered using VMAT 
 
 To investigate if it is feasible to dose-escalate image-defined dominant intra-
prostatic lesions in the context of whole prostate SABR, and assess the impact 
of this strategy on tumour control probability and normal tissue complication 
probability 
 
 To investigate the impact of flattening filter free beams for prostate SABR 
planning compared to planning using conventional flattened beams 
 
 To perform a systematic review of the literature regarding radiation-induced 
second malignancies following prostate radiotherapy 
 
 To compare radiation-induced second malignancy estimates for prostate SABR 
delivered using VMAT with other external beam techniques used for prostate 
cancer treatment. 
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Chapter 2 : Developing a class solution for prostate 
stereotactic ablative radiotherapy 
 
2.1 Introduction 
 
Radiation dose escalation in localised PCa has been shown to result in improved 
biochemical control [184]. Ultra-hypofractionation within the context of SABR is an 
attractive approach to dose escalation, allowing higher biologically equivalent doses to 
be delivered in a small number of high dose fractions. There is also radiobiological 
rationale for such an approach: evidence suggests that PCa has a low α/β ratio 
(~1.5Gy), making it theoretically more sensitive to large dose per fraction 
treatments [34,35,37,38]. There is also evidence that the neighbouring late responding 
rectal and bladder tissues have higher α/β ratios than PCa (~3-6Gy) [35,36,38-41]. This 
situation can be exploited by delivering larger hypofractionated doses to the prostate 
for equivalent levels of late toxicity (Chapter 1).  
 
Volumetric modulated arc therapy (VMAT) uses a linear accelerator to deliver 
radiotherapy in one or more arcs. While the beam is continuously switched on, the 
dose rate, gantry rotation speed and MLC positions are continuously altered to create 
highly conformal plans  [24-26]. In comparison to IMRT, VMAT plans display at least 
comparable conformity with more efficient MU use and faster delivery times [24-33]. 
 
Delivering prostate SABR with VMAT is an attractive option: it offers dose escalation, 
the theoretical benefits of hypofractionation, the convenience of a few fraction 
treatment, together with the high conformity, MU efficiency and rapid delivery 
achievable with VMAT. While much has been published regarding VMAT in PCa [25-
33] and regarding prostate SABR (Chapter 1), little exists in the literature regarding the 
PCa SABR planning with VMAT. 
 
This planning study assesses prostate SABR using VMAT as a key preparatory step in 
facilitating future clinical studies. The impact of different arc arrangements is assessed 
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and CTV-PTV margins consistent with daily online fiducial based image guidance and 
CBCT are compared. The impact of the inclusion of the proximal seminal vesicles 
(proxSV) within the CTV is also evaluated.  
 
2.2 Materials and Methods  
 
2.2.1 Patients and volumes 
 
Datasets from 15 early PCa patients were chosen. Patients were asked to have 
comfortably full bladders and received enemas prior to scanning to ensure empty 
rectums. The bladder, rectum (anus to recto-sigmoid junction), femoral heads (FH), 
penile bulb (PB) and bowel were contoured as organs at risk. The CTV was the whole 
prostate gland. Patients were CT-scanned in the supine position using 2mm slices. 
 
Part I: Seven datasets were used. The CTV was expanded isotropically by 6mm to 
create the PTV. Each dataset was planned using four different arrangements of one 
and two arcs:  
 one full 360° arc (1FA) 
 one partial 210° arc (255°→105°; 1PA)  
 two full 360° arcs (2FA) 
 two partial arcs (210° (255°→105°) and 180° (270°→90°); 2PA) 
 
Seven datasets were chosen as this was the minimum number of cases required to 
achieve statistical significance at the level selected (see below) [185]. Within the local 
department three to five datasets are usually considered adequate for the initial phases 
of class solution development. 
 
Part II: Fifteen datasets were planned using 1PA and 6mm CTV-PTV margins, 
reflecting margins used with fiducial marker based daily online IGRT [186-188]. All 15 
datasets were re-planned using 8mm CTV-PTV margins, reflecting margins compatible 
with daily CBCT (without fiducials) [141]. 
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Part III:  the fifteen datasets were re-planned including the prostate and proximal 1cm 
of SV within the CTV, expanded by 6mm to PTV. 
 
 
2.2.2 Selection of SABR dose 
 
The PTV prescription dose was 42.7Gy in 7 fractions, intended for delivery on alternate 
weekdays over three weeks. The BED and EQD2 received by the prostate and late and 
early responding tissues can be calculated as described in Chapter 1. The α/β for the 
prostate was considered as 1.5Gy. For late and early responding tissues, α/β was 
considered as 3Gy and 10Gy respectively [35]. This assumes no ongoing tumour cell 
repopulation or repopulation delay time which is acceptable in this setting [42,43]. 
Thus, as shown in Table 2.1, compared to conventionally fractionated radiotherapy 
delivering a dose of 78Gy in 39 fractions (standard European prostate fractionation), a 
higher BED is delivered to the prostate but a similar BED is delivered to the late 
responding tissues which will theoretically result in equivalent late effects. In addition, 
the SABR regimen also delivers a lower dose to the early responding tissues. As with 
the SABR doses of 35-36.25Gy in 5 fractions discussed in Chapter 1, using a dose of 
42.7Gy in 7 fractions results in the exploitation of the lower α/β of PCa in order to 
deliver a higher BED to the prostate but a dose to the late responding tissues that is 
biologically equivalent to that received from conventional fractionation. Figure 2-1 also 
illustrates how the lower α/β of PCa can be exploited by using high doses per fraction.  
 
Assuming that the late responding tissues have a traditional α/β ratio of 3Gy adopts a 
more conservative approach than assuming a higher α/β ratio for the late responding 
tissues, as has been suggested [35,36,38-41]. For example, assuming a higher α/β 
ratio for the late responding rectal tissues at 5.4Gy [41], and delivering a dose of 
42.7Gy in 7 fractions, would result in these tissues receiving a dose that is lower than 
that delivered using conventional fractionation (BED5.4 and EQD25.4: 90.9Gy and 
66.4Gy respectively), i.e. the radiobiological advantage of the low α/β ratio of PCa 
increases with higher α/β values for the late responding rectal tissues. 
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Table 2.1 Biologically equivalent doses with conventional and SABR dose and fractionation schedules 
Treatment EBRT 
dose 
Dose per 
fraction 
BED to 
prostate 
tumour 
(α/β=1.5Gy) 
EQD2 to 
prostate 
tumour 
(α/β=1.5Gy) 
 
BED to 
early 
responding 
tissues 
(α/β=10Gy) 
EQD2 
to early 
responding 
tissues 
(α/β=10Gy) 
 
BED to 
late 
responding 
tissues 
(α/β=3Gy) 
EQD2 
to late 
responding 
tissues 
(α/β=3Gy) 
 
 
78Gy in 39 
fractions 
78Gy 2Gy 182.0Gy 78Gy 93.6Gy 78Gy 130.0Gy 78Gy 
SABR 42.7Gy 6.1Gy 216.3Gy 92.7Gy 68.7Gy 57.3Gy 129.5Gy 77.7Gy 
BED: Biologically equivalent dose, EQD2: equivalent dose in 2Gy fractions, EBRT: external beam radiotherapy,                                               
SABR: stereotactic ablative radiotherapy 
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Figure 2-1 Impact of hypofractionation in exploiting the low α/β ratio of prostate cancer 
At higher doses per fraction, the ratio of prostate cells killed to late responding rectal tissues killed is greater than at lower doses per fraction. 
The higher the α/β ratio of the late responding tissues (or the lower the α/β of the prostate), the greater the gap between cell kill and late rectal 
damage. Prostate α from  [37] and rectal α from  [189]. Surviving fraction=exp –(αd+βd2). (d=dose per fraction) 
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The SABR prescription dose used in this study is currently used in the Hypo-RT-PC 
trial, a phase III Scandinavian trial comparing 42.7Gy in 7 fractions with 78Gy in 39 
fractions (for the same biological rationale as above) delivered using IMRT or 3D-
CRT [133]. 
 
2.2.3 PTV coverage 
 
The following coverage requirements were specified and were in line with the coverage 
requirements specified in the Hypo-RT-PC trial [133]: 
 Dose received by 95% of the PTV was at least 95% of the PD (D95%≥40.6Gy) 
 minimum prostate dose: ≥40.6Gy, (Dmin≥40.6Gy (95%))   
 dose received by 99% of the PTV: ≥38.4Gy (D99%≥38.4Gy (90%)) 
 
In addition, it was specified that: 
 maximum dose: ≤120% (Dmax ≤51.2Gy) 
 conformity index (to limit high dose spill and as recommended by the ASTRO 
Emerging Technology Committee recommendations [190]; CI; defined below) 
should be less than 1.2 
 where feasible, dose received by 98% of the PTV: ≥95% of the PD 
(D98%≥95%) and dose received by 2% of the PTV: ≤107% (D2%≤107%).  
 
As SABR generally encourages dose escalation, it was acceptable if the median dose 
exceeded the prescription dose of 42.7Gy, as long as the maximum dose did not 
exceed 51.2Gy (120%). 
 
2.2.4 Defining organ at risk constraints 
 
There is no consensus regarding the appropriate dose-volume constraints which 
should be adopted when delivering prostate SABR. As shown above, the BED to the 
late responding tissues is similar with doses of 42.7Gy in 7 fractions and 78Gy in 39 
fractions, assuming a late responding tissue α/β ratio of 3Gy. Late responding tissues, 
however, are not only exposed to a dose of 42.7Gy but receive a range of doses, the 
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magnitude and proportions of which will influence the risk of late toxicity. The Hypo-RT-
PC trial protocol specifies three dose-volume constraints for the rectum for the SABR 
schedule (V38.4Gy≤15%, V32Gy≤35% and V28Gy≤45%, where VxGy is the volume of 
structure receiving at least xGy [133]).  There is, therefore, no constraint controlling the 
very high dose regions (e.g. above 40Gy). As the long term consequences of the doses 
used for prostate SABR are uncertain it seemed prudent to assess if treatment 
planning was feasible with the addition of further dose-volume constraints. The recently 
completed UK CHHiP trial delivered 74Gy in 37 fractions as standard and specified a 
range of dose-volume constraints for the rectum [191,192]. Preliminary safety results 
reported low rates of RTOG grade 2 or greater late rectal and bladder toxicity at two 
years (4.3% and 2.2% respectively) [52]. In the first instance, therefore, using the 
CHHiP trial dose-volume constraints for 74Gy in 37 fractions, biologically equivalent 
constraints were calculated for a seven fraction schedule (as used for SABR).  
 
For example, the CHHiP trial specified that the rectal V70Gy should be less than 
15% [191,192]. In a 37 fraction treatment (such that d=1.892Gy) the BED to late rectal 
tissues is 114.144Gy. For the same BED using an alternative fraction regimen 
therefore: 
 
114.144 = 






)/(
1

d
D  
 
For a seven fraction regimen therefore,  
114.144 = 






)3(
17
d
d  or: 
 
114.144 =
2
3
7
7 dd    or: 
  
0 = 144.1147
3
7 2  dd  
 
This must be solved as a linear-quadratic equation according to the formula: 
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d = 
a
acbb
2
42 
 
 
where: a = 
3
7
, b = 7 and c= -114.114 
 
Thus, d= 5.653Gy 
 
For 7 fractions, D = 7d = 7 x 5.653 = 39.57Gy 
 
Thus the biologically equivalent constraint to the CHHiP trial V70Gy<15% for a 74Gy in 
37 fraction regimen is V39.57Gy<15% for a 7 fraction treatment. In order to be 
conservative, all numbers were rounded down to one decimal place, i.e. 
V39.5Gy<15%. 
 
The same process was employed to derive biologically equivalent constraints for a 7 
fraction schedule using all the CHHiP trial 74Gy in 37 fraction rectal constraints (Table 
2.2).  
 
It is clear from Table 2.2 that the three dose-volume constraints from the Hypo-RT-PC 
trial are more stringent for intermediate doses, but no very high and low dose 
constraints are specified. The rectal constraints adopted in this study therefore 
consisted of a combination of calculated biologically equivalent constraints for the very 
high and low dose regions and the Hypo-RT-PC trial constraints for the intermediate 
and high dose regions (Table 2.3). 
 
Biologically equivalent constraints to 74Gy in 37 fractions for a 7 fraction schedule were 
also derived for the bladder, femoral heads, bowel and penile bulb using the same 
process described above and are also shown in Table 2.3.  
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Table 2.2 Comparison of rectal dose-volume constraints from i) the CHHiP trial 
for 74Gy in 37 fractions, ii) calculated biologically equivalent constraints for a 7 
fraction treatment and iii) dose-volume constraints from the Scandinavian trial 
using 42.7Gy in 7 fractions 
i ii iii 
CHHiP trial [191] Calculated biologically 
equivalent constraint for 7 
fraction treatment 
Dose-volume constraints 
used in Hypo-RT-PC 
Scandinavian trial protocol 
using 7 fraction 
treatment [133] 
V74Gy<3% V41.4Gy<3%  
V70Gy<15% V39.5Gy<15%  
  V38.4Gy≤15% 
V65Gy<30% V37.1Gy<30%  
V60Gy<50% V34.7Gy<50%  
  V32Gy≤35% 
V50Gy<60% V29.9Gy<60%  
  V28Gy≤45% 
V40Gy<70% V24.8Gy<70%  
V30Gy<80% V19.6Gy<80%  
CHHiP: Conventional versus Hypofractionated High-dose intensity-modulated 
radiotherapy for Prostate cancer 
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Table 2.3 Dose-volume constraints adopted for planning study 
* Dose-volume constraints adopted from Hypo-RT-PC phase III trial. Those constraints 
without an asterisk are biologically equivalent to those used in the CHHiP 
(Conventional versus Hypofractionated High-dose intensity-modulated radiotherapy for 
Prostate cancer) trial for 74Gy in 37 fraction treatments.                                     
**Constraints for the penile bulb were for guidance only and did not have to be 
achieved. 
 
 
2.2.5 Planning 
 
Monaco® version 3.2 (Elekta AB, Sweden) with a Monte Carlo (MC) calculation,  the 
Agility™ 5mm MLC system (Elekta AB, Sweden), a maximum of 150 control points per 
arc, 1% MC variance per plan, 6MV photons, 30 sectors and a 3mm calculation grid 
were employed. Monaco® is a treatment planning system that allows the user to 
specify both physical (i.e. dose-volume) objectives and biological objectives, where 
organs at risk may be handled as serial or parallel structures and the specified doses 
are stated as equivalent uniform doses (EUD), rather than physical doses. The concept 
of EUD is such that two different dose distributions are considered equivalent if the 
biological effects of these dose distributions are the same [193]. Thus a non-uniform 
Volume Constraints 
Rectum V41.4Gy(97%)<3%  
V38.4Gy(90%)≤15%* 
V32.0Gy(75%)≤35%* 
V28.0Gy(65%)≤45%* 
V24.8Gy(58%)<70%  
V19.6Gy(46%)<80%  
Bladder V41.4Gy(97%)<5% 
V34.7Gy(81%)<25% 
V29.9Gy(70%)<50% 
Femoral heads Dmax≤29.9Gy (70%)* 
V29.9Gy(70%)<50% 
Bowel V29.9Gy(70%)< 17cc 
Penile bulb (objective 
only)** 
V29.9Gy(70%)<50% 
V34.7Gy(81%)<10% 
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dose distribution can be represented by a single dose value (the EUD) which states the 
biological effect of the non-uniform dose distribution if it were delivered 
homogeneously.  It can be calculated according to [194]:  
 
EUD= 
n
total
i
i
n
i
V
V
D









1
 
 
where Di is the dose to dose bin i, Vi is the volume of dose bin i, Vtotal is the total volume 
of the tissue and n is a volume effect parameter. Large values of n (i.e. close to 1) 
represent a large volume effect as in parallel structures, and so EUD is approximately 
equal to the mean dose) and small values of n (i.e. approaching zero) represent a 
small volume effect as in serial structures where EUD approaches the maximum dose). 
 
As such the doses entered when creating EUD based prescriptions in Monaco® can be 
very different to the desired physical dose-volume outcomes. Although biological cost 
functions were employed in this planning study, these were purely used as levers to 
meet the desired physical constraints, as per Departmental policy. This explains why 
cost functions for parallel organs were often used alongside cost functions for serial 
organs within the same structure (see below). 
 
The class solution that was developed is shown in Figure 2-2 with explanation of the 
various prescription components in Table 2.4 below.
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Figure 2-2 Class solution for prostate SABR with explanation of prescription components in table below  
This solution could be applied to any of the four arc arrangements investigated. 
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Table 2.4 Explanation for prescription components shown in Figure 2-2 
Continued overleaf. 
Structure Cost 
function 
Explanation 
Target Target 
Penalty 
Specifies dose to be received by the target. The required dose shown in ‘Isoconstraint’ column. Dose is 
prescribed to the volume of target which should receive at least this dose (not visible here).  
Quadratic 
overdose 
To stop dose ‘over-shooting’. The preferred dose limit is shown in the ‘Reference dose’ column, and the size of 
the penalty for overdosing is shown in the ‘Isoconstraint’ column. Larger numbers indicate a lesser penalty for 
overdosing. 
Underdose 
DVH 
Aims to ensure optimal dose coverage of the structure, thus reinforcing the coverage requirements from the 
‘Target Penalty’ function. Desired dose specified (‘Reference dose’ column) with volume (‘Isoconstraint’ column) 
that should ideally receive this. This objective is frequently found to be ‘infeasible’ (‘Status’ column), but in this 
situation the optimiser still works to come as close to achieving the objective as possible. 
Organ at risk 
(rectum/ 
bladder) 
Serial 
(continued 
overleaf) 
Works to limit dose at one point of the DVH and in cases used here, the objective is acting on the high dose end 
of the DVH. Specifies maximum equivalent uniform dose that it desired that the structure receives. Dose (as 
equivalent uniform dose) specified in ‘Isoconstraint’ column. Penalty for overdosing must also be specified (not 
visible here). Reducing the isoconstraint to bring structure into tolerance effectively ‘tucks-in’ the tip of the DVH 
curve, while tightening the penalty attempts to pull the whole of the DVH curve to the left.                                           
In cases where there is overlap of an organ at risk with the PTV, and there is concern that the organ at risk may 
easily receive too high a dose, this objective can be ‘optimised over all voxels’ so that it is applied to the whole of 
the structure, including areas of overlap with the PTV. ‘Optimising over all voxels’ can create an area of conflict 
between trying reduce the dose received by an organ at risk and achieving optimal target coverage, but normal 
tissues are given priority over target coverage. The ‘optimise over all voxels’ option was employed for the rectum 
in the above prescription.  
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Table 2.4 cont. Explanation for prescription components shown in Figure 2-2. Continued overleaf. 
Structure or 
prescription 
element 
Cost 
function 
Explanation 
Organ at risk 
cont. 
(rectum/ 
bladder) 
Serial 
cont. 
It is also possible to specify that the cost function is only applied at a specified distance from the PTV, allowing a 
dose gradient to form between the target and organ at risk. In the case of the bladder, a 5mm shrink margin was 
applied to the serial objective so that it was only applied to areas of bladder more than 5mm from the PTV: 
because the bladder volumes were generally large, the objective could often be achieved while still allowing small 
portions of bladder that were within 5mm of the PTV, or were overlapping with the PTV, to receive doses around 
the prescription dose. 
Parallel Works to try to reduce doses across a range of the DVH. A dose is specified (as equivalent uniform dose) and the 
corresponding volume of tissue is specified which may receive this dose or higher (and so may be safely 
sacrificed; ‘Isoconstraint’ column). A penalty for overdose is also specified (not visible here). 
Body   (i.e. 
non-specified 
normal 
tissue) 
Quadratic 
overdoses 
Limits dose to normal tissues surrounding the target. Maximum dose specified (‘Reference dose’) and penalty 
specified (‘Isoconstraint’ column) for overdosing (small numbers indicate stricter penalties). Each objective is also 
specified with shrink margin to determine how far from the PTV the objective is applied. In general the 40.6Gy 
objective was prescribed with 0mm shrink margin and so was applied immediately beyond the PTV while the 20Gy 
was prescribed with a shrink margin of 2cm, and so was only applied at distances greater than 2cm from the PTV. 
Structure 
layering  
- Any structure above another in the prescription ‘owns’ any overlapping voxels. A cost function is only applied to 
the voxels within a structure that are ‘owned’ by that structure. For example, PTV is below CTV in the prescription 
so that PTV cost functions are only applied to PTV voxels outside CTV. The situation can be altered by selecting 
to ‘optimise over all voxels’ so that areas of overlap between structures are acted on by the objectives specified for 
both overlapping structures. Note: regardless of layering or which voxels are ‘owned’ by which structures, the DVH 
statistics reported by the planning system relate to the whole structure. 
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Table 2.4 cont. Explanation for prescription components shown in Figure 2-2 
Structure or 
prescription 
element 
Cost 
function 
Explanation 
Isoeffect 
column 
- Number displayed shows how close the plan is to the desired ‘Isoconstraint’ in the neighbouring column. 
Relative 
impact, 
Weight and 
Status 
columns 
- Displays how hard the optimiser is working to achieve the desired objective. ‘++++’ indicates the hardest work. 
Also indicated in the ‘Weight’ column, where higher numbers up to 9999 indicate difficulty in meeting the objective. 
When an objective harder than this, it is then considered ‘infeasible’ in the ‘Status’ column. In this situation the 
optimiser continues to try to get the best possible outcome, despite not being able to achieve the desired objective. 
If the objective is considered impossible, then it is considered ‘offensive’ and the optimiser will not try to meet the 
objective at all. 
Multicriterial 
(not used 
here) 
- If ‘Multicriterial’ is selected, then not only does the optimiser try to meet the specified objective, but it tries to 
achieve the best possible outcome for that structure (e.g. the lowest possible rectal dose). Although this is an 
attractive option, it increases planning time considerably and was therefore found to be infeasible. 
Manual (not 
used here) 
- This would be selected if manual optimisation, rather than computer based optimisation, was desired. This was not 
used here. 
Optimisation 
mode: 
constrained 
- Using the constrained mode, normal tissues are given priority over target coverage when the optimiser is trying to 
create the best plan. 
DVH: dose-volume histogram
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2.2.6 Plan evaluation 
 
The following were recorded: 
 CTV: median dose (D50%), D2%, D98% (Dx% represents the dose received by 
volume x) and volume receiving 100% of the PD (V100%) 
 PTV: D50%, D2%, D98% and D95%  
 Organ at risk mean doses and D2%  
 Volume of rectum and bladder receiving at least 95% (V95%), 80% (V80%), 
50% (V50%) and 20% (V20%) of the PD to reflect very high, high, intermediate 
and low doses respectively 
 CI: volume of 95% isodose/PTV volume [195]- reflects high dose spill 
 conformation number (CN): (Volume of PTV receiving 95% isodose/PTV 
volume) x (Volume of PTV receiving 95% isodose/volume of 95% 
isodose) [195]- reflects coverage and high dose spill 
 homogeneity index (HI): (D2%-D98%)/D50% [196] 
 R50 (to assess intermediate dose spill): volume of 50% isodose/PTV volume 
 maximum dose 2cm from PTV (Dmax2cm; also to assess intermediate dose 
spill) 
 MU per fraction  
 estimated delivery time (EDT) 
 
2.2.7 Verification 
 
Three 210 partial arc plans were delivered using a Synergy® linear accelerator (Elekta 
AB, Sweden) and verified using the Delta4 phantom (ScandiDos AB, Sweden). Plans 
were evaluated at the 3%/3mm level (i.e. all doses analysed with respect to lying within 
3% of the expected dose and within 3mm of the expected position) and at the 2%/2mm 
level. A gamma index of <1 has to be achieved in >95% of points for a plan to pass 
verification (Departmental standard is to verify plans at 3mm and 3%). One of these 
plans was also verified using high dose film at the 3%/3mm level. Delivery was also 
timed during verification. 
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2.2.8 Statistics 
 
The Wilcoxon signed-rank test was used to compare parameters as data was not 
presumed to be normally distributed. Median values and ranges are therefore 
presented throughout. Statistical Package for the Social Sciences (SPSS) version 19.0 
(IBM Corporation, Armonk, New York, USA) was used for calculations. Tests were two-
tailed. 
 
Multiple statistical comparisons are made but a full Bonferroni correction would be 
over-conservative as several tests are not independent. In part I of the study, the small 
sample size limits the degree of statistical significance achievable. As a pragmatic 
approach, p≤0.02 was considered statistically significant for part I of the study (this 
corresponded to all seven alternate arc plans displaying a change in the same direction 
from the corresponding 360 plans in order for statistical significance to be reached) 
and p≤0.005 was considered significant in parts II and III. 
 
2.3 Results 
 
2.3.1 Part I: arc arrangements  
 
Adequate CTV (prostate only) and PTV coverage was achieved and organ at risk 
constraints were met using all arc arrangements (Figure 2-3; Table 2.5). Plans were 
highly conformal with CI<1.2 and CN≥0.81, and doses were homogeneous (HI: 0.08-
0.12; Table 2.6; D98%≥95% and D2%≤107% in all cases). Compared to 1FA, there 
were no significant differences in CTV and PTV coverage with different arc 
arrangements, with the exception of 2FA, where there was a significant reduction in 
CTV V100% (1FA vs. 2FA: 97.9% vs. 95.2%, p=0.016; median values presented) and 
a statistically significant, but clinically insignificant, reduction in PTV D50% (43.5Gy vs. 
43.4Gy, p=0.016, Table 2.5).  
 
58 
 
Figure 2-3 Example of prostate plans from one dataset using a) one 360° arc, b) one 210° partial arc, c) two full arcs and d) 
two partial arcs (210° and 180°), all using 6mm CTV-PTV margins 
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Table 2.5 Coverage using four different arc arrangements 
Median (and range) shown. All alternative arc arrangements are compared to one full arc. Non-significant p values not shown. p≤0.02 
considered statistically significant. *: p=0.016  
 Beam arrangement 
 One full arc One partial arc Two full arcs Two partial arcs 
CTV coverage 
D50% (Gy) 44.0 (43.8-44.6) 44.3 (43.8-44.5) 43.9 (43.8-44.5) 44.1 (43.8-44.6) 
D2% (Gy) 45.9 (45.5-46.1) 45.8 (45.2-46.1) 45.7 (45.0-46.3) 45.8 (45.5-46.2) 
D98% (Gy) 42.7 (42.3-43.5) 42.7 (42.4-43.3) 42.3 (42.1-43.0) 42.6 (42.3-43.5) 
V100% (%) 97.9 (94.3-100) 98.7 (94.1-99.9) 95.2 (91.3-99.4)* 97.4 (93.4-99.9) 
PTV coverage 
D50% (Gy) 43.5 (43.4-44.0) 43.7 (43.6-43.9) 43.4 (43.3-43.9)* 43.7 (43.3-44.1) 
D2% (Gy) 45.6 (45.2-45.9) 45.5 (45.1-45.7) 45.3 (44.7-45.8) 45.6 (45.3-45.7) 
D98% (Gy) 40.8 (40.6-41.8) 40.8 (40.6-41.6) 40.8 (40.8-41.6) 40.9 (40.6-41.5) 
D95% (%) 41.6 (41.4-42.3) 41.5 (41.2-42.1) 41.5 (41.4-42.2) 41.6 (41.4-42.2) 
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Table 2.6 Conformity and plan delivery using four different arc arrangements                                                                                                                                                                                                       
Median (and range) shown. All alternative arc arrangements are compared to one full arc. Non-significant p values not shown. p≤0.02 
considered statistically significant. *: p=0.016 
 Beam arrangement 
 One full arc One partial arc Two full arcs Two partial arcs 
Conformity 
Conformity index**  1.16 (1.12-1.18) 1.14 (1.10-1.18) 1.16 (1.14-1.19) 1.15 (1.09-1.19) 
Conformation number† 0.85 (0.83-0.87) 0.85 (0.84-0.88) 0.84 (0.81-0.85) 0.85 (0.82-0.88) 
Homogeneity index‡  0.11 (0.09-0.11) 0.11 (0.09-0.12) 0.10 (0.08-0.11) 0.11 (0.09-0.12) 
Intermediate dose spill     
Maximum dose at 2cm (Gy) 25.3 (23.2-25.9) 25.7 (23.9-26.7) 25.1 (23.2-27.5) 24.9 (24.2-25.2) 
R50§ 3.7 (3.5-3.9) 3.8 (3.6-4.0) 3.9 (3.8-4.0)* 3.8 (3.7-4.1) 
Plan delivery 
Monitor units per fraction 2049 (1559-2498) 1785 (1423-1922) 2209 (1742-2445) 2010 (1747-2234) 
Estimated delivery time 
(seconds) 
173 (143-216) 152 (126-165) 206 (159-231)* 188 (158-212) 
 ** Conformity index: volume of the 95% isodose/volume of PTV, † Conformation number: (Volume of PTV receiving 95% isodose/ volume of 
PTV) x (Volume of PTV receiving 95% isodose/volume of 95% isodose), ‡ homogeneity index: (D2%-D98%)/D50%, §R50: volume of 50% 
isodose/volume of PTV 
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Compared to 1FA, partial arc arrangements resulted in significant reductions in rectal 
mean dose (1FA vs. 1PA: 15.1Gy vs. 13.2Gy, p=0.016, 1FA vs. 2PA: 15.1Gy vs. 
13.0Gy, p=0.016), V50% and V20%, Table 2.7, Figure 2-4). Compared to 1FA, there 
were no statistically significant differences in bladder doses when using alternative arc 
arrangements. Partial arc arrangements resulted in significant increases in FH mean 
doses and D2% (Table 2.7), although doses remained well within tolerance. A 
statistically significant, but clinically insignificant, increase in R50 occurred using 2FA 
(1FA vs. 2FA: 3.7 vs. 3.9, p=0.016). Compared to 1FA, 1PA resulted in reduced EDTs 
in 6 of 7 cases but this result did not reach the selected level for statistical significance 
(1FA vs. 1PA: 173s vs. 152s, p=0.047; Table 2.6). Similarly, compared to 1FA, 1PA 
resulted in reduced MU requirements in 6 of 7 cases but this also did not reach the 
selected level for statistical significance (1FA vs. 1PA: 2049MU vs. 1785MU, p=0.031; 
Table 2.6). There was a significant increase in EDT using 2FA (1FA vs. 2FA: 173s vs. 
206s, p=0.016).  
 
Given target coverage and conformity equivalence, significant reductions in rectal 
mean dose, V50% and V20%, together with the MU and EDT advantages for most 
patients, the 210° partial arc was selected for further investigation. 
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Table 2.7 Plan statistics for organs at risk using four different arc arrangements 
Median (and range) shown. All alternative arc arrangements are compared to one full arc. Non-significant p values not shown. p≤0.02 
considered statistically significant. *: p=0.016. Continued overleaf. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Beam arrangement 
 One full arc One partial arc Two full arcs Two partial arcs 
Organs at risk 
Rectal Dmean (Gy) 15.1 (13.0-18.1) 13.2 (11.3-15.4)* 16.5 (12.5-18.9) 13.0 (11.4-15.1)* 
Rectal D2% (Gy) 41.8 (41.6-42.2) 41.9 (41.7-42.2) 41.7 (41.6-42.0) 41.8 (41.7-41.9) 
Rectal V95% (%) 4.0 (3.3-4.8) 4.2 (3.8-5.1) 3.9 (3.6-5.0) 3.8 (3.4-5.2) 
Rectal V80% (%) 10.5 (8.0-11.6) 10.2 (8.0-11.7) 10.9 (8.5-11.9) 10.0 (7.6-11.4)* 
Rectal V50% (%) 26.5 (21.7-41.7) 20.0 (16.1-24.9)* 39.2 (19.7-48.2) 19.0 (15.1-23.6)* 
Rectal V20% (%) 64.1 (53.3-76.1) 56.8 (45.3-70.6)* 66.7 (54.3-76.5) 60.3 (50.0-69.6)* 
Bladder Dmean (Gy) 7.5 (4.4-8.4) 7.5 (0.3-8.1) 7.6 (4.5-8.7) 7.3 (4.6-8.5) 
Bladder D2% (Gy) 42.6 (40.9-43.4) 41.9 (1.2-43.6) 42.6 (40.3-43.4) 42.7 (40.9-43.6) 
Bladder V95% (%) 2.9 (2.1-5.2) 2.8 (1.8-5.0) 2.9 (1.9-5.1) 2.9 (2.1-4.9) 
Bladder V80% (%) 4.7 (3.4-8.0) 4.4 (3.3-7.8) 4.6 (3.3-7.9) 4.4 (3.6-7.7) 
Bladder V50% (%) 11.4 (7.1-14.3) 12.1 (7.6-13.9) 11.7 (7.2-15.1) 12.2 (7.8-15.3) 
Bladder V20% (%) 22.7 (14.0-34.5) 22.7 (14.4-33.4) 23.1(14.8-34.0) 22.1 (14.4-33.1) 
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Table 2.7 continued. Plan statistics for organs at risk using four different arc arrangements 
Median (and range) shown. All alternative arc arrangements are compared to one full arc. Non-significant p values not shown. p≤0.02 
considered statistically significant. *: p=0.016 
 Beam arrangement 
 One full arc One partial arc Two full arcs Two partial arcs 
Organs at risk 
Left femoral head Dmean 
(Gy) 
7.8 (0.7-12.3) 8.9 (0.8-13.1) 
 
6.9 (0.8-11.1) 10.0 (0.8-14.4)* 
 
Left femoral head D2% 
(Gy) 
14.7 (2.6-19.9) 15.9 (2.8-18.2) 
 
12.7 (3.0-16.9) 19.3 (2.4-20.5) 
Right femoral head 
Dmean (Gy) 
8.7 (1.4-11.3) 12.2 (2.0-15.9)* 
 
8.1 (1.5-11.5) 12.2 (1.9-15.5)* 
 
Right femoral head D2% 
(Gy) 
15.7 (7.1-18.3) 19.5 (9.9-20.6)* 
 
13.5 (7.4-15.9) 19.4 (12.3-20.3)* 
 
Bowel Dmean (Gy) 0.5 (0.3-1.2) 0.5 (0.3-1.1) 
 
0.5 (0.3-1.2) 0.5 (0.3-1.1) 
 
Bowel D2% (Gy) 1.1 (0.6-3.8) 1.2 (0.7-3.7) 1.2 (0.7-3.9) 1.2 (0.7-3.7) 
Penile bulb Dmean (Gy) 9.1 (1.3-37.3) 8.8 (1.4-38.7) 9.9 (1.3-38.8) 9.0 (1.2-37.5) 
Penile bulb D2% (Gy) 19.7 (1.7-43.5) 19.6 (1.9-43.4) 22.1 (1.7-43.6) 20.0 (1.6-42.9) 
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Figure 2-4 DVH comparisons for four beam arrangements (median values plotted) 
* Rectal V20% and V50% for one partial arc and two partial arcs significantly less than one full arc (p<0.02) 
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2.3.2 Part II: CTV-PTV margins 
  
Fifteen datasets were planned using 1PA and 6mm CTV-PTV margins. Adequate CTV 
and PTV coverage was achieved and organ at risk constraints were met, and were 
generally well within desired limits (Figure 2-5). In order to achieve adequate coverage 
and/or respect organ at risk constraints it was necessary to accept D2%>107% and/or 
D98%<95% in five cases (33%).  
 
Datasets were re-planned using 1PA and 8mm CTV-PTV margins (Figure 2-5 and 
Figure 2-6). In 12 cases (80%) it was possible to achieve CTV and PTV coverage and 
meet organ at risk constraints. In three cases it was necessary to relax the uppermost 
bladder constraint (V41.4Gy<5%) to up to 8.7% to achieve adequate coverage. Other 
bladder constraints were achieved. It was necessary to accept D2%>107% and/or 
D98%<95% in 12 cases (80%), resulting in a small reduction in homogeneity using 
8mm margins (6mm vs. 8mm HI: 0.11 vs. 0.13, p<0.001). Of the three patients where 
the uppermost bladder constraint had to be relaxed, two had median lobe hypertrophy 
protruding into the bladder and relatively small bladder volumes (208cm3 and 249cm3). 
The third patient had a very large median lobe and the largest volume prostate in the 
series (60.0cm3).  
 
Compared to plans using 6mm CTV-PTV margins, there were no significant differences 
in CTV and PTV median doses although 8mm margins resulted in a small but 
significant reductions in PTV D95% (6mm vs. 8mm: 41.4Gy vs. 40.8Gy, p<0.001, 
Figure 2-7, Table 2.8) and PTV D98% (6mm vs. 8mm: 40.6Gy vs. 40.0Gy, p=0.001, 
Table 2.8), and significant increases in rectal and bladder mean doses and V95%, 
V80%, V50% and V20% (Figure 2-5, Table 2.9). There were statistically significant, but 
clinically insignificant, increases in mean bowel dose using 8mm margins (Table 2.9; 
i.e. despite a statistically significant difference, the magnitude of difference between 
mean bowel doses was very small, and the absolute mean bowel doses for both 6mm 
and 8mm margins were also very low). There was also a significant increase in right 
mean FH dose, but this remained well within tolerance, as well as an increase in PB 
mean dose and D2% (Table 2.9). There was no significant difference in CI, which 
considers high dose spill (but not PTV coverage), nor CN, which reflects PTV coverage 
as well as high dose spill (Table 2.10). ………………………………………………………
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Figure 2-5 DVH comparisons for 6mm and 8mm CTV to PTV margins (median values plotted) 
† PTV D95% significantly less using 8mm margins compared to 6mm margins (p<0.005)                                                                              
*rectal/ bladder V20%, V50%, V80% and V95% significantly less using 6mm vs. 8mm margins (p<0.005) 
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Figure 2-6 Example of prostate plans from one dataset using a) one 210° partial 
arc with 6mm CTV-PTV margins, b) one 210° partial arc with 8mm CTV-PTV 
margins and c) one 210° partial arc including the proximal seminal vesicles 
within the CTV with 6mm CTV-PTV margins     
    
        
      
      
 
 
CTV with prox SV 
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Table 2.8 Coverage comparing PTVs: Prostate + 6mm (P+6mm), Prostate + 8mm (P+8mm) and Prostate + proximal seminal vesicles + 
6mm ((P+SV)+6mm) 
Median (and range) shown. Non-significant p values not shown. P+8mm and (P+SV)+6mm compared to P+6mm. p≤0.005 considered 
statistically significant. *: p<0.001, ¥: p=0.001 
 PTV 
 P+6mm P+8mm (P+SV)+6mm 
CTV coverage  
D50% (Gy) 44.3 (43.8-45.0) 44.2 (43.8-45.5) 44.4 (43.6-45.9) 
D2% (Gy) 45.9 (45.2-46.7) 46.2 (45.4-48.0) 46.4 (46.0-48.2)¥ 
D98% (Gy) 42.7 (41.9-43.6) 42.4 (41.7-43.5) 42.6 (42.0-43.3) 
V100% (%) 97.8 (88.5-100) 96.7 (88.8-99.9) 97.4 (85.8-99.9) 
PTV coverage  
D50% (Gy) 43.6 (43.2-44.1) 43.6 (43.3-44.8) 43.5 (43.0-44.7) 
D2% (Gy) 45.6 (45.1-46.4) 45.7 (45.1-47.7) 45.7 (44.7-48.1) 
D98% (Gy) 40.6 (39.5-41.6) 40.0 (39.4-41.3)¥ 40.2 (39.6-41.1)* 
D95% (Gy) 41.4 (40.6-42.1) 40.8 (40.6-41.9)* 40.9 (40.6-41.7)¥ 
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Table 2.9 Plan statistics for organs at risk for PTVs: Prostate + 6mm (P+6mm), Prostate + 8mm (P+8mm) and Prostate + proximal 
seminal vesicles + 6mm ((P+SV)+6mm)  
Median (and range) shown. Non-significant p values not shown. P+8mm and (P+SV)+6mm compared to P+6mm. p≤0.005 considered 
statistically significant. *: p<0.001, ¥: p=0.001, #: p=0.004, §: p=0.005. Continued overleaf. 
 PTV 
 P+6mm P+8mm (P+SV)+6mm 
Organs at risk  
Rectal Dmean (Gy) 13.2 (10.2-15.5) 15.0 (11.3-17.6)* 14.5 (11.7-18.1)* 
Rectal D2% (Gy) 41.8 (41.6-42.5) 41.7 (41.6-42.0) 41.9 (41.6-42.2) 
Rectal V95% (%) 4.3 (3.4-5.1) 5.2 (3.7-7.1)* 4.9 (3.5-6.5) 
Rectal V80% (%) 10.2 (6.7-14.0)  12.8 (7.0-19.0)* 12.7 (7.2-17.4)* 
Rectal V50% (%) 20.1 (14.5-30.5) 25.2 (16.2-32.9)* 25.8 (16.3-36.8)* 
Rectal V20% (%) 56.2 (44.4-70.6) 60.5 (48.0-71.0)* 66.1 (49.3-73.8)* 
Bladder Dmean (Gy) 7.5 (0.3-11.0) 7.9 (5.2-13.5)* 8.0 (5.0-14.2)¥ 
Bladder D2% (Gy) 42.8 (1.2-49.9) 43.4 (42.5-45.4) 43.2 (40.5-46.0) 
Bladder V95% (%) 3.5 (1.8-5.7) 5.2 (3.1-9.4)* 4.4 (2.0-7.1) 
Bladder V80% (%) 6.1 (3.3-9.3) 7.8 (4.60-13.6)* 7.3 (4.0-10.9)§ 
Bladder V50% (%) 13.4 (7.6-19.5) 14.4 (9.6-27.0)* 14.4 (9.3-22.8)¥ 
Bladder V20% (%) 22.7 (14.4-42.9) 28.1 (15.9-49.1)* 26.2 (15.0-59.6)# 
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Table 2.9 cont. Plan statistics for organs at risk for PTVs: Prostate + 6mm (P+6mm), Prostate + 8mm (P+8mm) and Prostate + 
proximal seminal vesicles + 6mm ((P+SV)+6mm) 
Median (and range) shown. Non-significant p values not shown. P+8mm and (P+SV)+6mm compared to P+6mm. p≤0.005 considered 
statistically significant. *: p<0.001, ¥: p=0.001, #: p=0.004, §: p=0.005 
 PTV 
 P+6mm P+8mm (P+SV)+6mm 
Organs at risk 
Left femoral head Dmean (Gy) 9.3 (0.8-13.1) 11.3 (0.8-14.7) 11.4 (0.7-13.6) 
Left femoral head D2% (Gy) 17.0 (2.8-19.8) 17.8 (2.6-23.0) 18.6 (2.4-21.3)* 
Right femoral head Dmean (Gy) 11.0 (2.0-15.9) 12.8 (2.3-16.7)* 13.4 (1.6-16.6) 
Right femoral head D2% (Gy) 19.9 (9.9-20.8) 20.2 (11.4-21.1) 19.9 (9.6-21.0) 
Bowel Dmean (Gy) 0.6 (0.1-2.0) 0.8 (0.3-2.2)* 0.8 (0.3-4.2)* 
Bowel D2% (Gy) 1.9 (0.7-12.5) 1.9 (0.8-10.7) 2.6 (0.7-17.2)* 
Penile bulb Dmean (Gy) 4.5 (1.4-38.6) 5.5 (1.6-41.5)* 4.3 (1.3-37.3) 
Penile bulb D2% (Gy) 8.0 (1.8-43.4) 14.5 (2.0-44.8)* 11.0 (1.6-42.5) 
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Table 2.10 Conformity and delivery data for PTVs: Prostate + 6mm (P+6mm), Prostate + 8mm (P+8mm) and Prostate + proximal 
seminal vesicles + 6mm ((P+SV)+6mm)  
Median (and range) shown. Non-significant p values not shown. P+8mm and (P+SV)+6mm compared to P+6mm. p≤0.005 considered 
statistically significant. *: p<0.001, $: p=0.002 
 PTV 
 P+6mm P+8mm (P+SV)+6mm 
Conformity 
Conformity index** 1.13 (1.00-1.18) 1.05 (1.02-1.19) 1.07 (1.00-1.17) 
Conformation number† 0.86 (0.84-0.91) 0.88 (0.82-0.90) 0.87 (0.84-0.91) 
Homogeneity index‡  0.11 (0.09-0.15) 0.13 (0.10-0.18)* 0.13 (0.10-0.19)* 
Intermediate dose spill 
Maximum dose at 2cm 
(Gy) 
25.7 (23.9-27.6) 25.8 (24.8-29.3) 26.0 (24.4-31.2) 
R50^ 3.7 (3.3-4.0) 3.5 (3.3-4.1) 3.6 (3.5-4.1) 
Plan delivery 
Monitor units per fraction 1814 (1423-1989) 1795 (1168-2201) 1910 (1653-2496)$ 
Estimated delivery time 
(seconds) 
160 (126-174) 157 (131-190) 161 (117-216) 
** Conformity index: volume of the 95% isodose/volume of PTV, † Conformation number: (Volume of PTV receiving 95% isodose/ volume of 
PTV) x (Volume of PTV receiving 95% isodose/volume of 95% isodose), ‡ homogeneity index: (D2%-D98%)/D50%, ^R50: volume of 50% 
isodose/volume of PTV
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Figure 2-7 Dose received by 95% of the PTV (D95%) using 6mm and 8mm CTV-
PTV margins    
                                                                                                                                                                  
 
 
2.3.3 Part III: inclusion of proxSV  
 
Datasets were re-planned using 1PA and 6mm CTV-PTV margins but including the 
proxSV within the CTV (Figure 2-6). In 13 cases CTV and PTV coverage was achieved 
and all organ at risk constraints were met. In two cases (13%; the same two cases with 
small bladder volumes and median lobe hypertrophy requiring relaxation of the 
uppermost bladder constraints using 8mm CTV-PTV margins) it was necessary to relax 
the uppermost bladder and rectal constraints up to 6.6% and 3.9% respectively to 
achieve coverage. Other constraints were met. It was possible to re-plan both to 
achieve coverage and meet all constraints by defining two PTVs: prostate plus 6mm, 
prescribed 42.7Gy, and prostate and proximal 1cm of SV plus 6mm, prescribed 32.4Gy 
(76%; EQD21.5=56.7Gy, a dose similar to that received by the base of the SV (proximal 
2cm) in the CHHiP trial: EQD21.5=52Gy [192]). 
                                                                                                                                                         
 
p<0.001 
73 
 
 
Adequate CTV and PTV coverage was achieved although, compared to treating the 
prostate alone, there were small but significant reductions in PTV D95% (prostate 
alone vs. prostate+SV: 41.4Gy vs. 40.9Gy, p=0.001, Figure 2-8) and PTV D98% 
(prostate alone vs. prostate+SV: 40.6Gy vs. 40.2Gy, p<0.001) and a small increase in 
CTV D2% (prostate alone vs. prostate+SV: 45.9Gy vs. 46.4Gy, p=0.001; Table 2.8). 
The bladder and rectum received significantly higher mean doses and V80%, V50% 
and V20% (Figure 2-9, Table 2.9). There were significant increases in left FH D2% and 
bowel mean dose and D2%, although these remained well within tolerance (Table 2.9). 
Compared to treating the prostate alone, plans were less homogeneous (prostate 
alone vs. prostate+SV HI: 0.11 vs. 0.13, p<0.001; in 11 cases (73%) it was necessary 
to accept D98%<95% and/or D2%>107%) and required increased MU (prostate alone 
vs. prostate+SV: 1814MU vs. 1910MU, p=0.002; Table 2.10).  
 
Figure 2-8. Dose received by 95% of the PTV (D95%) when treating prostate alone 
and treating the prostate plus proximal seminal vesicles  
 
                            
SV: Seminal vesicles 
 
p=0.001 
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Figure 2-9 DVH comparisons for CTV containing prostate alone and CTV containing prostate + proximal seminal vesicles (median 
values plotted) 
† PTV D95% significantly less with prostate + proximal seminal vesicles in CTV compared to prostate alone (p≤0.005)                                  
*rectal/ bladder V20%, V50% and V80% significantly less with prostate alone in CTV compared to prostate plus proximal seminal vesicles 
(p≤0.005), SV: seminal vesicles 
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2.3.4 Verification 
The pass rates for the three plans verified using the Delta4 phantom and delivery times 
are shown in Table 2.11. Thus all plans verified well. An example of the Delta4 output 
is shown in Figure 2-10. The one plan which was also verified using high dose film 
(Figure 2-11), also passed with 95.75% of points having a gamma index of <1 at 3% 
and 3mm. 
 
Table 2.11 Verification outcomes 
Plan Pass rate (Gamma 
index <1) at 
3%/3mm 
Pass rate (Gamma 
index <1) at 
2%/2mm 
Delivery time 
(seconds) 
1 99.8% 97.3% 203 
2 100.0% 99.6% 213 
3 99.8% 98.1% 192 
 
Figure 2-10 Delta4 verification for one of the three plans 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Criteria: 
2mm and 2% 
Criteria: 
3mm and 3% 
76 
 
Figure 2-11 High dose film verification 
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2.4 Discussion 
 
Much has been published regarding SABR in PCa (Chapter 1) and the use of VMAT in 
PCa  [25-30,33]. There is, however, very little in the literature regarding the optimal 
planning of prostate SABR using VMAT. It is important and relevant to develop linear 
accelerator-based solutions for prostate SABR as this delivery method is more widely 
available than alternatives such as Cyberknife™ (Accuray®, USA). In this current 
study, prostate SABR planned with VMAT was found to be optimal using 1PA. Using 
6mm CTV-PTV margins, compatible with daily fiducial based IGRT, was consistently 
feasible in terms of target objectives and organ at risk constraints. All arc arrangements 
investigated resulted in highly conformal plans but a single 210° partial arc was 
preferred: conformity was maintained while rectal mean dose, V50% and V20% were 
reduced, and most patients also benefitted in terms of EDT and MU requirements. FH 
doses increased but remained well within tolerance.  
 
It was possible to plan treatment using 8mm CTV-PTV margins but it was necessary to 
relax the uppermost bladder constraint in three cases (20%) with smaller bladder 
volumes and/or median lobe hyperplasia. Similarly, it was possible to treat the prostate 
and proximal SV but it was necessary to relax the uppermost bladder and rectal 
constrains in two cases (13%). When using 8mm CTV-PTV margins, or including the 
proximal SV within the target, although PTV coverage was adequate, there was a 
significant reduction in V95% and a significant increase in rectal and bladder mean 
doses and in volumes receiving very high, high, intermediate and low doses. This is 
unsurprising as the PTV overlaps with the rectum and bladder, thus CTV volume and 
CTV-PTV margin width influence the extent of overlap, limiting the extent of PTV 
coverage possible while respecting organs at risk.  
 
The optimal organ at risk constraints for prostate SABR remain unknown [96]. In this 
study constraints from the HYPO-RT-PC trial were adopted and additional constraints 
were added which were biologically equivalent to those used in the CHHiP trial which 
reported low 2-year toxicity [52,133,191,192].  
 
In the Hypo-RT-PC trial, which employs the same SABR dose, no constraint is 
specified for very high rectal doses and there are no bladder constraints [133]. Several 
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of the Cyberknife™ prostate SABR trials stipulate that rectal and bladder V100% 
should not exceed 5% and 10% respectively [61,76,90,91]. This study specified a 3% 
restriction on rectal V97% and a 5% restriction on bladder V97%. This approach, 
therefore, may be considered conservative. With a new technique, however, caution is 
appropriate. Furthermore, when uppermost constraints were met, or minimally 
exceeded, in this current study, all lower constraints were more than adequately 
achieved. This may translate into low late toxicity rates when these constraints are 
employed clinically. Caution must be exercised, however, when comparing constraints 
from different studies as the length of contoured rectum may differ, and this should be 
specified to aid meaningful comparisons. Once a consensus is reached regarding 
constraints for prostate SABR, these must be accompanied by specification of the 
length of rectum over which they apply. Absolute volume-based constraints (i.e. dose 
to 1cm3) would be an alternative strategy which would remove some of the variation 
resulting from differences in rectal contouring, although at present there is insufficient 
data on which to define such parameters. 
 
As discussed in Chapter 1, the current evidence for SABR as primary treatment for 
localised PCa is mainly in the form of small prospective studies, 15 using Cyberknife™ 
and 8 using linear accelerators [57-61,68-85]. There is variation in dose-fractionation 
schedules, organ at risk constraints, use of androgen deprivation, CTV-PTV margins, 
IGRT techniques and inclusion of SV within the CTV (often the SV are not treated, 
even in non-low risk patients). Overall, toxicity rates, quality of life outcomes and PSA 
control appear encouraging.  
 
At the time this study was performed, delivering prostate SABR using VMAT had not 
been widely reported. Two groups had reported production and delivery of SABR 
VMAT plans [182,183]. Agazaryan et al, using RapidArc® VMAT (Varian, USA) in 10 
patients, delivered 40Gy in 5 fractions and found that two full arcs resulted in improved 
homogeneity and conformity compared to one. It is currently uncertain whether 
homogenous or heterogeneous dose distributions are preferable [57]. In contrast to the 
RapidArc® study, this current study found no significant improvement in homogeneity 
or conformity using two arcs which may relate to differences in the planning algorithms 
and linear accelerator delivery associated with each technique.  
 
Miften et al delivered 50Gy in 5 fractions to six patients mainly using 1FA [182]. CI 
ranged from 1.09 to 1.21, CN from 0.75 to 0.82 and treatment times from 8 to 13 
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minutes. This current study demonstrated similar CI, slightly improved CN, and 
measured delivery times were shorter than those measured by Miften et al.  
 
Robust IGRT is required for SABR. Several SABR trials employ intra-fraction motion 
tracking and correction, allowing small CTV-PTV margins (3-5mm) [58,83,197]. For this 
study, 6mm margins were evaluated which are sufficient to account for residual set-up 
inaccuracy and uncorrected intra-fraction motion when using fiducial markers for daily 
online IGRT [186-188], particularly in the setting of relatively fast treatment 
delivery [164,198,199]. Larger CTV-PTV margins carry the risk of increased toxicity but 
with 6mm margins, planning was successful in terms of target coverage and organ at 
risk constraints. 
 
CBCT soft tissue matching (without fiducials) is an alternative IGRT technique. Given 
uncertainties and inter-observer variability, CTV-PTV margins of about 8mm are 
required [141]. When planning with 8mm margins, although PTV coverage was 
adequate, there was a small but significant reduction in D95%, and significant 
increases in rectal and bladder mean doses and in volumes receiving very high, high, 
intermediate and low doses. Furthermore, in three patients (20%) it was necessary to 
relax the uppermost bladder constraint to achieve coverage: two had small bladder 
volumes and median lobe hyperplasia and one had the largest volume prostate in the 
series and a very large median lobe (all resulting in a larger proportion of bladder within 
or close to the PTV). The clinical consequences of such bladder overdoses are 
unknown [40]. Neo-adjuvant androgen deprivation could reduce prostate and median 
lobe volume, potentially facilitating planning in these cases. Since 6mm margins were 
consistently feasible in terms of organ at risk constraints, then implanted fiducial 
markers, and the accompanying smaller CTV-PTV margins, should be used in 
preference to CBCT without fiducials.  
 
When including the proxSV in the CTV, and using 6mm CTV-PTV margins (a potential 
solution for patients with early intermediate risk disease who are at increased risk of SV 
invasion) although PTV coverage was adequate, there was a small but significant 
reduction in D95%. In addition, significant increases in rectal and bladder mean doses 
and in volumes of rectum and bladder receiving high, intermediate and low doses were 
observed when the proxSV were included in the CTV. Furthermore, in 13% of cases it 
was necessary to relax the uppermost bladder and rectal constraints. Ensuring full 
bladders and using biodegradable spacers to increase prostate to rectal distance could 
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potentially allow proxSV inclusion, without exceeding constraints [180].  The use of 
neo-adjuvant hormone deprivation could also facilitate planning. Another strategy is to 
create two PTVs (prostate and prostate plus proxSV) and prescribe a reduced dose to 
the PTV containing the prostate plus proxSV. Given that constraints could not be met 
consistently when including the proximal 1cm of SV, it is unlikely that prescribing the 
same dose to greater lengths of SV would be feasible, thus excluding higher risk 
patients from this linear accelerator-based treatment option. Treating the prostate 
alone, as in many of the existing SABR trials, appears likely to be the safest option.  
 
The HYPO-RT-PC trial which uses the same SABR dose as here, and from where 
some of the coverage requirements and constraints for this study were adopted, 
prescribes 42.7Gy as the mean dose to the PTV [133]. The trial also specifies that the 
global maximum dose should be no more than 107%. Prescribing to the mean dose is 
not common practice in radiotherapy, and so this approach was not adopted here. 
When delivering IMRT, prescribing to the median PTV dose is recommended by 
ICRU83 [196], but this report was not written in the SABR era, and the concept of 
SABR generally promotes dose escalation within the centre of the volume [56,200], in 
part facilitating the ablative nature of the treatment. Prescribing to the median PTV 
dose in the context of SABR is therefore somewhat counter-productive and this 
approach is generally not adopted. For this current study it was therefore decided not 
to prescribe to the mean or median PTV dose (which is also practically difficult in 
Monaco®) but to allow cautious dose escalation (to a maximum point dose of 120% of 
the prescription dose). The median dose received by the PTV was therefore higher 
than the prescribed dose, and so the overall strategy was more in-keeping with SABR. 
At the same time, however, this strategy was sufficiently cautious so that the urethra 
(although not identified here) would be unlikely to receive damaging doses (urethral 
constraints for 7 fraction regimen: Dmax 58.1Gy, D10%<53.3Gy, D50%<50.7Gy; with 
maximum permissible point dose of 120%, (51.2Gy), exceeding these constraints is 
unlikely- see Chapter 3 for further explanation and discussion).  When designing this 
study it was also specified that where possible the D2% should be limited to ≤107%. 
During planning it was noted that where this was not quickly and easily achieved, 
marked losses in target coverage could result from trying to lower the D2% by only a 
small amount. As the target dose was already being controlled through the 
specification of a maximum dose, the additional benefit from also specifying a desirable 
limit for the D2%, which could potentially restrict the opportunity for gentle dose 
escalation and compromise coverage, was ultimately considered questionable. For 
future planning, therefore, the desirable D2% limit of 107% was not used, and the 
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target dose was limited by the maximum point dose of 120% and organ at risk 
constraints. 
 
This approach remains conservative compared to SABR in other tumour sites where 
not only are higher doses per fraction employed, but very heterogeneous distributions 
are utilised allowing much greater dose escalation towards the centre of the PTV (e.g. 
lung cancer SABR in the UK prescribes 54Gy in 3 fractions, 55Gy in 5 fractions and, 
most conservatively, 60Gy in 8 fractions, and doses can escalate to a maximum of 
140%, or 145% as a minor deviation [201]). Indeed, the need to respect the urethra, 
and so restrict the degree of permissible heterogeneity and accompanying  dose 
escalation within the prostate, has led to the suggestion that the term SABR in the 
context of prostate ultra-hypofractionation is inappropriate [63]. While this suggestion is 
perhaps justified when a linear accelerator is used for prescribing SABR and where the 
urethra has not been defined, the comment is perhaps less justified with the 
Cyberknife™ is used: where a dose of 38Gy in 4 fractions is prescribed, the dose 
distribution is designed to reflect that achieved by HDR-brachytherapy, and doses up to 
150% and 200% of the prescribed dose have been permitted  [57,202]. Here the 
urethra is defined to avoid marked escalation in this region.  
 
This planning study has limitations: patient numbers were limited, the appropriate dose-
volume constraints are unknown and only one treatment planning system and delivery 
device were evaluated. Despite these limitations, it remains important to develop linear 
accelerator-based solutions for prostate SABR: as mentioned above, this delivery 
method is more widely available than alternatives such as Cyberknife™ and is also 
considerably faster than Cyberknife™, (where delivery times per fraction are in the 
order of 40 minutes [63]), potentially making linear accelerator-based VMAT solutions a 
more applicable and practical option for the majority. 
 
Since performing this work, two groups have compared prostate SABR plans using 
RapidArc® with Cyberknife™. Both groups used full arc RapidArc® plans.  
 
MacDougall et al compared six prostate datasets, each planned using RapidArc® and 
Cyberknife™ [63]. To ensure a level platform for comparison, the target coverage and 
organ at risk constraints were the same for both planning modalities, although, 
appropriately, smaller CTV-PTV margins were used for Cyberknife™ plans since intra-
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fraction motion tracking is possible using this system. A relatively homogenous 
prescription was used so that 99% of the PTV received 35Gy (in 5 fractions) which 
contained the prostate but no SV, and the maximum dose was limited to 39.4Gy. This 
resulted in a mean PTV dose of around 37Gy (95% of 37Gy=35.2Gy, 107% of 
37Gy=39.6Gy). The group found no dosimetric disadvantage to using RapidArc®, and 
homogeneity was more consistently achieved and conformity was consistently better 
using RapidArc®. There was also a clear time delivery benefit using RapidArc® (mean 
estimated delivery time for Cyberknife™ 39 minutes vs. 3 minutes for RapidArc®) [63].  
 
Lin et al also recently compared RapidArc® and Cyberknife™ plans for prostate SABR, 
delivering a dose of 37.5Gy in 5 fractions to the prostate and proxSV [203]. Ten 
datasets were compared using a maximum rectal dose constraint only (Group 1) and 
10 datasets were compared using dose-volume rectal constraints (without a maximum 
rectal dose constraint; Group 2). CTV-PTV margins were 5mm in all directions except 
for 3mm posteriorly. In both groups, 95% of the PTV received at least 95% of the 
prescription dose. PTV coverage was superior in the RapidArc® plans in both group 1 
and group 2, and maximum CTV and PTV doses were higher in the Cyberknife™ 
plans. In the RapidArc® plans, conformity was improved, heterogeneity was less and 
the volume of tissue receiving low dose irradiation (considered as the volume of the 5% 
isodose) was also lower. Maximum rectal doses were lower using RapidArc®, as was 
the volume of rectum receiving low doses (V10%, V20%, V30% and V40% in Group 1, 
and V10% and V20% in Group 2). Although not compared statistically, using dose-
volume constraints (Group 2) as opposed to a maximum rectal dose constraint 
(Group1) resulted in improved target coverage, increased maximum rectal doses and 
V100% and V90%, but lower volumes of rectal V10% to V80%. The group 
acknowledged that although these statistically significant differences were observed, in 
clinical terms, the RapidArc® and Cyberknife™ plans were likely to be 
indistinguishable.  There were, however, significant advantages to RapidArc® in terms 
of MU efficiency (RapidArc® plans required about one-third of the MU compared to 
Cyberknife™) and delivery times (median delivery time for Cyberknife™ was 54 
minutes per fraction and for RapidArc® was 2.5 to 3.5 minutes of beam on time per 
arc, with clinical treatment slots of 20 to 25 minutes (including time for IGRT)) [203].  
 
While the conclusions from both studies are justified, it should be acknowledged that 
the relatively homogenous prescription strategy adopted in the first of the two 
studies [63], is not how prostate SABR Cyberknife™ treatments would necessarily be 
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prescribed as these are usually prescribed to a peripheral isodose (between the 60% 
and 92% isodose [61,71,72,204]), in order to facilitate rapid dose fall-off beyond the 
PTV and dose escalation in the centre of the PTV [56,200]. In the second of these two 
RapidArc®  vs. Cyberknife™ planning studies [203], the prescription dose was 
normalised to the 80 to 90% isodose which would allow escalation to up to around 
125% of the prescription dose in the centre of the PTV. This strategy, by allowing more 
dose heterogeneity, is more similar to existing prostate SABR Cyberknife™ prescribing 
strategies and, although not in-keeping with traditional linear accelerator prescribing 
(i.e. restricting target doses to between 95% and 107%), is more in-keeping with the 
concept of SABR, whether delivered by Cyberknife™ or linear accelerator 
platforms [56,200]. The approach adopted in this current study, by allowing escalation 
up to a maximum of 120%, is similar to prescribing to the 83% isodose, again in-
keeping with the concept of SABR. 
 
2.5 Conclusions 
 
In conclusion, delivering prostate SABR using VMAT offers dose escalation, the 
theoretical benefits of hypofractionation, the convenience of a few fraction treatment, 
and the highly conformal plans, MU efficiency and rapid delivery achievable with 
VMAT. It has been demonstrated that prostate SABR planning using VMAT is 
consistently feasible when treating the prostate alone using 6mm CTV-PTV margins, 
compatible with fiducial marker daily online IGRT which is, therefore, the preferred 
method for SABR IGRT. A 210° arc treating the prostate alone was optimal, allowing 
highly conformal plans to be delivered quickly and efficiently. Clinical trials are required 
to evaluate this technique in practice.  
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Chapter 3 : Prostate stereotactic ablative radiotherapy (SABR) 
using volumetric modulated arc therapy (VMAT) to dominant 
intra-prostatic lesions (DILs) 
 
3.1 Introduction 
 
External beam radiotherapy in PCa traditionally considers the whole prostate as the 
CTV, without Gross Tumour Volume (GTV) definition. Modern imaging allows 
identification of dominant intra-prostatic lesions (DILs) [205]. These are frequently the 
source of local failure and so can be considered as GTVs [206-208]. Increased 
radiation doses in PCa result in increased biochemical control [184], but dose 
escalation to the whole prostate is limited by the tolerance of surrounding normal 
tissues. An alternative strategy could irradiate the whole prostate but simultaneously 
dose-escalate DILs [207].  
 
Delivering boosts to DILs has been the subject of a small number of planning studies 
and early phase trials where boost doses have been delivered using BT or EBRT, 
either sequentially or as simultaneous integrated boosts (SIB) [207,209-218]. In 
addition, phase III trials are in progress which compare conventionally fractionated 
dose-escalated EBRT to the whole prostate, with and without SIB to the DILs (the 
FLAME (Focal Lesion Ablative Microboost in Prostate Cancer) trial [219] and the 
HEIGHT (Hypofractionated External Beam Image-Guided Highly Targeted 
Radiotherapy) trial [220]. The existing literature concerning simultaneous EBRT DIL 
boosts uses conventional fractionation or at most moderate hypofractionation to treat 
the prostate and DILs [207,209-219].  
 
As discussed before, SABR uses ultra-hypofractionation to deliver escalated doses in a 
small number of treatments. Theoretically this is radiobiologically advantageous. 
Prostate cancer may have a low α/β ratio (~1.5Gy) and so should be sensitive to high 
doses per fraction  [34,35,37,38], while the neighbouring late responding tissues are 
thought to have higher α/β ratios (~3-6Gy) [35,36,38-41], allowing escalated doses to 
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be delivered to the prostate, for levels of late toxicity which are theoretically equivalent 
to those observed following conventional fractionation.  
 
This study investigates boosting DILs using volumetric modulated arc therapy (VMAT) 
within the context of SABR: a SABR dose was prescribed to the prostate with a 
simultaneous DIL SABR boost. The impact on tumour control probability (TCP) and 
normal tissue complication probability (NTCP) was examined.  
 
3.2 Methods 
 
3.2.1 Imaging and contouring 
 
Ten prostate datasets were selected (the first patients in an in-house pilot study 
investigating DIL boosting in the context of HDR-brachytherapy). Clinical 
characteristics are shown in Table 3.1. Patients received multi-parametric MRI and 
planning CT scans within a period of a few hours. MRI datasets were acquired on an 
Avanto (Siemens AG, Munich, Germany) 1.5-Tesla scanner, using phased-array pelvic 
coils and consisted of T2-weighted MRI, diffusion-weighted (DWI) and dynamic 
contrast-enhanced (DCE) MRI. For DWI MRI, apparent diffusion coefficient (ADC) 
maps were generated from a single-shot spin echo-echo planar imaging sequence 
with b-values 0, 150, 500smm-2. For DCE MRI, Ktrans maps were generated by fitting a 
Tofts [221] 1-compartment model to concentration-time data for 200 acquisitions with 
temporal resolution 2s, acquired using a 3D spoiled gradient echo sequence, with a 
bolus injection of 0.1mmolkg-1 Dotarem (Guerbet Group, Villepinte, France) 
administered at 3mls-1 after 10s and a patient-specific arterial input function measured 
in the iliac artery. An experienced radiologist delineated DILs on the MRI sequences 
based on low-intensity on T2W MRI, low ADC map values and high Ktrans map values, 
together with the prostate and prostatic urethra. The CTVDIL was the combined DIL 
volume from each MRI sequence (Figure 3-1), expanded by 4mm in all directions to 
create the PTVDIL.  
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Table 3.1 Clinical and imaging characteristics 
Patient Age Clinical T 
stage 
Gleason 
score 
Presenting 
PSA 
Use of neo-
adjuvant 
androgen 
deprivation 
Prostate 
volume 
(cm
3
) 
Number 
of DILs 
Volume 
of DILs 
(cm
3
) 
Distance of closest 
PTVDIL edge from 
rectum (negative if 
overlapping; cm) 
Distance of closest 
PTVDIL edge from 
bladder (negative if 
overlapping; cm) 
1 66 T2a 7 27 Yes 52.6 1 25.6 -0.2 -0.3 
2 56 T1c 7 4 Yes 24.1 2 3.6 
0.2 
0 
0.3 
0 
1.5 
3 69 T2 7 7 No 44.2 2 4.6 
1.1 
-0.6 
-0.5 
0.2 
1.6 
4 58 T2 7 3 Yes 21.7 3 1.0 
0.2 
0.2 
-0.1 
0.2 
0 
1.0 
0.2 
1.1 
5 76 T2c 9 21 Yes 12.3 1 0.5 0.6 0.2 
6 64 T2a 7 6 Yes 28.9 3 0.3 
0.2 
0.6 
0.3 
0 
-0.3 
0.6 
1.4 
2.0 
7 69 T2 7 31 Yes 14.9 2 0.3 
0.1 
0.7 
0.3 
0.9 
0.8 
8 65 T2 8 39 Yes 23.9 1 1.0 0.6 1.0 
9 68 T1c 7 11 Yes 59.7 1 0.1 0.6 2.6 
10 61 T1c 7 5 No 21.8 1 4.4 -0.4 -0.4 
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Figure 3-1 DIL defined on a) T2-weighted, b) Diffusion-weighted and c) Dynamic 
contrast-enhanced MRI, d) Combined DIL volume (CTVDIL), e) dose distribution 
without DIL boost, f) dose distribution with PTVDIL boost to 125% 
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Images were co-registered with the planning CT using automatic soft tissue matching 
(non-deformable) with manual alteration if necessary, paying particular attention to the 
prostate-rectal interface and regions containing DILs. Patients received enemas and 
were encouraged to have comfortably full bladders. The rectum, bladder and femoral 
heads were contoured as organs at risk. Due to the small size of the urethra, this 
structure was expanded ~1.5mm circumferentially to create Planning organ at Risk 
Volumeurethra (PRVurethra), with diameter 5-6mm.  For the purposes of anal NTCP 
evaluation, the anus was defined as the most caudal 3cm of the rectal structure [222]. 
 
The CTVprostate was the prostate alone which was expanded by 6mm in all directions to 
create the PTVprostate. 
 
The proximal 1cm of SV were included in a separate CTV: CTVprostate+SV, which was 
expanded 6mm to form PTVprostate+SV. 
 
3.2.2 Prescription and coverage 
 
The PTVprostate prescription was 42.7Gy in 7 fractions (intended for delivery on alternate 
weekdays over 15 days). Coverage requirements are shown in Table 3.2. Plans were 
initially produced prescribing 42.7Gy to the prostate, without DIL boosts. Plans were 
then created with simultaneous DIL boosts: the PTVDIL prescription was increased in 
5% increments, starting at 115% of the PTVprostate prescription, until organ at risk or 
conformity constraints were reached. If a boost of 115% was not achievable, the PTVDIL 
prescription was reduced in 5% increments until the plan became acceptable.  
 
Plans were then created which delivered the highest achievable PTVDIL prescription to 
DILs, 42.7Gy to the prostate, and with inclusion of the proxSV within PTVprostate+SV, 
initially prescribed 32.4Gy in 7 fractions (EQD21.5:56.7Gy), a microscopic tumoricidal 
dose, and then 36.5Gy in 7 fractions (EQD21.5:70.0Gy), a higher dose which has been 
suggested as more realistic for achieving tumour control [89]. 
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Table 3.2 Coverage requirements and organ at risk constraints 
Continued overleaf. 
Volume Requirement/ Constraint Source/ Explanation 
CTVprostate Minimum dose=40.6Gy (95%) HYPO-RT-PC Phase III trial, 42.7Gy in 7 fraction arm [133] 
PTVprostate Volume receiving 40.6Gy 
(V95%)≥95%/  Dose to 
95%(D95%)≥40.6Gy (95%) 
HYPO-RT-PC Phase III trial, 42.7Gy in 7 fraction arm [133] 
PTVprostate Dose to 99% (D99%) ≥38.4Gy 
(90%)  
HYPO-RT-PC Phase III trial, 42.7Gy in 7 fraction arm [133] 
PTVDIL Volume receiving 95% of prescribed 
dose ≥95%/  Dose to 
95%(D95%)≥95% of prescribed 
dose 
 
PTVprostate+SV minus 
PTVprostate 
Volume receiving 95% of prescribed 
dose (V95%)≥95% 
Applicable when including proximal SV within prescription 
Conformity index ≤1.2 Volume of 95% isodose/PTV volume 
To limit high dose spill  [190] 
R50 ≤5.5 Volume of 50% isodose/PTV volume 
To limit intermediate dose spill  [190] 
Maximum dose at 2cm 
from PTV 
≤29.9Gy (70%) 
 
To limit intermediate dose spill 
Minor deviation to ≤34.2Gy (80%) permitted if all other constraints met 
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Table 3.2 cont. Coverage requirements and organ at risk constraints 
Volume Requirement/ Constraint Source/ Explanation 
Rectum 
(recto-sigmoid junction 
to anus) 
V41.4Gy(97%)<3%  
 
Biologically equivalent for 7 fraction regimen to 74Gy in 37 fraction arm of Phase III CHHiP 
trial [191] 
V38.4Gy(90%)≤15%  HYPO-RT-PC Phase III trial, 42.7Gy in 7 fraction arm [133] 
V32.0Gy(75%)≤35%  HYPO-RT-PC Phase III trial, 42.7Gy in 7 fraction arm [133] 
V28.0Gy(65%)≤45%  HYPO-RT-PC Phase III trial, 42.7Gy in 7 fraction arm [133] 
V24.8Gy(58%)<70%  Biologically equivalent for 7 fraction regimen to 74Gy in 37 fraction arm of Phase III CHHiP 
trial [191] 
V19.6Gy(46%)<80% Biologically equivalent for 7 fraction regimen to 74Gy in 37 fraction arm of Phase III CHHiP 
trial [191] 
Bladder V41.4Gy(97%)<5%* 
V34.7Gy(81%)<25% 
V29.9Gy(70%)<50% 
All biologically equivalent for 7 fraction regimen to 74Gy in 37 fraction arm of Phase III CHHiP 
trial [191] 
 
Femoral heads Dmax≤29.9Gy (70%) HYPO-RT-PC Phase III trial, 42.7Gy in 7 fraction arm [133] 
V29.9Gy(70%)<50% Biologically equivalent for 7 fraction regimen to 74Gy in 37 fraction arm of Phase III CHHiP 
trial [191] 
Urethra Dmax <58.1Gy 
D10% <53.3Gy 
D50% <50.7Gy 
Biologically equivalent for 7 fraction regimen to 38Gy in 4 fraction arm of phase III PACE trial 
(based on high dose rate brachytherapy monotherapy constraints) [134] 
CHHiP: Conventional versus Hypofractionated High-dose intensity-modulated radiotherapy for Prostate cancer, PACE: Prostate Advances in Comparative 
Evidence, * V41.4Gy relaxed to <9% in two cases with median lobe hypertrophy and small bladder volumes which meant prescription of prostate dose without 
DIL boost not possible if maintaining V41.4Gy<5%. 
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The prescription doses for both the prostate and DIL PTVs were such that 95% of the 
structure received at least 95% of the prescription dose (i.e. D95%≥95%) and in the 
case of PTVs including the proxSV, ≥95% of the volume formed from PTVprostate+SV 
minus PTVprostate received ≥95% of the prescribed dose. In addition, the minimum dose 
received by the prostate was 40.6Gy (95% of the prostate PD) and the minimum dose 
received by 99% of the PTVprostate was 38.4Gy (90% of the prostate PD). To allow 
gradients for DIL boosting and to maximise PTVDIL doses, there were no limits on dose 
heterogeneity. 
 
3.2.3 Organs at risk 
 
Constraints are shown in Table 3.2 and are the same as those developed in Chapter 2. 
Urethral constraints (applied to the PRVurethra) were added, and were biologically 
equivalent for a seven fraction schedule as those used in the PACE trial for patients 
receiving Cyberknife™ (Accuray®, USA) prostate SABR in a heterogeneous dose 
distribution (38Gy in 4 fractions [134]). These constraints were originally based on 
those used for HDR brachytherapy. 
 
3.2.4 Plans 
 
Four plans were produced for each dataset: 
Plan set A: No DIL boost delivery, no SV in prescription 
Plan set B:  Boost to DILs, no SV in prescription 
Plan set C:  Boost to DILs, proxSV prescribed intermediate dose 
Plan set D: Boost to DILs, proxSV prescribed higher dose 
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3.2.5 Planning 
 
Monaco® version 3.3 (Elekta AB, Sweden) was used for planning with a MC algorithm 
and the Agility™ Multi-leaf collimator with 5mm leaves (Elekta AB, Sweden) and 6MV 
photons. VMAT was planned with one anterior 270° arc (225°→135°) for nine patients 
and for one patient, with bilateral hip prostheses, three partial arcs 
(290°→70°,180°→240°,120°→180°). A 270 arc was selected for patients without 
artificial hips in preference to the 210 arc from Chapter 2 since it was presumed that 
providing additional posterior radiation would assist with dose delivery to the SV but, by 
continuing to exclude the rectum from entry beams, the rectal dose disadvantages 
observed when using full arc beam arrangements in Chapter 2 would not occur. The 
final plan in each set was calculated using a 2mm grid. There were a maximum of 150 
control points per arc and 30 sectors were used for planning. An uncertainty of 1% per 
plan was accepted. Normal tissues were prioritised over target coverage.  
 
An example of the prescription used for boosting DILs is shown in Figure 3-2. 
Explanations for the prescription components are those in Chapter 2, Table 2.4. In 
addition, as the PRVurethra was contained within the prostate, the PRVurethra was placed 
at the top of the prescription so that it ‘owned’ its voxels. This meant that the cost 
functions applied to the PRVurethra did not have to compete with those applied to the 
prostate (or PTVDILs, if these overlapped). A maximum dose cost function was applied 
to the PRVurethra structure to prevent marked urethral overdose and this was not altered 
during planning. A serial objective was also applied and this cost function was 
‘tweaked’ during planning to either bring the PRVurethra into tolerance (by applying a 
stricter penalty for overdose) or to allow further dose escalation in DILs (by relaxing the 
penalty for overdose). In addition, target structures below the PTVDIL (=PTVboost in 
Figure 3-2) in the prescription (i.e. PTVprostate and PTVproxsv in Figure 3-2) 
employed two quadratic overdoses rather than just one. The one specifying a lower 
dose was applied with a 3mm shrink margin and so was only applied to voxels more 
than 3mm away from the higher target structure in the prescription (often with a very 
loose penalty to facilitate dose escalation), while the second quadratic overdose 
permitted a higher dose (up to that prescribed to the PTVDIL) and was applied with a 
0mm shrink margin so that it was applied to all voxels beyond the higher target 
structure in the prescription, including those next to and within 3mm of that target. This 
allowed a dose gradient to form between one dose level and the next.
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Figure 3-2 Prescription used for boosting DILs 
 
DIL: dominant intra-prostatic lesion 
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The ‘Conformality’ constraint was also used in the prescription (Figure 3-2; ‘patient’ 
structure). This was a new function in Monaco® version3.3 for use in the non-specified 
normal tissues. It aims to limit dose spread in the 5cm of normal structures surrounding 
the lowest PTV structure in the prescription and tries to replace the requirement for 
multiple quadratic overdoses with multiple shrink margins in the region around the PTV. 
A quadratic overdose cost function was still required to act on regions more than 5cm 
beyond the lowest PTV structure in the prescription. 
 
3.2.6 Modelling 
 
TCP was calculated using the LQ-Poisson Marsden model, originally described by 
Nahum and Sanchez-Nieto [223]. As described in the original paper, TCP in response 
to dose D, delivered in n fractions of dose d, and initial clonogen number N0, is 
determined according to the equation: 
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whereby the calculated TCP is averaged for a population in which radiosensitivity 
varies according to a Gaussian distribution over i values with mean,

 , and standard 
deviation, σα. Within this population, a fraction of patients, ig , have radiosensitivity 
i  , and  
i
ig 1 .  For a patient with radiosensitivity α receiving a non-uniform 
dose distribution represented by a differential dose-volume histogram (DVH) containing 
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j bins of volume vj each of which receives dose dj for n fractions, to total dose Dj, the 
final expression is combined to become: 
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where ρclon represents the initial clonogenic cell density. 
The potential for accelerated repopulation can also be included in the above calculation 
such that: 
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where γ= ln2/Td where Td is average doubling time, T is overall treatment time and Tk is 
the time at which proliferation commences after the first radiotherapy fraction.  
 
Therefore six parameters are required for TCP calculation: 
i) 

     (mean population radiosensitivity) 
ii) σα (standard deviation of population radiosensitivity) 
iii) α/β (alpha/beta ratio of tumour) 
iv) ρclon  (initial clonogen cell density) 
v) Td (average doubling time) 
vi) Tk (time at which repopulation begins after first fraction of radiotherapy) 
 
Three sets of parameters are used for TCP calculation, each representing a different 
α/β for PCa: 10Gy, 3Gy and 1.5Gy (Table 3.3). The parameters used were those that 
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Uzan and Nahum fitted to the RT01 trial data [224]. These parameters include a 
realistic clonogen number for all the α/β ratios assessed, and also take into account 
individual variation in radiation sensitivity (σα). This is in contrast to other studies which 
have demonstrated very low α/β ratios for PCa, but only in the setting of an 
unrealistically low number of clonogens or without taking into account population 
variation in radiation sensitivity [37,225,226]. Given the short overall time required for 
SABR delivery (i.e. 15 days) and the greater presumed time for repopulation to begin 
(i.e. Tk=45 days (Table 3.3)), the effect of repopulation is excluded from TCP 
calculations in this study. 
 
Table 3.3 TCP parameters 
Parameters from [224] 
 
  
(Gy-1) 
σα 
(Gy-1) 
α/β 
(Gy) 
ρclon 
(cm-3) 
 
Td (days) 
 
Tk (days) 
 
High α/β 
Non-DIL 
prostate* 
0.301 0.114 10 
 
6.2∙104 0 45 
DIL 0.301 0.114 10 
 
1.0∙107 0 45 
Low α/β 
Non-DIL 
prostate* 
0.217 0.082 3 6.2∙104 0 45 
DIL 0.217 0.082 3 1.0∙107 0 45 
Very low α/β 
Non-DIL 
prostate* 
0.155 0.058 1.5 
 
6.2∙104 0 45 
DIL 0.155 0.058 1.5 
 
1.0∙107 0 45 
TCP: tumour control probability, DIL: dominant intra-prostatic lesion 
*Non-DIL prostate is the whole prostate structure minus DIL(s) 
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Clonogen density in the DIL region was assumed as 1x107cm-3. Using a similar 
approach to Nutting et al [213], it was assumed the ratio of clonogens in DIL(s) to 
clonogens in the non-DIL prostate was 90:10. Clonogen density (ρclon) in the non-DIL 
prostate was therefore: 
 
)65.21_(_)_(
90
10
)21.1_(_____101
3
37
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clon

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TCP was calculated using differential DVHs for the CTVDIL and the non-DIL prostate 
(i.e. CTVprostate minus CTVDIL(s)). 
 
NTCP for the rectum, bladder and femoral heads were calculated according to the 
Lynam-Kutcher-Burman model [227,228] using Niemierko's concept of equivalent 
uniform dose (EUD) [194]: 
 
 
Initially each DVH bin was converted to the equivalent dose in 2Gy fractions according 
to: 
 
EDQ2=
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/
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D  
 
As a conservative approach [38], an α/β ratio of 3Gy was used for equivalent dose 
conversion. 
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EUD was then calculated: as before, this reduces a non-uniform dose distribution to a 
single dose which in a uniformly irradiated tissue would result in the same level of cell 
kill (and NTCP) as in the non-uniform dose: 
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n
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where Di is the dose to dose bin i, Vi is the volume of dose bin i, Vtotal is the total volume 
of the tissue and n is a volume effect parameter. Large values of n (i.e. close to 1) 
represent a large volume effect as in parallel structures, and so EUD is approximately 
equal to the mean dose, and small values of n (i.e. approaching zero) represent a small 
volume effect as in serial structures where EUD approaches the maximum dose.  
 
NTCP is then calculated according to: 
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and 
 
t = 
50
50
TDm
TDEUD


  
 
TD50 is the dose that will result in 50% probability of complication in a uniformly 
irradiated tissue and m is inversely proportional to the slope of the steepest point on 
the NTCP vs. dose response curve (thus larger values of m represent more shallow 
dose-complication slopes). 
 
 
Thus three parameters are required for NTCP calculation: 
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i) TD50 (the dose that will result in a 50% probability of complication in a uniformly 
irradiated tissue) 
ii) m (inversely related to slope at the steepest point of the NTCP curve) 
iii) n (volume effect parameter) 
 
NTCP parameters are shown in Table 3.4. The QUANTEC (Quantitative Effects of 
Normal Tissue Effects in the Clinic) rectal NTCP parameters used for the principal 
analysis of rectal NTCP were selected as these were derived from meta-analysis and 
thus included a large number of patients [229]. These consider the risk of grade 2+ 
rectal bleeding or toxicity. Additional parameters, albeit derived from smaller patient 
numbers, were also selected to explore additional endpoints (severe rectal bleeding 
and frequency, and anal incontinence) and to personalise NTCP calculations based on 
a previous history of abdominal surgery or not (Table 3.4). The correct NTCP 
parameters for the bladder have proven difficult to define [40] and, in the setting of 
ultra-hypofractionation and modern radiotherapy dose distributions, little guidance is 
available. The traditional Burman parameters were therefore adopted for NTCP, 
accepting that these may not provide completely reliable NTCP estimates in the setting 
in which they have been used here [230]. The traditional Burman NTCP parameters 
were also selected for calculation of femoral head NTCP [230]. VMAT results in low 
femoral head doses and so low complication rates would be expected. This is not the 
only recent study to use relatively old parameters for bladder and femoral head NTCP 
calculations [210,212]. Long term clinical SABR data is required before the 
appropriateness of these NTCP parameters in the setting of SABR and VMAT can be 
further addressed. 
 
TCP and NTCP calculations were performed using BioSuite [224] using differential 
DVHs with 0.1Gy bin width. 
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Table 3.4 NTCP parameters 
Organ End-point TD50 
(Gy) 
m n Source 
Principal rectal NTCP evaluation 
Rectum 
 
Grade 2+ late toxicity or 
rectal bleeding 
76.9 0.13 0.09 Michalski et 
al  [229] 
Supplementary anorectal NTCP evaluation 
Rectum Severe** rectal bleeding- all 
patients 
81 0.14 0.13 Peeters et 
al [222] 
Rectum Severe** rectal bleeding- 
patients without history of 
abdominal surgery 
85 0.14 0.11 Peeters et 
al [222] 
Rectum Severe** rectal bleeding- 
patients with history of 
abdominal surgery 
78 0.14 0.11 Peeters et 
al [222] 
Rectum Severe** frequency- all 
patients 
84 0.24 0.39 Peeters et 
al [222] 
Anus* Severe** anal incontinence- 
all patients 
105 0.43 1 Peeters et 
al [222] 
Anus* Severe** anal incontinence- 
patients without history of 
abdominal surgery 
157 0.45 1 Peeters et 
al [222] 
Anus* Severe** anal incontinence- 
patients with history of 
abdominal surgery 
74 0.45 1 Peeters et 
al [222] 
 
Bladder 
 
Contracture/ volume loss 80 0.11 0.5 Burman et 
al [230] 
Femoral 
heads 
Necrosis 65 0.12 0.25 Burman et 
al [230] 
NTCP: normal tissue complication probability                                                          
*Anus defined as most caudal 3cm of the rectal structure [222].                                   
**Severe symptoms considered as: i) rectal bleeding requiring transfusion or laser 
treatment, ii) faecal incontinence with the loss of mucus, blood or stools requiring the 
use of pads more than two times each week and iii) stool frequency of 6 or more 
episodes per day [222]. 
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3.2.7 TCP sensitivity analysis 
 
To assess the sensitivity of the TCP calculations to small alterations in TCP input 
parameters, a one-factor-at-a-time sensitivity analysis was performed [231]. For each 
plan, TCP for the prostate and DILs were recalculated after changing each of the 
following input parameters up and down by 10%: 

 , clonogen density, α/β and σα.  
 
The relative variation rate was calculated according to: 
Relative variation rate (%) = 
100
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where O1 is the original TCP and O2 is the modified TCP. 
 
A sensitivity index (SI) was calculated for each plan according to: 
SI= 
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where I1 is the original input factor and I2 is the modified input factor (i.e. ±10%), and O1 
and O2 are as above. SI values of 1 would indicate the same magnitude of change in 
output as the change in input (i.e. a 10% change in output in response to a 10% 
change in input). SI values closer to 0 indicate a smaller change in TCP in response to 
a 10% alteration in input parameter. Negative values represent a change in TCP in the 
opposite direction to the change in the input parameter.  
 
3.2.8 Statistics 
 
The Wilcoxon signed-rank exact test was used to compare plan parameters, TCP and 
NTCP as a normal distribution was not presumed. Median values and ranges are 
therefore presented. The following were compared:  
103 
 
 Plan set B to Plan set A (i.e. boost to DIL(s), no SV in prescription vs. no boost 
to DILs, no SV in prescription)  
 Plan set C to Plan set B (i.e. boost to DILs, proxSV prescribed intermediate 
dose vs. boost to DILs, no SV in prescription) 
 Plan set D to Plan set C (i.e. boost to DILs, proxSV prescribed higher dose vs. 
boost to DILs, proxSV prescribed intermediate dose).  
 
Linear correlations were examined using Pearson’s correlation coefficient (r). SPSSv19 
(IBM corporation, Armonk, New York, USA) was used. Tests were two-tailed. A p value 
of <0.05 was considered statistically significant. 
 
3.3 Results 
 
17 PTVDILs were defined (one, two and three DILs in five, three and two cases 
respectively). Median PTVDIL volume was 3.4cm
3 (range:1.5-51.6cm3). Median 
PTVprostate volume was 61.8cm
3 (range:38.9-128.5cm3).  
 
In two cases, when creating the non-boost plans (Plan Set A), it was not possible to 
achieve adequate coverage and also meet the uppermost bladder constraint of 
V41.4Gy<5%. In both cases this was the result of median lobe hypertrophy 
accompanied by relatively small bladder volumes (163cm3 and 173 cm3) at the time of 
planning. When the uppermost bladder constraint was relaxed to 9%, then coverage 
was achieved. In these two cases, therefore, when creating the boost plans, boost 
doses were escalated until reaching rectal, urethral or conformity constraints, and 
ensuring that the uppermost bladder constraint was limited to less than 9%. 
 
When treating the prostate alone, and prescribing the highest feasible boost to DILs 
(Plan set B), the median PTVDIL prescription was 125% of the PTVprostate prescription 
(53.4Gy in 7 fractions, EQD21.5:139.3Gy), and ranged from 110% (EQD21.5:110.3Gy) to 
140% (EQD21.5:171.6Gy). The median D50% received by a PTVDIL was 55.1Gy 
(EQD21.5:147.5Gy, range: 49.6Gy (EQD21.5:121.7Gy) to 62.6Gy (EQD21.5:186.8Gy)). 
104 
 
Unsurprisingly, delivering boosts to PTVDILs compared to not, resulted in significant 
increases in PTVDIL D50%. This was accompanied by increases in monitor units and 
estimated delivery times (Table 3.5). 
 
When including the proxSV, prescribed 32.4Gy (Plan set C) or 36.5Gy (Plan set D), it 
was possible to deliver the same PTVDIL prescription as when boosting DILs without 
proxSV inclusion. Furthermore, there was no significant difference in PTVDIL D50% 
(Table 3.5). Plans prescribing 32.4Gy to the proxSV (Plan set C), compared to plans 
delivering DIL boosts but without proxSV prescription (Plan set B), resulted in 
significant increases in CI, R50 and Dmax2cm. Similarly, prescribing 36.5Gy (Plan set 
D) to the proxSV, compared to 32.4Gy (Plan set C), resulted in increases in CI, R50 
and Dmax2cm (Table 3.5). 
 
During planning, the rectum was the most frequent dose-limiting structure. For all boost 
plans (Plan sets B, C and D) linear correlations were observed between the PTVDIL 
prescription achieved and the minimum distance of a PTVDIL from the rectum (r=0.56, 
p=0.019) and the volume of PTVDIL overlapping with the rectum (r=-0.66, p=0.004). In 
addition, PTVDIL D50% correlated with the volume of PTVDIL overlapping with the 
rectum (Plan sets B, C and D: r=-0.69, -0.58, -0.62, p=0.002, 0.016, 0.008) and, in Plan 
sets B and D, with the minimum distance of PTVDIL from the rectum (Plan set B: r=0.62, 
p=0.008, Plan set D: r=0.50, p=0.045). No significant correlations were observed 
between PTVDIL minimum distance from, or volume of overlap with, the urethra or 
bladder, and the PTVDIL prescription or D50%. There was no correlation between DIL 
volume and PTVDIL prescription or PTVDIL D50%.  
 
In the case of smaller volume prostate PTVs (e.g. PTVprostate volume <60cm
3), 
respecting conformity index (CI) constraints was an additional dose-limiting factor and 
for large volume prostate PTVs (e.g. PTVprostate volume >100cm
3), respecting the 
maximum dose 2cm from the PTVprostate (Dmax2cm) was also dose-limiting.  
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Table 3.5 Plan parameters 
 Volume treated  
p value where significant 
(Plan set B compared with Plan set 
A, Plan set C compared with Plan 
set B and Plan set D compared 
with Plan set C) 
 Plan set A: 
No boost to dominant 
intra-prostatic lesions 
(DILs), Prostate 
alone (n=10) 
Plan set B: 
Boost to DILs, 
Prostate alone 
(n=10) 
Plan set C: 
Boost to DILs, Proximal 
seminal vesicles treated 
to intermediate dose 
(n=10) 
Plan set D: 
Boost to DILs, 
Proximal seminal 
vesicles treated to high 
dose (n=10) 
 Median Range Median Range Median Range Median Range  
Highest achievable 
PTVDIL prescription (% 
of PTVprostate  
prescription) 
- - 125 110-140 125 110-140 125 110-140 Identical 
Median dose to PTVDIL 
(D50%; Gy) 
43.8 43.4-45.3 55.1* 49.6-62.6 54.9 50.1-62.5 55.3 49.5-61.8 *Plan set B > A: p<0.001 
 
Conformity index  (see 
Table 3.2 for definition) 
1.05 1.00-1.12 1.06 1.02-1.11 1.13
†
 1.09-1.17 1.16
‡
 1.12-1.20 
†
 Plan set C > Plan set B: p=0.004 
‡
 Plan set D > Plan set C p=0.004 
R50 (see Table 3.2 for 
definition) 
3.55 3.31-4.05 3.57 3.34-4.14 4.16
†
 3.97-4.73 4.32
‡
 4.06-4.94 
†
 Plan set C > Plan set B: p=0.002 
‡
 Plan set D > Plan set C: p=0.004 
Maximum dose at 2cm 
from PTV (Gy) 
26.1 23.2-31.0 27.4 25.5-32.7 29.0
†
 26.8-33.4 29.8
‡
 27.2-33.2 
†
 Plan set C > Plan set B: p=0.002 
‡
 Plan set D > Plan set C: p=0.049 
Monitor units per 
fraction  
1980 1655-
2654 
2313* 2117-
2562 
2314 1948-2618 2372 2099-2773 * Plan set B > A: p=0.027 
 
Estimated delivery time 
(seconds) 
209 173-314 253* 230-353 248 211-343 260 229-312 * Plan set B > A: p=0.01 
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TCP for DILs and the non-DIL prostate varied depending on the α/β and accompanying 
parameters employed (Table 3.6). TCP levels were lowest for α/β=10Gy (TCP non-DIL 
prostate <90%, TCP DIL ≤96%) and highest with α/β=1.5Gy (TCP non-DIL prostate 
≥94%, TCP DIL ≥89%). For all α/β ratios, boosting DILs resulted in significant 
increases in TCP in DILs and the non-DIL prostate. The higher the α/β, the greater the 
benefit of boosting DILs, with gains in median TCP of 14% (from 76.5% to 90.5%) 
when boosting for α/β=10Gy, compared to 6.7% (90.3% to 97.0%) for α/β=3Gy and 
4.4% (94.4% to 98.8%) for α/β=1.5Gy. There was no difference in TCP when including 
the proxSV within the prescription. With α/β=1.5Gy, in non-boost plans (Plan set A), 
TCP for DILs and for the remaining prostate exceeded 90% and 95% respectively in 9 
of 10 cases. The one remaining patient had an exceptionally large DIL (CTVDIL: 
25.6cm3). TCP in this case (based on α/β=1.5Gy) was 89.3% and 94.4% for the DIL 
and non-DIL prostate respectively. TCP relative variation rates and sensitivity analysis 
results are shown in Table 3.7 and Table 3.8 respectively. Small changes in TCP input 
parameters had greatest impact with α/β~10Gy and least with α/β~1.5Gy. 
 
NTCP for Grade 2+ late rectal complications (QUANTEC parameters) was consistently 
low (<3.5%) when prescribing SABR to the whole prostate, without DIL boosting (Plan 
set A; Table 3.6). There was a significant increase in rectal NTCP when delivering DIL 
boosts. Prescribing to the proxSV did not increase rectal NTCP further. Rectal NTCP 
was <15% in 35 of 40 plans. A strong linear correlation was noted between the 
maximum dose received by 0.5cm3 (Dmax0.5cc) of rectum and rectal NTCP in all boost 
plans (i.e. Plan sets B, C and D; r: 0.88, 0.97, 0.95 respectively, all p≤0.001, Figure 
3-3). Rectal NTCP did not exceed 5% and 15% in cases where rectal Dmax0.5cc did 
not exceed 44.1Gy and 47.1Gy respectively. There was no correlation between rectal 
NTCP and PTVDIL prescription or D50%, except in Plan set C, where a moderate 
correlation was observed between rectal NTCP and D50% (r=0.488, p=0.047). 
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Table 3.6 Tumour control probability (TCP) and normal tissue complication probability (NTCP) 
  
Plan set A:                   
No boost to dominant 
intra-prostatic lesions 
(DILs), Prostate alone 
                                   
Plan set B:                    
Boost to DILs, 
Prostate alone 
 
Plan set C:                  
Boost to DILs, Proximal 
seminal vesicles treated 
to intermediate dose 
                                        
Plan set D:                   
Boost to DILs, Prostate 
plus proximal seminal 
vesicles treated to high 
dose 
                                                  
p value where 
significant                       
(Plan set B vs. A, C vs. 
B and D vs, C)              
 
 
α/β 
(Gy) 
Median 
(%) 
Range     
(%) 
Median 
(%) 
Range   
(%) 
Median 
(%) 
Range       
(%) 
Median 
(%) 
Range      
(%) 
 
TCP Non-DIL 
Prostate 
(Prostate minus 
DIL(s)) 
10 80.5 76.9-83.0 87.9* 82.2-89.9 87.7 83.9-89.0 87.2 82.6-88.5 
*Plan set B > A: 
p=0.002 
3 92.0 90.4-93.1 95.5* 93.1-96.5 95.3 93.6-96.1 95.2 93.3-95.8 
*Plan set B > A: 
p=0.002 
1.5 95.5 94.4-96.2 97.7* 96.3-98.4 97.5 96.5-98.1 97.4 96.4-97.9 
*Plan set B > A: 
p=0.002 
TCP DIL(s) 
10 76.5 58.6-84.0 90.5* 79.5-96.3 90.7 80.0-96.2 90.6 79.4-96.0 
*Plan set B > A: 
p<0.001 
3 90.3 81.6-93.7 97.0* 92.7-99.2 97.0 93.0-99.2 97.1 92.4-99.1 
*Plan set B > A: 
p<0.001 
1.5 94.4 89.3-96.6 98.8* 96.2-100 98.7 96.4-100 98.8 96.0-100 
*Plan set B > A: 
p<0.001 
NTCP rectum  3 2.8 1.4-3.3 11.4* 3.8-30.8 10 0.6-47.1 9.6 3.5-31.9 
*Plan set B > A: 
p=0.002 
NTCP bladder 3 0 0 0 0 0 0 0 0  
NTCP femoral 
heads 
3 0 0 0 0 0 0 0 0  
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Table 3.7 Relative variation rates (%) following a change in TCP parameter by up or down 10% (median (and range))           
All results p<0.001 using Wilcoxon signed-rank test to compare high α/β with low α/β, and low α/β with very low α/β. 
DIL: dominant intra-prostatic lesion, TCP: tumour control probability 
   increased 
10% 
 reduced 
10% 
Clonogen 
density 
increased 
10% 
Clonogen 
density 
decreased 
10% 
α/β increased 
10% 
α/β  
decreased 
10% 
 increased 
10% 
   decreased 
10% 
α/β  high (~10Gy) 
Non-DIL 
Prostate 
6.53             
(5.01-9.88) 
-8.39               
(-11.96- -6.67) 
-0.34               
(-0.52-0) 
0.35             
(0.11-0.69) 
-1.75                 
(-2.99- -1.22) 
1.92                
(1.33-3.12) 
-2.71                  
(-2.89- -2.31) 
3.02              
(2.70- 3.25) 
DIL 
5.74         
(2.39-14.41) 
-7.67              
(-18.26- -3.85) 
-0.23               
(-0.76-0) 
0.23                
(0-0.85) 
-1.65                 
(-5.97- -0.62) 
1.76            
(0.52-6.83) 
-2.54                 
(-3.26- -1.19) 
2.73             
(1.71-3.25) 
α/β low (~3Gy) 
Non-DIL 
Prostate 
3.28           
(2.38-4.76) 
-4.55              
(-6.64- -3.63) 
-0.11               
(-0.22-0) 
0.11                
(0-0.22) 
-1.16                 
(-2.10- -0.83) 
1.22            
(0.73-1.99) 
-2.11                 
(-2.65- -1.88) 
2.11            
(1.76-2.65) 
DIL 
2.55         
(0.81-8.33) 
-4.16              
(-9.93- -2.02) 
-0.10              
(-0.25-0) 
0.10               
(0-0.37) 
-0.95                 
(-4.04- -0.20) 
 
1.16            
(0.20-4.41) 
-1.96                  
(-2.82- -1.21) 
1.77         
(0.81-3.31) 
α/β  very low (~1.5Gy) 
Non-DIL 
Prostate 
2.21            
(1.52-3.39) 
-3.244             
(-4.56- -2.74) 
-0.10               
(-0.11-0) 
0.10                
(0-0.21) 
-0.82                 
(-1.38- -0.61) 
0.82           
(0.41-1.48) 
-1.80                 
(-2.12- -1.52) 
1.65         
(1.22-2.22) 
DIL 
1.68           
(0-5.26) 
-2.98               
(-7.39- -1.30) 
0                     
(-0.22-0) 
0.05               
(0-0.22) 
-0.62                 
(-3.02- -0.10) 
0.61                
(0-2.46) 
-1.53                 
(-2.80- -1.10) 
0.61             
(0-2.46) 
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Table 3.8 Median sensitivity indices (and ranges) based on changing each TCP parameter up or down by 10%      
Numbers closer to zero indicate smaller changes in response to a 10% change in TCP input parameter. Negative numbers indicate a change in 
the opposite direction to which the TCP input parameter was changed. All results p<0.001 using Wilcoxon signed-rank test to compare high α/β 
with low α/β, and low α/β with very low α/β. DIL: dominant intra-prostatic lesion, TCP: tumour control probability 
   increased 
10% 
  reduced 
10% 
Clonogen 
density 
increased 
10% 
Clonogen 
density 
decreased 
10% 
α/β increased 
10% 
α/β  
decreased 
10% 
  increased 
10% 
  decreased 
10% 
α/β  high (~10Gy) 
Non-DIL 
Prostate 
0.66          
(0.51-0.99) 
0.83         
(0.66-1.21) 
-0.04              
(-0.05-0) 
-0.03               
(-007- -0.01) 
-0.19                        
(-0.32- -0.13) 
-0.18            
(-0.29- -0.13) 
-0.29                        
(-0.31- -0.25) 
-0.28                           
(-0.30- -0.25) 
DIL 
0.59       
(0.25-1.68) 
0.76     
(0.37-1.91) 
-0.02             
(-0.08-0) 
-0.02            
(-0.08-0) 
-0.17            
(-0.65- -0.07) 
-0.17            
(-0.63- -0.05) 
-0.27                  
(-0.35- -0.13) 
-0.26                          
(-0.30- -0.16) 
α/β low (~3Gy) 
Non-DIL 
Prostate 
0.33       
(0.25-0.49) 
0.44     
(0.35-0.65) 
-0.01             
(-0.02-0) 
-0.01            
(-0.02-0) 
-0.12            
(-0.22- -0.09) 
-0.12            
(-0.19- -0.07) 
-0.22                 
(-0.28- -0.20) 
-0.20                           
(-0.25- -0.17) 
DIL 
0.26      
(0.08-0.84) 
0.40     
(0.19-0.99) 
-0.01             
(-0.03-0) 
-0.01            
(-0.03-0) 
-0.10            
(-0.43- -0.02) 
-0.11            
(-0.41- -0.02) 
-0.21                 
(-0.30- -0.13) 
-0.17                          
(-0.31- -0.08) 
α/β  very low (~1.5Gy) 
Non-DIL 
Prostate 
0.23      
(0.16-0.35) 
0.31     
(0.26-0.44) 
-0.01             
(-0.01-0) 
-0.01            
(-0.02-0) 
-0.09             
(-0.15- -0.06) 
-0.08            
(-0.14- -0.04) 
-0.19                 
(-0.22- -0.16) 
-0.16                          
(-0.21- -0.12) 
DIL 
0.18           
(0-0.54) 
0.29      
(0.12-0.73) 
0                  
(-0.02-0) 
-0.01            
(-0.02-0) 
-0.06             
(-0.32- -0.01) 
-0.06             
(-0.23-0) 
-0.16                 
(-0.30- -0.12) 
-0.13                            
(-0.26-0) 
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Figure 3-3 Correlation between the maximum dose received by 0.5cm3 of rectum 
and rectal NTCP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NTCP: normal tissue complication probability 
 
 
Of the five ‘worst’ rectal NTCP plans, (QUANTEC parameters, i.e. NTCP>15%), three 
came from one dataset containing two DILs, the larger abutting the rectum, both 
boosted to 130%. The two other ‘worst’ plans came from one dataset containing a large 
PTVDIL (51.6cm
3) prescribed 125%, which overlapped with the rectum. All five cases 
were re-planned with the aim of delivering the same PTVDIL prescription while 
respecting the constraints in Table 3.2 and also reducing rectal Dmax0.5cc to <47.1Gy. 
In four cases the same PTVDIL prescription level was achieved albeit with lower PTVDIL 
D50%. Rectal NTCP was reduced considerably (from 30.8%, 47.1%, 31.9% and 22.6% 
to 1.7%, 3.4%, 2.5% and 8.9% respectively), accompanied by small reductions in DIL 
Plan set A 
(no correlation) 
Plan set B 
Plan set C Plan set D 
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TCP (Table 3.9). In one case it was not possible to maintain coverage, respect 
constraints and lower rectal dose, and so PTVDIL prescription was lowered by 5% to 
120%, which resulted in reduced rectal NTCP (31% to 5.6%). Thus rectal NTCP 
became <15% in all cases. 
 
Results of anorectal NTCP calculations using alternative parameters are shown in 
Table 3.10. Median values were encouragingly low. Rates of severe rectal bleeding 
and frequency, and anal incontinence were relatively low when considering PCa 
patients as a whole (maximum NTCPs of 5.9%, 0.7% and 3.5% for bleeding, frequency 
and incontinence respectively) and patients with no history of abdominal surgery 
(maximum NTCP 9.1% and 2.9% for rectal bleeding and anal incontinence 
respectively). When considering patients with a history of abdominal surgery, the risk of 
severe anal incontinence remained relatively low (maximum 6.4%) while the risk of 
severe rectal bleeding was greater than 10% in four plans, all of which had 
unacceptable NTCP levels according to the QUANTEC parameters. The re-plans 
described above resulted in reductions in the risk of severe rectal bleeding in the 
setting of previous abdominal surgery in all cases (from 11.8% to 0.5%, 20.9% to 1.2%, 
13.5% to 0.9% and 13.8% to 2.5%). The maximum NTCP levels for severe rectal 
bleeding for all patients (5.9%), and patients with no history of abdominal surgery 
(9.1%), mentioned above, also occurred in those plans which were unacceptable 
according to the QUANTEC parameters, Again, the re-plans resulted in reductions in 
NTCP in these settings (5.9% to 0.2% and 9.1% to 0.4%). 
 
The risk of severe rectal bleeding was significantly less using ‘no boost’ plans 
compared to boost plans for all patients and those with and without a history of 
abdominal surgery. The other statistically significant differences were clinically 
irrelevant (Table 3.10).                                                 .
112 
 
     Table 3.9 Impact of re-planning five ‘worst’ rectal NTCP plans 
   DIL: dominant intra-prostatic lesion, NTCP: normal tissue complication probability, PD: prescription dose 
 
 
 
Dataset Original 
boost level  
(% of PD) 
Re-planned 
boost level 
(% of PD) 
Original 
maximum 
dose received 
by 0.5cm3 
rectum (Gy) 
Re-planned 
maximum 
dose received 
by 0.5cm3 
rectum (Gy) 
Original 
rectal NTCP 
(%) 
Re-planned 
rectal NTCP 
(%) 
Original DIL 
TCP 
(%, α/β ratio 
1.5Gy and 
accompanying 
parameters) 
Re-planned 
DIL TCP 
(%, α/β ratio 
1.5Gy and 
accompanying 
parameters) 
1 130 130 50.9 42.6 30.8 1.7 98.8 
99.8 
98.1 
99.1 
1 130 130 52.6 44.4 47.1 3.4 98.9 
99.9 
98.0 
99.0 
1 130 130 50.5 42.7 31.9 2.5 98.8 
99.9 
98.1 
99.1 
2 125 125 49.5 46.5 22.6 8.9 96.3 96.2 
2 125 120 50.2 45.2 31.0 5.6 96.5 95.1 
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Table 3.10 Anorectal NTCP (%) calculated using alternative parameters (median and (range)) 
 Plan set A: 
No boost to 
DILs, Prostate 
alone 
 
Plan set B: 
Boost to DILs, 
Prostate alone 
 
Plan set C: 
Boost to DILs, 
Proximal seminal 
vesicles treated to 
intermediate dose 
Plan set D: 
Boost to DILs, 
Prostate plus 
proximal seminal 
vesicles treated 
to high dose 
p value where significant 
(Plan set B compared with Plan 
set A, Plan set C compared with 
Plan set B and Plan set D 
compared with Plan set C) 
Severe§ rectal bleeding- all 
patients 
0.4                  
(0.2-0.6) 
1.3*              
(0.7-2.8) 
1.3                              
(0.5-5.9) 
1.25                               
(0.6-4.1) 
*p=0.002: plan set B > Plan set A 
Severe§ rectal bleeding- no 
abdominal surgery 
0.5                 
(0.2-0.7) 
1.8*              
(0.7-4.7) 
1.7                             
(0.6-9.1) 
1.6                                  
(0.7-5.6) 
*p=0.002: plan set B > Plan set A 
Severe§ rectal bleeding- 
previous abdominal surgery  
1.5                
(0.8-2.0) 
5.0*              
(2.1-11.8) 
4.6                             
(1.7-20.9) 
4.4                                 
(2.0-13.8) 
*p=0.002: plan set B > Plan set A 
Severe§ rectal frequency- all 
patients 
0.3                
(0.2-0.4) 
0.4                
(0.2-0.5) 
0.4                             
(0.3-0.6) 
0.5                                 
(0.3-0.7) 
 
Severe§ anal incontinence- 
all patients 
1.9                
(1.1-3.4) 
2.1                 
(1.1-3.5) 
2.0                               
(1.1-2.8) 
2.0                                  
(1.1-3.3) 
 
Severe§ anal incontinence- 
no abdominal surgery 
1.9                
(1.4-2.9) 
2.1                 
(1.4-2.9) 
2.0†                            
(1.4-2.5) 
2.0                                  
(1.4-2.8) 
†p=0.031: plan set C < Plan set B 
 
Severe§ anal incontinence- 
previous abdominal surgery 
2.9 
(1.4-6.2) 
3.4 
(1.4-6.4) 
3.2† 
(1.4-4.9) 
3.1                                   
(1.4-5.9) 
†p=0.031: plan set C < Plan set B 
 
NTCP: normal tissue complication probability, §Severe symptoms considered as: i) rectal bleeding requiring transfusion or laser treatment, ii) 
faecal incontinence with the loss of mucus, blood or stools requiring the use of pads more than two times each week and iii) stool frequency of 
6 or more episodes per day [222]
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3.4 Discussion 
 
This study investigated boosting DILs while maintaining organ at risk constraints in the 
context of SABR. DIL dose escalation to a median of 125% of the PTVprostate 
prescription (EQD21.5: 139Gy) was feasible. This resulted in increased TCP in DILs and 
the non-DIL prostate, likely because of the dose gradients required to deliver boosts. 
DIL boosting also increased rectal NTCP and, in some cases, rectal NTCP became 
unacceptable. 
 
Simultaneous EBRT DIL boosts up to 4.1Gy and 2.7Gy per fraction have been 
delivered in planning and clinical studies respectively, to total doses up to EQD21.5 
220Gy and 114Gy [207,209-219]. The non-DIL prostate has received up to 2.8Gy and 
2.7Gy per fraction in planning and clinical settings respectively (up to EQD21.5: 93.5Gy 
and 81.4Gy) [207,209-219]. Late grade 2+ rectal and bladder toxicity rates up to 15% 
and 43% are reported clinically [207]. At the time of writing, no other publications were 
identified which examined TCP and NTCP using SABR to the whole prostate 
(EQD21.5:92.7Gy) with simultaneous SABR DIL boosts. Previous studies have 
observed the impact of DIL location on boost feasibility [210,211]. In this current study 
it was also found that PTVDIL proximity to the rectum and volume of rectal overlap 
influenced PTVDIL prescription level and PTVDIL D50%. Unlike studies using 
conventional fractionation, prescribing SABR also requires strict limits for high and 
intermediate dose spill. These also influenced the boosts that could be achieved.  
 
It was possible to prescribe the same PTVDIL prescriptions and achieve similar PTVDIL 
median doses when including the proxSV, both when prescribing 32.4Gy and 36.5Gy. 
This potentially provides a SABR option for intermediate risk PCa patients, at higher 
risk of SV invasion. Including the proxSV resulted in 'bowing out' of isodoses 
posteriorly, reflected by increases in CI and R50. Despite this, there was no significant 
increase in rectal NTCP. The estimation of TCP was limited to that for the prostate and 
DILs only, and did not consider TCP in terms of disease in the SV as there is little 
evidence regarding suitable parameters for calculating TCP in this region. 
 
115 
 
This study has limitations and several factors would have to be addressed before 
adopting this strategy clinically. Firstly, the optimal method for defining DILs is debated. 
Existing studies employ multi-parametric MRI, MR spectroscopy, radio-labelled Indium 
and choline-PET (positron emission tomography). Multi-parametric MRI was used in 
this study, in-keeping with  guidelines [205]. Based on histopathological correlation with 
prostatectomy specimens, T2-weighted sequences combined with DWI sequences, or 
DWI combined with DCE sequences, have sensitivities and specificities of 70 to 
87%  [232,233]. Combining all three sequences results in receiver-operator-curve area 
under the curve of 0.94 [234]. Secondly, accurate image co-registration is essential. A 
soft-tissue auto-match with manual correction as necessary was adopted here. 
Deformable registration might prove superior, as this could deal with alterations is 
prostate shape and discrepancies in prostate size between imaging modalities more 
adequately than was possible using rigid registration, but this has not been validated in 
the setting of DILs. The optimal method of registration might well include models which 
add additional DIL margins to specifically take account of registration errors, although 
techniques requiring additional margins may prove difficult to implement without 
unacceptable increases in NTCP. Uncertainties resulting from DIL definition and 
registration will reduce the actual TCP benefit achieved from DIL boosting to less than 
that calculated here. Thirdly, the addition of catheterisation at planning would facilitate 
reliable identification of the urethra. Although patients in this current study were not 
catheterised at planning, it would be essential if this strategy were to be adopted 
clinically. 
 
Fourthly, robust image-guidance together with appropriate CTV-PTV margins are 
essential. For the CTVprostate and CTVprostate+SV, 6mm CTV-PTV margins were used, 
compatible with daily online fiducial-based image-guidance (without intra-fraction 
tracking) [186-188]. There is evidence that intra-fraction motion becomes more 
problematic with increasing daily treatment time, particularly beyond 8 minutes [199]. 
The plans in this study had average estimated delivery times of 4.2 minutes (maximum 
5.9 minutes). Intra-fraction motion, therefore, may not be a major 
concern [164,198,199]. The use of flattening filter free (FFF) treatments, however, 
could further reduce delivery times. Five boost plans were re-planned using FFF, and 
estimated delivery times reduced by 116 seconds on average. While IMRT (rather than 
VMAT) could potentially achieve similar boosts, the longer delivery times would be 
more of a concern in the absence of intra-fraction tracking. If intra-fraction motion 
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tracking was available in conjunction with VMAT techniques, then smaller CTV-PTV 
margins could be feasible, which in turn might allow further DIL dose escalation, 
although whether this would indeed be the case, and the resulting impact on TCP and 
NTCP, would need separate investigation. 
 
Fifthly, the most appropriate CTV-PTV margin for use around a DIL is uncertain. A 
variety of margins have previously been adopted, ranging from 0 to 8mm [207]. The  
phase III FLAME trial, which prescribes 77Gy in 35 fractions to the prostate, with or 
without a 95Gy simultaneous DIL boost, employs 4mm DIL CTV-PTV margins [219]. In 
this current study 4mm margins were also adopted. The concept of a DIL CTV-PTV 
margin within a larger (i.e. whole prostate) PTV margin is not consistent with the 
derivation of margins using the traditional ‘van Herk’ methods, which are based on the 
CTV receiving the appropriate dose with standard penumbra of 5mm, and doses falling 
from 95% at the edge of the PTV to 20% at the edge of the penumbra [235]. In the 
case of DILs, doses were falling from a median of 125% to around 100%. Furthermore, 
the dose fall-off around the DILs was relatively shallow, such that each DIL was 
generally well encompassed within the 95% isodose relevant to that DIL, thus adding 
additional coverage security to that created by the 4mm CTV-PTV DIL margin, to help 
account for intra-fraction motion as well as uncertainties in DIL definition and 
registration.  
 
Adequately addressing the above issues, while relevant in the context of conventional 
fractionation, is even more important in the context of SABR, where the TCP and 
NTCP consequences of inaccurate dose delivery are greater. 
 
The optimal organ at risk constraints for prostate SABR are unknown [96]. The same 
constraints as the HYPO-RT-PC trial, the phase III trial which delivers the same 
PTVprostate prescription [133] were adopted here, and additional constraints were added. 
Despite this relatively conservative approach, plans which included DIL boosts were 
sometimes associated with unacceptable rectal NTCP. The ‘acceptable’ level of grade 
2+ late rectal complications has not been defined. QUANTEC suggests constraints for 
conventional 3D-CRT which should result in no more than 15% late grade 2+ rectal 
complications [229]. Most of the plans here satisfied this limit but five did not. Strong 
correlations between rectal Dmax0.5cc and rectal NTCP were demonstrated. This is 
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unsurprising as NTCP modelling considered the rectum as a serial structure, thus 
higher doses have greater impact on NTCP. Re-planning the five ‘worst’ cases, aiming 
to reduce rectal Dmax0.5cc yet still deliver the highest possible boost, resulted in 
considerable reductions in rectal NTCP, and  only once  was it necessary to reduce the 
PTVDIL prescription to achieve this.  
 
When considering alternative NTCP parameters for anorectal toxicities, and 
personalising NTCP based on a history of abdominal surgery, NTCP levels were 
generally low. Those plans where NTCP levels were highest, based on alternative 
parameters, were those where rectal NTCP was unacceptable using QUANTEC 
parameters, and the re-plans predicted acceptable NTCP levels.  
 
In this study, DIL boost doses were escalated until organ at risk constraints were met. 
The variability in rectal NTCP shows that this strategy cannot be considered isotoxic. 
True isotoxic planning would involve specifying a maximum level of rectal NTCP and 
planning to achieve maximal TCP while respecting this. Indeed Azzeroni et al adopted 
this approach, although not in the context of SABR [210]. Similarly, however, they 
observed variability in TCP and concluded that maximising TCP for all patients would 
be limited by the need to maintain rectal NTCP within acceptable limits [210]. The 
proposed phase II BIOPROP (BIologically Optimised Prostate cancer Radiotherapy Or 
dose Painting) trial (Clatterbridge Cancer Centre) also plans to adopt an isotoxic 
approach to prostate planning. A dose of 60Gy in 20 fractions is prescribed to the 
whole prostate and image defined DILs are escalated up to a maximum median dose 
of 68Gy in 20 fractions based on fixed NTCP levels (5%) for rectal bleeding and faecal 
incontinence [236]. 
 
The applicability of the modelling approach adopted here in the setting of SABR is 
uncertain [229].  The TCP and NTCP models employed rely on the LQ-model. There is 
debate about the appropriateness of this model at high doses per fraction, therefore 
calling into question the validity of the calculations in this SABR study [237,238]. Two 
points, however, should be emphasised. Firstly, the concern about the validity of the 
LQ-model begins at fraction sizes of at least 10Gy [237,238], while the doses in this 
study were all less than 10Gy per fraction. Secondly, the concern regarding the LQ-
model at high doses per fraction is that it over-estimates cell killing, thus over-
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estimating NTCP [238]. The potential inaccuracies in the NTCP calculations in this 
study can therefore be considered safe. Regarding TCP, sensitivity analysis revealed 
TCPs based on α/β~1.5Gy are most robust to small changes in input parameters. If the 
‘true’ TCP parameters for ultra-hypofractionation are slightly different to those adopted 
here, and if PCa α/β is ~1.5Gy, then these TCP calculations will be the most reliable. 
Long term clinical SABR data is required before these issues can be resolved. 
 
NTCP calculations used total rectal and bladder volumes, rather than structure walls. 
Total rectal volume is considered a suitable surrogate for the rectal wall if the rectum is 
empty, as occurred here, thus justifying this approach [239]. The parameters used for 
bladder NTCP estimation were originally designed using total bladder volume, and so 
this is how bladder NTCP was calculated here. It has also been suggested that bladder 
DVHs fit clinical data better than dose-wall histograms [240]. Similar to existing DIL 
planning studies which examine NTCP in the setting of boosting 
DILs [210,212,213,216], urethral NTCP was not estimated due to a lack of robust 
modelling parameters. The urethral constraints, however, were biologically equivalent 
to those for HDR brachytherapy, and included a maximum dose, which could limit 
problems similar to those encountered with rectal NTCP in the absence of a maximum 
dose constraint. 
 
The differences between DILs and the non-DIL prostate are incompletely understood. 
A higher clonogen density in DILs than the remaining prostate was assumed and 
therefore the DILs and non-DIL prostate were handled separately. If DILs are the most 
likely source of local failure, then TCPs calculated for DILs are more relevant. CTVs 
were used for TCP calculations instead of PTVs, thus avoiding the uncertainties which 
arise since the CTV-PTV margin contains a lower clonogen density than the CTV. The 
α/β for PCa is debated. TCP varied with the α/β adopted: α/β=1.5Gy resulted in the 
highest TCP and the benefit of boosting DILs was least in this setting. Indeed, in non-
boost plans, α/β=1.5Gy resulted in TCP greater than 94% and greater than 89% for the 
non-DIL prostate and DILs respectively. Non-boost plans were also associated with low 
rectal NTCP, and so, if PCa α/β is ~1.5Gy, then prostate SABR without DIL boosting is 
safe and acceptable. If α/β is higher, then TCP is more limited, even with DIL boosting, 
and boosting DILs to higher doses in an effort to achieve greater increases in TCP 
would cause unacceptable increases in rectal NTCP. As mentioned above, the 
uncertainties associated with DIL definition and registration will result in the realised 
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TCP from boosting being less than that calculated, thus reinforcing the role of SABR to 
the whole prostate without DIL boosting, if the α/β of PCa is ~1.5Gy. 
 
The impact of the α/β ratio of PCa on TCP is further illustrated in Figure 3-4. TCPs 
were calculated in BioSuite using the parameters described in Table 3.3 using ‘single 
dose’ fictitious CTVDIL DVHs (in practice, for BioSuite to calculate TCP, it was 
necessary to create DVHs where a small volume received 0.1Gy above and below the 
dose under investigation, thus DVHs had three dose levels: xGy received by a 3cm3 
volume, (x-0.1)Gy received by 0.01cm3 and (x+0.1Gy received by 0.01cm3). TCPs 
were calculated for doses based on a 7 fraction regimen. 
 
Figure 3-4 Impact of prostate cancer α/β ratio and dose on TCP based on a seven 
fraction schedule  
 
TCP: tumour control probability 
 
As demonstrated from the calculations performed in this study, based on a 7 fraction 
schedule, differences in TCP with dose depend on the PCa α/β ratio. Based on 
α/β=1.5Gy, the non-boost prescription dose (42.7Gy in 7 fractions) is approaching the 
upper plateau of the dose-TCP curve, and so increases in dose have only a small 
effect on overall TCP. With α/β=10Gy, a dose of 42.7Gy falls on the steep part of the 
dose-TCP curve, and further increases in dose will initially result in more marked 
increases in TCP. Doses of above about 60Gy in 7 fractions (i.e. 141% of the prostate 
7 fraction schedule 
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prescription dose) are required before the upper plateau of the dose-TCP curve for 
α/β=10Gy is approached.  
 
Although this planning study included some patients with higher risk disease than 
would be envisaged appropriate for treatment with this technique, this approach was 
justifiable as approximately 43% of patients with low-intermediate risk PCa have DILs 
identifiable on MRI [241]. Most patients also received neo-adjuvant androgen 
deprivation which is used less frequently in lower risk patients. If adopted clinically, the 
impact of hormonal therapy on DIL appearance would need to be considered where 
relevant [242]. 
 
Using BT to boost DILs in the context of whole prostate BT is an alternative option to 
this external beam technique. This approach has the advantage of removing the impact 
of prostate motion and, because of the rapid dose fall-off, higher boosts may be 
achievable while still respecting organ at risk constraints. For both these reasons, it 
may be that the gain achieved from boosting DILs in the context of BT would be greater 
than that achieved here. The uncertainties in terms of DIL definition and co-registration, 
however, still remain and, like the situation here, will reduce any realised TCP gain 
from boosting to less than any calculated gain. 
 
In the previous chapter it was discussed that when prescribing whole prostate SABR, 
allowing gentle dose escalation but restricting the maximum point dose to 120% was 
unlikely to result in excessive urethral toxicity. In Chapter 2 the urethra was not defined 
and so this could not be confirmed. In this current study, urethras were defined on MRI 
by an experienced radiologist. In the non-boost plans, where a similar prescribing 
strategy was used as in Chapter 2, the median D50% dose received by the PTVprostate 
and prostate was 43.6Gy and 43.9Gy respectively while the doses received by the 
PRVurethra were well within tolerance (Table 3.11). Thus gentle dose escalation was 
achieved beyond the prescription dose of 42.7Gy, in keeping with the concept of 
SABR, while keeping the urethra well within tolerance, which should be reassuring 
when adopting non-boost whole prostate SABR in a clinical setting, although clinical 
trials will be required to establish if this strategy results in low levels of urethral toxicity 
in practice. 
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Table 3.11 Urethral doses (PRVurethra) in non-boost plans (Plan set A) 
 Median Range Constraint 
D50% (Gy) 43.7 43.0-44.9 <50.7 
D10% (Gy) 45.0 44.7-47.1 <53.3 
Dmax (Gy) 46.3 45.3-48.1 <58.1 
 
 
Since performing this work, two groups have published planning studies which 
investigate boosting DILs in the context of SABR. Tree et al published comparisons 
between Cyberknife™ and RapidArc® VMAT (as a double arc, Varian, USA) when used 
for SABR DIL boost delivery [243]. TCP and NTCP were not assessed. For a series of 
fifteen patients, the whole prostate and proximal SV were prescribed 36.25Gy in 5 
fractions (EQD21.5=91Gy) while the DIL regions (defined on T2-weighted and DW MRI) 
were simultaneously boosted to 47.5Gy (EQD21.5=149Gy). For the purposes of a pure 
dosimetric comparison, plans for both Cyberknife™ and RapidArc® were generated 
using 5mm CTV-PTV margins in all directions, except for 3mm posteriorly. For DILs, a 
0mm CTV-PTV margin was adopted. Based on this comparison, rectal and bladder 
doses were generally higher for Cyberknife™, although for both technologies, the same 
number of rectal dose constraints (11 out of 75), and a similar number of bladder dose 
constraints, were exceeded. The RapidArc® plans were also produced with larger 
CTV-PTV margins (8mm in all directions except for 5mm posteriorly) around the 
prostate and proximal SVs, to represent the situation where intra-fraction motion 
monitoring was not available. Again, a 0mm margin was used around the DILs. 
Increasing the size of the CTV-PTV margin resulted in increased rectal and bladder 
doses, and a marked increase in the number of exceeded rectal constraints to 37 out of 
75. In addition, at least one constraint was exceeded in 13 out of 15 plans, highlighting 
the difficulty with larger CTV-PTV margins when a fixed boost level is required [243]. 
These problems could perhaps have been avoided by adopting an approach similar to 
the one used in this current study, by varying the boost dose, depending on rectal and 
bladder doses.  
 
In addition, Udrescu et al recently published a planning study comparing prostate 
SABR delivering: i) 32.5Gy in 5 fractions to the PTVprostate (EQD21.5=74Gy), ii) 40Gy in 5 
fractions to the PTVprostate (EQD21.5=109Gy) and iii) 32.5Gy in 5 fractions to the 
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PTVprostate with a simultaneous boost of 40Gy to DILs (defined using T2-weighted and 
DCE MRI sequences) [244]. A 3mm CTV-PTV margin was applied to the prostate and 
a 5mm margin (3mm posteriorly) was applied to the DILs, based on daily online image 
guidance of fiducial markers using CBCT and intra-fraction motion tracking. No dose 
constraints were adopted, except plans were optimised to ensure that the rectum, 
bladder and femoral head doses were as low as possible while maintaining coverage. 
A 9-field coplanar IMRT technique was used for planning. Dose escalation to the whole 
prostate (from 32.5Gy to 40Gy) resulted in increases in all rectal and bladder dose 
parameters other than maximum rectal dose. Focal dose escalation to the DILs also 
resulted in increases in all rectal and bladder dose parameters, other than the median 
bladder dose and the dose received by 25cm3 of bladder. The magnitude of the 
increase in rectal and bladder doses with focal dose escalation, however, was about 
half of that observed when escalating the whole prostate to 40Gy, and so the group 
concluded that focal boosting was the preferable option and required validation in 
clinical trials [244]. The TCP and NTCP consequences of dose escalation were not 
evaluated, and so the value and harm of this approach cannot be assessed. 
 
3.5 Conclusions 
 
Accepting the limitations and uncertainties discussed above, it is technically feasible to 
create SABR VMAT plans which boost DILs. This increases TCP. Rectal NTCP also 
increases and can become unacceptable, although high levels of rectal NTCP can be 
reduced by minimising maximum rectal doses. TCP is influenced by prostate α/β ratio. 
The higher the true α/β in PCa, the smaller the gap between doses required for 
adequate tumour control and acceptable rectal toxicity. Boosting DILs in the context of 
SABR should be approached with caution. If adopted, strict organ at risk constraints 
are required, including maximum rectal dose constraints. If  PCa α/β  is ≤1.5Gy, then 
for most patients, high TCP can be achieved with low NTCP by delivering one SABR 
dose to the whole prostate, without DIL boosting, and thereby avoiding the 
uncertainties associated with the DIL definition and planning process. 
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Chapter 4 : Impact of flattening filter free mode on prostate 
stereotactic ablative radiotherapy (SABR) planning 
 
4.1 Introduction 
 
Conventional radiotherapy is delivered with a flattening filter placed within the machine 
head to compensate for the non-uniform, forward-peaked photon fluence generated 
from the target, thus creating a flat uniform profile across the full width of the 
radiotherapy field. With modern planning systems and MLCs which move during 
treatment, photon fluence can be modulated as required, without the need for the 
flattening filter. As such, there has been increasing interest in the removal of the 
flattening filter from the machine head. This has been shown to have several 
advantages including increased dose rates and reduced out-of-field doses [245].  
 
The feasibility of planning prostate radiotherapy without a flattening filter has not been 
extensively investigated. Two groups have demonstrated the equivalence of prostate 
treatment plans using  flattening filter free (FFF) and standard (flattened) beams in the 
setting of conventionally fractionated IMRT planned using Varian (USA) planning 
systems [246,247]. As well as no significant difference in plan quality, both groups 
observed a reduction in the number of MU required for treatment delivery using 
FFF [246,247]. One other group recently compared FFF with standard (flattened) 
prostate plans in the context of Rapid Arc® VMAT (Varian, USA) and moderate 
hypofractionation (57Gy in 19 fractions) [248]. Again, using Varian systems, dose 
distributions were similar for FFF and flattened plans. Compared to standard (flattened) 
plans, FFF plans had shorter delivery times when a single arc was adopted, while MU 
requirements were greater [248]. 
 
The impact of FFF on prostate planning in the context of SABR has not yet been 
investigated and, given the evidence above, although equivalence in dose distributions 
would be expected, this should be confirmed if SABR FFF techniques are considered 
for clinical implementation. This study therefore aims to compare prostate VMAT 
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planning for SABR using FFF and standard (flattened) beams. In contrast to the above 
studies, plans were generated using an Elekta (Sweden) platform with energy-matched 
flattened and FFF beams. Removal of the flattening filter removes a source of beam 
hardening and as such the energy of the FFF beam drops compared to the equivalent 
flattened beam. Elekta systems, however, ‘retune’ the beam to match the relative dose 
in water at 10cm deep for a 10x10cm standard 6MV beam, 100cm source-to-surface 
distance [249].  
 
4.2 Methods 
 
4.2.1 Planning 
 
Fifteen prostate datasets were used for planning. Based on the class solution 
developed in Chapter 2, plans were generated using a single anterior 210 VMAT arc 
(255→105) with the Agility™ Head (Elekta AB, Sweden) and 6MV standard 
(flattened) and energy-matched FFF beams. As before, the PD was 42.7Gy in 7 
fractions. Planning was performed using Monaco version 3.3 (Elekta AB, Sweden) with 
a MC calculation, a maximum of 150 control points per arc and 1% MC uncertainty per 
plan.  A 2mm calculation grid was employed for enhanced dosimetric information (in 
contrast to the 3mm grid employed in Chapter 2). Coverage requirements were based 
on those used in Chapter 2 with the additional requirement that the volume of CTV 
receiving 100% of the PD was at least 95% (i.e. CTV V42.7Gy≥95%) (Table 4.1), thus 
giving the PD a defined role in the prescription. Organ at risk constraints for the rectum, 
bladder, FHs and bowel were also those adopted in Chapter 2 (Table 4.1).  
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Table 4.1 Coverage requirements and organ at risk constraints 
Volume Requirement/ Constraints 
CTVprostate Minimum dose=40.6Gy (95%) 
CTVprostate Volume receiving 42.7Gy (V100%)≥95% 
PTVprostate Volume receiving 40.6Gy (V95%)≥95%/ 
Dose to 95%(D95%)≥40.6Gy (95%) 
PTVprostate Dose to 99% (D99%) ≥38.4Gy (90%)  
Maximum dose Dmax<120% (51.2Gy) 
Conformity index* ≤1.2 
R50** ≤5.5 
Maximum dose at 2cm 
from PTV 
≤29.9Gy (70%) 
 
Rectum 
(recto-sigmoid junction to 
anus) 
V41.4Gy(97%)<3%  
V38.4Gy(90%)≤15%  
V32.0Gy(75%)≤35%  
V28.0Gy(65%)≤45%  
V24.8Gy(58%)<70%  
V19.6Gy(46%)<80% 
Bladder V41.4Gy(97%)<5% 
V34.7Gy(81%)<25% 
V29.9Gy(70%)<50% 
Femoral heads Dmax≤29.9Gy (70%) 
V29.9Gy(70%)<50% 
Bowel V29.9Gy(70%)<17cc 
Penile bulb† V29.9Gy(70%)<50% 
V34.7Gy(81%)<10% 
* Conformity index: volume of the 95% isodose/volume of PTV,  
**R50: volume of 50% isodose/volume of PTV,  
†dose constraints for the penile bulb were for guidance only and did not have to be 
achieved. 
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The final prescription is shown in Figure 4-1. Explanations for the various cost functions 
are those described in Chapter 2. It was found that the ‘Underdose DVH’ was not as 
necessary using Monaco® version 3.3 as it was when using version 3.2 in Chapter 2, 
and so this was omitted from the prescription, unless obtaining coverage proved 
difficult based on the ‘Target penalty’ function alone. 
 
4.2.2 Plan evaluation 
 
Plans were evaluated and compared according to:  
 CTV: median dose (D50%), D2%, D98% and volume receiving 100% of the PD 
(V100%) 
 PTV: D50%, D2%, D98% and D95%  
 Organ at risk mean doses and D2%  
 Volume of rectum and bladder receiving at least 95% (V95%), 80% (V80%), 
50% (V50%) and 20% (V20%) of the PD to reflect very high, high, intermediate 
and low doses respectively 
 CI: volume of 95% isodose/PTV volume [195] 
 conformation number (CN): (Volume of PTV receiving 95% isodose/PTV 
volume) x (Volume of PTV receiving 95% isodose/volume of 95% 
isodose) [195] 
 homogeneity index (HI): (D2%-D98%)/D50% [196] 
 R50: volume of 50% isodose/PTV volume 
 maximum dose 2cm from PTV (Dmax2cm) 
 MU per fraction  
 estimated delivery time (EDT) 
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Figure 4-1 Prescription 
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4.2.3 Statistics 
 
The Wilcoxon signed-rank exact test was used to compare parameters for FFF and 
standard (flattened) plans as data was not presumed to be normally distributed. Median 
values and ranges are therefore presented. SPSS v19.0 (IBM Corporation, Armonk, 
New York, USA) was used for calculations. Tests were two-tailed. As for Chapter 2 part 
III, p≤0.005 was considered statistically significant to account for multiple statistical 
testing (a full Bonferroni correction would be over-conservative as several factors 
would not be independent of others). 
 
4.2.4 Verification 
 
For one dataset, both the standard (flattened) and FFF plans were verified on a 
Synergy® linear accelerator (Elekta AB, Sweden) with conventional and high dose rate 
modes using the Delta4 phantom (ScandiDos AB, Sweden) and using a semi-flex 
chamber (PTW, Freiburg, Germany) positioned within an in-house solid water IMRT 
phantom. 
 
4.3 Results 
 
4.3.1 Plans 
 
Plans were successfully generated using standard (flattened) and FFF beams and all 
mandatory constraints (i.e. rectal, bladder and FH constraints) were met. In addition, 
fourteen of the fifteen standard (flattened) and corresponding FFF plans met both PB 
constraints, and doses were well within the desired limits. In the one remaining case, 
the PTV overlapped with the PB, thus it was not possible to maintain coverage and 
respect the PB constraints. Target coverage is shown in Table 4.2 and conformity, MU 
requirements and estimated delivery times are shown in Table 4.3. Doses to organs at 
risk are shown in Table 4.4. 
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Target coverage (Table 4.2), conformity and homogeneity (Table 4.3) were equivalent 
between standard (flattened) and FFF plans other than for a small but statistically 
significant reduction in the maximum dose at 2cm from the PTV (Dmax2cm) using FFF 
compared to standard (flattened) beams (median Dmax2cm FFF vs. flattened: 24.8Gy 
vs. 25.5Gy, p=0.004; Table 4.3).  
 
With regard to organ at risk doses, there was a statistically significant increase in rectal 
V80% using FFF but this was not clinically relevant (median rectal V80% FFF vs. 
flattened: 10.2% vs. 10.0%; Table 4.4). There was a small but statistically significant 
increase in mean PB dose with FFF compared to flattened plans, and there was a 
significant increase in PB D2% (Table 4.4).  
 
Table 4.2 Plan statistics for FFF plans compared to flattened plans: coverage  
Median (and range). p≤0.005 considered statistically significant 
 Standard (Flattened) FFF p value  
(if significant) 
CTV coverage 
D50% (Gy) 44.4 (43.8-45.0) 44.5 (44.0-45.0) - 
D2% (Gy) 46.1 (43.4-47.0) 46.2 (45.6-47.4) - 
D98% (Gy) 42.8 (42.4-43.4) 42.8 (42.4-43.3) - 
V100% (%) 98.4 (95.6-100) 98.9 (95.7-100) - 
PTV coverage 
D50% (Gy) 43.5 (43.3-43.9) 43.7 (43.3-43.9) - 
D2% (Gy) 45.8 (45.0-46.7) 45.8 (45.3-46.9) - 
D98% (Gy) 40.5 (39.8-41.0) 40.2 (39.8-41.2) - 
D95% (Gy) 41.2 (40.6-41.6) 40.8 (40.7-41.7) - 
FFF: flattening filter free 
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Table 4.3 Plan statistics for FFF plans compared to flattened plans: dose spread, 
monitor unit requirements and estimated delivery times  
Median (and range). p≤0.005 considered statistically significant 
 Standard (Flattened) FFF p value  
(if significant) 
Dose spread 
Conformity index* 1.06 (1.00-1.11) 1.04 (1.00-1.15) - 
Conformation 
number† 
0.89 (0.86-0.92) 0.90 (0.86-0.91) - 
Homogeneity index‡  0.12 (0.10-0.15) 0.13 (0.10-0.16) - 
Maximum dose at 
2cm (Gy) 
25.5 (23.0-29.3) 24.8 (22.6-29.2) p=0.004 
FFF<flattened 
R50^ 3.6 (3.3-3.8) 3.6 (3.4-4.0) - 
Delivery parameters 
Monitor units per 
fraction 
1621 (1422-1818) 1681 (1467-1813) p=0.002 
flattened<FFF 
Estimated delivery 
time (seconds) 
169.7 (149.8-189.5) 87.5 (78.9-96.7) p<0.001 
FFF< flattened 
FFF: flattening filter free  
* Conformity index: volume of the 95% isodose/volume of PTV          
† Conformation number: (Volume of PTV receiving 95% isodose/ volume of PTV) x 
(Volume of PTV receiving 95% isodose/volume of 95% isodose),                                                                                            
‡ homogeneity index: (D2%-D98%)/D50%,   
^R50: volume of 50% isodose/volume of PTV 
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Table 4.4 Plan statistics for FFF plans compared to flattened plans: organs at 
risk                                                                  
Median (and range). p≤0.005 considered statistically significant 
 Standard 
(flattened) 
FFF (flattening 
filter free) 
p value  
(if significant) 
Rectal Dmean (Gy) 13.7 (10.2-15.6) 13.8 (10.4-15.6) - 
Rectal D2% (Gy) 41.9 (41.7-42.1) 41.8 (41.5-42.4) - 
Rectal V95% (%) 4.0 (3.3-4.8) 4.1 (3.4-4.8) - 
Rectal V80% (%) 10.0 (6.5-14.4) 10.2 (6.9-14.5)  p=0.003 flattened<FFF 
Rectal V50% (%) 22.1 (13.9-31.3) 22.6 (14.5-31.2) - 
Rectal V20% (%) 58.3 (43.7-70.4) 59.4 (44.3-71.3) - 
Bladder Dmean (Gy) 7.0 (4.1-10.3) 7.1 (4.2-10.2) - 
Bladder D2% (Gy) 43.0 (39.4-43.7) 42.6 (39.5-43.8) - 
Bladder V95% (%) 3.6 (1.7-5.7) 3.5 (1.8-5.5) - 
Bladder V80% (%) 5.9 (2.9-8.9) 5.9 (3.0-9.0) - 
Bladder V50% (%) 12.6 (6.7-19.0) 12.6 (6.7-19.2) - 
Bladder V20% (%) 22.1 (12.8-41.4) 22.6 (13.5-41.2) - 
Left femoral head 
Dmean (Gy) 
9.8 (0.7-13.0) 10.1 (0.7-13.1) - 
Left femoral head D2% 
(Gy) 
16.1 (1.8-18.3) 16.1 (2.1-19.0) - 
Right femoral head 
Dmean (Gy) 
10.7 (1.5-15.0) 11.0 (1.6-15.2) - 
Right femoral head 
D2% (Gy) 
19.0 (8.7-20.2) 18.7 (9.6-20.1) - 
Bowel Dmean (Gy) 0.6 (0.2-1.7) 0.6 (0.2-1.8) - 
Bowel D2% (Gy) 1.6 (0.6-13.6) 1.7 (0.6-12.2) - 
Penile bulb Dmean 
(Gy)* 
3.1 (1.2-36.2) 
3.0 (1.2-9.6) 
3.6 (1.2-35.5) 
3.5 (1.2-10.6) 
p=0.004 flattened<FFF 
p=0.001 flattened<FFF 
Penile bulb D2% (Gy)* 7.4 (1.7-43.5) 
6.3 (1.7-31.5) 
9.1 (1.7-43.6) 
9.0 (1.7-32.6) 
p<0.001 flattened<FFF 
p<0.001 flattened<FFF 
* lower line of data is with the dataset which failed to meet penile bulb constraints 
because of overlap with PTV omitted 
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FFF plans required a statistically significant increase in MU (FFF vs. flattened: 1681 vs. 
1621 MU per fraction, p=0.002) and estimated delivery times using FFF were 
significantly shorter (FFF vs. flattened: 87.5 seconds vs. 169.7 seconds, p=0.001) 
(Figure 4-2; Table 4.3).  
 
The similarity between standard (flattened) and FFF plans in terms of target coverage 
and rectal and bladder doses is illustrated in Figure 4-3.  
 
Figure 4-2 Box and whisker comparison of treatment times for flattening filter 
free (FFF) and standard (flattened) plans 
 
p<0.001 
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Figure 4-3 Dose-volume histograms for standard (flattened) and flattening filter 
free (FFF) plans (median values plotted) 
 
 
 
 
It was noted that there were small but statistically significant increases in right FH 
mean dose compared to left FH mean doses in both FFF and flattened plans (median 
values, mean dose right FH vs. left FH: 11.0 vs. 10.1Gy, p=0.002 for FFF plans, 10.7 
vs. 9.8Gy, p=0.003 for flattened plans). In addition, there were significant increases in 
right FH D2% compared to left FH D2% in both FFF and flattened plans (median 
values, D2% right FH vs. left FH: 18.7 vs. 16.1Gy, p=0.001 for FFF plans and 19.0 vs. 
16.1Gy, p=0.001 for flattened plans). All FH doses, however, were very well within 
tolerance (Dmax=29.9Gy and V29.9Gy<50%), making the differences in left and right 
FH doses of little clinical concern.  
 
 
CTV PTV 
Rectum Bladder 
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4.3.2 Verification 
 
The standard (flattened) and FFF plan both passed the Delta4 verification with scores 
of 100% at 3%/3mm. For the chamber measurement, there was 0.1% difference in the 
measured dose from the expected dose for the standard (flattened) plan and, for the 
FFF plan, there was 0% difference between the measured and expected doses (<3% 
difference is optimal, <5% difference is mandatory). Measured delivery times for the 
standard (flattened) and FFF plans were 163 seconds and 84 seconds respectively. 
 
4.4 Discussion 
 
Standard (flattened) and FFF prostate SABR VMAT plans were similar in terms of 
target coverage and rectal, bladder and FH doses, and both types of plan passed 
verification well. The largest advantage of FFF over standard (flattened) plans was in 
terms of more rapid delivery times: median estimated delivery times improved from 170 
seconds per fraction to 88 seconds with FFF. The delivery time advantage of FFF was 
also confirmed during verification.  
 
Faster delivery times offer patient benefits in terms of reducing the opportunity for intra-
fraction motion, which has been shown to become increasingly problematic with 
increasing treatment time [199]. Potentially, faster delivery times could potentially allow 
smaller CTV-PTV margins to be adopted [164], which could, in turn, facilitate dose 
escalation and/ or reduced toxicity. Faster delivery times also provide service delivery 
benefits, allowing greater throughput and efficiency within the Radiotherapy 
Department. 
 
The equivalence between standard (flattened) and FFF prostate planning has 
previously been demonstrated in the context of IMRT with conventional 
fractionation [246,247], as well as in the context of VMAT (RapidArc®) and moderate 
hypofractionation [248]. The feasibility of prostate radiotherapy planning in the context 
of SABR VMAT using energy-matched FFF beams and an Elekta platform has not 
previously been demonstrated, and so this exercise is worthwhile. 
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An increased number of MU were required for delivery of FFF plans in this study. This 
is not unexpected in the setting of FFF beams where the centrally peaked non-flattened 
beam profile means that more MU are required to deliver off-axis doses. Where beams 
are not energy-matched, then increased MU are also required to compensate for the 
drop in beam energy resulting from the loss of beam hardening. The two studies which 
compared standard and FFF prostate planning in the setting of conventional 
fractionation using Varian systems, however, found that a lower number of MU were 
required for FFF treatments [246,247]. Despite appearing contradictory, this finding can 
be explained by the fact that neither of these studies recalibrated the FFF beam MU to 
match those of the flattened beam, and so simply removing the flattening filter without 
MU recalibration resulted in an increase in dose per MU for the FFF beam, thus the 
expected increase in MU for FFF plan delivery was not observed [246,247]. The one 
study comparing standard and FFF plans in the context of moderate hypofractionation 
did observe an increase in the number of MU required for FFF treatments [248]. Here 
the FFF beam MU had been recalibrated to match the flattened beam such that 100MU 
resulted in 1Gy being delivered to the maximum depth dose [248], as was the case in 
this current study. To overcome the lower dose off-axis profile of the FFF beam, and 
the loss of beam energy in the setting of non-energy-matched beams, the increase in 
MU is as expected. 
 
There was a small dosimetric disadvantage to FFF in terms of PB mean dose and 
D2%. For all but one dataset, the doses received by the PB were well within the 
specified PB constraints, and so the small increase in dose resulting from FFF is 
unlikely to be of clinical significance. In the one remaining case, the PTV overlapped 
with the PB, and constraints could not be met for either standard or FFF planning. It is 
acknowledged that the PB itself is not the organ critical for normal erectile 
function [250,251]. Despite this, a dose-volume relationship between PB dose and risk 
of erectile dysfunction has been demonstrated and QUANTEC recommends that the 
mean dose received by 95% of the PB should not exceed 50Gy and that it may be 
appropriate to also keep the dose received by 70% (i.e. D70%) of the structure to less 
than 70Gy and the dose received by 90% of the structure (i.e. D90%) to less than 
50Gy, although target coverage should not be compromised to achieve these 
goals [250,251]. If the biologically equivalent doses reported by QUANTEC are 
recalculated for a 7 fraction schedule, then the mean dose to 95% of the PB should be 
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<29.9Gy, D70% should be <39.5Gy and D90% should be <29.9Gy. As with the 
constraints used for planning here, 14 of the standard (flattened) and corresponding 
FFF plans met the QUANTEC recommendations comfortably. As above, therefore, the 
significance of the higher PB mean and D2% doses with FFF plans observed here is 
unlikely to be clinically relevant for the majority of patients.  
 
For both the standard (flattened) and FFF plans, a small amount of asymmetry in terms 
of FH mean doses and D2% was noted. Doses, however, remained very well within 
tolerance for all patients and are therefore unlikely to be clinically relevant. Indeed, 
asymmetry in FH doses but which remain within tolerance, when observed elsewhere, 
has not been felt to be of clinical concern [252,253]. 
 
FFF has also been shown to result in reduced out-of-field doses [245], which potentially 
could result in a reduction in the risk of radiation-induced second cancers. This will be 
investigated in Chapter 6. 
 
Since commencing this work one group has reported preliminary outcomes (median 
follow-up 11 months) for a cohort of 40 low and intermediate risk PCa patients treated 
with linear accelerator-based SABR delivering a dose of 35Gy in 5 fractions using 
RapidArc® VMAT with 10MV FFF (one or two full arcs were employed, the CTV 
contained the prostate and, in cases at higher risk of SV invasion, some or all of the SV 
were also included and 3-5mm CTV-PTV margins were used) [84]. All plans met the 
desired constraints. Grade 2 CTCAEv4 acute rectal and GU toxicity was reported in 
10% and 40% of cases respectively, and no grade 3 or greater acute toxicities 
occurred [84]. A spacer gel was used selectively in eight patients to increase the rectal-
prostate distance [84]. These initial clinical results, reporting the implementation of FFF 
beams in prostate SABR are encouraging, but longer clinical follow-up is required to 
establish efficacy and long-term toxicity. 
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4.5 Conclusions 
 
In summary, prostate SABR VMAT planning is feasible using FFF, and results in 
similar target coverage, conformity and rectal, bladder and FH doses. Plans were also 
deliverable. The biggest advantage of FFF planning was the significant improvement in 
delivery time, which offers both patient and service delivery benefits.  
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Chapter 5 : Radiation-induced second primary cancers in 
patients irradiated for prostate cancer: a systematic review 
of clinical evidence 
 
5.1 Introduction 
 
The development of a radiation-induced second primary cancer (RISPC) is one of the 
most serious long term consequences of successful cancer treatment. Patients 
diagnosed with early or locally advanced PCa face a variety of treatment options, 
several of which involve ionising radiation: EBRT, BT or combination EBRT-BT might 
be employed. Modern radiotherapy techniques such as IMRT result in changes in dose 
distribution and scatter which have resulted in theoretical concerns about an increased 
risk of RISPC [254]. Patients are now diagnosed with PCa at an earlier stage than in 
the past and so may receive treatment sooner in the course of the disease. In addition, 
patients now survive for longer following their diagnosis. As such the long term 
consequences of treatment, including the risk of RISPC, become particularly relevant.  
 
Studies of Atomic bomb survivors demonstrated that there is a latency period of at 
least five years before the development of solid RISPCs [255]. A second primary 
cancer (SPC) is generally considered radiation induced if:  i) it is diagnosed after a 
latency period (usually considered to be five years or more) following irradiation, ii) it 
occurs within the radiation field (for prostate radiotherapy, this includes the rectum, 
bladder, anus, prostate, soft tissues, bones or joints of the pelvis and pelvic 
lymphoma), iii) it is a different histological type to the original cancer and iv) the second 
tumour was not evident at the time of radiotherapy [256,257]. More commonly, PCa 
patients may develop subsequent SPCs which are not radiotherapy induced, but are 
the result of genetic and environmental factors. The distinction between RISPC and 
SPC can become blurred as regions beyond the primary radiation field are exposed to 
scattered doses of radiation, and theoretically these may increase the risk of RISPCs in 
out-of-field regions. 
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When evaluating SPCs in irradiated PCa patients, registry databases provide very 
large numbers of patients for analysis, and therefore have sufficient power to observe 
differences between patient groups. The information within registries, however, is less 
complete than that from institutional series. In depth details regarding treatment are 
often absent and details of potential confounding factors (e.g. smoking status) are often 
not recorded. Reaching valid conclusions about the impact of radiation from 
multivariate models when important information regarding potential cofounders is 
missing, is therefore challenging. Registries may also suffer from under-reporting of 
SPCs, particularly in elderly patients. 
 
Institutional data provides more detailed information and so confounding factors may 
be easier to identify. Patient numbers, however, are smaller and therefore the power to 
detect real differences in SPC incidences is limited. Institutional data does not come 
with its own ‘normal population’ for comparison, and so external comparators must be 
used. Some institutional studies only report crude rates of SPC, rather than making 
comparisons with SPC in non-irradiated patients or the general population, thus limiting 
the usefulness of this data. Series examining survival following prostate irradiation may 
report numbers of deaths due to SPCs but, again, risk comparisons may not be 
performed. 
 
This work reviews published registry and institutional data with particular regard to the 
impact of treatment technique on the risk of second cancers. 
 
5.2 Objectives 
 
To evaluate SPCs in PCa patients treated with radiotherapy, and to evaluate whether 
different radiotherapy techniques result in different risks of SPCs.  
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5.3 Methods 
 
A systematic search of the literature was performed using Medline, EMBASE (Excerpta 
Medica dataBASE) and the Cochrane Library databases. Search terms were related to 
SPC and RISPC, and radiotherapy and PCa. The actual search terms are shown in 
Appendix D. References and “related articles” of relevant articles were also reviewed. 
Studies in English which reported rates of, or mortality from, SPC overall, or rectal or 
bladder cancer specifically, following curative irradiation for prostate adenocarcinoma 
were included. Studies published in full text and abstract form were included. Studies 
involving radiotherapy for paediatric and non-adenocarcinoma PCa were excluded. 
Studies examining prostate cancers as a whole, without specifically differentiating 
between treatment modalities were also excluded (i.e. where SPCs in surgically and 
irradiated patients were not examined separately). Case studies and series limited to 
10 or fewer patients, and studies examining palliative radiotherapy alone, were 
excluded. The last search was performed on the 10th September 2013. This strategy 
identified 651 different articles. Reasons for exclusion included articles: not dealing with 
SPC (n=241), planning studies (n=101), primary tumour not prostate adenocarcinoma 
(n=74), about management of SPC but not risk (n=3), review articles (n=53), case 
reports (n=25), not in English language (n=24), patients treated with non-standard 
therapy (e.g. high dose chemotherapy; n=6), letters/editorials without new data (n=19), 
studies reporting laboratory based work (n=6), early versions of later full study (n=14), 
patients treated with palliative therapies alone (n=20), studies examining risks related 
to concomitant imaging (n=3), studies examining PCa patients as a whole but not 
examining irradiated PCa patients specifically (n=2), studies examining specific second 
cancer other than rectal or bladder cancer (n=3) and studies that evaluated risk from 
radiation but did not specifically evaluate risks from PCa radiation (n=10). In total, 14 
SEER (Surveillance, Epidemiology and End Results) registry, 5 other registry and 21 
institutional studies were identified, as well one abstract which reported the results of a 
screening trial that examined second cancers and 6 studies which reported only 
mortality due to SPC (Figure 5-1).  
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Figure 5-1 Schema of article selection process 
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5.4 Results 
 
The majority of evidence addresses SPC and RISPC in patients treated with primary 
EBRT (mainly in the form of non-conformal and 3D-CRT techniques) which is 
discussed initially, considering risk of SPC overall, then rectal cancer and then bladder 
cancer, before evaluating SPCs following other irradiation techniques.  Throughout this 
review, crude rates are stated as such and, wherever available, adjusted risk ratios and 
comparisons are presented in preference to unadjusted figures. 
 
5.4.1 Overall second cancer risk associated with EBRT for prostate 
cancer 
 
Compared to the general (i.e. non-prostate cancer) population, 5 out of 5 registry 
studies did not find irradiated patients to be at any significantly increased risk of SPC, 
both when considering all durations of follow-up (i.e. beyond any exclusion periods) 
and also when considering follow-up beyond five years [258-262] (Table 5.1). Although 
not reaching the threshold for statistical significance, Rapiti et al did conclude that 
compared to the general population, irradiated PCa patients were at a slight increased 
risk beyond five years which the group  considered to be of “borderline significance” 
(p=0.056) [262]. Brenner et al found irradiated PCa patients to be at a significantly 
reduced risk of SPCs (Standardised incidence ratio (SIR): 0.89) compared to the 
general population, although when patients under the age of 60 were considered alone, 
no difference in risk was observed [259]. The low SPC incidence observed amongst 
irradiated PCa patients was attributed to the relatively elderly population evaluated. 
Bagshaw et al, a single institution study, also found irradiated patients not to be at 
increased risk of SPC compared to the general population [263]. 
 
Comparing irradiated PCa patients with a non-irradiated PCa cohort may be 
considered more representative than comparisons with the general population, and in 
this situation different results are observed to those above (Table 5.2). All four registry 
studies found irradiated patients to be at increased risk of SPC compared to non-
irradiated PCa patients [258,259,261,264]. This increased risk began after one year of 
follow-up in two of these studies [258,264], and was observed after five years of follow-
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up in the three studies which specifically examined this time period [259,261,264].Risk 
increased further beyond 10 years of follow-up in the one study which examined this 
period [259]. Similarly, data from prostate patients treated within the PLCO (prostate, 
lung, colorectal and ovarian) screening trial demonstrated that irradiated PCa patients 
had a significantly increased risk of any second cancer beyond 30 days and beyond 5 
years compared to non-irradiated PCa Patients (rate of any SPC: 15.5/1000 person-
years in irradiated patients vs. 11.4/1000 person-years in non-irradiated patients) [265]. 
 
In terms of single institution studies, Huang et al compared SPC incidence between 
2120 irradiated and 2120 surgically treated patients within a matched-pair 
analysis [266]. Most irradiated patients were treated with EBRT alone (as opposed to 
with EBRT-BT). Over all durations of follow-up there was no significant increased risk 
of SPC in irradiated patients, but, in keeping with the registry studies above, after 5 and 
10 years there was a significant increase in risk of SPC in irradiated patients. After 10 
years this risk was almost five times that of surgical patients [266]. In contrast, Movsas 
et al, the smallest study examined here, and the study with the shortest median follow-
up, found irradiated PCa patients to be at no increased risk of SPC over all durations of 
follow-up, from 5 to 9.9 years, and beyond 10 years, compared to PCa patients from 
the SEER database (of whom only 12.5% were irradiated) [267]. 
 
Single institution studies reporting crude rates of SPC (Table 5.3) include  Johnstone et 
al who reported a crude SPC rate  of 17.5% beyond one year of PCa diagnosis, in a 
series of 154 irradiated patients after a median follow-up of 10.9 years [268]. This was 
not significantly different to the rate of non-prostate cancers diagnosed prior to PCa 
diagnosis (p=0.288). Zilli et al reported a crude rate of SPC of 5.4% beyond six months 
of follow-up [269].Long term trial results reported by Bolla et al revealed a crude rate of 
SPCs in irradiated patients of 7.7% over all durations of follow-up [270]. Median follow-
up is variable between these studies, and no comparisons with other population groups 
are performed, limiting the usefulness of these figures. Studies examining mortality in 
irradiated PCa patients (Table 5.4) reveal that up to 4.1% of patients (crude rates) 
irradiated with EBRT die from SPCs although, as above, duration of follow-up is 
different in all studies and so these figures must be interpreted with 
caution  [267,270,271]. In one study, 10% of all deaths were the result of second 
malignancies  [272].  
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Table 5.1 Studies examining second primary cancers at any site in prostate cancer patients irradiated using external beam radiotherapy 
compared to general population 
CI: confidence interval, FU: follow-up, NR: not reported, NS: not significant, SEER: Surveillance, Epidemiology and End Results, SIR: standardised incidence ratio,   
* p value and/or confidence interval not reported, ** The group concluded irradiated patients were at a slightly increased risk which was “of borderline significance” 
Study 
 
Type of data Period 
examined 
No. 
patients 
Median follow-
up (years) 
Exclusions Time period(s) 
assessed 
Risk of second 
cancer at any site 
(based on p<0.05 
or CI not including 
1.0) 
Magnitude of risk 
(SIR, 95% CI or p 
value in 
parentheses if 
available) 
Pawlish 
1997 [258] 
Retrospective, 
SEER registry 
1973 -1982 2,087 6.1 (mean FU 
reported) 
<1 year FU >1 year FU No difference 1.03 (0.91-1.16) 
 
Brenner 
2000 [259] 
Retrospective, 
SEER registry 
1973-1993 51,584 
 
4 
(mean FU 
reported) 
<2months > 2 months 
 
>5 years 
 
>10 years 
Reduced 
 
Reduced 
 
Reduced 
0.89* 
 
0.92* 
 
0.96* 
Berrington de 
Gonzalez 
2011 [261]
 
Retrospective, 
SEER registry 
1973-2002 76,363 9.4 (mean FU 
reported) 
<5 years >5 years No difference 0.98 (NS*) 
Pickles 
2002 [260]
 
 
Retrospective,  
British Columbia 
Tumor Registry 
1984-2000 9,890 
 
4.77 <2 months > 2 months 
 
2 months- 5 years 
 
>5 years 
 
>10 years 
No difference 
 
No difference 
 
 
No difference 
 
No difference 
1.01 (p=0.9) 
 
0.96 (NS*) 
 
 
1.08 (NS*) 
 
1.12 (NS*) 
Rapiti 
2008 [262] 
Retrospective,  
Geneva Cancer 
Registry 
1980-1998 264 
 
7.8 <5 years >5 years 
 
5-9 years 
 
≥10 years 
No difference** 
 
No difference 
 
No difference 
1.35 (p=0.056) 
 
1.28 (NS*) 
 
1.55 (NS*) 
Bagshaw 
1988 [263] 
Retrospective, 
single centre 
1956-1985 914 NR None All periods No difference 0.93 (p=0.48) 
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Table 5.2 Studies examining second primary cancers at any site in prostate cancer patients irradiated using external beam radiotherapy 
compared to non-irradiated prostate cancer patients 
Continued overleaf. 
Study Type of data Period No. patients Median 
follow-up 
(years)
†
 
Exclusions Time period(s) 
assessed 
Risk of second 
cancer at any site 
(based on p<0.05 
or CI not including 
1.0) 
Magnitude of risk 
(Relative risk or other 
where stated (95% CI 
and/or p value if 
available)) 
Pawlish 
1997       
[258] 
Retrospective, 
SEER registry 
1973 -
1982 
2,087 RT 
6,390 no RT 
6.1 
(mean) 
<1 year  >1 year  Increased 1.23 (1.06-1.42) 
Brenner 
2000       
[259] 
Retrospective, 
SEER registry 
1973-
1993 
51,584 RT 
70,539 no RT 
 
4  
(mean) 
<2months  
 
> 2 months 
 
>5 years 
 
>10 years 
 
 
No difference 
 
Increased 
 
Increased 
Percentage increase in risk: 
 
4 (-1-9, p=0.08) 
 
11 (3-20, p=0.007) 
 
27 (9-48, p=0.002) 
Abdel-
Wahab 
2008       
[264]
 
Retrospective, 
SEER registry 
1973- 
2002 
48,400 RT 
40,733 no RT 
 
5.3 RT 
4.3 no RT 
<1 year 
 
 
>1 year 
 
>5 years 
Increased 
 
Increased 
HR: 1.137 (1.087-1.190) 
 
HR: 1.263 (1.167-1.367) 
Berrington 
de 
Gonzalez 
2011       
[261]
 
Retrospective, 
SEER registry 
1973-
2002 
76,363 RT 
 
123,800 no RT 
9.4 RT 
(mean) 
10.1 no RT 
(mean) 
<5 years >5 years Increased 1.26 (1.21-1.30) 
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Table 5.2 cont. Studies examining second primary cancers at any site in prostate cancer patients irradiated using external beam 
radiotherapy compared to non-irradiated prostate cancer patients 
Study Type of data Period No. patients Median 
follow-up 
(years)
†
 
Exclusions Time period(s) 
assessed 
Risk of second 
cancer at any site 
(based on p<0.05 
or CI not including 
1.0) 
Magnitude of risk 
(Relative risk or other 
where stated (95% CI 
and/or p value if 
available)) 
Movsas 
1998 [267]
 
 
Retrospective, 
single centre 
1973-
1993 
543 RT 
 
18,135 no RT* 
3.9 RT 
 
3.9 no RT 
(mean) 
<2 months  
 
>2 months 
 
>2 months- 9 years 
 
1-4.9 years 
 
5-9.9 years 
 
10+ years 
 
 
No difference 
 
No difference 
 
No difference 
 
No difference 
 
No difference 
Crude rates (RT vs no RT):  
 
5.7% vs 5.8% (p=0.99) 
 
0.74% vs 0.9% (p=0.89) 
 
3.8% vs 3.6% (p=0.95) 
 
4.3% vs 4.4% (p=0.89) 
 
0% vs 8.3% (p=0.56) 
Huang 
2011 [266] 
Retrospective, 
single centre 
matched-pair 
analysis 
1984-
2005 
2,120 RT 
2,120  no RT 
 
7.15 RT 
6.99 no RT 
 
None All durations  
 
>5 years 
 
>10 years 
No difference 
 
Increased 
 
Increased 
HR: 1.14 ( 0.94 to 1.39) 
 
HR: 1.86 (1.36-2.55)  
 
HR: 4.94 (2.18-11.2) 
Black 
2013 [265] 
Prospective, 
trial data 
1993-
2001 
3,216 RT 
4,263 no RT 
 
6 (mean) <30 days >30 days 
 
>5 years 
Increased 
 
Increased 
1.25 (1.1-1.5) 
 
1.6 (1.2-2.1) 
RT: external beam radiotherapy, HR: hazard ratio, CI: confidence interval, NR: not reported, SEER: Surveillance, Epidemiology and End Results,        
† if follow-up for each treatment group reported separately, then this is presented, * Non-RT patients from Connecticut Cancer Registry, approximately 
12.5% received RT despite being considered as ‘no RT’ group 
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Table 5.3 Studies reporting second cancer rates in irradiated prostate cancer patients without comparison to other populations 
Study Type of data Period  No. 
patients 
Median follow-
up (years) 
Exclusions Time 
period(s) 
assessed 
Crude rate of second  
cancer at any site 
Crude rate 
of second 
rectal 
cancer  
Crude rate 
of second 
bladder 
cancer 
Johnstone 
1998 [268]
 
Retrospective, 
single centre 
1974-
1988 
154 10.9 <1 years >1 year 17.5% (27/154) 
diagnosed ≥1 year of 
prostate cancer 
diagnosis 
(vs 14.9% (23/154) 
diagnosed before or 
within one year of 
prostate cancer 
diagnosis (p=0.288) ) 
See Table 
5.5* 
See Table 
5.5* 
Gardner 
2002 [273]
 
 
Retrospective 
single centre 
(EBRT+ proton 
boost) 
1976- 
1992 
39 13.1 None All durations 
of FU 
NR 2.6% (1/39) 0% (0/39) 
Zilli    
2010 [269] 
Retrospective 
single centre 
2002 - 
2009 
276 3.5 <6 months >6 months 5.4% (15/276) 1.8% (5/276) 1.1% (3/276) 
Bolla et al 
2010 [270] 
Prospective, 
clinical trial 
data 
1987-
1995 
415 9.1  None All durations 
of FU 
7.7% (32/415) NR NR 
EBRT: external beam radiotherapy, NR: not reported, * risk comparisons with general population performed for rectal and bladder cancers 
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Table 5.4 Deaths due to second cancers following irradiation in prostate cancer patients 
Study Type of data No. 
patients 
Period Median follow-up (years) Patients dying due to second malignancy (crude rate based on all patients 
in study or other when specified, actual numbers in parentheses) 
External beam radiotherapy 
Movsas 
1998 [267]
 
Retrospective, 
single centre 
543 1973-1993 3.9 2.8% (15/543) 
Kannan  
2005 [271]
 
Retrospective, 
single centre 
51 1998-2002 2.7 2.0% (1/51) 
Bolla et al 
2010 [270]
 
Prospective, 
clinical trial 
data 
415 1987-1995 9.1  4.1% (17/415) 
 
Nguyen  
2010 [272]
 
Retrospective, 
single centre 
929  1987-2004 7.5 10% of all deaths due to second cancers 
Zelefsky 
2012 [274] 
Retrospective, 
single centre 
897 
(mainly 
IMRT) 
1998-2001 7.5 10-year mortality rate for in-field SPC: 0.12% (95%CI:0-0.36%)* 
10-year mortality rate for extra-pelvic SPC: 1.97% (95%CI:1.01-2.92%)* 
Post-operative radiotherapy 
Ciezki 
2012 [275] 
Retrospective, 
SEER registry 
20,545 
surgery 
and PORT 
1973-2008 9.5 20-year age-adjusted mortality rate for colorectal cancer: 0.06% 
20-year age-adjusted mortality rate for bladder cancer: 0.14% 
  
Bellavita 
2011 [276]
 
Retrospective, 
single centre 
214 1998-2007 4.8 1.9% (4/214) 
Brachytherapy studies 
Bittner  
2008 [277]
 
Retrospective, 
single centre 
1,354 1995-2004 5.4 3.0% (41/1354) 
7.2% (cumulative hazard of death from second cancer) 
Rodriguez 
2009 [278]
 
Retrospective, 
single centre 
150 2003-2006 4.1 (mean) 2.0% (3/150) 
 
 
Henry 
2012 [279] 
Retrospective, 
single centre 
1805 1995-2005 6-17 years 0.06% (1/1805) died from rectal cancer 
0.2% (3/1805)  died from bladder cancer 
Zelefsky 
2012 [274] 
Retrospective, 
single centre 
413 1998-2001 7.7 10-year mortality rate for in-field SPC: 0%* 
10-year mortality rate for extra-pelvic SPC: 0.78% (95%CI:0.01-1.67%)* 
CI: confidence interval, SEER: Surveillance, Epidemiology and End Results, SPC: second primary cancer, *Based on competing risk analyses to account for other causes of death
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Overall, therefore, an increase in SPC has not been consistently demonstrated in 
irradiated patients compared to the general population. There is more consistent 
evidence, however, of an increase in SPC risk in comparison to non-irradiated PCa 
patients, particularly with increasing durations of follow-up. This raises the possibility 
that PCa patients are different to the general population, and so non-irradiated PCa 
patients and the general population should not be considered equivalent. 
 
Patient age has an impact on SPC incidence, as illustrated by Brenner et al 
above [259]. Length of follow-up is also important, and studies with shorter durations of 
follow-up may not detect all SPCs. Brenner et al and Huang et al illustrated that the 
relative risk of SPC in irradiated patients increased over time compared to surgically 
treated patients [259,266]. Brenner et al demonstrated a 6% increase in relative risk of 
second solid tumour overall, which increased to 15% and 34% beyond 5 and 10 years 
respectively. In absolute terms, the risk of radiation-associated SPC was 1 in 290 over 
all durations of follow-up, 1 in 125 beyond 5 years and 1 in 70 for those surviving 
beyond 10 years [259]. Similarly, Pickles et al reported a crude risk estimate of 1 in 220 
over all durations of follow-up, which is not dissimilar [260]. Berrington de Gonzalez et 
al, more recently, concluded that the number of excess second solid cancers in 
irradiated PCa patients surviving beyond one year attributable to radiotherapy was 1 in 
114, with 10% of all second cancers being attributable to radiotherapy [261]. 
 
5.4.2 Second rectal cancer risk associated with EBRT for prostate 
cancer 
 
Amongst the six SEER registry studies examining rectal cancer in irradiated PCa 
patients compared to the general population (Table 5.5), three showed no increase in 
rectal cancer risk, including when follow-up beyond five and eight years was 
specifically examined [258,280,281], while three demonstrated increased 
risk [259,261,282]. Two of the studies to demonstrate an increase in rectal cancer risk 
compared to the general population were the only two studies which examined follow-
up beyond 10 years, as well as other time periods and, in both cases, the increased 
risk of rectal cancer was only present beyond 10 years [259,282]. In the third study 
which demonstrated increased risk of rectal cancer in irradiated patients compared to 
the general population, this risk was demonstrated beyond five years [261]. Of the 3 
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non-SEER registry studies, one found no increase in risk from irradiation beyond 5 
years, nor beyond 10 years [262] although the number of irradiated PCa patients was 
relatively small, while another demonstrated increased risk of rectal cancer following 
irradiation beyond 6 months and beyond 5 years of follow-up [283], and the third 
demonstrated an increased risk of colorectal cancer beyond 2 months of follow-up and 
between 2 months and 5 years of follow-up, but not beyond 5 years or beyond 10 
years [260].  
 
Of the two single institution studies examining rectal cancer in irradiated PCa patients 
compared to the general population, one found no difference in the risk of rectal cancer 
following irradiation over all durations of follow-up [263], and one found an increased 
risk within one year of follow-up only [268].  
 
Seven of the ten SEER registry studies comparing second rectal cancer incidence 
between irradiated and non-irradiated PCa patients demonstrated that irradiated 
patients were at increased risk (Table 5.6) [259,261,264,281,282,284,285]. This 
increased risk has mainly been observed after longer durations of follow-up (i.e. 
beyond 5 and 10 years) and appears to increase with increasing durations of follow-up. 
For example, the hazard ratios reported by Nieder et al, increase from 1.11 when 
considering follow-up from 6 months to 5 years (non-significant) to 1.39 (significant) 
between 5 and 10 years of follow-up to 1.79 (significant) from beyond 10 years [281]. 
Of the remaining SEER studies, two report no increase in risk of second rectal cancer, 
one of which examined follow-up beyond 5 years specifically [258,286]. The one 
remaining SEER study, by Kendall et al, demonstrated that the specific comparator 
group with which irradiated PCa patients are compared might impact on the relative 
risk observed: when irradiated PCa patients were compared to patients treated 
surgically, there was a significantly increased risk of rectal cancer in irradiated patients, 
while compared to patients who did not receive RT or surgery, the risk of rectal cancer 
was significantly less, which the group felt was unrealistic [287]. Thus risk ratio was 
influenced by comparator group. The group therefore suggested an unidentified 
confounding factor was influencing results and, after further analysis, concluded that 
there was insufficient evidence to confirm that irradiation for prostate cancer induced 
rectal cancer [287]. Indeed, Kendal et al’s analysis from 2007 did not demonstrate any 
increase in the risk of second rectal cancer in irradiated patients over all durations of 
follow-up or beyond five years [286]. 
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Table 5.5 Studies examining second rectal and second bladder cancers in prostate cancer patients irradiated using external beam 
radiotherapy compared to general population 
Continued overleaf.  
Study Type of 
data 
Period  No. 
patients 
Median 
follow-
up 
(years) 
Exclusions Time period 
assessed 
Risk of second 
rectal cancer 
(based on p<0.05 
or confidence 
interval not 
including 1.0) 
Magnitude of 
risk of rectal 
cancer (SIR (95% 
CI or p value if 
available) 
Risk of second 
bladder cancer 
(based on p<0.05 
or confidence 
interval not 
including 1.0) 
Magnitude of 
risk of bladder 
cancer (SIR (95% 
CI or p value if 
available) 
Neugut 
1996 [280] 
Retro, 
SEER 
registry 
1973 - 
1990 
34,889 NR <6 months  >6months- 
5years 
 
5-8 years 
 
>8 years 
Reduced  
 
 
No difference 
 
No difference  
0.7 (0.5-0.9) 
 
 
0.8 (0.5-1.2) 
 
0.8 (0.4-1.3) 
No difference 
 
 
No difference 
 
Increased 
1.0 (0.8-1.2) 
 
 
1.3 (1.0-1.7) 
 
1.5 (1.1-2.0) 
Pawlish 
1997 [258] 
Retro, 
SEER 
registry 
1973 -
1982 
2,087 6.1 
(mean) 
<1 year  >1 year 
 
>5 years 
No difference 
 
NR 
 0.95 (0.45-1.74) 
 
NR 
Increased 
 
Increased 
1.49 (1.07-2.02) 
 
1.60 (1.05-2.35) 
Brenner 
2000 [259] 
Retro, 
SEER 
registry 
1973-
1993 
51,584  
 
4  
(mean) 
<2months > 2 months 
 
>5 years 
 
>10 years 
Reduced 
 
Reduced 
 
Increased 
0.82* 
 
0.95* 
 
1.18* 
Increased 
 
Increased 
 
Increased 
1.10* 
 
1.20* 
 
1.32* 
Nieder 
2008 [281] 
Retro, 
SEER 
registry 
1988-
2003 
93,059 4.1 6 months 
 
>6 months No difference 
 
0.99 (0.90-1.10) 
 
Increased 1.42 (1.34-1.50) 
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Table 5.5 cont. Studies examining second rectal and second bladder cancers in prostate cancer patients irradiated using external beam 
radiotherapy compared to general population. Continued overleaf. 
Study Type of 
data 
Period  No. 
patients 
Median 
follow-up 
(years) 
Exclusions Time period 
assessed 
Risk of second 
rectal cancer 
(based on p<0.05 
or confidence 
interval not 
including 1.0) 
Magnitude of 
risk of rectal 
cancer (SIR (95% 
CI or p value if 
available) 
Risk of second 
bladder cancer 
(based on p<0.05 
or confidence 
interval not 
including 1.0) 
Magnitude of 
risk of bladder 
cancer (SIR (95% 
CI or p value if 
available) 
Huo 
2009 [282]
 
Retro, 
SEER 
registry 
1973-
2005 
211,882 NR None All 
 
<6 months 
 
6 months- 5 
years 
 
>5 to 10 
years 
 
>10 years 
No difference 
 
No difference 
 
No difference 
 
 
No difference 
 
 
Increased 
1.04 (0.97-1.11) 
 
0.99 (0.77-1.27) 
 
0.96 (0.88-1.05) 
 
 
1.06 (0.93-1.20) 
 
 
1.44 (1.22-1.71) 
NR NR 
 
 
 
 
 
 
 
 
 
 
Berrington 
de 
Gonzalez 
2011  [261]
 
Retro, 
SEER 
registry 
1973-
2002 
76,363 
RT 
123,800 
no RT 
9.4 (mean) 
 
<5 years >5 years Increased
†
 1.12 (p≤0.05) Increased 1.31 (p≤0.05) 
Pickles 
2002 [260]
 
 
Retro,  
British 
Columbia 
Tumor 
Registry 
1984-
2000 
9,890  
 
4.8 <2 months > 2 months 
 
>2 months to 
5 years 
 
>5 years 
 
 
>10 years 
Increased
‡
 
 
Increased
‡
 
 
 
No difference
‡
 
 
 
No difference
‡
 
1.21 (p≤0.01)
‡
 
 
1.21 (p≤0.05)
‡
 
 
 
1.24 (NS*)
‡
 
 
 
1.01 (NS*)
‡
 
No difference 
 
No difference 
 
 
No difference 
 
 
No difference 
1.04 (NS*) 
 
0.86 (NS*) 
 
 
1.30 (NS*) 
 
 
1.64 (NS*) 
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Table 5.5 cont. Studies examining second rectal and second bladder cancers in prostate cancer patients irradiated using external beam 
radiotherapy compared to general population. Continued overleaf. 
Study Type of 
data 
Period  No. 
patients 
Median 
follow-
up 
(years) 
Exclusions Time period 
assessed 
Risk of second 
rectal cancer 
(based on p<0.05 
or confidence 
interval not 
including 1.0) 
Magnitude of 
risk of rectal 
cancer (SIR (95% 
CI or p value if 
available) 
Risk of second 
bladder cancer 
(based on 
p<0.05 or 
confidence 
interval not 
including 1.0) 
Magnitude of risk 
of bladder cancer 
(SIR (95% CI or p 
value if available) 
Rapiti 
2008 [262] 
Retro,  
Geneva 
Cancer 
Registry 
1980-
1998 
264  
 
7.8 <5 years >5 years 
 
>5 – 9 years 
 
≥10 years 
No difference 
 
No difference 
 
No difference 
2.0 (0.2 to 7.2) 
 
1.2 (0.04-6.9) 
 
5.3 (0.2-29.3) 
No difference 
 
No difference 
 
No difference 
1.84 (NS*) 
 
0.80 (NS*) 
 
5.15 (NS*) 
Margel 
2011 [283]
 
 
Retro,  
Israel 
Cancer 
Registry 
1982 -
2005 
2,163 11.2 <6 months >6 months 
 
>5 years 
Increased 
 
Increased 
1.81 (1.2-2.5) 
 
1.30 (1.05-2.8) 
NR NR 
Bagshaw 
1988 [263] 
Retro, 
single 
centre 
1956-
1985 
914 NR None All No difference 0.54 (p=0.21) No difference 1.08 (p=0.8) 
Johnstone 
1998 [268]
 
Retro, 
single 
centre 
1974-
1988 
154 10.9 None <1 year 
 
1-4 years 
 
4-10 years 
 
>10 years 
Increased 
 
No difference 
 
No difference 
 
No difference 
p<0.001** 
 
p=0.64** 
 
p=0.80** 
 
p=0.69** 
Increased 
 
No difference 
 
No difference 
 
No difference 
p<0.001** 
 
p=0.88** 
 
p=0.75** 
 
p=0.66** 
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Table 5.5 cont. Studies examining second rectal and second bladder cancers in prostate cancer patients irradiated using external beam 
radiotherapy compared to general population 
Study Type of 
data 
Period  No. 
patients 
Median 
follow-
up 
(years) 
Exclusions Time period 
assessed 
Risk of second 
rectal cancer 
(based on p<0.05 
or confidence 
interval not 
including 1.0) 
Magnitude of 
risk of rectal 
cancer (SIR (95% 
CI or p value if 
available) 
Risk of second 
bladder cancer 
(based on 
p<0.05 or 
confidence 
interval not 
including 1.0) 
Magnitude of risk 
of bladder cancer 
(SIR (95% CI or p 
value if available) 
Chrouser 
2005 [288]
 
 
Retro, 
single 
centre 
1980- 
1998 
1,743 7.1 
(mean) 
<30 days  >30 days 
 
>30 days to 
1 year 
 
1-4 years 
 
5-9 years 
 
10-19 years 
NR NR No difference 
 
No difference 
 
 
No difference 
 
No difference 
 
No difference 
0.798 (0.511-1.187) 
 
0.292 (0.007-1.619) 
 
 
0.909 (0.469-1.586) 
 
0.665 (0.267-1.367) 
 
1.37 (0.373-3.507) 
Singh 
2005 [289]
 
 
Retro, 
single 
centre 
1996- 
2003 
210 NR <6 months >6 months NR NR Increased 7.27 (3.132-14.331) 
Retro: retrospective, SEER: Surveillance, Epidemiology and End Results, SIR: standardised incidence ratio, CI: confidence interval, NR: not reported, NS: not-
significant, * no p value or confidence interval provided, ** SIRs and confidence intervals not reported, 
†
includes rectal and rectosigmoid junction cancers,                  
 
‡
risk reported is for colorectal cancer 
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Table 5.6 Studies examining second rectal and bladder cancers in prostate cancer patients irradiated using external beam radiotherapy 
compared to non-irradiated prostate cancer patients                                                                                                                                                                                                          
Continued overleaf. 
Study Type 
of data 
Period No. patients Median 
follow-
up 
(years)
ϐ
 
Exclusions Time 
period(s) 
assessed 
Risk of second 
rectal cancer 
(based on 
p<0.05 or CI 
not including 
1.0) 
Magnitude of risk of 
second rectal cancer 
(Relative risk or other 
where stated, (95% CI 
or p value if 
available)) 
Risk of second 
bladder cancer 
(based on 
p<0.05 or CI 
not including 
1.0) 
Magnitude of risk  of 
second bladder 
cancer 
(Relative risk or 
other where stated, 
(95% CI or p value if 
available)) 
Pawlish 
1997    
[258] 
Retro, 
SEER 
registry 
1973 -
1982 
2,087 RT 
6,390 no RT 
6.1 
(mean) 
<1 year >1 year  No difference NR Increased OR: 1.63 (p<0.05)
§
 
Brenner 
2000      
[259] 
Retro, 
SEER 
registry 
1973-
1993 
51,584 RT 
70,539 no RT 
 
4  
(mean) 
<2months  
 
 
> 2 months 
 
>5 years 
 
>10 years 
 
 
 
No difference 
 
No difference 
 
Increased 
Percentage increase in 
risk: 
 
-2 (-18-18, p=0.87) 
 
35 (-1- 86, p=0.06) 
 
105 (9-292, p=0.03) 
 
 
 
Increased 
 
Increased 
 
Increased 
Percentage increase 
in risk: 
 
15 (2-31, p=0.02) 
 
55 (24-92, p<0.01) 
 
77 (14-163, p=0.01) 
Baxter 
2005    
[284]
 
Retro, 
SEER 
registry 
1973-
1994 
30,552 RT 
55,263 no RT 
7.9 RT 
8.3 no 
RT 
<5 years >5 years Increased HR: 1.7 (1.4-2.2) NR NR 
Kendal 
2006    
[287]
 
Retro, 
SEER 
registry 
1973-
2001 
33,831 RT 
167,607 no 
RT (surgical 
patients) 
 
5.1 RT 
5.1 no 
RT 
 
None All  
 
0-10 years 
 
>10 years 
Increased 
 
Increased 
 
Increased 
2.38 (2.21-2.55)* 
 
2.16 (2.00-2.33) 
 
15.62 (12.01-19.83) 
NR NR 
Kendal 
2006    
[287]
 
Retro, 
SEER 
registry 
1973-
2001 
33,831 RT 
36,335 no RT 
(non-surgical 
and no RT 
patients) 
5.1 RT  
3.3 no 
RT 
None All  
 
0-10 years 
 
>10 years 
Reduced 
 
Reduced 
 
No difference 
0.69 (0.64-0.75)
¤
 
 
0.66 (0.61-0.71) 
 
0.93 (0.64-1.46) 
NR NR 
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Table 5.6 cont. Studies examining second rectal and bladder cancers in prostate cancer patients irradiated using external beam 
radiotherapy compared to non-irradiated prostate cancer patients. Continued overleaf.  
Study Type 
of data 
Period No. patients Median 
follow-
up 
(years)
ϐ
 
Exclusions Time 
period(s) 
assessed 
Risk of second 
rectal cancer 
(based on 
p<0.05 or CI 
not including 
1.0) 
Magnitude of risk of 
second rectal cancer 
(Relative risk or other 
where stated, (95% CI 
or p value if 
available)) 
Risk of second 
bladder cancer 
(based on 
p<0.05 or CI 
not including 
1.0) 
Magnitude of risk  of 
second bladder 
cancer 
(Relative risk or 
other where stated, 
(95% CI or p value if 
available)) 
Moon 
2006   
[285]
 
Retro, 
SEER 
registry 
1973-
1999 
39,805 EBRT 10 <5 years > 5years Increased OR: 1.60 (1.29-1.99) 
 
Increased OR: 1.63 (1.44-1.84) 
 
 
 
Kendal 
2007   
[286]
 
Retro, 
SEER 
registry 
Not 
stated 
520,780 (RT 
and no RT) 
NR None 
 
 
All 
 
>5 years 
No difference 
 
No difference 
NR 
 
HR: 1.13 (0.98-1.31) 
No difference 
 
Increased 
NR 
 
HR: 1.23 (1.15-1.32) 
Nieder 
2008   
[281] 
Retro, 
SEER 
registry 
1988-
2003 
93,059 RT 
109,178 no 
RT 
4.1 6 months 
 
>6 months 
 
6 months- 5 
years 
 
5-10 years 
 
>10 years 
Increased 
 
No difference 
 
 
Increased 
 
Increased 
HR: 1.26 (1.08-1.47) 
 
HR: 1.11 (0.90-1.37) 
 
 
HR: 1.39 (1.09-1.79) 
 
HR: 1.79 (1.05-3.07) 
Increased 
 
Increased 
 
 
Increased 
 
Increased 
HR: 1.88 (1.70-2.08) 
 
HR: 1.69 (1.47-1.94) 
 
 
HR: 2.26 (1.89-2.69) 
 
HR: 1.83 (1.31-2.55) 
Abdel-
Wahab 
2008   
[264]
 
Retro, 
SEER 
registry 
1973- 
2002 
48,400 RT 
40,733 no RT 
 
5.3 RT 
4.3  no 
RT 
<1 year 
 
 
 
 
 
1-5 years 
 
>5 years 
 
 
 
Increased
†
 
 
Increased
†
 
Percentage increase in 
risk: 
 
0.07%, p<0.001
†
 
 
0.16%, p=0.023
†
 
 
 
 
Increased
†
 
 
Increased
†
 
Percentage increase 
in risk: 
 
0.07% p<0.001
†
 
 
0.16% p=0.023
†
 
 
Huo 
2009   
[282]
 
Retro, 
SEER 
registry 
1973-
2005 
211,882 RT 
424,028 no 
RT 
NR None All  Increased 1.91 (1.52-1.89) NR NR 
 
 
 
158 
 
Table 5.6 cont. Studies examining second rectal and bladder cancers in prostate cancer patients irradiated using external beam 
radiotherapy compared to non-irradiated prostate cancer patients. Continued overleaf.  
Study Type 
of data 
Period No. patients Median 
follow-
up 
(years)
ϐ
 
Exclusions Time 
period 
assessed 
Risk of 
second rectal 
cancer (based 
on p<0.05 or 
CI not 
including 1.0) 
Magnitude of risk of 
second rectal cancer 
(Relative risk or other 
where stated, (95% CI 
or p value if 
available)) 
Risk of second 
bladder cancer 
(based on 
p<0.05 or CI 
not including 
1.0) 
Magnitude of risk  of 
second bladder 
cancer 
(Relative risk or 
other where stated, 
(95% CI or p value if 
available)) 
Singh 
2010   
[290]
 
Retro, 
SEER 
registry 
1973-
2005 
124,141 RT 
163,111 no 
RT 
5.3 RT                 
4.0 No 
RT 
None All 
 
>6months 
 
>5years 
 
>10years 
NR NR Increased 
 
Increased 
 
Increased 
 
Increased 
HR: 1.19 (1.11-1.28) 
 
HR: 1.33 (1.23-1.44)  
 
HR: 1.58 (1.38-1.81)  
 
HR: 1.91 (1.40-2.62)  
Berrington 
de 
Gonzalez 
2011   
[261]
 
Retro, 
SEER 
registry 
1973-
2002 
76,363 RT 
123,800 no 
RT 
9.4 RT 
(mean) 
10.1 no 
RT 
(mean) 
<5 years 5-9 years 
 
10-14 years 
 
≥15 years 
Increased
‡
 
 
Increased
‡
 
 
 
Increased
‡
 
1.39 (1.29-1.50)
‡
 
 
1.59 (1.41-1.80)
‡
 
 
 
1.91 (1.53-2.38)
‡
 
Increased
‡
 
 
Increased
‡
 
 
 
Increased
‡
 
1.39 (1.29-1.50)
‡
 
 
1.59 (1.41-1.80)
‡ 
 
 
1.91 (1.53-2.38)
‡
 
Pickles 
2002    
[260]
 
 
Retro,  
British 
Columbia 
Tumor 
Registry 
1984-
2000 
9,890 RT 
29,371 no RT 
4.77 RT 
1.7 no 
RT 
<2 months > 2 months Increased 
(colorectal) 
1.21 (p=0.03) No difference NR (NS) 
 
 
 
 
Boorjian 
2007      
[291]
 
 
Retro, 
CaPSU
RE 
Disease 
Registry 
1989-
2003 
2,471 RT 
4,608 no RT 
3.25 <30 days 
 
>30 days No difference NR (p=0.14) Increased HR: 1.96 (1.12-3.45) 
 
 
Bhojani 
2010    
 [292]
 
 
Retro, 
Quebec 
Health 
Plan 
database 
1983- 
2003 
9,390 RT 
8,455 no RT 
NR < 5years  >5 years 
 
>10years 
Increased 
 
No difference 
HR: 1.9 (p=0.01) 
 
HR: 1.6 (p=0.5) 
Increased 
 
No difference 
HR: 1.5 (p=0.01) 
 
HR: 2.0 (p=0.1) 
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Table 5.6 cont. Studies examining second rectal and bladder cancers in prostate cancer patients irradiated using external beam 
radiotherapy compared to non-irradiated prostate cancer patients 
Study Type 
of data 
Period No. patients Median 
follow-
up 
(years)
ϐ
 
Exclusions Time 
period 
assessed 
Risk of second 
rectal cancer 
(based on 
p<0.05 or CI 
not including 
1.0) 
Magnitude of risk of 
second rectal cancer 
(Relative risk or other 
where stated, (95% CI 
or p value if 
available)) 
Risk of second 
bladder cancer 
(based on 
p<0.05 or CI 
not including 
1.0) 
Magnitude of risk  of 
second bladder 
cancer 
(Relative risk or 
other where stated, 
(95% CI or p value if 
available)) 
Movsas 
1998     
[267]
 
Retro, 
single 
centre 
1973-
1993 
543 RT 
18,135 ‘no 
RT’** 
3.9 RT 
3.9 no 
RT 
(mean) 
<2 months >2 months 
 
 
NR NR No difference 
 
NR 
Singh 
2005   
[289]
 
Retro, 
single 
centre 
1996- 
2003 
210 RT 
416 no RT 
NR <6 months >6 months NR NR No difference NR (No difference 
based on overlapping 
confidence intervals 
for SIRs for  RT vs 
general population 
and no RT vs general 
population 
Huang 
2011   
[266] 
Retro, 
single 
centre 
matched
-pair 
analysis 
1984-
2005 
2,120 RT 
2,120 no RT 
6.99 RT 
7.15 no 
RT 
None All 
 
>5 years 
 
>10 years 
No difference 
 
No difference 
 
No difference 
HR: 0.91 (0.39-2.14) 
 
HR: 1.98 (0.36-10.83) 
 
p=0.31
¥
 
Increased 
 
Increased 
 
Increased 
HR: 2.02 (1.2-3.41) 
 
HR: 4.49 (1.70-11.85)  
 
HR: 9.70 (1.23-76.57) 
Black 
2013   
[265] 
Prosp, 
trial 
data 
1993-
2001 
3,216 RT 
4,263 no RT 
6 (mean) >30 days >30 days No difference 
(colorectal) 
1.5 (0.9-2.4)  No difference 1.6 (0.9-2.8)  
 
CaPSURE: University of California, San Francisco Cancer of the Prostate Strategic Urology Research Endeavor,  CI: confidence interval, HR: hazard ratio, NR: not reported, OR: odds 
ratio, Prosp: prospective, Retro: retrospective, SEER: Surveillance, Epidemiology and End Results,*HR for all time periods also available: 2.42 (95%CI: 2.08-2.81), ** Non-RT patients 
from Connecticut Cancer Registry, approximately 12.5% received RT despite being considered as ‘no RT’ group, 
†
ratio reported for any ‘primary pelvic’ second cancer, considered as 
rectum, bladder, anus, anal canal, anorectum, prostate and other cancer from the bones, joints and lymphomas, and based on comparison of age adjusted estimates only, not full Cox 
model, 
‡
 ratio reported for organs considered to be in ‘high dose’ (>5Gy) sites, includes rectum and bladder, 
¥
 hazard ratio not calculated as too few events, 
§
 Relative risk also 
reported: 1.59 (95%CI: 1.09-232), 
ϐ
 if follow-up for each treatment group reported separately, then this is presented, ¤HR for all time periods also available: 0.69 (95%CI: 0.58-0.82) 
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Of the three non-SEER registry studies comparing second rectal cancer risk in 
irradiated PCa patients and non-irradiated patients, all of which contain fewer patients 
than the SEER studies, two demonstrate an increase in risk in irradiated patients, in 
one from two months onwards, and in the other, beyond five years [260,292]. The third 
non-SEER registry study demonstrated no increase in risk of second rectal cancer in 
irradiated patients from 30 days [291]. 
 
The one single institution study which compared second rectal cancer risk between 
irradiated and non-irradiated patients, did so in the context of a matched-pair analysis. 
Patient numbers were smaller than in the above registry studies. No increase in risk in 
irradiated PCa patients was observed, both when considering risk from early on in the 
follow-up period, and after longer time periods [266]. Similarly, results of the PLCO trial 
found irradiated PCa patients to be at no increased risk of second colorectal cancers 
beyond 30 days compared to non-irradiated patients [265]. 
 
 Two studies report crude rates of rectal cancer in irradiated PCa patients without 
comparison to other population groups.  Crude rates of 2.6% after a median follow-up 
of 13.1 years are reported in one series, and of 1.8% after a median follow-up of 3.5 
years in another [269,273] (Table 5.3). 
  
Clearly there are discrepancies between studies. There is a suggestion, however, that 
where an increased risk of rectal cancer is observed, this is mainly when follow-up 
beyond 5 or 10 years is included in the evaluated time period. Beyond five years, 
cancers may be considered radiation induced [259,281-285,287,292]. Trials with 
shorter durations of follow-up, or few patients with follow-up beyond 5 or 10 years, 
therefore may not detect all the second rectal cancers that develop and therefore 
underestimate the true rate. Indeed, the study by Rapiti et al demonstrated that the 
median time to rectal cancer was 8.8 years, while median follow-up was only 7.4 years, 
which was therefore insufficient to detect all second rectal cancers [262]. One study 
revealed an increase in rectal cancer within one year of follow-up but not beyond [268]. 
This could be attributed to surveillance bias, whereby patients with rectal symptoms 
following radiotherapy are investigated and incidental rectal cancers are detected [268].  
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The increased risk of second rectal cancer is more consistently observed when 
irradiated PCa patients are compared to non-irradiated patients, as opposed to when 
irradiated patients are compared to the general population, again highlighting that there 
are differences between comparator groups. Differences in length of follow-up between 
treatment groups may contribute to these discrepancies. Since the risk of developing 
SPC increases with time, failure to adequately correct for duration of follow-up, may 
result in inaccurate conclusions. This particular criticism was levelled at Moon et al 
(who demonstrated an increased risk of second rectal cancer in irradiated patients 
compared to non-irradiated PCa patients) [285] by Kendal et al (who, after correcting 
for duration of follow-up, demonstrated no increase in risk in irradiated patients) [286]. 
Subsequent studies which have also adjusted for length of follow-up, however, have 
demonstrated an increase in rectal cancer risk compared to non-irradiated 
patients [261,281,282,292]. 
 
Another important factor is selection bias: although detailed information from registries 
is generally not available, it is possible that surgically treated patients as a whole have 
less co-morbidity than patients treated with radiotherapy. These patients may also have 
fewer risk factors for rectal cancer. Age also impacts on the risk of rectal 
SPC [284,287], and the majority of the studies have tried to adjust for this [258-
260,262,267,280-287,291,292]. Indeed, Berrington de Gonzalez et al demonstrated 
that the risk of developing a second cancer within a region irradiated to high dose 
(>5Gy, includes the rectum and bladder) lessened with an increasing age at diagnosis 
of PCa, to become non-significant for patients diagnosed with PCa aged 75 years or 
greater [292]. 
 
In terms of absolute risks, Baxter et al reported the risk of second rectal cancer over 10 
years (from 5 to 15 years) as 5.1 per 1000 for surgically treated patients and 10 per 
1000 for patients treated with radiotherapy [284].  Over a median of 10 years 
(beginning from 6 months of PCa diagnosis), Margel et al calculated that the absolute 
increase in rectal cancer risk as a result of irradiation was 13 per 1000 [283].  
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5.4.3 Second bladder cancer risk associated with EBRT for prostate 
cancer 
 
All five SEER studies which compared the risk of bladder cancer in irradiated PCa 
patients with the general population (Table 5.5) report increased risk in irradiated 
patients, albeit over different periods of follow-up: three report increased risk beginning 
from early in the follow-up period and, where examined, persisting beyond 5 and 10 
years [258,259,281], while one study reports increased risk beginning after 8 years and 
not before [280], and the other demonstrated increased risk beyond 5 years and did not 
examine any other end points [261]. The two non-SEER registries comparing risk of 
second bladder cancer in irradiated patients compared to the general population report 
no difference in risk within 5 years, beyond 5 years and beyond 10 years of follow-up, 
although the study by Rapiti et al is relatively small [260,262]. Amongst the four single 
institution studies comparing risk in irradiated patients with the general population, two 
show no increase in the risk of bladder cancer in irradiated patients over all the follow-
up periods examined (including 10-19 years in one study) [263,288]. Of the other two 
institutional studies, one demonstrated increased risk within one year of follow-up, but 
no increase in risk beyond this period [268], and the other showed increased risk 
beyond six months [289]. 
 
All but one of the 11 registry studies which compare the risk of second bladder cancer 
with non-irradiated PCa patients, show a consistently increased risk of second bladder 
cancer [258,259,261,264,281,285,286,290-292] (Table 5.6). The increased risk is often 
seen from early on in the follow-up period and frequently persists and increases 
beyond 5 and, if assessed, beyond 10 years. The one study which demonstrates no 
increased risk is that by Pickles et al who examined risk from two months and did not 
specifically examine longer time periods [260]. 
 
Of the three single institution studies comparing the risk of second bladder cancer in 
irradiated PCa patients compared to non-irradiated PCa patients, two show no 
difference in risk from early in the follow-up period [267,289], while the remaining study 
shows increased risk in irradiated patients over all durations of follow-up and beyond 5 
and beyond 10 years [266] (Table 5.6). Results for irradiated PCa patients from the 
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PLCO trial suggest no difference in the risk of second bladder cancer beyond 30 days 
in irradiated and non-irradiated patients [265]. 
 
In terms of single institution studies reporting crude rates of second bladder cancers 
(Table 5.3), Zilli et al reported a crude rate of 1.1% in a series of 276 patients with 
median follow-up of 3.5 years, and Gardner et al reported no cases of bladder cancer 
in a series of 39 patients followed up for a median of 13.1 years [269,273]. In both 
studies, risk comparisons were not performed. 
 
Overall therefore, there does appear to be an increase in the risk of second bladder 
cancer in irradiated PCa patients, particularly when compared to non-irradiated PCa 
patients. As was observed when considering second rectal cancer, the increased risk 
of second bladder cancer from irradiation is less consistently observed when 
comparisons are made with the general population. In the case of institutional data, 
small patient numbers may be the reason for these discrepancies. Amongst registry 
data, there may be fundamental differences in comparator populations, duration of 
follow-up or how adequately differences in follow-up are corrected. Selection bias 
between surgical and irradiated patients may also have an impact. Of great importance 
when considering bladder cancer, is smoking history and the potential confounding 
impact this may have. If more smokers are refused surgery due to co-morbidities, then 
there will be excess smokers in irradiated patient cohorts. Registry data frequently 
does not contain information regarding smoking status. By comparing the proportion of 
smokers amongst PCa patients treated with surgery and RT in an earlier case-control 
study, Brenner et al suggested that it was unlikely there were excess smokers in the 
irradiated patient cohort examined, and therefore concluded that smoking was unlikely 
to be a confounding factor [259]. The University of California, San Francisco Cancer of 
the Prostate Strategic Urology Research Endeavor (CaPSURE) disease registry, 
however, contains data about smoking, and Bhojani et al used this to demonstrate that 
both smoking and irradiation were independent risk factors for second bladder cancer 
and that patients treated with RT who were also smokers were more than three and a 
half times more likely to develop bladder cancer than non-smoking patients who did not 
receive RT (Hazard ratio (HR): 3.65; 95%CI:1.45 to 9.16; [292]).  
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The increased risk of bladder cancer is frequently reported as beginning within five 
years of follow-up in the above studies and so radiation is not the likely cause of these 
early bladder tumours. Surveillance bias, as a result of regular oncological or urological 
follow-up may play a part in this, while the impact of smoking may also be involved in 
early (i.e. less than five years from RT) and late (i.e. beyond five years of RT) bladder 
cancer development. Beyond five years the risk of bladder cancer appears to increase 
further, and radiation may be attributed to this although the factors mentioned above 
should also be considered. 
 
5.4.4 Impact of treatment technique:  older treatments 
 
The studies discussed above have evaluated SPC incidences in cohorts where all 
patients, or the vast majority of patients, received EBRT. Many of the SEER analyses 
have included patients treated in the 1970s and early 1980s when large pelvic fields 
and cobalt machines were often employed [258,259,261,264,280,282,284,285,287]. 
SPC risks from these treatments may therefore be different to those observed with 
more contemporary techniques. Some studies have adjusted for the year or era of 
diagnosis to try to take different treatment techniques into consideration although date 
of treatment did not appear to impact SPC risk [261,281,282,284]. 
 
5.4.5 Impact of treatment technique: 3D-conformal radiotherapy and 
IMRT 
 
It is not possible to separate the impact of more conformal EBRT techniques and older 
large field treatments from most studies. Initial indications of potential reductions in 
SPC risk with more contemporary treatment techniques were demonstrated by Rapiti et 
al, who found a reduction in colorectal cancer incidence in patients irradiated to higher 
doses (68 to 80Gy) compared to those treated to less than 67Gy (Relative risk 
(RR):0.2; 95% CI: 0.04 to 0.91 [262]. This reduction in risk was attributed to the 
introduction of smaller volume conformal radiotherapy techniques which accompanied 
dose escalation. Significance was lost, however, after adjustment for socio-economic 
status [262]. In addition, the study by Pickles et al, which excluded patients treated with 
cobalt and included fewer patients treated with large pelvic fields, found no increase in 
the incidence of SPC overall in irradiated patients compared to the general 
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population [260]. The group suggested that it was the increased use of smaller fields 
that resulted in no difference in SPC overall or bladder SPC, although a significant 
increase in colorectal tumours was observed [260]. Two other studies also evaluated 
SPC in more contemporary irradiated populations, however, and these have 
demonstrated increased bladder SPC risk compared to the general population and 
non-irradiated patients [281,291]. One of these studies also revealed an increase in 
rectal cancer beyond five years in irradiated compared to non-irradiated patients [281]. 
 
Huang et al was the first institutional study to specifically evaluate differences in EBRT 
treatment technique [266] (Table 5.7). Using a matched-pair analysis comparing 
irradiated and surgically treated patients in an effort to minimise confounding factors, 
they demonstrated that patients treated with 2D conventional RT were at increased risk 
of any SPC (HR: 1.76; 95% CI: 1.32 to 2.35) and bladder cancers (HR: 2.97; 95% CI: 
1.50-5.89) .  There was no difference in the risk of rectal cancer. In contrast, patients 
treated with 3D-CRT or intensity-modulated radiotherapy (IMRT), had no increase in 
the incidence of SPCs overall, nor in rectal or bladder cancer. The group 
acknowledged that the numbers of patients in each RT subset was relatively small (769 
in the 2D conventional RT subset and 616 in 3D-CRT/ IMRT) and that the median 
follow-up in the 3DCRT/ IMRT group was relatively short (4.96 years) in comparison to 
the 2D conventional RT group (9.26 years) [266]. Unfortunately numbers were too 
small to analyse SPC in patients treated with 3D-CRT and IMRT separately. Some 
radiotherapy planning studies, however, have raised theoretical concerns that 
increased low dose irradiation and leakage (because of increased monitor unit 
requirements) with IMRT might increase SPC incidence [254,293-298].                                                                      
 
Zelefsky et al reported outcomes for a series of 897 patients treated predominantly with 
IMRT [299]. After a median follow-up of seven years, compared to the general 
population, there was no significant increase in the development of any second 
malignancy beyond one and five years [299] (Table 5.7). Similarly, compared with the 
general population (and excluding non-melanoma skin cancers), there was no 
significant increase in risk of second in-field and out-of-field malignancies beyond one 
and beyond five years.  Within the analysis the group also compared the risk of any 
second malignancy between patients receiving IMRT (the majority) and 3D-CRT 
(number of patients not reported), and no significant difference was found 
(p=0.59) [299]. 
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Table 5.7 Studies examining second primary cancers at any site, rectal cancers and bladder cancers in prostate cancer patients irradiated 
using modern external beam techniques compared to general population and compared to surgical prostate cancer patients 
Study Type of data Period  No. 
patients 
Median 
follow-
up 
(years) 
Exclusions Time 
period 
assessed 
Risk of any second 
cancer based on 
p<0.05 or 
confidence interval 
not including 1.0 
(magnitude,  and 
(95% CI)) 
Risk of second 
rectal cancer based 
on p<0.05 or 
confidence interval 
not including 1.0 
(magnitude, and 
(95% CI)) 
Risk of second 
bladder cancer 
based on p<0.05 or 
confidence interval 
not including 1.0 
(magnitude,  and 
(95% CI)) 
Compared to general population 
Zelefsky 
2012       
[299] 
Retrospective, 
single centre 
1998-
2001 
897 
(mainly 
IMRT) 
7 <1 years >1 year 
 
 
 
>5 years 
No difference 
(SIR: 0.881 (0.701-
1.082)) 
 
No difference 
(SIR: 0.937 (0.673-
1.295)) 
No difference 
(SIR: 1.179 (0.739-
1.720))* 
 
No difference 
(SIR: 1.336 (0.611-
2.339))* 
No difference 
(SIR: 1.179 (0.739-
1.720))* 
 
No difference 
(SIR: 1.336 (0.611-
2.339))* 
Compared to surgically treated patients 
Huang 
2011       
[266] 
Retrospective, 
single centre 
matched-pair 
analysis 
1984-
2005 
616 3D-
CRT/ 
IMRT 
616  
surgery 
4.96 RT 
4.90 
surgery 
 
None All 
durations  
 
No difference 
(HR: 0.81 (0.55-1.21, 
p=0.30)) 
 
No difference  
(HR: 0.24 (0.03-
2.18)) 
No difference 
(HR: 0.83 (0.25-
2.72)) 
Zelefsky 
2012       
[274] 
Retrospective, 
single centre 
1998-
2001 
897 RT 
(mainly 
IMRT) 
1348 
surgery 
7.5 RT  
9.4 
surgery 
 
 
None 0-10 
years 
No difference 
(Multivariate 
analysis: no 
significant difference 
between techniques) 
No difference 
(10-year likelihood 
RT vs. surgery: 4% 
vs. 3% (NS))* 
No difference 
(10-year likelihood 
RT vs. surgery: 4% 
vs. 3% (NS))* 
CI: confidence interval, HR: hazard ratio, NS: not significant, SIR: standardised incidence ratio, * figures shown are for any second in-field/pelvic cancer which 
includes rectal and bladder cancers 
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In a second publication, including the same irradiated population with slightly longer 
follow-up (7.5 years), Zelefsky et al compared SPC risks with 1348 patients treated 
with radical prostatectomy (median FU 9.4 years) and 413 patients treated with BT 
(median follow-up 7.7 years; Table 5.7) [274]. There was no significant difference in the 
rates of second rectal or bladder cancer with treatment type (10-year actuarial 
likelihood of pelvic second malignancy: 3%, 4% and 2% for patients treated with 
surgery, EBRT and BT, p=0.29). Multivariate Cox regression revealed that only age 
and smoking history were significant predictors of SPC, while treatment type (i.e. 
surgery, BT or EBRT) was not [274]. Survival following SPC diagnosis was also no 
different between irradiated and surgically treated patients [274]. 
 
5.4.6 Impact of treatment technique:  Brachytherapy 
 
Since the introduction of prostate BT, studies examining the impact of BT on SPC have 
been published. Four studies have compared SPC incidence after BT with that in the 
general population [281,299-301] (Table 5.8). Two single institution studies, have 
examined the risk of any SPC compared to the general population, and neither have 
shown any increase in risk in patients treated with BT, including when follow-up beyond 
five years is examined specifically [299,300]. The risk of rectal cancer has also been 
shown to be no greater than that in the general population over various time points, 
including beyond five years, in both SEER and single institution studies [281,300]. In 
terms of bladder cancer, one SEER analysis found patients treated with EBRT-BT to 
be at increased risk of second bladder cancer beyond six months compared to the 
general population, while patients treated with BT monotherapy were not at any 
increased risk [281]. Liauw et al, a single institution study, demonstrated more than 
double an increase in bladder cancer in patients treated with BT or EBRT-BT over all 
durations of follow-up compared to the general population. The risk was maintained 
over longer periods of follow-up (and was equivalent to an absolute excess risk of 35 
per 10,000), but did not reach statistical significance [301]. Hinnen et al, also a single 
institution study, found an increased risk of second bladder cancer in patients treated 
with BT in years 1 to 4 of follow-up but not over all durations of follow-up, nor between 
5 and 15 years. An increased risk in BT patients aged less than 60 was also observed 
(SIR: 5.84, 95% CI: 2.14-12.71) [300]. In addition, Zelefsky et al, a third single 
institution study, found no difference in the risk of any in-field cancer, which includes 
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rectal and bladder cancers, in BT treated patients compared to the general population, 
beyond one and beyond five years of follow-up [299]. 
 
Four studies, one registry and three single institution, have compared the incidence of 
any SPC in patients irradiated with BT or EBRT-BT with non-irradiated PCa patients 
(Table 5.9) [264,266,274,300]. Three of the four, all single institution studies, 
suggested no increased risk of any SPC following BT or EBRT-BT [266,274,300]. The 
fourth study, importantly, is the largest to examine SPC in patients managed with BT 
and the only one to specifically examine longer periods of follow-up [264]. On 
multivariate analysis there was no difference in risk for SPC beyond one year for 
patients treated with BT or EBRT-BT compared to non-irradiated patients (Table 
5.9) [264]. The hazard ratios for ‘late’ SPCs (i.e. SPC developing beyond five years) in 
patients treated with BT alone, however, increased over time (0.721 at five years, 
0.930 at seven years and 1.2 at nine years) but did not reach significance. Similarly, 
the hazard ratios for patients treated with EBRT-BT increased over time and only 
became significant at nine years (HR of 1.317; 95%CI: 1.053 to 1.647). Amongst 
patients treated with BT, however, the median time to develop ‘late’ SPC was 6.9 years 
while the median follow-up amongst BT patients without SPC was only 6.3 years, thus 
the duration of follow-up was insufficient [264]. With regard to RISPC specifically 
(defined in this study as cancers developing after five years in any primary pelvic site, 
including rectal and bladder tumours), no significant difference in risk was observed 
amongst patients treated with BT or EBRT-BT compared to patients receiving neither 
surgery nor RT [264] (Table 5.10). 
 
None of the studies, with one exception, which compare the risk of second rectal or 
second bladder cancer in patients managed with BT or EBRT-RT with non-irradiated 
PCa patients (Table 5.10) demonstrate an increased risk in patients managed with BT 
or EBRT-BT [264,266,274,285,300]. The time periods examined are variable, but 
follow-up beyond five years is examined in two of these studies [264,285]. The one 
exception is the study by Nieder et al, the largest study and the only one to specifically 
examine risk beyond 10 years. Patients treated with EBRT-BT were found to be at 
increased risk of second rectal cancer beyond 10 years (patients treated with BT 
monotherapy were at no increased risk). In addition, patients treated with BT or EBRT-
BT were at increased risk of second bladder cancer from 6 months, between 6 months 
and 5 years and between 5 and 10 years [281]. Significance was lost beyond 10 years 
although fewer patients were followed up for this length of time.  
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Table 5.8 Studies examining second primary cancers at any site, second rectal cancers and second bladder cancers in prostate cancer 
patients irradiated using brachytherapy compared to general population                                                                                                                                
Continued overleaf.                                                                                                                                  
Study Type 
of data 
Period No. 
patients 
Median 
follow-up 
(years)
†
 
Exclusions Time 
period(s) 
assessed 
Risk of second cancer 
at any site based on 
p<0.05 or confidence 
interval not including 
1.0 (SIR and (95% CI)) 
Risk of second rectal 
cancer based on p<0.05 
or confidence interval 
not including 1.0 (SIR 
and (95% CI)) 
Risk of second bladder 
cancer based on p<0.05 
or confidence interval 
not including 1.0 (SIR 
and (95% CI)) 
Nieder 
2008    
[281] 
Retro, 
SEER 
registry 
1988-
2003 
22,889 
BT 
4.1 <6 months 
 
>6 months NR Reduced 
(0.68 (0.49-0.93)) 
 
No difference 
(1.10 (0.92-1.31)) 
Nieder 
2008    
[281] 
Retro, 
SEER 
registry 
1988-
2003 
17,956 
EBRT-BT 
4.1 <6 months 
 
>6 months NR No difference 
(0.86 (0.65-1.14)) 
Increased 
(1.39 (1.19-1.64)) 
Liauw 
2006    
[301]
 
Retro,  
single 
centre 
1987  - 
1994 
348 
(125 BT, 
223 
EBRT-
BT) 
11.4 BT 
10.2 
EBRT-BT 
None All durations 
 
 
0-1 years 
 
 
1.1-5 years 
 
 
5.1-10 years 
 
 
10.1-20 years 
 
 
>5 years 
NR  NR Increased 
(2.34 (1.26-3.42)) 
 
No difference 
0 
 
No difference 
(2.80 (0.73-4.87)) 
 
No difference 
(2.33 (0.60-4.06)) 
 
No difference 
(2.35 (0.05-4.66)) 
 
No difference 
(2.34 (0.95-3.72)) 
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Table 5.8 cont. Studies examining second primary cancers at any site, second rectal cancers and second bladder cancers in prostate 
cancer patients irradiated using brachytherapy compared to general population 
Study Type 
of data 
Period No. 
patients 
Median 
follow-
up 
(years)
†
 
Exclusions Time 
period(s) 
assessed 
Risk of second cancer 
at any site based on 
p<0.05 or confidence 
interval not including 
1.0 (SIR and (95% CI)) 
Risk of second rectal 
cancer based on p<0.05 
or confidence interval 
not including 1.0 (SIR 
and (95% CI)) 
Risk of second bladder 
cancer based on p<0.05 
or confidence interval 
not including 1.0 (SIR 
and (95% CI)) 
Hinnen 
2011    
[300]
 
 
Retro,  
single 
centre 
1989-
2005 
1,187 BT 7.1  None All durations 
 
 
1-4 years 
 
 
5-15 years 
No difference 
(0.94 (0.78-1.12)) 
 
No difference 
(1.03 (0.80-1.30)) 
 
No difference 
(0.78 (0.56-1.04)) 
No difference 
(0.90 (0.41-1.72)) 
 
No difference 
(0.41 (0.05 to 1.48)) 
 
No difference 
(1.78 (0.71 to 3.67)) 
No difference 
(1.69 (0.98 to 2.70)) 
 
Increased 
(2.14 (1.03 to 3.94)) 
 
No difference 
(0.92 (0.25 to 2.35)) 
Zelefsky 
2012     
[299] 
Retro, 
single 
centre 
1998-
2001 
413 
(322 BT, 
91 EBRT 
(IMRT)-
BT) 
7.5 <1 year >1 year 
 
 
>5 years 
No difference 
(0.821 (0.565-1.124)) 
 
No difference 
(0.635 (0.304-1.085)) 
No difference 
(0.753 (0.276-1.465))* 
 
No difference 
(0.944 (0.195-2.274))* 
No difference 
(0.753 (0.276-1.465))* 
 
No difference 
(0.944 (0.195-2.274))* 
BT: brachytherapy, CI: confidence interval, EBRT-RT: combination external beam radiotherapy and brachytherapy, IMRT: intensity-modulated radiotherapy, NR: not reported, Retro: 
retrospective, SEER: Surveillance, Epidemiology and End Results, †if follow-up for each treatment group reported separately, then this is presented, *: SIR quoted is for any in-field 
cancer, which includes rectal and bladder cancers 
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Table 5.9 Studies examining second primary cancers at any site in prostate cancer patients irradiated using brachytherapy compared to 
non-irradiated prostate cancer patients   
Continued overleaf. 
Study Type of data Period  No. patients Median 
follow-up 
(years) 
Exclusions Time 
period(s) 
assessed 
Risk of second cancer at any 
site  
(based on p<0.05 or CI not 
including 1.0) 
Magnitude of risk (HR or other 
where stated (95% confidence 
interval)) 
Abdel-
Wahab 
2008 [264]
 
Retrospective, 
SEER 
database 
1973- 
2002 
10,223 BT 
40,733 no RT 
3.3 BT 
4.3 no RT 
 
<1 year >1 year 
 
5 years 
 
7 years 
 
9 years 
No difference 
 
No difference 
 
No difference 
 
No difference 
0.958 (0.869-1.057) 
 
0.721 (0.435-1.197) 
 
0.930 (0.575-1.504) 
 
1.200 (0.736-1.956) 
Abdel-
Wahab 
2008 [264]
 
Retrospective, 
SEER 
database 
1973- 
2002 
9,096 EBRT-
BT 
40,733 no RT 
3.8 EBRT-BT 
4.3 no RT 
<1 year >1 year 
 
5 years 
 
7 years 
 
9 years 
No difference 
 
No difference 
 
No difference 
 
Increased 
1.012 (0.920-1.112) 
 
0.920 (0.699-1.211) 
 
1.101 (0.910-1.331) 
 
1.317 (1.053-1.647) 
Hinnen 
2011 [300]
 
Retrospective,  
Single centre 
1989-
2005 
1,187 BT 
701 no RT 
7.1 BT 
8.7 no RT 
None All durations 
of FU 
No difference 0.87 (0.64-1.18) 
Huang  
2011 [266]
 
Retrospective, 
single centre 
matched-pair 
analysis 
1984-
2005 
333 BT 
333 no RT 
6.67 BT 
6.62 no RT 
None All durations 
of FU 
No difference 0.53 (0.28-1.01) 
Huang  
2011 [266]
 
Retrospective, 
single centre 
matched-pair 
analysis 
1984-
2005 
402 EBRT-BT 
402 no RT 
8.81 EBRT-
BT 
8.87 no RT 
 
None All durations 
of FU 
No difference  0.83 (0.50-1.38) 
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Table 5.9 cont. Studies examining second primary cancers at any site in prostate cancer patients irradiated using brachytherapy compared 
to non-irradiated prostate cancer patients 
Study Type of data Period  No. patients Median 
follow-up 
(years) 
Exclusions Time 
period(s) 
assessed 
Risk of second cancer at 
any site  
(based on p<0.05 or CI not 
including 1.0) 
Magnitude of risk (HR or other 
where stated (95% confidence 
interval)) 
Zelefsky 
2012 [274] 
Retrospective, 
single centre 
1998-
2001 
413 BT  
(322 BT, 91 
EBRT 
(IMRT)-BT) 
1,348 no RT 
7.7 BT  
9.4 no RT 
 
 
None 0-10 years No difference 10 year second cancer 
actuarial likelihood BT vs. 
surgery: 13% vs. 11% 
(p=0.37). HR non-significant 
on multivariate analysis 
 BT: brachytherapy, CI: confidence interval, EBRT-BT: combination external beam radiotherapy and brachytherapy, HR: hazard ratio, IMRT: intensity-modulated radiotherapy, SEER: 
Surveillance, Epidemiology and End Results 
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Table 5.10 Studies examining second rectal and bladder cancers in prostate cancer patients irradiated using brachytherapy compared to 
non-irradiated prostate cancer patients                                                                                                                                                                                                
Continued overleaf.  
Study Type 
of data 
Period No. patients Median 
follow-
up
¥ 
(years) 
Exclusions Time 
period(s) 
assessed 
Risk of second 
rectal cancer 
(based on 
p<0.05 or 
confidence 
interval not 
including 1.0) 
Magnitude of risk of 
second rectal 
cancer (RR or other 
where stated, 95% 
CI or p value if 
available) 
Risk of second 
bladder cancer 
(based on 
p<0.05 or 
confidence 
interval not 
including 1.0) 
Magnitude of risk 
of second bladder 
cancer (RR or other 
where stated, 95% 
CI or p value if 
available) 
Moon 
2006    
[285]
 
Retro, 
SEER 
registry 
1973-
1999 
1285 BT 
94,541 no 
RT 
10 <5 years 
 
>5 years No difference OR: 0.3 (NS*) 
 
No difference OR: 1.4 (NS*) 
Moon 
2006    
[285]
 
Retro, 
SEER 
registry 
1973-
1999 
2219 EBRT-
BT 
94,541 no 
RT 
10 <5 years 
 
>5 years No difference OR: 1.59 (NS*) No difference OR: 1.08 (NS*) 
Abdel-
Wahab 
2008    
[264]
 
Retro, 
SEER 
registry 
1973- 
2002 
10,223 BT 
40,733 no 
RT 
3.3 RT 
4.3 no 
RT 
<1 year 1-4.9 years 
 
 
≥5 years 
No difference** 
 
 
No difference** 
0.01% difference in 
risk (NS)** 
 
0.17% difference in 
risk (NS)** 
No difference** 
 
 
No difference** 
0.01% difference in 
risk (NS)** 
 
0.17% difference in 
risk (NS)** 
Abdel-
Wahab 
2008    
[264] 
Retro, 
SEER 
registry 
1973- 
2002 
9,096 EBRT-
BT 
40,733 no 
RT 
3.8 RT 
4.3 no 
RT 
<1 year 1-4.9 years 
 
 
≥5 years 
No difference** 
 
 
No difference** 
0.09% difference in 
risk (NS)** 
 
0.05% difference in 
risk (NS)** 
No difference** 
 
 
No difference** 
0.09% difference in 
risk (NS)** 
 
0.05% difference in 
risk (NS)** 
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Table 5.10 cont. Studies examining second rectal and bladder cancers in prostate cancer patients irradiated using brachytherapy 
compared to non-irradiated prostate cancer patients. Continued overleaf.  
Study Type 
of data 
Period No. patients Median 
follow-
up
¥ 
(years) 
Exclusions Time period 
assessed 
Risk of second 
rectal cancer 
(based on 
p<0.05 or 
confidence 
interval not 
including 1.0) 
Magnitude of risk of 
second rectal 
cancer (RR or other 
where stated, 95% 
CI or p value if 
available) 
Risk of second 
bladder cancer 
(based on 
p<0.05 or 
confidence 
interval not 
including 1.0) 
Magnitude of risk 
of second bladder 
cancer (RR or other 
where stated, 95% 
CI or p value if 
available) 
Nieder 
2008   
[281] 
Retro, 
SEER 
registry 
1988-
2003 
22,889 BT 
109,178 no 
RT 
4.1 6 months 
 
>6 months 
 
6 months- 5 
years 
 
5-10 years 
 
>10years 
No difference 
 
No difference 
 
 
No difference 
 
No difference 
HR: 1.08 (0.77-1.54) 
 
HR: 0.96 (0.63-1.44) 
 
 
HR: 1.49 (0.75-2.94) 
 
HR: 1.13 (0.15-8.42) 
Increased 
 
Increased 
 
 
Increased 
 
No difference 
HR: 1.52 (1.24-1.87) 
 
HR: 1.48 (1.17-1.86) 
 
 
HR: 1.64 (1.03-2.62) 
 
HR: 0.47 (0.06-3.38) 
Nieder 
2008   
[281] 
Retro, 
SEER 
registry 
1988-
2003 
17,956 
EBRT-BT 
109,178 no 
RT 
4.1 6 months 
 
>6 months 
 
6 months- 5 
years 
 
5-10 years 
 
>10years 
No difference 
 
No difference 
 
 
No difference 
 
Increased 
HR: 1.21 (0.89-1.65) 
 
HR: 1.05 (0.71-1.55) 
 
 
HR: 1.26 (0.69-2.29) 
 
HR: 3.25 (1.25-8.44) 
Increased 
 
Increased 
 
 
Increased 
 
No difference 
HR: 1.85 (1.54-2.22) 
 
HR: 1.81 (1.46-2.25) 
 
 
HR: 1.80 (1.22-2.67) 
 
HR: 1.64 (0.75-3.59) 
Hinnen 
2011   
[300]
 
Retro, 
Single 
centre 
1989-
2005 
1,187 BT 
701 no RT 
7.1 BT 
8.7 no 
RT 
None All durations 
of FU 
No difference
†
 HR: 0.96 (p=0.92)
†
 No difference
§
 HR: 1.13 (p=0.75)
§
 
 
 
175 
 
Table 5.10 cont. Studies examining second rectal and bladder cancers in prostate cancer patients irradiated using brachytherapy 
compared to non-irradiated prostate cancer patients 
Study Type 
of data 
Period No. patients Median 
follow-
up
¥ 
(years) 
Exclusions Time period 
assessed 
Risk of second 
rectal cancer 
(based on p<0.05 
or confidence 
interval not 
including 1.0) 
Magnitude of risk 
of second rectal 
cancer (RR or 
other where 
stated, 95% CI or 
p value if 
available) 
Risk of second 
bladder cancer 
(based on 
p<0.05 or 
confidence 
interval not 
including 1.0) 
Magnitude of risk 
of second bladder 
cancer (RR or 
other where stated, 
95% CI or p value if 
available) 
Huang  
2011   
[266]
 
Retro, 
single 
centre 
matched
-pair 
analysis 
1984-
2005 
333 BT 
333 no RT 
6.67 BT 
6.62 no 
RT 
 
None All durations 
of FU 
No difference HR: NR (too few 
events to analyse), 
p=0.32 
 
 
 
No difference HR: 0.66 (0.11-3.95) 
 
Huang  
2011   
[266]
 
Retro, 
single 
centre 
matched
-pair 
analysis 
1984-
2005 
402 EBRT-
BT 
402 no RT 
8.81 
EBRT-
BT 
8.87 no 
RT 
None All durations 
of FU 
No difference HR: 1.00 (0.14-
7.06) 
 
 
 
No difference HR: 2.98 (0.31-28.7) 
 
 
 
 
 
Zelefsky 
2012      
[274] 
Retro, 
single 
centre 
1998-
2001 
413 BT  
(322 BT, 91 
EBRT 
(IMRT)-BT) 
1,348 no RT 
7.7 BT  
9.4 no 
RT 
 
None 0-10 years No difference
‡
 10 year actuarial 
risk BT vs. surgery: 
2% vs. 3% (NS)
‡
 
No difference
‡
 10 year actuarial risk 
BT vs. surgery: 2% 
vs. 3% (NS)
‡
 
BT: brachytherapy, CI: confidence interval, EBRT-BT: combination external beam radiotherapy and brachytherapy, HR: hazard ratio, IMRT: intensity-modulated radiotherapy, NR: Not 
reported, NS: not significant, OR: odds ratio, Retro: retrospective, RR: relative risk, SEER: Surveillance, Epidemiology and End Results, *no p value or confidence interval reported,    
** difference in any ‘primary’ pelvic second primary cancer (includes rectum and bladder) based on comparisons of age-adjusted estimates and not on multivariate Cox regression, 
†
risk of second cancer in any location in digestive tract, 
‡
risk of any second pelvic tumour reported, 
¥
 if follow-up for each treatment group reported separately, then this is presented, 
§
risk of second cancer in any location in urinary tract 
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Three studies have compared patients treated with BT with patients treated with EBRT 
(Table 5.11) [264,274,302]. One of these studies, a SEER analysis, suggested that 
between 1 and 15 years of follow-up, patients treated with BT or EBRT-BT were at 
reduced risk of any SPC compared to patients irradiated using EBRT [264]. When 
follow-up beyond 5 years was examined specifically, however, no differences in risk 
were observed [264]. Neither of the other two studies, both single institution studies, 
have demonstrated any difference in the risk of any SPC between patients irradiated 
with BT compared to patients irradiated using EBRT [274,302]. Similarly, no difference 
in the risk of second pelvic/ primary pelvic SPC has been observed between patients 
treated with BT and EBRT-BT compared to those treated with EBRT (in the two studies 
which assessed this) [264,274]. While these results are encouraging overall, it should 
be remembered that the patient numbers are often lower than in similar studies which 
have examined risks in EBRT patients, and the duration of follow-up may not always be 
sufficient.   
 
Gutman et al examined the frequency of colorectal cancers before and after BT or 
EBRT-BT [303] (Table 5.12). After a median follow-up of 4.6 years, no differences in 
the frequency of colorectal cancers were observed, nor were there any differences in 
the geographical location of second colorectal primaries. In addition, the addition of 
supplemental EBRT (i.e. EBRT-BT) did not increase the risk of colorectal cancer 
compared to using BT alone [303].  
 
Of the eight single institution studies examining SPC following BT without comparisons 
to other population groups (Table 5.12), crude rates range from 0% for any SPC, rectal 
and bladder cancer up to 11.1%, 0.8% and 1.2% for any SPC, second rectal and 
second bladder cancers respectively [279,303-309]. It is likely that some studies have 
insufficient follow-up to detect all SPCs and most single institution studies contain a 
relatively small number of patients. The age of the patient population may also have an 
impact. For example, Yagi et al reported no cases of SPC in patients aged less than 60 
but a crude rate of 7.6% in patients aged over 60, after median follow-up of 4.3 
years [308].  
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Table 5.11 Studies examining second primary cancers at any site in prostate cancer patients irradiated using brachytherapy compared to 
patients irradiated using external beam radiotherapy                                                                                                                                         
Continued overleaf.                                                                                                                                
Study Type of data Period No. patients Median 
follow-
up 
(years) 
Exclusions Time period 
assessed 
Risk of any second 
cancer based on 
p<0.05 or confidence 
interval not including 
1.0  (magnitude of 
risk) 
Risk of second  
rectal cancer based 
on p<0.05 or 
confidence interval 
not including 1.0 
(magnitude of risk) 
Risk of second 
bladder cancer  
based on p<0.05 or 
confidence interval 
not including 1.0 
(magnitude of risk) 
Abdel-
Wahab 
2008    
[264]
 
Retrospective, 
SEER 
database 
1973- 
2002 
10,223 BT 
48,400 
EBRT 
3.3 BT 
5.3 
EBRT 
<1 year 1-15 years 
 
 
 
1-5 years 
 
 
 
>5 years 
 
 
Reduced  
(0.28% reduction in 
risk, p=0.025)
†
 
 
No difference  
(0.15% difference in 
risk, NS)
†
 
 
No difference  
(0.49% difference in 
risk, NS)
†
 
NR 
 
 
 
No difference  
(0.08% difference in 
risk, NS)* 
 
No difference  
(0.004% difference in 
risk, NS)* 
NR 
 
 
 
No difference  
(0.08% difference in 
risk, NS)* 
 
No difference  
(0.004% difference in 
risk, NS)* 
Abdel-
Wahab 
2008    
[264]
 
Retrospective, 
SEER 
database 
1973- 
2002 
9,096 EBRT-
BT 
48,400 
EBRT 
3.8 
EBRT-
BT 
5.3 
EBRT 
<1 year 1-15 years 
 
 
 
1-5 years 
 
 
 
>5 year 
Reduced  
(0.28% reduction in 
risk, p=0.025)
†
 
 
No difference  
(0.2% difference in risk, 
NS)
†
 
 
No difference 
(0.33% difference in 
risk, NS)
†
 
NR 
 
 
 
No difference  
(0.03% difference in 
risk, NS)* 
 
No difference  
(0.12% difference in 
risk, NS)* 
NR 
 
 
 
No difference  
(0.03% difference in 
risk, NS)* 
 
No difference  
(0.12% difference in 
risk, NS)* 
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Table 5.11 cont. Studies examining second primary cancers at any site in prostate cancer patients irradiated using brachytherapy 
compared to patients irradiated using external beam radiotherapy                                                                                                                                               
Study Type of data Period No. 
patients 
Median 
follow-
up 
(years) 
Exclusions Time period 
assessed 
Risk of any second 
cancer based on 
p<0.05 or confidence 
interval not including 
1.0  (magnitude of 
risk) 
Risk of second  
rectal cancer based 
on p<0.05 or 
confidence interval 
not including 1.0 
(magnitude of risk) 
Risk of second 
bladder cancer  
based on p<0.05 or 
confidence interval 
not including 1.0 
(magnitude of risk) 
Reddy 
2010    
[302]
 
Retrospective, 
single centre 
1996 -
2008 
1,758 
EBRT 
2,317 BT 
5.7 
EBRT  
2.8 BT 
None All durations 
of follow-up 
No difference 
(Multivariate analysis 
OR: 1.226 (0.887-
1.695)) 
NR NR 
 
 
 
Zelefsky 
2012      
[274] 
Retrospective, 
single centre 
1998-
2001 
413 BT  
(322 BT, 
91 EBRT 
(IMRT)-BT) 
897 EBRT 
7.7 BT  
7.5 
EBRT 
None 0-10 years No difference 
(HR on multivariate 
analysis NS) 
No difference 
(10 year actuarial 
risk (BT vs EBRT): 
2% vs 4% (NS))** 
No difference 
(10 year actuarial risk 
(BT vs EBRT): 2% vs 
4% (NS))** 
EBRT: external beam radiotherapy, BT: brachytherapy, EBRT-BT: combination EBRT and BT, IMRT: intensity-modulated radiotherapy, NR: not reported, NS: non-significant, HR: 
hazard ratio, OR: odds ratio, SEER: Surveillance, Epidemiology and End Results, * risks shown for any second ‘primary’ pelvic second cancer (includes rectum and bladder) and are 
based on are based on comparisons of age-adjusted estimates and not on multivariate Cox regression, ** risks shown for any pelvic second cancer (includes rectal and bladder 
cancer), 
†
 based on comparisons of age-adjusted estimates and not on multivariate Cox regression 
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Table 5.12 Studies reporting second cancer rates in patients treated with brachytherapy or combination external beam radiotherapy and 
brachytherapy without comparison                                                                                                                                                                                                  
Study Type of data Period 
examined 
No. patients Median follow-
up (years) 
Exclusions Crude rate of any 
second cancer 
Crude rate of 
second rectal 
cancer 
Crude rate of 
second bladder 
cancer 
Gutman 
2006 [303]
 
Retrospective, 
single centre 
1995-2004 652 BT 
699 EBRT-BT 
4.6 
 
None NR 0.3% (n=4) post-
radiation vs 0.2% 
(n=3) pre-radiation 
NR 
Swartz 
2010 [304]
 
Prospective, 
single centre 
1997 - 1999 86 BT or EBRT-
BT 
Minimum FU 10 
years 
None 0 0 0 
Wilcox 
2011 [306]
 
Retrospective, 
single centre 
Not stated 431 BT or 
EBRT-BT 
6.9 None <1%* NR NR 
Henry 
2012 [279] 
Retrospective, 
single centre 
1995-2005 1,805 BT 6-17 years NR 11.1% (201/1805) 0.6% (11/1805) 1.2% (21/1805) 
Laing 
2012 [305] 
Prospective, 
single centre 
1999-2011 121 (all <55 
years) BT or 
EBRT-BT 
Minimum FU >3 
years 
NR 0 0 0 
Lilleby 
2012 [307] 
Prospective, 
single centre 
2004-2009 275 EBRT-BT 
(mainly high risk 
patients) 
3.7 None 1.1% (3/275; all 
colorectal cancers) 
0.4% (1/275) 0 
 
 
Yagi 
2012 [308] 
Retrospective, 
single centre 
2005-2008 86 BT aged <60 
 
685 BT aged 
>60 
4.3 NR Patients aged<60: 0 
 
Patients aged>60: 
7.6% (52/685) 
Patients aged<60: 0 
 
 
Patients aged>60: 
1.3% (9/685; bladder 
or rectal cancers) 
Patients aged<60: 0 
 
 
Patients aged>60: 
1.3% (9/685; 
bladder or rectal 
cancers) 
Buckstein 
2013 [309] 
Retrospective, 
single centre 
1990-2002 102 BT 
29 EBRT-BT (all 
<60 years) 
11.5 (minimum 
FU 10 years) 
None 3.1% (4/131) 0.8% (1/131) 0.8% (1/131) 
BT: brachytherapy, EBRT-BT: combination external beam and brachytherapy, FU: follow-up, NR: not reported, *<1% “rate of possible radiation-induced cancer” (not defined further) 
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Studies examining survival following BT suggest that up to 3% of patients may die from 
SPC following BT or EBRT-BT (crude rate, Table 5.4) [277-279]. The cumulative 
hazard of death due to a SPC was found to be 7.2% in one study of 1354 patients 
treated with either BT or EBRT-BT after 12 years [277]. In another series, based on 
competing analysis to take into account other causes of death, the  10 year risks of 
death from second malignancy following BT was 0.8% for out-of-field SPC and 0% for 
in-field SPC in a series of 413 patients, and this was not significantly different to 
mortality rates following EBRT (or surgery) [274]. 
 
Overall, evidence from patients treated with BT or EBRT-BT is encouraging, and is less 
suggestive of an increased risk of SPCs as has been observed in studies evaluating 
patients treated with EBRT. Three studies have suggested an increase in bladder 
cancer risk beginning in the first few years of follow-up, which could be at least partly 
attributed to surveillance bias [281,300,301]. Importantly, there is a suggestion from 
two of the largest cohorts, that the risk of a SPC, although low, may increase with time 
and so it is likely that follow-up in general has been insufficient to detect all potential 
late increases in SPC incidence  [264,281].  
 
5.4.7 Impact of treatment technique:  Proton therapy 
 
Protons result in high doses of radiation being delivered to the target with rapid dose 
fall off beyond the target. Entrance doses from protons are lower than when using 
photon radiation, and exit doses are minimal, both of which result in reduced normal 
tissue irradiation compared to photon radiotherapy [293]. Given these differences in 
dose distribution, planning studies have suggested that proton therapy should result in 
lower risks of second cancer compared to photon radiotherapy [295,310-313]. Only one 
study was identified which reported SPC rates in patients treated with proton therapy 
for PCa [273]. Treatment consisted of a photon 4-field box delivering 50.4Gy in 28 
fractions followed by a 27Gy conformal perineal proton boost. After a median follow-up 
of 13.1 years, one of the 39 patients (2.6%) developed rectal cancer [273]. Clearly no 
comparisons to other populations have been performed and this series is too small to 
draw any firm conclusions. Furthermore, the relative contribution of the EBRT and 
proton components cannot be assessed. Larger numbers of patients treated with 
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proton monotherapy will be required before any conclusion can be drawn regarding the 
impact of proton therapy on SPC incidence in PCa patients.  
 
5.4.8 Post-operative radiotherapy 
 
Four registry studies and one single institution study have examined SPC risk in 
patients treated with post-operative radiotherapy (PORT) following 
prostatectomy [275,288,290,291,314] (Table 5.13).  
 
Chrouser et al included a subset of 184 PCa patients managed with PORT in their 
single institution analysis and compared bladder cancer incidence to the general 
population [288]. No increased risk of bladder cancer was observed in patients 
receiving PORT over several time points. 
 
Compared to patients treated with radical surgery alone, Abdel-Wahab et al, using a 
SEER registry, demonstrated that there was a significantly increased risk of a ‘primary 
pelvic’ SPC (i.e. tumour likely to arise within the irradiated field: bladder, rectum, anus, 
anal canal and anorectum) in patients who received PORT beyond one year and 
beyond five years of follow-up [314]. There was no increase in the risk of ‘secondary’ 
pelvic tumours (recto-sigmoid, penis, small intestine, ureter, other urinary primaries, 
male genital organs, testes and pelvic lymphoma) or non-pelvic tumours beyond one 
and beyond five years [314]. Overall the group estimated that radiation increased the 
risk of a pelvic RISPC by an age-adjusted rate of 374 per 100,000 [314]. Ciezki et al, 
another SEER analysis, used 20-year competing risk regression to compare second 
rectal and bladder cancers between patients treated with surgery and PORT and 
patients treated with surgery alone [275]. At 20 years, the cumulative incidence of 
second rectal cancer was 0.74% and 1.06% in patients treated with surgery alone and 
surgery followed by PORT respectively. The cumulative incidence of second bladder 
cancer at 20 years was 1.7% and 2.7% in patients treated with surgery alone and 
surgery plus PORT respectively. Multivariate analysis revealed a significantly increased 
risk of second rectal and bladder cancers amongst irradiated patients. Older age was 
also a significant predictor of second bladder cancer (HR: 1.01,  p=0.003) [275]. 
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Table 5.13 Risk of second rectal and bladder cancers following post-operative radiotherapy for prostate cancer compared to the general 
population and compared to non-irradiated patients      
    Continued overleaf.  
Study Type of data Period No. patients Median 
follow-up 
(years) 
Exclusions Time period 
assessed 
Risk of second rectal  
cancer based on p<0.05 or 
confidence interval not 
including 1.0  (magnitude 
and (95% confidence 
interval)) 
Risk of second bladder cancer 
based on p<0.05 or confidence 
interval not including 1.0  
(magnitude and (95% 
confidence interval)) 
Compared to general population 
Chrouser 
2005        
[288]
 
Retrospective, 
Single centre 
1980- 
1998 
184 
 
7.1 (mean 
for whole 
study 
population) 
None All durations 
 
 
<1 year 
 
 
1-4 years 
 
 
5-9 years 
 
 
10-19 years 
 
NR No difference 
(SIR:2.345 (0.943-4.832)) 
 
No difference 
(SIR:0 (0-15.18)) 
 
No difference 
(SIR:3.643 (0.990-9.312)) 
 
No difference 
(SIR:1.799 (0.218-6.475)) 
 
No difference 
(SIR:1.890 (0.048-10.53)) 
Compared to prostate patients managed in other ways 
Abdel-
Wahab 
2009        
[314]
 
Retrospective, 
SEER registry 
1973- 
2002 
5,044 surgery 
and PORT 
80,157 surgery 
NR <1 year >1 year 
 
 
>5 years 
Increased* 
 (HR:1.53 (1.22- 1.90)) 
 
Increased* 
(HR:1.82 (1.36-2.43)) 
Increased* 
(HR:1.53 (1.22- 1.90)) 
 
Increased* 
(HR:1.82 (1.36-2.43)) 
 
 
183 
 
Table 5.13 cont. Risk of second rectal and bladder cancers following post-operative radiotherapy for prostate cancer compared to the 
general population and compared to non-irradiated patients   
Study Type of data Period No. patients Median 
follow-up 
(years) 
Exclusions Time period 
assessed 
Risk of second rectal  
cancer based on p<0.05 or 
confidence interval not 
including 1.0  (magnitude 
and (95% confidence 
interval)) 
Risk of second bladder cancer 
based on p<0.05 or 
confidence interval not 
including 1.0  (magnitude and 
(95% confidence interval)) 
Compared to prostate patients managed in other ways 
Singh 
2010 [290]
 
Retrospective, 
SEER registry 
1973-
2005 
32,744 surgery 
and PORT 
163,111 no 
surgery, no RT 
7.8 PORT 
4.0 No 
surgery, no 
RT 
None 
(simultaneous 
diagnoses 
excluded) 
All time 
periods 
 
 
>6months 
 
 
>5years 
 
 
>10years 
NR Increased 
(HR:1.18 (1.07-1.29)) 
 
Increased 
(HR:1.28 (1.15-1.42))  
 
Increased 
 (HR:1.52 (1.30-1.78))  
 
Increased 
(HR:1.94 (1.40-2.67))  
Ciezki 
2012 [275] 
Retrospective, 
SEER registry 
1973-
2008 
20,545 surgery 
and PORT 
127,189 
surgery alone 
9.5 surgery 
and PORT 
9.2 surgery 
alone 
<3 years 20 years Increased 
(HR: 1.45 (1.23-1.71)) 
Increased 
(HR:1.72 (1.55-1.91)) 
Boorjian 
2007 [291]
 
 
Retrospective, 
CaPSURE 
Disease 
Registry 
1989-
2003 
232 surgery 
and PORT 
4339 surgery 
alone 
3.25 for 
whole 
study 
population 
<30 days >30 days NR No difference  
(HR: NR, p=0.12) 
HR: hazard ratio, NR: not reported, PORT: post-operative radiotherapy, SEER: Surveillance, Epidemiology and End Results, SIR: standardised incidence ratio, * ratio reported for any 
‘primary pelvic’ second cancer considered as rectum, bladder, anus, anal canal, anorectum and other cancer from the bones, joints and lymphomas  involving the pelvis 
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Singh et al, also using SEER data, observed that patients treated with surgery and 
PORT had an increased risk of second bladder cancers overall as well as beyond six 
months of follow-up (HR: 1.28) compared to patients treated with neither surgery, nor 
RT [290]. The risk increased beyond five years and increased further beyond 10 years 
of follow-up (HRs: 1.52 and 1.94 respectively).  The duration of follow-up in the PORT 
group was almost twice that in the comparator group (median 93.6 months and 48.4 
months respectively) and so it is possible that the incidence of bladder cancer was 
lower in the reference group as a result of insufficient follow-up [290].  
 
In a small subset of patients within the CaPSURE disease registry, Boorjian et al did 
not find patients receiving PORT to be at increased risk of second bladder cancer 
beyond 30 days compared to patients treated with surgery alone [291]. 
 
One series of 214 patients treated with PORT reported death due to second 
malignancy in 1.9% of patients after median follow-up of 4.8 years (crude rate) [276] 
while Ciezki et al reported very low age-adjusted mortality rates from second colorectal 
or bladder cancers [275] (Table 5.4). 
 
Compared to surgically treated PCa patients who do not receive PORT, there is, 
therefore, a reasonably consistent suggestion of an increased risk of second 
bladder/rectal cancers following PORT, and this risk appears to increase with time but 
may also be present early on in the follow-up period. Compared to the general 
population the same increase in risk has not been observed, although the number of 
patients in this particular analysis was small [288]. 
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5.5 Discussion 
 
There is much heterogeneity in the above studies, in terms of methods, comparisons 
and results, which makes it difficult to draw firm conclusions. Increases in SPC have 
been observed in irradiated PCa patients in some studies, more so when compared to 
non-irradiated PCa patients, and less consistently when compared to the general 
population. The majority of the evidence suggests that the risk of SPC increases over 
time, particularly for SPCs occurring within the radiation field and, if these occur 
beyond five years, they may be considered RISPCs. 
 
Solid second primary cancers which occur within five years of irradiation are not 
generally considered RISPCs. Other explanations for an excess of early SPCs must 
therefore be sought. Surveillance bias is one explanation, as patients presenting with 
both bladder and bowel symptoms following RT may be investigated and incidental 
SPCs may be identified. Alternatively, there may be genetic or environmental factors 
which are common to PCa and other cancers, and therefore patients with PCa are 
likely to develop other cancers, within five years of prostate irradiation or beyond. This 
is one possible reason for increased cancer rates which have at times been observed 
when comparing irradiated PCa patients to the general population. If this were the 
case, then the same increased risk should be observed when comparing non-irradiated 
PCa patients to the general population. In practice, this is not consistently the case, 
and non-irradiated PCa patients have been shown to have similar (or even reduced) 
rates of second malignancy compared to the general population in terms of cancer 
overall, and in terms of rectal and bladder cancer 
specifically [258,259,262,280,283,300]. Surveillance bias is perhaps, therefore, a better 
explanation for increased early SPCs in irradiated patients. Beyond five years, radiation 
for in-field SPCs, and genetic or environmental factors for either in-field or out-of-field 
SPCs, may potentially contribute. 
 
Differences in comparator group are important to consider when evaluating relative 
SPC risks. As well as the general population, comparisons have been made with non-
irradiated PCa patients. This patient group might consist of surgically treated patients, 
PCa patients treated with neither surgery nor RT, or a mixture of surgically treated 
patients and patients treated with neither surgery, nor-RT. Although differences 
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between these non-irradiated groups were not analysed in detail here, it should not be 
assumed that any of these PCa patients are pure surrogates for the general population 
or that they are equivalent to each other. While all these non-irradiated patients have 
PCa, and therefore common factors contributing to this, there are likely variations in 
genetic or environmental factors in each of these patient groups that may contribute to 
or reduce the risk of other cancers.  
 
If the non-irradiated comparator group consists of purely surgically treated patients, 
selection bias may contribute to differences in SPC risk between surgically treated and 
irradiated patients. Patients who are fit enough to undergo an operation may have 
fundamental differences to patients who are only deemed well enough to undergo 
radiotherapy, and as such surgically treated patients may lack risks factors for certain 
SPCs.  
 
If the non-irradiated comparator group is patients treated with neither surgery nor RT, 
many of these patients may have significant co-morbidities which render them unfit for 
either definitive treatment. Again, this population of patients will have different risks of 
SPC to PCa patients overall. Furthermore, these patients may not be as thoroughly 
followed up or investigated for possible second malignancy compared to fitter healthier 
patients, thus creating additional bias in comparisons and under-reporting of SPC 
rates. 
 
When the non-irradiated comparator group is a mixture of surgically treated patients as 
well as those who receive no definitive therapy, a mixed population is potentially 
created, consisting of surgically fit patients and patients unfit for any definitive therapy, 
leading to further difficulties in making non-biased comparisons.  
 
It has been suggested that comparing irradiated patients to surgically treated patients 
results in fewer confounding factors than comparisons to the general population or 
other non-irradiated PCa patients [266]. Certainly, in clinical practice, if patients are fit 
enough to consider surgery or RT, then it can be argued that this is the most relevant 
comparison. 
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The length of follow-up between comparator groups is also important, and where this is 
insufficient in any group or not adequately corrected for, reported outcomes may be 
inaccurate in that group.  
 
Smoking is an important potential confounding factor, especially when considering 
bladder and lung cancer. As discussed above, smokers may be refused surgery and 
therefore cohorts of patients treated with radiotherapy may contain a higher proportion 
of smokers, which in turn will increase the risk of SPCs. PCa patients treated with 
radiotherapy may also be older than surgically treated patients and this too may have 
an impact on risks of SPC. Indeed, age at PCa diagnosis has been shown to be 
another important factor: increasing age has been associated with  a reduced risk of 
second cancers within high dose (>5Gy) regions [261], while increasing age has been 
shown to be a significant predictor of bladder SPC [290,291]. Most studies have 
adjusted for age when calculating risks [258-262,264-267,274,275,280-
292,299,300,314]. Similarly most studies have adjusted for race and grade of tumour. It 
is possible that other confounding factors exist which are more common in irradiated 
than non-irradiated PCa patients, and these may also contribute to SPC risk within or 
beyond five years.  
 
A recently identified potential confounding factor is visceral adiposity [269]. Zilli et al 
intended to investigate the impact of total abdominal adiposity on clinical and 
pathological PCa features [269]. Incidentally they observed that increased visceral 
adiposity was an independent significant predictor of SPCs (HR: 1.014; p=0.0001). 
 
While many of the studies have included patients treated with now out of date 
techniques, the registry studies by Nieder et al  and Boorjian et al which included 
patients from 1988/1989 to 2003,  are considered more contemporary EBRT 
populations, and so the risks observed in these studies may be considered more 
relevant to today’s PCa patients [281,291]. It is worth noting, therefore, that both of 
these studies found the risk of bladder cancer to be increased in irradiated 
patients [281,291], and one demonstrated an increased risk of rectal cancer as 
well [281]. Insufficient follow-up (mean approximately four years) may explain the 
absence of increased rectal cancer risk from EBRT in the other of these studies [291]. . 
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Studies including patients from the 1970s and early 1980s would have included 
patients diagnosed before the routine use of PSA. As such a greater proportion of 
patients would be diagnosed with locally advanced disease and so would have inferior 
survival compared to patients in today’s society where many more patients are 
diagnosed at an earlier stage. A significant proportion of patients from the past may 
therefore have died prior to developing SPC, and so the relative risks of SPC reported 
from these studies may actually be lower than what would be expected from modern 
day PCa patients [281]. 
 
With the advent of more conformal treatments, it was hoped that SPC risk might 
reduce, although the clinical evidence to support this is based on limited evidence from 
only two relatively small populations irradiated with IMRT/3D-CRT [266,274,299] and 
on extrapolated evidence from two other studies [260,262]. Longer follow-up and larger 
numbers of patients will be required. Studies examining the impact of BT or EBRT-BT 
on SPC risk appear promising, although, once again, longer follow-up will be required 
before definitive conclusions can be drawn. 
 
5.6 Conclusions 
 
Given the multiple factors involved, and heterogeneity among studies, it is very difficult 
to tease out definitive answers regarding irradiation and the risk of SPCs. Putting all the 
potential confounders and biases aside, however, it must be acknowledged that a small 
increased risk of SPC and RISPC in irradiated PCa patients has been observed in 
several studies. The risk of RISPC appears small, in the range of 1 in 220 to 1 in 290 
over all durations of follow-up, based on older external beam radiation techniques. 
Importantly, the risk appears to increase with time, and beyond five years, SPCs in the 
region of the original field may be considered RISPCs. To date there is insufficient 
clinical data to draw firm conclusions about the impact of more modern RT techniques, 
although limited evidence is encouraging. As PCa survival improves, the risk of second 
malignancy becomes more relevant, especially when treating younger patients. Second 
primary cancer risks must therefore be borne in mind when considering which patients 
to irradiate and which technique to employ. 
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5.7 Update at time of thesis write-up 
 
The search strategy was re-run at the time of thesis compilation (last search date 1st 
July 2014). This revealed an additional 71 records, including 8 repeats. Of the 
remaining 63 new articles, reasons for exclusion included: initial primary cancer not 
PCa (n=9), not dealing with new primary cancer (n=11), case reports (n=5), review/ 
commentary (n=9), planning studies (n=12), letters not containing new data (n=3), 
laboratory or biomarker based studies (n=5), imaging study (n=1), not specifically 
dealing with irradiated PCa patients (n=1) and not in English language (n=2). Five 
additional studies were therefore identified that could be added, one of which was a full 
paper which had previously been included in abstract form only. The outcomes from all 
five studies are largely in-keeping with findings from the studies reviewed earlier, and 
are discussed below. 
 
Nam et al used the Ontario Cancer Registry to retrospectively compare complications 
following either prostatectomy or radiotherapy treatment for PCa [315]. Patients 
received treatment between 2002 and 2009. In total, 15,870 patients were included 
who received surgery and 16,595 patients who received radiotherapy (without surgery). 
Patients who received surgery were younger and had less co-morbidity than those who 
received radiotherapy. Patients with less than five years follow-up were excluded from 
the second malignancy analysis. The maximum duration of follow-up was nine years. 
Compared to the general population, and in keeping with studies discussed earlier, 
patients receiving radiotherapy aged 65 to 90 were at no increased risk of second 
cancer at any site (SIR: 0.8, 95%CI:0.7-1.0). When patients aged between 40 to 65 
were examined specifically, however, an increased risk of SPC was observed (SIR:3.5, 
95%CI:2.3-4.7), which influenced the overall SIR such that when considering all 
patients, there appeared to be an increased risk of SPC in irradiated patients compared 
to the general population (SIR:2.0, 95%CI:1.7-2.3). When irradiated patients were 
compared to surgically treated patients within a Cox proportional hazards model, 
irradiated patients were found to be at increased risk of second cancers from five to 
nine years (HR:2.08, 95%CI:1.48-2.91, p<0.0001). Increasing age and greater co-
morbidity were also identified as risk factors for second malignancy. Although the data 
were not provided, the group reported that when the analysis was restricted to only 
those irradiated patients who received ‘contemporary’ radiotherapy (i.e. 3D planning), 
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the hazard ratio for any SPC for radiotherapy versus surgery was maintained. An 
unadjusted numerical comparison (i.e. not within a Cox model) of the number of 
patients developing GI and GU cancers also found these tumours  to be more common 
in irradiated patients compared to surgically treated patients (p<0.0001) [315]. This 
study has been criticised for issues including selection bias, the manner in which 
radically treated patients were identified from the database, the relatively short follow-
up and the lack of inclusion of potential confounders in the Cox model (including PCa 
stage, Gleason score and smoking history (although this is frequently not available in 
registry data)) [316-319]. At least 40% of the SPCs identified occurred outside the 
treatment field, including tumours at sites with known links to smoking, and so the 
impact of smoking was felt to be of particular importance. Issues with selection bias are 
difficult to avoid when performing retrospective analyses such as this, and some of the 
criticisms raised to this study, could also be applied to the earlier registry studies, as 
discussed before. 
 
Okajima et al evaluated SPCs in a single institution study of 150 patients irradiated for 
PCa [320]. After a median follow-up of 48 months (range 12 to 142 months),  16 
patients (11%) developed SPCs more than two months from the PCa diagnosis, 
including two cases of bladder cancer but no cases of rectal cancer. The median time 
to develop a SPC was 44 months (range 13 to 83 months), and so several of these 
tumours would not be considered radiation-induced. Compared to the expected 
incidence in the general population, there was no significant increase in the risk of any 
SPC (SIR at four years post-treatment: 1.21, p=0.501, SIR at five years post treatment: 
0.96, p=non-significant), nor bladder cancer specifically (SIR at four years post-
treatment: 4.55, p=0.072, SIR at five years post treatment: 3.57, p=0.110). As with 
similar single institution studies, this study is limited by a small sample size and 
relatively short follow-up. 
 
Musunuru et al provided a full report of the single institution BT data previously 
included in abstract form [279,321]. The risk of SPC at any site, or rectal or bladder 
cancer specifically, did not appear to be higher in BT treated patients compared to the 
general population. In a series of 1574 patients with a median follow-up of 8 years 
(interquartile range 6 to 10 years, patients with <1 year of follow-up excluded, 31% of 
patients had greater than 10 years of follow-up), the SIR for SPC at any site was 0.70 
(95%CI:0.57-0.84) over all durations of follow-up, 0.92 ((95%CI:0.71-1.18) for follow-up 
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between one and four years, and 0.55 (95%CI:0.42-0.74) for follow-up beyond five 
years. For rectal cancer, the SIR was 0.83 (95%CI:0.46-1.53) over all durations of 
follow-up, 1.30 (95%CI:0.64-2.68) for follow-up between one to four years, and 0.45 
(95%CI:0.16-1.31) for follow-up beyond five years. For bladder cancer, SIR was 1.54 
(95%CI:0.96-2.46) over all durations of follow-up, 1.69 (95%CI:0.87-3.34) for between 
one and four years of follow-up and 1.42 (95%CI:0.75-2.7) for follow-up beyond five 
years. The group concluded that there was a potentially increased risk of second 
bladder cancer in BT treated patients compared to the general population, although this 
did not reach statistical significance. The effect was mostly observed in the early follow-
up period where it was attributed to increased surveillance rather than radiotherapy. As 
before, it is only those BT studies with larger patient numbers and longer durations of 
follow-up that suggest that there could be an increased risk of SPC following BT, and 
so larger patient numbers and longer follow-up are still required in this and similar 
studies before a firm conclusions regarding SPC following BT can be drawn. 
 
Roach et al performed a post hoc analysis of SPCs in 1979 irradiated PCa patients 
from the RTOG 9408 trial [322]. Patients were treated between 1994 and 2001. Rates 
of SPC were compared between patients irradiated using whole pelvic radiotherapy 
(WPRT) and patients who received prostate only radiotherapy. No significant difference 
was identified in the risk of second cancer at 10 years (19.1% for WPRT vs. 16.9% for 
prostate only radiotherapy, p=0.87). There was, however, a trend towards increased 
death from SPC following WPRT (9.1% for WPRT vs. 4.2% for prostate only 
radiotherapy at 10 years) although this did not reach statistical significance (p=0.061). 
The group concluded that this observation required further work to determine its clinical 
significance and validity. 
 
Ferrer et al examined toxicity following pelvic VMAT (48.6Gy in 27 fractions) with a 
hypofractionated whole prostate boost (67.5Gy in 27 fractions) in a series of 28 high 
risk PCa patients treated between June 2010 and November 2012 [323]. After a 
median follow-up of six months, one patient was diagnosed and died from a second 
cancer (crude death rate: 4%). Given the relatively short follow-up in this series, this 
cancer was unlikely to have been radiation-induced.  
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Thus none of these studies alter the conclusions reached in the main text. Problems 
can be encountered both when using large, potentially incomplete registry data, as well 
as when trying to draw conclusions from relatively small studies or studies with short 
durations of follow-up. As before, there remains a suggestion that EBRT can result in 
an increase in SPC compared to non-irradiated PCa patients, while the evidence 
concerning BT remains encouraging but too immature to draw firm conclusions. 
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Chapter 6 :  Radiation-induced second primary cancer risks 
from modern external beam radiotherapy for early prostate 
cancer: impact of stereotactic ablative radiotherapy (SABR), 
volumetric modulated arc therapy (VMAT) and flattening 
filter free (FFF) radiotherapy 
 
6.1 Introduction 
 
One the most serious long-term consequences of successful radiotherapy treatment is 
the development of a RISPC. As treatment techniques improve along with survival, the 
development of RISPC becomes a more significant clinical issue. As discussed in the 
previous chapter, there is clinical evidence that suggests that PCa patients treated with 
EBRT, compared to patients treated surgically, are at increased risk of developing 
RISPC, and that this risk increases over time. The vast majority of the clinical literature 
concerning RISPC in PCa patients, however, consists of patients treated with older 
radiotherapy techniques. Theoretical concerns have been raised that modern 
techniques such as IMRT may increase RISPC risk [254]. The clinical evidence 
concerning patients treated with more modern techniques is currently too immature to 
determine if these concerns are warranted. Until more clinical data is available, 
planning studies can be used to estimate RISPC risks. In PCa, such planning data 
exists in terms of comparisons of IMRT with 3D-conformal radiotherapy [294,297,324-
327]. Studies comparing IMRT and 3D-CRT at equivalent energies have consistently 
demonstrated an increase in RISPC risk from IMRT [294,297,324,325]. The magnitude 
of the increase in risk depends on the models and methods used for RISPC calculation 
but, in absolute terms, the increase in risk can be very small. Those studies which have 
directly compared 6MV IMRT with higher energy 3D-CRT treatments, as are often 
employed clinically, however, do not demonstrate an increase in risk from 
IMRT [326,327]. The RISPC risk from IMRT compared to 3D-CRT, therefore, may not 
be as high as has perhaps been historically presumed. Little data exist concerning 
techniques such as SABR (although it has been postulated that this should reduce 
RISPC risk [328]) and VMAT. It has previously been demonstrated that the use of FFF 
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in PCa treatment results in a reduction in out-of-field doses [329], although 
quantification and comparisons of RISPC risk in in-field, close-to-field and out-of-field 
organs have not been widely performed.  
 
This study aims to compare the RISPC risks from modern radiation techniques used to 
treat early PCa using doses, fractionations and beam energies that are employed in 
day to day clinical practice. Conventionally fractionated schedules delivered using 
10MV 3D-conformal radiotherapy (3D-CRT), 6MV 5-field IMRT, 6MV VMAT with 
standard (flattened) and energy-matched 6MV FFF beams are evaluated together with 
SABR delivered using 6MV VMAT with standard (flattened) and energy-matched FFF 
beams. Schneider’s concept of Organ Equivalent Dose (OED) [330], which considers 
the effects of fractionation, has been employed. In addition, the impact of in-field and 
out-of-field dose is included (as opposed to out-of-field dose in isolation). For organs in 
close proximity to the treatment field (where the majority of RISPCs have been shown 
to develop [261]), RISPC risk has been estimated using DVH data, while for organs 
further from the treatment volume, chamber measurements were used to assess 
RISPC risk. 
 
6.2 Methods 
6.2.1 Contouring 
Three prostate datasets were selected which were typical for patients diagnosed with 
low risk, localised PCa. The CTV was defined as the prostate alone and was expanded 
by 6mm in all directions to create the PTV, a margin compatible with daily online image 
guidance with fiducial markers in situ [186-188]. The rectum (recto-sigmoid junction to 
anus), bladder and femoral heads were contoured as organs at risk. All pelvic bones 
were also contoured and used to represent the dose received by bones. A 5mm shrink 
margin was created within the bladder and the subtraction of this structure from the 
whole bladder structure was used to represent the bladder wall. The patients’ rectums 
were empty at the time of the planning scan and so the whole rectal volume was taken 
to represent the dose received by the rectum, as has been previously shown to be 
acceptable [239].  
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6.2.2 Advanced radiotherapy planning 
 
Five external beam treatment plans were produced for each dataset using Monaco® 
v3.3 (Elekta AB, Sweden) with a MC algorithm, 6MV photons, a 2mm calculation grid 
and the Agility™ head (Elekta AB, Sweden). A 5-field step and shoot IMRT plan was 
produced, delivering 78Gy in 39 fractions, with a standard (flattened) 6MV beam with 
the following beam angles: 180 (posterior), 252, 324, 36 and 108. Two VMAT 
plans delivering 78Gy in 39 fractions were produced using one 240 arc (240 to 120, 
30 sectors), one with a standard (flattened) 6MV beam and one with an energy-
matched 6MV FFF beam. Two SABR plans delivering 42.7Gy in 7 fractions were 
produced, also using one 240 VMAT arc (240 to 120, 30 sectors), one with a 
standard (flattened) 6MV beam and one with energy-matched 6MV FFF. (As before, 
‘energy-matched’ means the FFF beam energy was re-tuned to match the relative dose 
in water at 10cm deep for a 10x10cm standard 6MV beam, 100cm source-to-surface 
distance [249]). For all VMAT plans, a 240 arc was used instead of the 210 arc 
adopted in earlier chapters as the manufacturer suggested that adopting an even 
number of sectors (i.e. 8 x 30 sectors as opposed to 7 x 30 sectors) might facilitate a 
more symmetrical plan in terms of femoral head dose.  
 
In all plans, doses were prescribed so that at least 95% of the PTV received at least 
95% of the prescription dose and the median dose was within 1Gy of the prescription 
dose. Organ at risk constraints for the conventionally fractionated schedules for the 
rectum and femoral heads were those used in the 78Gy in 39 fraction arm of the Hypo-
RT-PC trial [133] and, for the bladder, were those used in the RTOG 0126 trial (79.2Gy 
in 44 fractions vs. 70.2Gy in 39 fractions using IMRT or 3D-CRT) [331] (Table 6.1). For 
SABR schedules, rectal constraints were those used in the HYPO-RT-PC trial [133] 
with additional constraints for the high and low dose regions, as defined in Chapter 2, 
and for the bladder, were biologically equivalent for a seven fraction schedule to those 
used in the 74Gy in 37 fraction arm of the UK Phase III CHHiP trial [191], as defined in 
Chapter 2 (Table 6.1). Femoral head doses were those used both in the HYPO-RT-PC 
trial [133] and biologically equivalent for a seven fraction schedule to those used in the 
UK Phase III CHHiP trial [191].  
196 
 
Table 6.1 Organ at risk constraints 
 
 
 
 
 
 
 
 
 
 
 
 
                             
CHHiP: Conventional versus Hypofractionated High-dose intensity-modulated radiotherapy for Prostate Cancer,                                                                           
RTOG: Radiation Therapy Oncology Group 
 
Volume 78Gy in 39 fraction 
constraints 
Source SABR constraints Source 
Rectum V70Gy(90%)<15% 
V59Gy(76%)<35% 
V51Gy(65%)<45% 
HYPO-RT-PC 
trial [133] 
V41.4Gy(97%)<3%  
V38.4Gy(90%)≤15%  
V32.0Gy(75%)≤35%  
V28.0Gy(65%)≤45%  
V24.8Gy(58%)<70%  
V19.6Gy(46%)<80%  
HYPO-RT-PC trial [133] plus biologically 
equivalent constraints to 74Gy arm of 
CHHiP trial for high and low dose 
regions [191] 
Bladder V80Gy(103%)<15% 
V75Gy(96%)<25% 
V70Gy(90%)<35% 
V65Gy(83%)<50% 
RTOG 0126 [331] V41.4Gy(97%)<5% 
V34.7Gy(81%)<25% 
V29.9Gy(70%)<50% 
Biologically equivalent constraints to 74Gy 
arm of CHHiP trial [191] 
Femoral 
heads 
Dmax≤55Gy(70%) HYPO-RT-PC 
trial [133] 
Dmax≤29.9Gy(70%) 
V29.9Gy(70%)<50% 
HYPO-RT-PC trial [133] and biologically 
equivalent constraints to 74Gy arm of 
CHHiP trial regions [191] 
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6.2.3 3D-conformal planning 
 
3D-conformal radiotherapy (3D-CRT) plans cannot be produced using Monaco® 
v3.3. A 10MV 3D-CRT 4-field (anterior, posterior, left and right lateral) was therefore 
produced for each dataset using Oncentra® MasterPlan (Elekta AB, Sweden) 
delivering 78Gy in 39 fractions with a standard (flattened) beam and using a 1cm 
mulitleaf collimator head. In terms of energy, 10MV was selected for the 3D-CRT 
plan as 6MV photons are less commonly used in this setting, thus 10MV was 
considered to produce the most clinically relevant data for comparison. 
 
For the 3D-CRT plans, the prescription dose was normalised to the centre of the 
PTV, and the PTV was encompassed by the 95% isodose, aiming for 100% 
coverage and accepting ≥95% coverage. Organ at risk constraints were those 
described in Table 6.1. The final plans were then transferred to Monaco® prior to 
DVH export so that DVHs for all six techniques were produced in the same way. 
 
The threshold for neutron production, which contributes to second malignancy risk, 
begins at 10MV. It has previously been demonstrated that the contribution of 
neutron contamination at 10MV is minimal and so this was neglected from all 
calculations for the 10MV plan [297,325]. 
 
 
6.2.4 In-field and close-to-field RISPC risk assessment 
 
Differential DVHs for the rectum, bladder wall, pelvic bones and pelvic soft tissue 
(total volume minus bones and prostate) for all three datasets were exported from 
Monaco® using 0.01Gy bin widths and used to calculate Organ Equivalent Doses 
(OED) and excess absolute risks (EAR) for second rectal and bladder cancers as 
well as for pelvic bone and soft tissue sarcomas, as described below. Average 
values from the three datasets are presented with the range of values obtained. 
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6.2.5 Out-of-field RISPC risk assessment 
 
As little variation in out-of-field dose is likely between datasets for each radiotherapy 
technique, only one of the three datasets was used to deliver each of the six 
techniques to the RANDO® phantom (The Phantom Laboratory, USA) in order to 
measure out-of-field dose. Plans were delivered on a Synergy® linear accelerator 
(Elekta, AB Sweden) with the Agility™ head and with and without FFF high dose 
rate mode. As the Agility™ head was not available for planning within MasterPlan, 
the 10MV 78Gy in 39 fraction 3D-CRT plan was approximated and delivered as a 
6x6cm 4-field QA (Quality Assurance) plan, created within Monaco. 
 
For conventionally fractionated treatments three fractions of 2Gy were delivered, 
while for each of the SABR plans, one fraction of 6.1Gy was delivered. The 
RANDO® phantom is an anthropomorphic phantom consisting of 35 slices each of 
2.5cm, and one slice of 8cm at the base. For treatment delivery the isocentre was 
positioned 1.75cm from the base of slice 32 (approximately at the level of the upper 
symphysis pubis). Chamber measurements were performed in the midline of the 
phantom at increasing distances from the isocentre (5cm, 10cm, 15cm, 20cm, 
25cm, 30cm, 40cm, 50cm, 60cm and 70cm) by substituting each relevant slice of 
the phantom for a 2.5cm tall perspex block with a chamber holder centred at 1.75cm 
from the base of the block (Figure 6-1). A 20x20cm wide and deep block was used 
in torso region and a 10x10cm wide and deep block was used in the head and neck 
region. Measurements were taken at a depth corresponding approximately to the 
midline of the phantom. Doses at specific distances from the isocentre were taken to 
represent doses received by organs located at approximately those distances from 
the isocentre (a homogenous dose distribution was assumed within each out-of-field 
organ; Table 6.2).  
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Figure 6-1 Experimental set-up for assessment of out-of-field dose  
Perspex slice holding chamber was substituted for various slices in the RANDO® 
phantom. 
 
 
 
Chamber measurements were performed using a semi-flex ionisation chamber 
(PTW GmbH, Germany) previously calibrated for 6MV flattened, 6MV FFF and 
10MV beams. Chamber readings were corrected for leakage, temperature and 
pressure. To estimate the impact of chamber drift on measurements, on the first full 
day of measurements, a second semi-flex chamber was positioned at 70cm from the 
isocentre and doses were recorded here at the same time as recording 
measurements at points closer to the isocentre (Figure 6-1). At 70cm, where the 
impact of drift was assumed to be greatest, the average standard deviation was 
2.57% of the mean reading at 70cm. Drift was therefore not considered likely to 
have a major impact on measured dose for the majority of readings, and would 
therefore be adequately encompassed within the 5% error assigned (below). 
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      Table 6.2 Source of dosimetric data and parameters for RED and EAR calculations  
       (Parameters from [332]) Continued overleaf. 
 
 
 
Site Source of 
dose data 
Position of 
chamber from 
isocentre (cm)† 
Mechanistic model Bell-
shaped 
model 
Plateau 
model 
β‡ γe 
(years) 
γa 
(years) 
   α 
(Gy-1) 
R α 
(Gy-1) 
α 
(Gy-1) 
(for calculation of EAR for 
mechanistic, bell-shaped, plateau 
and linear models) 
Rectum DVH - 0.033 0.56 0.031 0.065 0.73 -0.056 6.9 
Bladder DVH - 0.219 0.06 0.213 0.633 3.8 -0.024 2.38 
Bone sarcoma DVH - Separate sarcoma model: α=0.067 based on intermediate 
repopulation (R=0.5),   β‡=0.20 
-0.013 -0.56 
Soft tissue 
sarcoma 
DVH - Separate sarcoma model: α=0.060,  based on intermediate 
repopulation (R=0.5),  β‡=0.60 
-0.013 -0.56 
Colon§ Chamber 20§ - - - - 7.4 -0.056 6.9 
Liver Chamber 25 - - - - 2.4 -0.021 3.6 
Stomach Chamber 30 - - - - 5.2 -0.002 1.9 
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    Table 6.2 cont. Source of dosimetric data and parameters for RED and EAR calculations (Parameters from [332]) 
Site Source of 
dose 
Position of 
chamber from 
isocentre (cm)† 
Mechanistic model Bell-
shaped 
model 
Plateau 
model 
β‡ γe 
(years) 
γa 
(years) 
Lung Chamber Average of 
readings at 40 
and 50 
- - - - 8.0 0.002 4.23 
Oesophagus Chamber Average of 
readings at 40, 
50 and 60 
- - - - 3.2 -0.002 1.9 
Thyroid Chamber 60 - - - - 0.40 -0.046 0.6 
Salivary gland Chamber 60 - - - - 0.73 -0.024 2.38 
Mouth Chamber 70 - - - - 0.73 -0.024 2.38 
Brain and CNS Chamber 70 - - - - 0.70 -0.024 2.38 
  DVH: dose-volume histogram, EAR: excess absolute risk, OED: Organ Equivalent Dose, RED: risk equivalent dose, † Positions based on work of   
Blais et al [333] and Scalzetti et al [334], ‡ β excess cases (10,000 person-years Gray)-1, based on A-bomb survivors exposed at 30 years and 
surviving to 70 years, and modified for a UK population (See Schneider et al 2011 [332] for further detail). Note this β is used for EAR calculation 
only. β within the α/β ratio is calculated from α based on α/β=3Gy for all tissues. §Point considered representative of dose received by transverse 
colon  
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Traditionally thermoluminescent dosimeters (TLDs) have been used for out-of-field 
dose measurements given their relative energy independence. Recently, it has been 
demonstrated that at about 10 to 20cm from the field edge, the mean energy spectra 
of photon beams is in the region of 200KeV, and in this region the energy spectra 
appear to plateau [329]. In addition, chamber measurements have been performed 
up to 22cm from the field edge with similar readings to those obtained from 
TLDs [329]. Energies down to 200keV were within the range of the chamber used 
here, thus providing confidence in the suitability of chamber measurements for out-
of-field regions both up to and beyond 20cm. In keeping with out-of-field chamber 
measurements performed by others, a 5% uncertainty was assumed for all out-of-
field measurements to account for potential inaccuracies resulting from the MV 
calibrated chamber, as well inaccuracies in positioning [329]. 
 
6.2.6 Assessment of head leakage and scatter 
 
To assess the proportion of out-of-field dose resulting from head leakage and head 
scatter, out-of-field chamber measurements were performed at increasing distances 
from the isocentre (10cm, 15cm, 20cm, 25cm, 30cm, 40cm, 50cm, 60cm and 70cm) 
as described above but with the phantom pelvis removed (slices 30 to 35 removed). 
The vast majority of any measured dose would therefore be the result of head 
leakage and head scatter. As before, 5% uncertainty was assumed for inaccuracies 
in chamber measurements and positioning. 
 
6.2.7 Second malignancy risk assessment 
 
The optimal method for predicting RISPC risk is unknown. A variety of models exist. 
These include the linear model which is considered appropriate for use in low dose 
out-of-field regions (up to about 4Gy of conventionally fractionated 
radiotherapy [254,326]), the plateau model which suggests that risk increases 
initially in a linear fashion as dose increases, before levelling off (due to cell 
sterilisation at higher doses with full normal tissue repair) and the bell-shaped 
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model, which suggests that risk increases in a linear fashion with dose before 
decreasing (also due to cell sterilisation at higher doses but without any normal 
tissue repair or repopulation). Schneider’s concept of OED states that two different 
dose distributions which result in the same RISPC risk have the same 
OED [330,332]. This model takes into account the effects of fractionation, and is 
designed to include the impact of the primary beam as well as out-of-field doses, 
and can employ linear, bell-shaped and plateau models as well as a mechanistic 
model (which incorporates an individual tissue specific repair and repopulation 
constants and therefore lies between the extremes of the plateau (assuming full 
repair) and bell-shaped (neglecting repair and repopulation) models. The OED 
concept is discussed in detail elsewhere [330,332], but in summary: 
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where VT is the total volume of the structure under consideration, VD is the volume of 
the dose bin i which receives dose Di and the RED is the risk equivalent dose for the 
dose bin receiving dose Di. RED is calculated according to:   
 
i) REDD  = D    
 
when a linear model is applied, as is appropriate for low dose out-of-field regions 
 
 
and 
 
ii) REDD  = 
 








 


D
R
R
D
D
eReRR
R
e
122
'
'
'
'
121



      
 
204 
 
 
according to Schneider’s mechanistic model which incorporates R, a tissue specific 
repair/ repopulation parameter [332]. Here, and in subsequent models, the impact of 
fractionation is also considered according to α’: 
 
 
T
T
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D
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where d is the dose per fraction, DT is the dose prescribed to the target and dT is the 
prescribed dose per fraction to the target. α and R were defined by Schneider et al 
by fitting the models to clinical data from Atomic bomb survivors and patients 
irradiated for Hodgkin’s disease [332]. β is such that α/β=3Gy. 
 
To illustrate the possible OED in the extreme scenarios of no repair/ repopulation, 
and full repair/ repopulation, RED and thus OED can also be calculated according 
to: 
 
iii)  REDD  =  DD 'exp   ,  
 
a bell-shaped model where the effect of repopulation or repair is neglected (R=0) 
 
and  
 
iv) REDD  = 
 
'
'exp1

 D
 ,            
 
a linear plateau model where the full repair/ repopulation is presumed (R=1). 
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All of the above models approach a linear model at low doses. 
 
When considering radiation-induced sarcoma, RED is calculated according to 
Schneider’s mechanistic sarcoma model [332]: 
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RED can also be used to calculate the excess absolute risk (EAR) of developing an 
RISPC in an organ with volume VT after exposure to dose RED at one age (agex) 
and attaining a greater age (agea), according to [332]: 
 
),(
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ii    
 
where β is the initial slope for the dose response curve for RISPC, VD  is the volume 
of the DVH bin receiving dose Di and RED is the REDD for that bin and μ is a 
modifying factor which adjusts for age at exposure (agex) and attained age (agea), 
calculated according to:  
 
μ (agex, agea) = exp(γe(age-30) + γa x ln(agea/70))  
 
where  γe and γa are age modifying factors and where β was originally calculated for 
persons exposed at age 30 years and attaining age 70 years [332]. 
 
All EAR calculations in this study were calculated for patients irradiated at age 60 
years and attaining 80 years. 
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The parameters used with each model and for calculation of EAR are shown in       
Table 6.2.  
 
OED is directly proportional to RISPC risk and so the ratio of OED from one 
technique to the OED from a different technique produces a relative risk ratio for 
RISPC [332].  
 
For tissues within the CT planning scan volume and in the in-field or close-to-field 
region (i.e. rectum, bladder wall, pelvic bone and pelvic soft tissue), where the dose-
risk relationship is not assumed to be linear (as pure linear models have not been 
shown to be the best fit to clinical data in higher dose regions), the OED concept 
was used to calculate the risks of rectal and bladder cancer, and pelvic bone and 
soft tissue sarcoma. For the rectum and bladder, OED was calculated using i) 
Schneider’s mechanistic model, ii) a bell-shaped model and iii) a plateau model. To 
estimate the risks of pelvic bone and soft tissue sarcoma, OED was calculated using 
Schneider’s mechanistic sarcoma model. For low dose out-of-field regions, where 
dose-response is considered linear, the OED concept was used with a linear model.  
 
All absolute doses, OEDs, relative risks and EARs are based on the total dose 
delivered over the whole treatment course. 
 
6.2.8 Integral dose assessment 
 
To investigate the relationship between integral dose and RISPC risk, integral dose 
was calculated for each tissue (as before, pelvic soft tissue consisted of the whole 
pelvic volume minus pelvic bones and prostate). Integral dose, which reflects the 
energy absorbed by the normal tissues, may be calculated using a differential DVH 
according to [335]: 
 
207 
 
ID = 
i
iiiDv    
 
where v is the volume of DVH bin i multiplied by the total dose received by that bin, 
Di, multiplied by the density, ρi, of that bin (assuming consistent density throughout 
each dose bin), and is measured in Gy-litres [335].  Since different fractionation 
schedules were adopted in this study, all doses were corrected to 2Gy fraction 
equivalent, and so integral dose in 2Gy fraction equivalent (IDEQD2) was calculated 
according to [335,336]:  
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Where vi, Di and ρi are as above, and di is the dose per fraction received by dose bin 
i, and α/β was taken as 3Gy. 
 
Volumes for rectum, bladder wall, pelvic tissue soft tissue and pelvic bones were 
taken from the DVH data. For out-of-field organs, volumes were established from 
typical male volumes as described in ICRP (International Commission on Radiation 
Protection) Publication 89 [337]. Density was taken as 1 gcm-3 for all tissues other 
than bone and lung where values of 1.3 g/cm3 [337] and 0.26 gcm-3 [338] were used 
respectively.  
 
Pearson’s correlation (r) was used to investigate any linear relationship between 
integral dose and OED. In view of multiple statistical testing (where several of the 
examined correlations would not be independent of others thus making a full 
Bonferroni correction over-conservative), a pragmatic approach was adopted, and a 
p value of <0.005 was considered statistically significant. SPSS version 19.0 (IBM 
Corporation, Armonk, New York, USA) was used for calculations. 
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6.3 Results 
6.3.1 Plans 
Plans were created for all three datasets for each technique according to the criteria 
described above (Table 6.1, Figure 6-2). The total number of monitor units (MU) 
required to deliver all the fractions and beam-on times per fraction for the delivered 
plans are shown in Table 6.3. 
 
Table 6.3 Monitor units and beam on time for delivered plan 
Plan Total Monitor Units per 
plan 
Beam-on time per fraction 
(seconds) 
SABR FFF 13,446 118 
SABR 13,010 225 
VMAT 78Gy FFF 25,2775 52 
VMAT 78Gy 24,040 76 
IMRT 78Gy 13,623 190 (338 including gantry 
motion between beams) 
3D-CRT 78Gy 10,429 54 (170 including gantry 
motion between beams) 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free,                                
IMRT: intensity-modulated radiotherapy, SABR: stereotactic ablative radiotherapy,                 
VMAT: volumetric modulated arc therapy 
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Figure 6-2 Comparison of physical dose distributions for different techniques 
 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy,                                                
SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy 
 
 
Dose (Gy) 
210 
 
 
6.3.2 In-field or close-to-field RISPC risks 
 
Ratios of OED, thus relative risks of second rectal and bladder cancers and pelvic bone 
and soft tissue sarcoma for each alternative technique relative to 3D-CRT, calculated 
using mechanistic, bell-shaped and plateau models, and averaged over three datasets, 
are shown in Figure 6-3. Actual OEDs are shown in Table 6.4a-c. Despite the variation 
in OEDs between individual datasets (maximum difference from average: 1.28Gy, 
largest standard deviation: 0.91Gy), there was much smaller variation between 
individual datasets in terms of relative risks (maximum difference from average: 0.18, 
largest standard deviation: 0.13). 
 
SABR techniques, both FFF and standard (flattened), resulted in the lowest OEDs for 
in-field and close-to-field tissues, and thus resulted in the greatest risk reductions 
relative to 3D-CRT, regardless of the model used. 
 
Considering all alternative 78Gy techniques relative to 3D-CRT, and all models, relative 
risks of rectal and bladder cancer or soft tissue sarcoma were within 9%, 8% and 2% of 
that for 3D-CRT respectively. Risk of bone sarcoma was lower using all alternative 
techniques compared to 3D-CRT. 
 
When comparing FFF with the equivalent flattened technique, for in-field and close-to-
field tissues, there was minimal difference in risk (average relative risks for FFF 
consistently within 2% of flattened techniques). 
 
 
211 
 
Figure 6-3 Relative risks of second malignancy in in-field or close-to-field tissues relative to 3D-conformal radiotherapy for whole 
treatment course 
3D-CRT: 3-dimensional conformal radiotherapy (shown as black dashed line), FFF: flattening filter free, IMRT: intensity-modulated radiotherapy,               
SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy.                                                                                                                                                                
Error bars display range of relative risks for the three datasets used for planning 
3D-CRT 78Gy  
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Table 6.4 Organ equivalent doses averaged over three datasets in in-field or close-to-field organs for whole treatment  
course (Gy): a) rectum 
 Rectum 
 Mechanistic model Range Bell-shaped model Range Plateau model Range 
SABR FFF 4.279 3.623- 
4.647 
3.291 2.814- 
3.599 
4.157 3.524- 
4.516 
SABR  4.221 3.498- 
4.583 
3.264 2.702- 
3.619 
4.102 3.401- 
4.462 
VMAT 78Gy 
FFF 
7.217 6.114- 
7.841 
4.959 4.230- 
5.519 
6.941 5.886- 
7.553 
VMAT 78Gy  7.142 6.093- 
7.773 
4.920 4.180- 
5.645 
6.873 5.862- 
7.512 
IMRT78Gy  7.503 6.396- 
8.178 
4.368 3.924- 
4.750 
7.128 6.096- 
7.765 
3D-CRT 78Gy  7.877 6.601- 
8.669 
4.688 4.011- 
5.116 
7.486 6.283- 
8.231 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy, SABR: stereotactic ablative radiotherapy, 
VMAT: volumetric modulated arc therapy 
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Table 6.4 Organ equivalent doses averaged over three datasets in in-field or close-to-field organs for whole treatment course (Gy):    
b) bladder  
 Bladder 
 Mechanistic model Range Bell-shaped model Range Plateau model Range 
SABR FFF 0.672 0.621- 
0.767 
0.649 0.603- 
0.727 
0.757 0.648- 
0.938 
SABR  0.667 0.616- 
0.770 
0.645 0.598- 
0.730 
0.753 0.641- 
0.938 
VMAT 78Gy FFF 0.886 0.876- 
0.901 
0.842 0.820- 
0.861 
1.064 0.932- 
1.267 
VMAT 78Gy  0.880 0.866- 
0.895 
0.835 0.813- 
0.860 
1.061 0.930- 
1.267 
IMRT78Gy  0.954 0.920- 
0.972 
0.909 0.840- 
0.948 
1.132 1.021- 
1.289 
3D-CRT 78Gy  0.891 0.850- 
0.912 
0.840 0.760- 
0.888 
1.100 0.987- 
1.262 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy, SABR: stereotactic ablative radiotherapy, 
VMAT: volumetric modulated arc therapy.  
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Table 6.4 Organ equivalent doses averaged over three datasets in in-field or close-to-field organs for whole treatment course (Gy):   
c) pelvic bone and soft tissue 
 Pelvic bone Pelvic soft tissue 
 Sarcoma model* Range Sarcoma model* Range 
SABR FFF 0.313 0.244- 
0.409 
0.172 0.149- 
0.215 
SABR  0.320 0.253- 
0.430 
0.171 0.151- 
0.211 
VMAT 78Gy 
FFF 
0.679 0.546- 
0.886 
0.381 0.330- 
0.472 
VMAT 78Gy  0.693 0.520- 
0.923 
0.386 0.326- 
0.484 
IMRT 78Gy  0.445 0.357- 
0.560 
0.388 0.341- 
0.473 
3D-CRT 78Gy  1.133 0.893- 
1.557 
0.392 0.332- 
0.507 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy, SABR: stereotactic ablative radiotherapy, 
VMAT: volumetric modulated arc therapy. *assuming intermediate repopulation and repair
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The EARs for in-field or close-to-field second cancers are shown in Figure 6-4. 
Excess absolute risks of in-field or close-to-field second cancers were low using all 
techniques and using all models. According to the mechanistic model, for the 
different techniques evaluated, the average EAR for rectal cancer ranged from 1.44 
to 2.69 per 10,000 person-years (PY). For bell-shaped and plateau models, the 
average EAR for second rectal cancer ranged from 1.12 to 1.70 and 1.40 to 2.56 per 
10,000 PY respectively. For second bladder cancer, average EAR according to the 
mechanistic model ranged from 1.70 to 2.42 per 10,000 PY, and according to the 
bell-shaped and plateau models, ranged from 1.64 to 2.31 and from 1.91 to 2.88 per 
10,000 PY respectively. Within each model, absolute differences in risk between 
radiotherapy techniques were also low, at most 1.25 per 10,000 PY in terms of 
rectal cancer (mechanistic model, based on average results for three datasets) and 
0.96 per 10,000 PY in terms of bladder cancer (plateau model). For each in-field or 
close-to-field site, absolute differences between models were also low: the greatest 
differences between models was observed for rectal cancers where differences 
ranged from 0.33 per 10,000 PY (SABR (flattened): bell-shaped model to 
mechanistic model) to 1.09 per 10,000 PY (3D-CRT: bell-shaped model to 
mechanistic model; based on average results for all three datasets). For the bladder, 
difference between models ranged from 0.27 per 10,000 PY (SABR FFF: bell-
shaped model to plateau model) to 0.66 per 10,000 PY (3D-CRT: bell-shaped model 
to plateau model).  
 
Comparing FFF with equivalent flattened techniques, differences in EAR were 
clinically irrelevant (largest difference between average EARs: 0.025 per 10,000 
PY). 
 
When comparing all conventionally fractionated techniques, the absolute differences 
between techniques were also small, at most 0.25 per 10,000 PY in terms of rectal 
cancer (mechanistic model) and 0.19 per 10,000 PY in terms of bladder cancer 
(bell-shaped model).    …..............................................................................................
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Figure 6-4 Excess absolute risks of second malignancy in in-field or close-to-field tissues for whole treatment course 
  
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy,                                                                  
SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy                                                                                                                                    
Error bars display range of excess absolute risks for the three datasets used for planning 
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6.3.3 Out-of-field RISPC risks 
 
RISPC risks in out-of-field organs relative to 3D-CRT (linear model) are shown in 
Figure 6-5. Actual OEDs for out-of-field organs are shown in Table 6.5. As for in-field or 
close-to-field tissues, SABR (both FFF and standard (flattened)) resulted in reduced 
RISPC risks relative to 3D-CRT in out-of-field organs. In contrast to in-field or close-to-
field tissues, FFF, in comparison to the equivalent flattened technique, resulted in 
relative RISPC risk reductions in out-of-field organs. The impact of FFF in reducing 
relative risk increased at greater distances from the treatment field. For example, in the 
region of the stomach (measured at 30cm from the isocentre), SABR FFF resulted in a 
20% risk reduction relative to SABR flattened, and VMAT 78Gy FFF resulted in a 19% 
risk reduction relative to VMAT 78Gy flattened. In the region of the oral cavity 
(measured at 70cm from the isocentre), both SABR FFF and VMAT 78Gy FFF resulted 
in 56% risk reductions relative to equivalent flattened techniques. 
 
In all out-of-field organs, IMRT resulted in increased RISPC risks relative to 3D-CRT, 
although the increases in risk were frequently small. At most, a 26% risk increase was 
observed in the region of the salivary gland and thyroid using IMRT relative to 3D-CRT. 
Similarly, VMAT 78Gy using a standard (flattened) beam resulted in increased RISPC 
risks in the majority of out-of-field organs of up to 55% relative to 3D-CRT. Increased 
risks of out-of-field RISPC, relative to 3D-CRT, however, were not observed when 
using VMAT 78Gy with FFF. 
 
The EARs for second cancers in out-of-field organs are shown in Figure 6-6. These are 
low for all sites and all techniques. At greater distances from the field, where the 
relative impact of FFF was greatest, in absolute terms, risks were very small. For 
example, in the region of the oral cavity, the 56% risk reduction observed for FFF 
relative to the equivalent flattened technique, equated to an absolute reduction of 0.002 
per 10,000 PY (from 0.004 to 0.002 per 10,000 PY for VMAT 78Gy flattened vs. VMAT 
78Gy FFF). For SABR, EAR reduced by 0.0014 per 10,000 PY (from 0.0025 to 0.0011 
per 10,000 PY for SABR flattened vs. SABR FFF).  
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Figure 6-5 Relative risks of second malignancy in out-of-field tissues relative to 3D-conformal radiotherapy (linear model) for whole 
treatment course 
 
3D-CRT: 3-dimensional conformal radiotherapy (shown as black dashed line), FFF: flattening filter free, IMRT: intensity-modulated radiotherapy,                                            
SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy                                                                                                                           
5% error bars shown to account for dosimetric uncertainty 
3D-CRT 78Gy 
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Table 6.5 Organ equivalent doses in out-of-field organs for whole treatment course (Gy) 
 colon liver stomach lungs oesophagus thyroid salivary 
gland 
oral 
cavity 
brain 
SABR FFF 0.116 0.039 0.022 0.007 0.005 0.003 0.003 0.002 0.002 
SABR  0.161 0.048 0.027 0.010 0.009 0.007 0.007 0.005 0.005 
VMAT 78GY FFF 0.217 0.075 0.042 0.013 0.011 0.007 0.007 0.004 0.004 
VMAT 78Gy  0.295 0.090 0.052 0.019 0.017 0.012 0.012 0.009 0.009 
IMRT 78Gy  0.248 0.098 0.058 0.019 0.016 0.010 0.010 0.006 0.006 
3D-CRT 78Gy  0.224 0.090 0.055 0.018 0.015 0.008 0.008 0.006 0.006 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy,                                             
SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy                                                                                
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Figure 6-6 Excess absolute risks of second malignancy in out-of-field organs (linear model) for whole treatment course 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy,                                                                    
SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy                                                                                                                      
5% error bars shown to account for dosimetric uncertainty 
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In absolute terms, the increased risk from IMRT relative to 3D-CRT was also small: the 
26% relative risk increase observed amounted to an EAR increase from 0.0041 per 
10,000 PY using 10MV 3D-CRT to 0.0051 per 10,000 PY using 6MV IMRT for salivary 
gland cancer, and from 0.0009 to 0.0011 per 10,000 PY in terms of thyroid cancer. 
Similarly the 55% risk increase in the region of the oral cavity and brain with VMAT 
78Gy (flattened) relative to 3D-CRT, amounted to absolute increases from 0.0028 to 
0.0043 and 0.0027 to 0.0041 per 10,000 PY for oral cavity and CNS cancers going 
from 3D-CRT to VMAT 78Gy respectively. 
 
6.3.4 Dose from machine head and machine scatter 
 
For all techniques, it was confirmed that the radiotherapy field edge (defined here as 
the 50% isodose) was contained within the phantom pelvis (slices 30 to 35), so that 
when the pelvis was removed, recorded doses would predominantly be the result of 
head scatter and leakage. Out-of-field measurements performed following removal of 
the phantom pelvis revealed that FFF resulted in reduced out-of-field doses due to 
head scatter and leakage compared to equivalent flattened techniques (Figure 6-7).  
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Figure 6-7 Out-of-field dose resulting from head leakage and head scatter 
  
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy,                                                                 
SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy                                                                                                                           
5% error bars shown to account for dosimetric uncertainty
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6.3.5 Components of dose and distance 
 
Dose fall-off with increasing distance from the isocentre with different techniques is 
illustrated in Figure 6-8. Figure 6-9 illustrates dose fall-off for out-of-field dose resulting 
from head leakage and scatter and Figure 6-10 illustrates dose fall-off for within patient 
scatter (total dose minus dose due to head leakage/scatter). As expected, total doses 
were lowest for SABR treatments although beyond 25cm doses were low for all 
techniques. Total out-of-field doses resulting from head leakage and head scatter were 
lower for FFF techniques compared to the equivalent flattened technique. A slight 
increase in dose from within patient scatter was observed with FFF compared to the 
equivalent flattened beam, but this was outweighed by the reduction in dose due to 
reduced head leakage/scatter with FFF, resulting in lower total doses with FFF 
compared to the equivalent flattened technique.  
 
Very small peaks in head leakage/scatter dose were observed at 15cm from the 
isocentre for both the VMAT 78Gy (flattened) and SABR (flattened) techniques which 
could be the result of treatment head geometry in flattened rotational modes [339]. The 
peaks in dose were, however, small and encompassed within the assumed 5% 
uncertainty (i.e. error bars overlapped for doses at 10 and 15cm for these techniques). 
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Figure 6-8 Total dose for whole treatment course with increasing distance from isocentre 
 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy,                                                                   
SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy                                                                                                                         
5% error bars shown to account for dosimetric uncertainty 
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Figure 6-9 Out-of-field dose for whole treatment course resulting from head leakage and head scatter with increasing distance from 
isocentre  
          
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy,                                                                  
SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy                                                                                                                       
5% error bars shown to account for dosimetric uncertainty 
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Figure 6-10 Out-of-field dose for whole treatment course resulting from within patient scatter (total dose minus dose from head 
leakage/ scatter) with increasing distance from isocentre  
            
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy,                                                                        
SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc therapy                                                                                                                              
5% error bars shown to account for dosimetric uncertainty 
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6.3.6 Relationship between RISPC risk and integral dose 
 
Integral doses in 2Gy fraction equivalent (IDEQD2) for individual organs are shown in 
Table 6.6. Correlations with OED are shown in Table 6.7. As would be predicted from 
the models, a strong linear correlation was observed between IDEQD2 and OED for all 
out-of-field organs (r=1.000 and p<0.001 for each out-of-field organ). In terms of both 
pelvic bone sarcoma and pelvic soft tissue sarcoma, significant correlations were also 
observed, while for rectal and bladder cancers, no significant relationships were 
observed at the p<0.005 level. If a less conservative significance level of p<0.05 was 
selected, significance correlations between rectal IDEQD2 and rectal OED would be 
observed according to the mechanistic and plateau models. Similarly for the bladder, a 
significant correlation would be observed between bladder IDEQD2 and OED 
according to the plateau model. Figure 6-11 displays the correlation between rectal 
IDEQD2 and OED according to the mechanistic model and demonstrates the 
weakness of this correlation in comparison to that seen for out-of-field organs 
(represented by the perfect correlation between stomach IDEQD2 and OED (Figure 
6-11b)). Figure 6-12 displays the significant correlations observed between IDEQD2 
and OED for pelvic bone and soft tissue sarcomas. Although these correlations are 
stronger in comparison to those observed for the rectum and bladder, they remain 
weaker than that observed for out-of-field organs. 
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Table 6.6 Integral doses in 2Gy fraction equivalent (Gy-litres) 
 SABR 
FFF 
SABR VMAT 78Gy 
FFF 
VMAT 78Gy IMRT 78Gy  3D-CRT 78Gy 
Rectum * 1.0985 1.0726 1.3737 1.3799 1.7475 1.8726 
Bladder* 0.6836 0.6895 0.8562 0.8701 0.9012 1.0939 
Pelvic bone* 8.4177 8.4299 11.4092 11.4958 8.4476 20.0963 
Pelvic soft tissue* 43.3331 42.2862 57.3973 58.0679 57.7826 58.4318 
Colon 0.0210 0.0292 0.0391 0.0533 0.0448 0.0403 
Liver 0.0427 0.0519 0.0808 0.0976 0.1064 0.0978 
Stomach 0.0020 0.0025 0.0038 0.0047 0.0052 0.0049 
Lungs 0.0072 0.0109 0.0145 0.0207 0.0213 0.0195 
Oesophagus 0.0001 0.0002 0.0003 0.0004 0.0004 0.0004 
Thyroid 0.0000 0.0001 0.0001 0.0001 0.0001 0.0001 
Salivary gland 0.0002 0.0003 0.0004 0.0006 0.0005 0.0004 
Oral cavity 0.0002 0.0005 0.0003 0.0008 0.0005 0.0005 
Brain 0.0020 0.0045 0.0034 0.0077 0.0051 0.0050 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy, SABR: stereotactic ablative radiotherapy, 
VMAT: volumetric modulated arc therapy, *Averaged values for three datasets 
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Table 6.7 Correlations between integral dose in 2Gy fraction equivalent (IDEQD2) and organ equivalent dose 
Organ Model Pearson’s correlation 
(r) 
p value 
Rectum Mechanistic model 0.549 0.018 
 Bell-shaped model 0.297 0.231 
 Plateau model 0.536 0.022 
Bladder Mechanistic model 0.464 0.053 
 Bell-shaped model 0.392 0.108 
 Plateau model 0.542 0.020 
Pelvic bone Sarcoma model 0.889 <0.001 
Pelvic soft tissue Sarcoma model 0.769 <0.001 
Colon Linear model 1.000 <0.001 
Liver Linear model 1.000 <0.001 
Stomach Linear model 1.000 <0.001 
Lungs Linear model 1.000 <0.001 
Oesophagus Linear model 1.000 <0.001 
Thyroid Linear model 1.000 <0.001 
Salivary glands Linear model 1.000 <0.001 
Oral cavity Linear model 1.000 <0.001 
Brain Linear model 1.000 <0.001 
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Figure 6-11 Correlations between integral dose in 2Gy fraction equivalent (IDEQD2) and Organ Equivalent Dose (OED) for a) the 
rectum (rectal organ equivalent dose calculated according to mechanistic model, p=0.018, not significant at selected significance 
level) and b) the stomach (representative of all out-of-field organs, p<0.001)  
 
 
 
a) b) 
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Figure 6-12 Correlations between integral dose in 2Gy fraction equivalent (IDEQD2) and Organ Equivalent Dose (OED) for a) pelvic 
bone sarcoma (p<0.001) and b) pelvic soft tissue sarcoma (p<0.001) 
 
a) b) 
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6.3.7 Femoral head doses 
 
As mentioned above, a 240 arc was used to investigate if using an even number of 
sectors resulted in the right and left femoral head receiving more similar doses than 
using a 210 arc. There were no statistically significant differences between doses 
received by the left and right FHs in SABR (FFF or flattened) or VMAT 78Gy (FFF or 
flattened) plans (Table 6.8), suggesting that the 240 arc may improve the symmetry in 
FH doses. Only a small number of plans, however, were analysed in respect of FH 
doses here. A larger number of datasets would need to be investigated for firmer 
conclusions to be drawn regarding the impact of a 240 arc on FH dose symmetry. 
Most importantly, using a 210 arc as in earlier chapters, or 240 arc as in this current 
chapter, resulted in FH doses which were very well within tolerance and lower than 
what would be achieved using 3-field or 4-field 3D-CRT. In addition, when the dose per 
fraction received by femoral heads is also considered, the differences in dose in terms 
of BED, or EQD2, are small. Bearing both these factors in mind, the differences in dose 
between right and left FHs are, therefore, unlikely to be of clinical concern in adult male 
patients. 
 
Table 6.8 Left and right femoral head doses using 240 arc (median values (and 
range)) 
 Left FH 
SABR plans 
Right FH 
SABR plans 
p 
value 
Left FH 
VMAT 78Gy 
plans 
Right FH 
VMAT 78Gy 
plans 
p 
value 
Mean 
dose 
(Gy) 
6.73 
(6.12-7.17) 
6.16 
(5.31-7.82) 
0.463 13.70 
(10.74-14.99) 
12.93 
(9.63-16.30) 
0.116 
D2% 
(Gy) 
16.11 
(15.11-17.10) 
13.60 
(13.38-17.04) 
0.345 27.96 
(26.98-29.93) 
28.64  
(22.71-33.41) 
0.753 
FH: femoral head, SABR: stereotactic ablative radiotherapy, VMAT: volumetric modulated arc 
therapy
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6.4 Discussion 
 
This study assessed risks of radiation-induced second malignancy following modern 
prostate radiotherapy techniques used in day to day practice. For all techniques, the 
EARs of second malignancy were low for the population examined. SABR techniques, 
however, conferred a consistently lower risk of second malignancy in in-field, close-to-
field, and out-of-field organs, while techniques employing FFF conferred lower second 
malignancy risks in out-of-field organs only, with the greatest relative impact being 
observed at greater distances from the field edge, where the absolute benefits were 
very small.  
 
Prostate SABR delivers a lower physical dose compared to conventionally fractionated 
treatments, and so, particularly in low dose out-of-field regions where the dose risk 
relationship is considered linear, and where the impact of fractionation is neglected, it is 
not really unexpected to observe a lower risk of radiation-induced malignancy following 
SABR treatments. For organs within and close to the radiotherapy field, both the lower 
physical dose and the impact of hypofractionation have an impact, and both these 
factors will have contributed to the lower second malignancy risk observed in these 
regions. Doses were not formally re-scaled in order to isolate the impact of fractionation 
(e.g. to compare second malignancy risk from the same physical dose delivered using 
2Gy per fraction and using a higher dose per fraction) as this is not how these doses 
are used in clinical practice. It can be deduced from the models used above that a 
higher dose per fraction with result in a larger value of α’, which, in turn, will result in 
lower values for RED according to all non-linear models, and thus lower second 
malignancy risk. The theoretical benefit of hypofractionation in terms of reduced 
second malignancy risk has previously been discussed elsewhere [328]. 
 
While other groups have assessed the relative impact of FFF on out-of-field doses in 
the treatment of PCa [340,341], as a result of reduced head scatter and leakage [245], 
attempts to quantify the absolute size of the benefit have not been made. It is relevant 
to consider any relative risk alongside the absolute risk when considering absolute 
clinical benefit, although it is acknowledged that the calculation of EAR, by virtue of 
how it is derived (i.e. as an extension of OED calculation), introduces uncertainties 
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additional to those already involved in the calculation of relative risk (i.e. age modifying 
factors and the initial slope of the dose-risk curve). Despite this, the observed absolute 
benefit from FFF at large distances from the isocentre was very small for this 
population. In the situation where patients are irradiated for PCa at a younger age, the 
benefit of FFF in terms of absolute reduction in second cancer risk will become more 
valuable (while relative risk reductions will be maintained). Thinking clinically, however, 
most patients irradiated for PCa are about the age range considered here, making the 
absolute risks calculated here relevant for the majority. 
 
The impact of FFF in PCa has also not been previously investigated in the setting of 
energy-matched FFF and standard (flattened) beams. Kry et al, however, evaluated 
non-energy matched FFF beams [341]. An increase in total out-of-field dose was 
observed at 3-15cm from the field edge which was attributed to the lower energy FFF 
beams resulting in increased within patient scatter, potentially increasing RISPC risks. 
Using energy-matched FFF beams, no such increase in total out-of-field dose was 
observed in this region, and the slight increase observed in within patient scatter was 
outweighed by the substantial reduction in head leakage/scatter. 
 
The impact of linear accelerator-based SABR techniques on second malignancy risk 
has not been widely examined and only one other group was identified who evaluated 
the absolute size of the benefit from prostate SABR techniques [342]. Dasu et al 
quantified risks of second rectal and bladder cancer following 42.7Gy in 7 fractions or 
78Gy in 39 fractions, both delivered using 3D-CRT [342]. Risks were calculated from 
exported DVHs using the competition model (which incorporates the effects of 
fractionation and predicts maximum cancer induction at doses of about 4Gy). Overall 
predicted risks of second cancers were low, and PTV margin size had a larger impact 
on risk than fractionation schedule. The group concluded that the risks of second rectal 
and bladder cancers were similar between conventionally fractionated and ultra-
hypofractionated regimens (numerically, in fact, the hypofractionated regimen resulted 
in a very small increase in the mean risk of second bladder and rectal cancer although 
standard deviations were wide and overlapping) [342]. Thus the potential in-field 
benefits of SABR that were observed in this current study were not observed in Dasu et 
al’s work. This likely reflects the differences in the modelling processes used: the 
competition model used predicts a maximum second cancer effect at around 
4Gy [342,343], which is not entirely supported by clinical evidence [261]. According to 
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the OED model and accompanying parameters, however, risks may become maximal 
at higher doses [332]. In addition, while both models incorporate fractionation, 
fractionation is incorporated into each model differently. Furthermore, the competition 
model incorporates risks coefficients directly into the calculation of risk, while 
calculating ratios of OED avoids this parameter, thus avoiding this potential source of 
uncertainty in relative risk assessment. Recalculating the risk of second bladder and 
rectal cancers for the datasets in this current study using the competition model and 
the same parameters as used by Dasu et al (Table 6.9), also resulted in broadly similar 
risks of second cancers between hypofractionated and all conventionally fractionated 
techniques (Table 6.10). Dasu et al, also acknowledged that there was a potential 
benefit from SABR in terms of RISPC risk in out-of-field organs as a result of the lower 
physical doses delivered, although they restricted their RISPC assessments to the 
bladder and rectum only [342]. 
 
Table 6.9 Competition model calculation and parameters 
From Dasu et al [342] 
 
 
Effect calculation (%) Parameter Rectum Bladder 
Effect for bin i of DVH = 
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Total effect over all bins in structure = 
  

 
i
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i
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v
DEffectv
 
Di =Dose received by bin i 
n= number of fractions 
vi= volume of DVH bin i 
α1 (Gy
-1) 0.00984 0.00328 
α2 (Gy
-1) 0.25 0.25 
β1 (Gy
-2) 0.00182 0.000437 
β2 (Gy
-2) 0.046 0.033 
α/β (Gy) 5.4 7.5 
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Table 6.10 Predicted percentage risks (%) of second rectal and bladder cancers 
based on competition model averaged for three datasets 
 Rectum Bladder 
 Average Range Average Range 
SABR FFF 0.57 0.55 - 0.59 0.22 0.20 - 0.25 
SABR 0.58 0.55 - 0.61 0.22 0.20 - 0.25 
VMAT 78Gy FFF 0.58 0.54 - 0.64 0.25 0.24 - 0.26 
VMAT 78Gy  0.58 0.55 - 0.63 0.25 0.24 - 0.26 
IMRT78Gy  0.54 0.51 - 0.61 0.27 0.24 - 0.29 
3D-CRT 0.47 0.43 - 0.55 0.25 0.22 - 0.27 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free,                                     
IMRT: intensity-modulated radiotherapy, SABR: stereotactic ablative radiotherapy,                  
VMAT: volumetric modulated arc therapy                     
                                                            
 
Few groups have evaluated RISPC risk in PCa following VMAT compared to other 
external beam photon techniques. Blais et al, however, compared RISPC in PCa 
following rotational IMRT (an approximation of VMAT) and 7-field IMRT using a plateau 
model which saturated at 4Gy [333]. Overall lifetime risks were calculated according to 
ICRP 103 risk coefficients and weightings [189]. No clinically significant difference in 
RISPC risks were observed using rotational-IMRT or IMRT. In the simple geometry 
case (where PTV did not overlap with the rectum or the bladder), risk was very slightly 
higher using IMRT at 4.78% compared to 4.56% with rotational IMRT, although the 
difference was considered clinically irrelevant. The small difference was attributed to 
increased MU requirements for the IMRT plan. In the complex geometry case, where 
there was overlap of the PTV with the rectum and bladder, a situation more close to 
day to day clinical practice, the difference in risk was minimal: risk was 5.73% using 
IMRT and 5.74% using rotational IMRT [333]. Alvarez Moret et al examined RISPC risk 
from quasiIMAT, a pseudo-rotational technique employing 36 equally spaced step and 
shoot beams to simulate an arc, and thus also an approximation of VMAT [344]. 
Estimates were calculated for quasiIMAT and IMRT using 36 and 72 segments. The 
OED concept was used, employing plateau and bell-shaped models. OED was similar 
using both models. For both IMRT and quasiIMAT, a higher number of segments 
resulted in higher OED in regions beyond the scanned volume. Total body OED was 
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similar with 36 segment quasiIMAT and IMRT. When 72 segments were used there 
was a small increase in total body OED with quasiIMAT which was attributed to 
increased MU requirements but this was considered insignificant [344]. Despite the 
increase in volume of normal tissue irradiated to a low dose due to the large number of 
beams with quasiIMAT, overall, therefore, quasiIMAT did not significantly increase SPC 
risk [344]. 
 
Rechner et al principally compared risks of bladder and rectal RISPC from VMAT with 
proton arc therapy [345]. Excess relative risks were calculated and ratios of excess 
relative risks were used for comparisons (another modelling process which 
incorporates the effects of fractionation and reports risk relative to that in an non-
irradiated population [346-348]). DVH data provided details of the therapeutic dose for 
VMAT and protons. For VMAT, DVH data were also used to estimate secondary 
radiation doses (i.e. dose resulting from head leakage and scatter and additional within 
patient scatter). Monte Carlo simulations and previously published data were used to 
estimate secondary radiation doses resulting from proton arc therapy. Proton arc 
therapy, resulting in low entrance doses and minimal exit doses,  predicted significantly 
lower risks of second bladder or rectal cancer according to bell-shaped and plateau 
models compared to VMAT while there was no significant difference in second rectal or 
bladder cancer risk when using a linear model. The group also compared calculated 
excess relative risks of second bladder and rectal from VMAT with those previously 
estimated from IMRT by another group [311]. Numerically, VMAT resulted in lower 
risks of second bladder and rectal cancer compared to IMRT (excess relative risk for 
bladder RISPC: 5.25 with VMAT and 8.88 with IMRT, excess relative risk for rectal 
RISPC: 2.09 with VMAT and 3.32 for IMRT) [345].  These risks, however, were 
calculated using a linear model, which is often considered inappropriate in higher dose 
regions [254,326]. The use of a different model may also explain why greater 
differences were observed between IMRT and VMAT by Rechner et al than what was 
observed in this current piece of work. 
 
Comparisons of the data presented here with those of other groups are difficult, not 
least, as mentioned above, because of the lack of similar comparisons with the specific 
techniques evaluated in this work, and also as a result of the different models used, but 
also because several studies calculate whole body risk, rather than individual organ 
risks as presented here. While parameters are available for calculating whole body risk 
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using the methods adopted in this study, caution is urged in carrying this out in 
situations of inhomogeneous dose distributions across the whole body, i.e. situations 
other than mantle radiotherapy [332]. Only individual organ risks were therefore 
calculated in this study. Patil et al also used the concept of OED and calculated EAR 
for second bladder and rectal cancers following radiotherapy for PCa using 6MV 
IMRT [349]. Calculations were based on DVH data from the Eclipse® (Varian, USA) 
planning system. The EAR for rectal cancer was slightly higher than what was 
observed here at 3.42 per 10,000 PY while that calculated for the bladder was lower at 
0.1 per 10,000 PY. The differences between these results and the results in this current 
study could be attributed to differences in the volumes irradiated, CTV to PTV margins, 
planning systems, beam arrangements and parameters used for risk calculations.  
 
Theoretical concerns have been raised regarding a potential large (at times >100%) 
increase in RISPC risk using IMRT compared to 3D-CRT [254,294,297,298,324]. Some 
of these studies have been criticised for neglecting the impact of the primary beam in 
risk evaluation and/ or the methods used in calculating risk [293,350]. More recent 
papers have suggested that any increased risk from 6MV IMRT would only be very 
small, particularly when compared to higher energy 3D-CRT (as often employed 
clinically) [326,327]. The theoretical increase in risk from IMRT is often attributed to two 
things: i) increased MU requirements for IMRT, resulting in increased head leakage, 
thus contributing to out-of-field dose, and ii) the change in dose distribution, resulting in 
an increased volume of normal tissue receiving low doses. Increased risks from 6MV 
IMRT and VMAT 78Gy (flattened) were observed here relative to 10MV 3D-CRT in out-
of-field organs of up to 26% and 55% respectively, likely the result of increased MU. In 
absolute terms, however, where the greatest relative risk increases were observed, 
absolute increases were very small. The addition of FFF to VMAT 78Gy, despite an 
increase in MU compared to 3D-CRT, however, did not result in any increase in second 
cancer risk in out-of-field organs compared to 3D-CRT, and relative risks were, in fact, 
reduced. Again, however, in absolute terms, the differences in second cancer risk in in-
field and out-of-field organs between 78Gy IMRT, VMAT 78Gy or VMAT 78Gy FFF 
were small, although the smallest absolute risks were observed for VMAT 78Gy FFF. 
 
When considering individual in-field or close-to-field tissues, the impact of a change in 
dose distribution when moving from 3D-CRT to IMRT did not translate into clinically 
relevant increases in RISPC risk according to the models and margins employed here.  
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Dose-volume histograms for all 78Gy treatments for one dataset are plotted in Figure 
6-13 to Figure 6-16. The relationship between dose and RED according to Schneider’s 
models has also been superimposed onto the DVH curves. Note that the values for 
RED are not shown, but the dose-RED curves are plotted purely to illustrate the shape 
of the dose-risk relationship.  
 
A Visual inspection of differential DVHs for the rectum for all 78Gy treatments (Figure 
6-13) are not suggestive that the rectum receives a greater proportion of low dose 
irradiation with IMRT, and dose distributions are largely similar between 3D-CRT and 
IMRT until around 40Gy where there is a peak in the 3D-CRT DVH. For IMRT, a 
smaller peak is seen around 48Gy. In Schneider’s model for rectal cancer induction, 
the risk peaks at about 23Gy using the bell-shaped model, and at about 35Gy 
according to the mechanistic and plateau models. The 40-50Gy region is therefore in 
the region of decreasing risk and the small 48Gy peak in the IMRT DVH falls in a lower 
risk portion of the curve compared to the larger 40Gy peak for the 3D-CRT curve. This 
may contribute to the slightly reduced risk observed in the risk of rectal cancer using 
IMRT relative to 3D-CRT (although in absolute terms the difference in risk is very 
small). Considering the VMAT treatments, a slightly higher proportion of rectal tissue 
receives doses in the 15 to 25Gy range compared to IMRT and 3D-CRT. This dose 
region falls in the highest risk portion of the bell-shaped model, thus resulting in the 
slightly increased risk of rectal cancer using VMAT relative to 3D-CRT and IMRT using 
this model. Considering the competition model, which predicts maximum effect at 
around 4Gy, IMRT and VMAT treatments display a slightly higher volume of tissue 
receiving doses in the 3 to 4Gy region compared to 3D-CRT, resulting in the slightly 
higher risks seen with IMRT and VMAT according to this model.   …………………….  
…..................................................
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Figure 6-13 Differential dose-volume histograms comparing 78Gy techniques: rectum 
 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy, RED: risk equivalent dose,                         
VMAT: volumetric modulated arc therapy                                                                               
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Figure 6-14 Differential dose-volume histograms comparing 78Gy techniques: bladder  
(only first 10.5Gy shown to allow differences to be more clearly observed) 
 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy, RED: risk equivalent dose,                       
VMAT: volumetric modulated arc therapy                                                                                
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Figure 6-15 Differential dose-volume histograms comparing 78Gy techniques: pelvic bones 
 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy, RED: risk equivalent dose,                       
VMAT: volumetric modulated arc therapy                   
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Figure 6-16 Differential dose-volume histograms comparing 78Gy techniques: pelvic soft tissues 
 
3D-CRT: 3-dimensional conformal radiotherapy, FFF: flattening filter free, IMRT: intensity-modulated radiotherapy, RED: risk equivalent dose,                         
VMAT: volumetric modulated arc therapy                                                                                
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In the case of the bladder DVHs (Figure 6-14), IMRT appears to result in a slight 
increase in the volume of tissue receiving 2 to 5Gy, which encompasses the area of 
maximal effect according to Schneider’s bladders models, thus resulting in the slightly 
higher relative risk of second bladder cancers from IMRT compared to 3D-CRT. For 
both VMAT treatments, a smaller volume of tissue receives doses in the region of 1 to 
2Gy compared to 3D-CRT, and similar volumes of tissues receive doses of 3 to 5Gy 
compared to 3D-CRT, thus resulting in only very slight second bladder cancer risk 
reductions using VMAT. These differences in dose distributions between techniques 
also explain the slight increase in second bladder cancer risk observed using IMRT 
compared to 3D-CRT, and similarities in risk between VMAT and 3D-CRT, according to 
the competition model. 
 
Considering the pelvic bone DVHs (Figure 6-15), VMAT results in a larger volume of 
tissue receiving very low doses (<1Gy) and IMRT results in a slight increased volume 
of tissue receiving doses around 2Gy and around 6-10Gy compared to 3D-CRT. 
Schneider’s model, however, predicts a peak in RISPC risk at around 54Gy. A small 
peak in dose is seen for the 3D-CRT plan at just above 40Gy, thus falling in the higher 
risk region of the dose-RED curve, and contributing to the increased relative risk of 
second bone sarcoma observed for 3-DRT compared to all other techniques, while the 
increased volume of bone receiving lower doses from IMRT and VMAT fall on a much 
lower risk part of the dose-risk curve, and thus contribute little to the calculated risk. 
 
In terms of the soft tissue DVHs (Figure 6-16), where perhaps one might expect to see 
the biggest impact of an increased volume of tissue receiving a lower dose of radiation 
with IMRT or VMAT techniques, it can be seen that VMAT, as with the pelvic bone 
DVHs, results in a higher volume of tissues receiving very low doses (i.e. <1Gy), while 
3D-CRT results in a slightly larger volume of tissue receiving 2-3 Gy.  Schneider’s 
model predicts maximum effect at around 58Gy and so it is doses in this region which 
will have the largest impact on risk. In the 50-60Gy region, the DVH is largely similar for 
all techniques, and there is only a very slight peak at about 42Gy for 3D-CRT. Overall, 
therefore, calculated risks for pelvic soft tissue sarcoma are similar for all four 
techniques, and the traditional concern that IMRT/VMAT techniques result in a larger 
volume of normal tissue receiving lower (and thus more cancer inducing) doses 
appears to contribute little to the overall calculated risk, according to the model used 
here.  
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Figure 6-17 to Figure 6-20 display DVHs for rectum, bladder, pelvic bone and pelvic 
soft tissue for the SABR FFF and standard (flattened) SABR techniques for one 
dataset. Once again, a graph of RED is plotted against dose (without vertical units for 
RED) to display the shape of the dose-RED relationship. Note, given the impact of 
fractionation, the dose-RED relationship peaks at a different point to that for 
conventionally fractionated treatments and the magnitude of RED is also different. It 
can be seen that for the rectum, bladder wall, pelvic bone and pelvic soft tissues, DVHs 
for the FFF and standard (flattened) treatments are very similar, thus resulting in similar 
RISPC risks for these techniques.  
 
Historically, it has on occasion been assumed that IMRT results in an increase in 
normal tissue integral dose, and thus an increase in second malignancy risk. More 
recent work has, however, suggested that integral dose is not necessarily higher 
following IMRT compared to 3D-CRT [326,351,352]. Caution should be exercised in 
using integral dose as a relative indicator of second malignancy risk [293]. While a 
correlation will be observed between integral dose and RISPC risk in the low dose out-
of-field regions, where a linear model can be applied, in the in-field and close-to-field 
regions, where non-linear models are considered more realistic, then the same 
assumption cannot be made [293]. Indeed, strong correlations were demonstrated 
between integral dose and OED for all out-of-field organs here. For the rectum and 
bladder, however, where most second cancers are reported clinically following prostate 
radiotherapy, such correlations were not apparent. Similarly, integral dose has been 
found to be a poor estimator of second malignancy risk in the context of lung 
cancer [336]. 
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Figure 6-17 Differential dose-volume histograms comparing SABR techniques: rectum 
                       
FFF: flattening filter free, RED: risk equivalent dose, SABR: stereotactic ablative radiotherapy 
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Figure 6-18 Differential dose-volume histograms comparing SABR techniques: bladder 
                                        
FFF: flattening filter free, RED: risk equivalent dose, SABR: stereotactic ablative radiotherapy 
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Figure 6-19 Differential dose-volume histograms comparing SABR techniques: pelvic bones 
 
FFF: flattening filter free, RED: risk equivalent dose, SABR: stereotactic ablative radiotherapy 
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Figure 6-20 Differential dose-volume histograms comparing SABR techniques: pelvic soft tissue 
                          
FFF: flattening filter free, RED: risk equivalent dose, SABR: stereotactic ablative radiotherapy 
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There are a number of limitations in this work. Firstly, there are uncertainties in all of 
the models and parameters which can be used to estimate second malignancy risk, 
including the models adopted here. Schneider’s concept of OED was employed as this 
incorporates fractionation, which is relevant for current practice. In addition, when used 
with Schneider’s mechanistic model, individual tissue repair and repopulation 
parameters are included: intuitively it seems likely that tissues exposed to radiation will 
undergo a degree of repair and repopulation, the extent of which may vary with tissue 
type and dose received. To illustrate the range of possible outcomes, however, based 
on scenarios of no repair and no repopulation, and full repair and repopulation, rectal 
and bladder cancer risk was also assessed based on bell-shaped and plateau models. 
All models suggested benefit from SABR in in-field or close-to-field tissues, which is 
where the majority of radiation-induced tumours are observed [261]. Similarly, all 
models predicted broadly comparable second rectal and bladder cancer risks from 3D-
CRT, 5-field IMRT and VMAT 78Gy (FFF or standard). For out-of-field organs, where it 
is generally accepted that a linear model is appropriate for risk assessment, a 5% 
uncertainty was assumed to account for dosimetric and positioning issues. As with 
higher dose regions, however, underlying uncertainties in the parameters and models 
used for calculation will remain. It should also be acknowledged that the second cancer 
induction models used in this study are based on mutation induction only, and do not 
take into account other potential factors, such as changes in the microenvironment 
following irradiation and inflammation, which may have independent dose-response 
relationships and different temporal patterns in second cancer induction. 
 
Secondly, the appropriateness of using these models for high dose per fraction 
treatments such as SABR could also be questioned. The SABR prescription, however, 
was 6.1Gy per fraction, within the 10Gy per fraction range in which the LQ-model is 
considered reliable [238]. In addition, most normal tissues received doses far below the 
prescription dose, and therefore a considerably lower dose per fraction. A further 
concern could be the use of a model incorporating repair and repopulation factors, in 
the setting of an ablative treatment. Although the ultra-hypofractionated regimens 
investigated here are termed SABR, and thus ablative, this and other prostate SABR 
regimens deliver doses per fraction much lower than those employed for ablative 
treatments in other sites such as small primary lung cancer and brain metastases. It is 
unclear exactly how much ablation is achieved from doses of 6.1Gy per fraction as 
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used here. If full ablation were to be achieved, then the risks calculated according the 
bell-shaped model would be perhaps most relevant. That said, however, as most of the 
normal tissues irradiated receive doses far below the high dose per fraction delivered 
to the target, a mechanistic model, which allows a degree of repair and repopulation, 
may be more appropriate. Only clinical evidence, once available, will be able to 
address this issue fully. 
 
Thirdly, a calibrated MV chamber was used for out-of-field measurements. TLDs have 
often been used given their relative energy independence. The concern regarding 
chamber out-of-field measurements is the lower energy spectra in this region. As 
mentioned earlier, it has been demonstrated that the mean energy spectra out to 20cm 
from the field edge are in the kilovoltage range, within the range of the chamber [329]. 
Chamber measurements up to 22cm from the field edge have been shown to have 
good correlation with TLD readings although it should be acknowledged that TLDs can 
prove difficult in terms of accuracy and reproducibility, with uncertainties of up to 10% 
being quoted [329]. At 10-20cm from the field edge, it appears the energy spectra are 
plateauing or at worst decreasing only very slowly, thus allowing chamber 
measurements to be taken at distances of 20cm and beyond, accepting 5% 
uncertainty [329]. In the situation that the chamber readings were inaccurate, 
presuming such an error was of a similar proportion for all techniques at each 
measurement point, then calculated relative risks will be maintained. Indeed, the out-of-
field relative risk reductions observed using FFF in this study, and the increasing 
impact of FFF at increasing distances from the treatment field, have been 
demonstrated elsewhere based on TLD measurements and Monte Carlo 
modelling [341,353]. Furthermore, in the case of EAR calculations, chamber measured 
doses would need to be considerably different to ‘true’ doses if the low EARs 
calculated here were, in reality, much higher. For example, in the region of the stomach 
(30cm from the isocentre), the calculated EAR was 0.34 per 10,000 PY using 3D-CRT 
78Gy. The measured dose would need to have been ‘out’ by a factor of about three if 
the true risk was 1 per 10,000 PY. For the same plan, in the region of the oral cavity 
(70cm from the isocentre), calculated EAR was 0.0028 per 10,000 PY for the 3D-CRT 
78Gy plan. The measured dose would need to be ‘out’ by a factor of about 350 if the 
true EAR was as high as 1 per 10,000 per year. In addition, while there are 
undoubtedly uncertainties arising from the measured doses in this study, much larger 
uncertainties arise from the models used for risk calculation. 
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Fourthly, in this study 6MV was adopted for all arc therapies and 10MV was used for 
3D-CRT as these are the energies commonly adopted clinically. The photo-neutron 
effect begins at around 10MV. The impact of neutron contamination on malignancy 
risks for the 10MV plan was not assessed here, but it has previously been 
demonstrated that this effect is minimal at 10MV [297,325].  
 
Fifthly, only three datasets were used to compare second malignancy risks in in-field 
and close-to-field organs amongst the six investigated irradiation techniques (i.e. 18 
plans in total), and only one dataset was used for out-of-field dose assessment. While 
three is a very low number, most existing planning studies which examine second 
malignancy risk following prostate radiotherapy do so using only one to three 
datasets [297,326,333,340,341,345], as it is generally the differences in radiation 
techniques that are the subject of interest rather than inter-patient variation in risk. 
While inter-patient variations in the bladder and rectum are likely, the position of the 
prostate in relation to the surrounding anatomy is likely to be more constant than other 
primary tumours which can adopt a variety of anatomical locations (and thus varying 
proximities to surrounding normal tissues), thus potentially resulting in a greater 
variation in relative risks from different irradiation techniques. In the case of the three 
prostate datasets used here, risk ratios were similar, thus supporting the suggestion of 
relative anatomical constancy for the prostate and surrounding tissues. For out-of-field 
dose measurements, doses are likely to be similar between patients, and so only one 
dataset was used for point dose measurements.  
 
Sixthly, the parameters adopted here were based on Atomic bomb survivors and 
patients irradiated for Hodgkin’s disease treated with radiotherapy. Some of these 
patients also received chemotherapy and it could be postulated that the risk of second 
malignancy may be partly influenced by the use of chemotherapy. This has been 
previously examined, and any impact resulting from the addition of chemotherapy to 
radiotherapy has not been found to be significant [332,354]. 
 
Lastly, for out-of-field organs it was assumed that the point dose measured was 
representative of the dose received by the whole organ. This is a reasonable approach 
for the majority of out-of-field organs where relatively homogenous doses are likely to 
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be received. This approach, however, is likely to be least satisfactory for the colon 
which covers a large geographical area at a variety of distances from the treatment 
field. The calculated OED and EAR for the colon should therefore be viewed with the 
greatest caution out of all the out-of-field organ results. The point chosen to measure 
the dose received by the colon was in the approximate location of the central portion of 
the transverse colon, and as such the OED and EAR calculated are perhaps best 
regarded as relating to this region only. A more accurate assessment of OED and EAR 
for the ascending and descending segments of the colon would have either required a 
series of point dose measurements toward the sides of the phantom and at increasing 
distances from the field. Alternatively, a DVH for the whole colon could be exported 
from the planning system, although in the case of the patients examined here, the 
planning scans did not contain the complete colon volume making this approach 
infeasible. 
 
The impact of image-guided radiotherapy (IGRT) on RISPC risk was not included in 
this study as this will vary with the IGRT technique employed. The CTV-PTV margin 
was intended for daily online IGRT with fiducial markers. Thus conventionally 
fractionated regimens will require at least 39 images while SABR will require at least 
seven images. If automatic couch adjustments are used, and treatment time is 
sufficiently fast, then further imaging following shifts or post-treatment would be 
unnecessary. The need for fewer images with ultra-hypofractionated regimens 
potentially adds additional RISPC benefit to SABR techniques. Of note, all the 
techniques evaluated in this study employed the same CTV-PTV margins. Advances in 
image-guided radiotherapy (IGRT) have facilitated CTV-PTV margin reduction, and the 
impact of CTV-PTV margin reduction on normal tissue irradiation and RISPC risk would 
require separate investigation. It has previously been suggested (based on the 
Competition model), however, that tighter margins result in less normal tissue high 
dose irradiation which in turn results in increased normal tissue exposure to lower, 
potentially RISPC-inducing, doses [342]. 
 
Different hardware and software combinations as well as treatment margins may all 
contribute to differences in second cancer risk [326,342]. These were minimised as far 
as possible in this study by delivering all plans on the same machine, by creating plans 
using the same planning system where possible, and by using the same CTV-PTV 
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margin. Differences in risks observed in this study should therefore largely be due to 
the doses, fractionations and planning techniques under evaluation.  
 
Proton therapy, TomoTherapy® (Accuray®, USA) and Cyberknife™ (Accuray®, USA) 
are other early PCa external beam techniques. Other groups have demonstrated very 
low RISPC risks from protons [295,310-313,345]. Risks from TomoTherapy® and 
Cyberknife™ have not been as widely evaluated. Hälg et al, however, measured out-
of-field doses for a variety of techniques including TomoTherapy® and 
Cyberknife™ [340]. TomoTherapy® resulted in out-of-field doses largely similar to 3D-
CRT and IMRT while Cyberknife™, despite delivering a SABR dose (thus lower 
physical dose), resulted in higher out-of-field doses, attributed to non-coplanar beams 
and increased MU: compared to 3D-CRT, in regions receiving <0.5Gy, Cyberknife™ 
resulted in 2.7 times the dose [340]. Absolute RISPC risks were not quantified, but 
would likely be very low in this region.  
 
The clinical data regarding second malignancy risk following prostate radiotherapy is 
largely based on older and often larger field techniques (Chapter 5). In terms of small 
field 3D-CRT techniques there are fewer data, and in terms of IMRT even less data are 
available. The clinical evidence that is available regarding modern techniques, 
however, is encouraging, and suggests that IMRT does not result in the large 
increased risk of second malignancy as has been historically presumed [266,274,299]. 
This data, however, is relatively immature and the patient numbers involved are 
relatively small. No clinical data has been reported which specifically examines second 
malignancy risk following VMAT, SABR or FFF in PCa. Until more clinical data is 
available, then planning data in conjunction with appropriate models must be used as a 
surrogate. 
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6.5 Conclusions 
 
In summary, RISPC risks were compared following contemporary clinically relevant 
radiotherapy techniques for early PCa. SABR techniques resulted in reduced relative 
RISPC risks in all organs, while FFF techniques resulted in reduced RISPC risks in out-
of-field organs relative to equivalent flattened techniques, particularly at greater 
distances from the treatment field. Overall, SABR FFF offered the greatest benefits in 
terms of RISPC risk reduction. Although large differences in relative risk were 
sometimes observed between techniques, in absolute terms, RISPC risks were low 
overall and absolute differences between techniques were also small. Until clinical data 
regarding RISPC in irradiated prostate patients treated with contemporary techniques 
matures, data from this and other planning studies should be considered when 
selecting appropriate radiation techniques for individual patients.  
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Chapter 7 : Summary and Future Work 
 
7.1 Summary 
 
Prostate cancer is the most common cancer in UK males [1]. External beam 
radiotherapy is one of several treatment options for men presenting with localised 
disease. Stereotactic ablative radiotherapy offers patients the theoretical benefits of 
hypofractionation, including the potential for increased cure, together with the 
convenience of a treatment which involves a small number of out-patient visits. This 
project aimed to investigate linear accelerator-based prostate SABR with the ultimate 
aim of optimising outcomes for PCa patients.  
 
A class solution was developed for prostate SABR prescribing. A single partial anterior 
VMAT arc was found to be optimal as this resulted in highly conformal plans with 
reduced rectal doses compared to a full arc arrangement. Most patients also benefited 
from the partial arc arrangement in terms of reduced estimated delivery times and 
monitor unit requirements. A 6mm CTV-PTV margin, compatible with daily online 
image guidance of fiducial markers was preferred as this margin resulted in lower 
organ at risk doses compared to a larger CTV-PTV margin which would be more 
appropriate for CBCT soft tissue matching. Including the proxSV within the CTV was 
possible but also resulted in increased organ at risk doses. 
 
Boosting dominant intra-prostatic lesions was feasible in the context of whole prostate 
SABR, and a median boost of 125% of the prescription dose was possible while 
maintaining organ at risk constraints. Boosting dominant lesions resulted in an increase 
in TCP but this benefit was offset by marked increases in NTCP.  The TCP benefit of 
DIL boosting was greatest in the setting of a prostate α/β ratio of 10Gy and least in the 
setting of a prostate α/β ratio of 1.5Gy. Indeed, if prostate α/β ratio is 1.5Gy, then high 
levels of TCP and low levels of NTCP can be achieved by whole prostate SABR 
without DIL boosting. 
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Creating prostate SABR plans using energy-matched FFF beams resulted in no 
clinically relevant dosimetric disadvantages compared to planning with the flattening 
filter in situ. The major advantage of FFF was reduced estimated delivery times. Plan 
verification showed both the FFF and conventional flattened plans to be deliverable, 
and confirmed the time advantage of FFF treatment delivery. 
 
There is clinical evidence which suggests that PCa patients treated with radiotherapy 
are at increased risk of second cancers, particularly when compared to non-irradiated 
PCa patients. The risk of second cancer appears to increase over time.  This evidence 
is largely based on studies which include patients treated with older radiation 
techniques and so may not be applicable to patients treated with more modern 
conformal techniques. The clinical evidence regarding more modern radiotherapy 
techniques such as IMRT or brachytherapy is encouraging, but patient numbers are too 
few and follow-up too short to draw firm conclusions about the RISPC risk in patients 
treated with these modern techniques. 
 
In the absence of clinical evidence with regard to second cancer risk, planning studies 
and models of second malignancy induction must be used to give estimations of 
RISPC risk following more modern radiotherapy techniques, including prostate SABR. 
SABR techniques reduced the risk of RISPC in in-field and out-of-field organs 
compared to 78Gy in 39 fractions 3D-CRT. FFF techniques, compared to flattened 
techniques, reduced RISPC risks in out-of-field organs. 78Gy IMRT and 78Gy VMAT 
delivered using a flattened beam resulted in increased RISPC risk in several out-of-
field organs compared to 3D-CRT. Although relative risk increases were at times 
marked, the absolute risk of second cancers was low and the absolute differences in 
risk between techniques were low. Overall, however, SABR with FFF resulted in the 
lowest risk of second cancers out of all the techniques evaluated. 
 
In summary, therefore, whole prostate SABR delivered using a single partial anterior 
VMAT arc results in highly conformal plans with rapid delivery times, particularly when 
delivered using FFF beams. High levels of TCP and low levels of NTCP are predicted 
from this technique, and risks of radiation-induced second cancers are also estimated 
to be low. Phase III clinical trials are required to investigate this technique in practice. 
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7.2 Future work 
 
As above, Phase III trials are required to evaluate prostate SABR in clinical practice 
and in comparison to conventionally fractionated radiation techniques. Long term 
follow-up of such patients is the only way to draw definitive conclusions in terms of 
prostate SABR efficacy, toxicity and appropriate organ at risk constraints, and long 
term second malignancy risk. Both the ongoing Phase III HYPO-RT-PC trial and the 
recently opened PACE trial will ultimately provide some of this evidence in comparison 
to 78Gy in 39 fraction schedules [133,134]. In addition, the PACE trial may provide 
additional information regarding the relative benefits, if any, of Cyberknife™ SABR 
prescribing compared to linear accelerator-based prescribing. The platform used for 
SABR delivery, however, is not randomised within the PACE trial, and so it could prove 
difficult to come to a firm conclusion about the optimal means of SABR delivery. An 
additional challenge that occurs in phase III trials examining radical treatments for 
patients with low and intermediate-risk PCa is the long time that it takes to reach 
meaningful clinical end-points [355]. For example, it takes many years (i.e. in excess of 
10 years) to obtain accurate outcomes in terms of PSA failure, particularly in patients 
with low-risk disease, and late toxicity also takes several years of follow-up for an 
accurate picture to develop [355,356]. In addition, where the anticipated differences in 
outcome from different treatment arms are small, or where treatments are considered 
likely to be equivalent (i.e. a non-inferiority trial), then very large patient numbers must 
be recruited and followed-up, again adding to the long duration required to reach a 
definitive outcome. The role of androgen deprivation in the setting of SABR should also 
be evaluated in randomised trials, although the same challenges will arise as 
mentioned above. 
 
Motion and image-guidance is one area which should be investigated specifically in the 
context of SABR delivered using VMAT. The 6mm CTV-PTV margin which was used 
throughout this project as compatible with daily online imaging of fiducial markers was 
based on work by others, and is the same as the margin used in the IGRT sub-study 
within the CHHiP trial [192]. The evidence used to support this margin was, however, 
not necessarily derived in the setting of SABR, nor in the setting of the rapid delivery 
times achievable with VMAT or VMAT with FFF [186-188]. This margin was 
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conservative and would be adequate in the setting in which it was used, based on: i) 
evaluation of a 20 fraction regimen of prostate IMRT with intra-fraction motion 
monitoring, where it was demonstrated that a 6mm homogenous margin was required 
to limit the reduction in prostate D99% to 1% or less in all patients in the absence of 
intra-fraction motion monitoring [187], ii) portal imaging of fiducial markers before each 
beam in a 4-field box arrangement during a 39 to 41 fraction course of radiotherapy 
where, using a 0mm action threshold, margins of 4.3mm, 4.9mm and 4.8mm in the left-
right, superior-inferior and anterior-posterior directions were found to be necessary to 
account for intra-fraction motion as well as set-up and interobserver variability [188] 
(these were based on the Van Herk margin ‘recipe’ which is designed to ensure that 
90% of patients receive a dose to the CTV that is at least 95% of the prescribed 
dose [235], and so the slightly larger 6mm margins defined above allow improved 
coverage in a greater proportion of patients), and iii) evaluation of a five fraction IMRT 
SABR regimen with pre-treatment and post-treatment portal imaging of fiducials, where 
margins of 1.4mm, 4.4mm and 5.2mm in the left-right, superior-inferior and anterior-
posterior directions were found to be adequate to account for intra-fraction motion [186] 
(again based on the Van Herk margin ‘recipe’ [235]).  It should be remembered that 
margin calculations for SABR should also consider the errors resulting from 
delineation, residual set up uncertainty and the impact of a very small number of 
fractions [235]. 
 
With the rapid delivery times achievable with VMAT and VMAT with FFF, it is likely that 
prostate intra-fraction motion will become less of a problem, allowing CTV-PTV margin 
reduction. The Royal College of Radiologists ‘On Target’ publication recommends that 
each centre should determine what the appropriate margins are for that centre [357] 
and so, in the context of prostate SABR VMAT, margins need to be formally evaluated. 
While pre-treatment and post-treatment CBCT or portal images will give some 
indication of intra-fraction motion, once kilovoltage intra-fraction motion monitoring 
during VMAT becomes more widely available [173], then obtaining a more accurate 
picture of intra-fraction motion will become possible to more fully inform margin 
calculation. In addition, kilovoltage intra-fraction motion monitoring during VMAT may 
also eventually facilitate tracking during treatment delivery, again facilitating margin 
reduction.  
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Another exciting area in the field of radiotherapy is the advent of MRI-only planning in 
conjunction with the development of the MRI-linear accelerator [358,359]. Contouring 
on MRI provides enhanced soft tissue discrimination compared to contouring on 
planning CT and being able to contour and plan using the MRI alone, removes the 
uncertainty that is currently introduced from co-registration of MRI and planning CT 
images [358]. In addition, online image-guidance and intra-fraction motion monitoring, 
using MRI in the setting of an MRI-linear accelerator, would provide far enhanced soft 
tissue images compared to what is currently achievable using CBCT or portal images, 
and without the need for fiducial marker insertion [359]. This could facilitate further 
margin reduction and, in turn, allow safe dose escalation to the whole prostate [359]. 
There could also be potential to boost DILs to higher doses with fewer uncertainties 
than are currently associated with the process, particularly if functional MRI sequences 
such as DCE sequences could be used for planning and image-guidance. In this 
setting, the TCP benefit and NTCP detriment of boosting DILs would have to be re-
assessed. The use of MRI for planning and image-guidance also removes the 
additional radiation that is currently received from planning CTs and CBCT or portal 
images thus, potentially, reducing radiation-induced second malignancy risk [358,359].  
 
While the MRI-linear accelerator is not currently ready for clinical implementation, an 
MRI-cobalt-60 system is now in clinical use (ViewRay System, ViewRay Incorporated, 
USA) [360]. This system incorporates a ring gantry with three cobalt-60 sources, each 
with MLCs and a 0.35-Tesla MRI, allowing MRI-based treatment planning, simple to 
complex (i.e. IMRT) plan delivery and MRI imaging for online set-up and intra-fraction 
motion monitoring and tracking. The system can also perform on-couch dose 
calculations based on the patient’s MRI images on each treatment day and, if 
necessary, a plan can be rapidly re-optimised (while the patient remains on the couch) 
to create an improved plan specific for the patient’s anatomy on that day (i.e. adaptive 
radiotherapy) [360]. Such a system could well deliver safe and accurate prostate SABR 
with small CTV-PTV margins, although this requires specific clinical investigation. 
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Appendix A: Definitions of biochemical failure used in prostate 
cancer 
 
 
ASTRO definition of biochemical failure: biochemical failure occurs after three 
consecutive rises in PSA after the post treatment nadir. The date of failure is at the 
midpoint between the nadir date and the first rise [1]. 
 
Phoenix definition of biochemical failure: biochemical failure occurs when the PSA 
reaches the post treatment nadir + 2ng/ml [2]. 
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Appendix B: Risk groups in prostate cancer  
 
 
Based on National Comprehensive Cancer Network® (NCCN [1]) and D’Amico [2] risk 
classifications: 
 
Low risk prostate cancer: clinical stage (c)T1-T2a and Gleason score ≤6 and 
PSA<10 
 
Intermediate risk prostate cancer: cT2b-T2c and/or Gleason score 7 and/or PSA10-
20 
 
High risk prostate cancer: cT3-T4 or Gleason score 8-10 or PSA>20 
 
Note: T2c disease is considered high rather than intermediate risk in the D’Amico 
classifications and two or more intermediate risk features may be considered high risk 
according to NCCN criteria. 
 
Intermediate risk prostate cancer can also be subdivided into low-intermediate and 
high-intermediate risk [3].  
 
Low-intermediate risk can be considered:  
Gleason score 6 with PSA>10, or Gleason score 3+4 with PSA<10 
 
High-intermediate risk can be considered:  
Gleason score 3+4 with PSA 10-20, or Gleason score 4+3 
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Appendix C: Clinical evidence for prostate SABR 
 
 
Table C1. Clinical studies delivering prostate SABR using the Cyberknife™ 
Table C2. Clinical studies delivering prostate SABR using a linear accelerator 
Table C3. Clinical studies delivering prostate SABR as a boost following conventional 
fractionation 
Table C4. Toxicity from prostate SABR Cyberknife™ studies 
Table C5. Toxicity from prostate SABR linear accelerator studies 
Table C6. Toxicity from prostate studies which delivered conventionally fractionated 
radiotherapy and a prostate SABR boost 
 
 
 
(References contained in full reference list (Chapter 8)) 
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Table C1 Clinical studies delivering prostate SABR using the Cyberknife™. Continued overleaf. 
Study and type 
of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Fuller et al 
2008  [57] 
Prospective 
phase II 
10 Maximum 
follow-up 
12 months 
Low and 
intermediate  
Cyberknife™ 
Fiducials 
Urinary 
catheter 
MRI fusion 
α-blockers 
 
Aimed to mimic 
HDR 
brachytherapy 
Prostate + up to 
2cm of SV + 2mm 
(except: 
 i) posteriorly at the 
point where 
prostate abuts 
rectum where 
margin reduced to 
0mm) 
ii) in intermediate 
risk + 5mm 
expansion 
posterolaterally 
PTV: 
V38.4Gy≥95% 
Dmax: 76Gy 
Rectal wall: 
Dmax= 38Gy 
Rectal mucosa: 
Dmax= 28.5Gy 
Urethra: 
Dmax= 45.6Gy 
Bladder: 
Dmax= 45.6Gy 
 
38Gy in 4 fractions 
(279) 
Prescribed to 56% 
isodose (median, 
range: 49%-67%, all 
relative to maximum 
value of 100%) 
NR NR Fall in median PSA from 
6.9ng/ml at baseline to 
0.95ng/ml at 4 months 
(=86% reduction) 
 
Friedland et al 
2009  [68] 
Prospective 
112 24 months Low 
(majority), 
intermediate 
and high 
All T1-T2 
Cyberknife™ 
4 Fiducials 
MRI fusion 
 
Prostate and 
proximal 1cm of SV 
+ 5mm (3mm 
posteriorly) 
PTV: 
V35Gy≥95% 
Rectum: 
V36Gy<1cc 
Bladder: 
V37Gy<10cc 
 
35 to 36Gy in 5 
fractions 
(198-209) 
 
5 consecutive 
days 
Yes- 19% 
(n=21) 
Fall in mean PSA from 
6.0ng/ml at baseline to 
3.1ng/ml at one month. 
Mean PSA nadir of 0.6ng/ml 
at 18 months. 95% of 
patients with PSA nadir of 
≤1.0ng/ml at 3 years. 3 PSA 
failures (based on 
persistently rising PSA) 
Kang et al 
(2011)  [70] 
and Choi et al 
(2007)  [361] 
Retrospective 
44 13 months 
(4-46) 
T1c-T3b 
Low, 
intermediate 
and high 
(majority) 
 
Cyberknife™ 
6 fiducials in 
sacrum or 
prostate 
Low risk: prostate 
only + 4mm (2mm 
posteriorly) 
Intermediate or 
high risk: prostate 
and SVs +4mm 
(2mm posteriorly) 
PTV: 
95% covered by 77-
80% isodose 
Rectum: 
Dmax=100%  
V50%<50% 
 
32-36Gy in 4 fractions  
(203-252) 
Prescribed to 
isocentre, 95% of PTV 
covered by 77-80% 
isodose 
4 consecutive 
days 
Yes-89% 
(n=39) 
5-year biochemical free 
survival 93.6% (100% in low 
and intermediate patients, 
91% in high risk patients, all 
failures in high risk group, 
Phoenix). 
Median PSA nadir 0.1ng/ml 
(range 0 to 1.13ng/ml) after 
median of 13 months 
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Table C1 cont. Clinical studies delivering prostate SABR using the Cyberknife™. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Townsend et 
al 2011 [71] 
Retrospective 
37 11.5 weeks Low 
(majority), 
intermediate 
and high 
Cyberknife™ 
3-4 fiducials 
MRI fusion 
Prostate + 5mm 
(3mm posteriorly) 
PTV: 
V100%: ≥97% 
Dmax: 115% 
Rectum: 
D1cc<36Gy 
V50%<50Gy 
Bladder: 
D10cc<37Gy 
 35 -37.5Gy in 5 
fractions 
(198-225) 
Prescription isodose: 
85% 
NR Yes- 25% 
(n=12) 
Fall in mean PSA from 
9.34ng/ml at baseline to 
2.41ng/ml at mean of 12 
weeks 
(n=28 for this analysis, 
includes boost and non-
boost patients- see ‘boost’ 
table) 
Jabbari et al 
2012 [72] 
 
20 18.1 
months 
(12.9-43.5) 
Mainly low 
and 
favourable  
intermediate 
Cyberknife™,  
3 fiducials,  
MRI fusion 
Prostate +/- Some 
or all SV on case by 
case basis 
0-2mm margin, no 
overlap with rectum 
Rectum: V75%<2cc 
Bladder: V75%<2cc 
Urethra: 
V120%<10%                 
Plus other 
constraints similar 
to HDR 
brachytherapy 
38Gy in 4 fractions 
(279) 
Prescription isodose 
60-80% 
Mostly 4 
consecutive 
days 
No Median PSA nadir 
0.47ng/ml, no evidence of 
progression 
 
 
 
 
King  et al 
2012 [61] 
Prospective 
phase II 
67 32.4 
months 
Low and 
favourable 
intermediate  
Previous 
TURP 
excluded 
Cyberknife™ 
Fiducials 
Prostate + 5mm 
(3mm posteriorly) 
Rectum: 
V50%<50% 
V80%<20% 
V90%<10% 
V100%<5% 
Bladder: 
V50%<40% 
V100%<10% 
Femoral heads: 
V40%<5% 
36.25Gy in 5 fractions 
(211) 
5 consecutive 
days (n=22) 
or 
alternate 
days (n=45) 
No 4-year biochemical relapse 
free survival 94% (95% CI 
85-102%; Phoenix) 
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Table C1 cont. Clinical studies delivering prostate SABR using the Cyberknife™. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Lee et al 
2012 [74] 
Retrospective 
29 41 months 
(12-69) 
Low, 
intermediate 
(majority) 
and high 
Cyberknife™, 3 
or 4 fiducials, 
Vacuum bag 
Prostate +5mm  (2-
3mm posteriorly) 
PTV: 
V100%>95% 
Rectum: 
 V50%<50% 
V100%<5% 
35-37.5Gy in  5 
fractions (198-225) 
Consecutive 
days (48%) 
Alternate 
days (52%) 
Yes - 21% 
(n=6) 
Fall in median  PSA from 
7.96ng/ml at baseline to 
median nadir of 0.33ng/ml 
after 23 months 
4-year biochemical relapse 
free survival 86% for all 
patients and 88% for those 
without androgen 
deprivation therapy 
2 PSA failures (Phoenix) 
PSA bounce in 28% 
(increase >0.2ng/ml) at 
median of 9 months, 
median bounce 0.69ng/ml 
 
McBride et al 
2012 [73] 
Prospective 
phase I 
45 44.5 
months (0-
62) 
Low 
≤80cc 
prostate 
IPSS≤15 
Cyberknife™, 4 
fiducials, 
urethra 
visualised with 
catheter if 
necessary 
MRI fusion for 
some 
Bowel prep 
  
Prostate + 5mm 
(3mm posteriorly) 
PTV: 
V100%≥95% 
Rectum: V36<1cc 
Bladder: V37.5<5cc 
Urethra: V49<10% 
Bulb: V29.5<50% 
36.25-37.5Gy in 5 
fractions (211-225; 
plus 1 patient, non-
protocol dose) 
Prescription isodose 
70% to 90% 
Median time: 
7 days         
(range 4-20) 
At least 12 
hours 
between 
fractions 
Not within 
6 months 
of 
irradiation 
3-year biochemical free 
survival 97.7% (Phoenix) 
Fall in median baseline PSA 
from 4.9ng/ml (range 1.4-
9.4ng/ml) at baseline to 
0.91ng/ml after 1 year 
PSA bounce in 20% 
(increase>0.4ng/ml)  at 
median of 11.6months 
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Table C1 cont. Clinical studies delivering prostate SABR using the Cyberknife™. Continued overleaf. 
Study and 
type of study 
(where 
available)  
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Aluwini et al 
2013 [60] 
Prospective 
50 23 months  Low 
(majority) 
and 
intermediate 
 ≤90cc 
prostate and 
IPSS ≤15  
Cyberknife™ 
4 fiducials 
Low fibre diet,  
Bowel prep, 
Urinary 
catheter 
MRI fusion 
 
Prostate +3mm PTV: 
V38Gy≥100% 
Dmax<57Gy 
Rectal wall 
Dmax<38Gy, 
Rectal mucosa 
Dmax<28.5Gy, 
Whole rectum 
D1cc<32.5Gy, 
Bladder: 
Dmax=41.8Gy,  
D1cc<38Gy, 
Urethra: 
Dmax=45.6Gy 
D5%<45.5Gy, 
D10%<42Gy, 
D50%<40Gy 
Sigmoid/ intestine: 
28.5Gy, 
Femoral head: 24Gy 
38Gy in 4 fractions 
(279) (plus 44Gy in 4 
fraction boost to 
dominant lesion in 14 
patients) 
4 consecutive 
days 
No 2-year biochemical 
control: 100% (Phoenix) 
Median PSA nadir 
0.6ng/ml in patients with 
≥24 months follow-up 
PSA bounce in 14% (7; 
defined as any transient 
rise in PSA),  mean time to 
bounce 12 months (range 
4.0 to 22 months) 
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Table C1 cont. Clinical studies delivering prostate SABR using the Cyberknife™. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Bolzicco et al 
2013 [59] 
Prospective 
100 36 months  
(6-76) 
Low, 
intermediate 
and high 
(minority) 
Cyberknife™ 
4 fiducials 
Empty rectum 
Urinary 
catheter to 
identify urethra 
at planning 
MRI fusion 
Low gas diet 
Prostate + one third 
of  SV + 5mm (3mm 
posteriorly) 
PTV: 
 V35Gy≥95% 
Rectum: 
 V38Gy<5%, 
Bladder: 
 V40Gy<5% 
Urethra:  
 V40Gy<5%, 
Penile bulb: 
V29Gy<25% 
Femoral head: 
V25Gy<25% 
35Gy in 5 fractions 
(198) 
Prescription isodose 
80% 
5 consecutive 
days 
Yes- 29% 
(n=29) 
4 episodes of biochemical 
relapse  (Phoenix) 
3-year biochemical 
progression free survival 
94.4% (95% CI: 85.3-
97.9%) 
Fall in median pre-SABR 
PSA from 5.03ng/ml at 
baseline to 0.73ng/ml at 1 
year and 0.67ng/ml at 2 
years and 0.45ng/ml at 3 
years. 
For patients receiving 
androgen deprivation: 
median pre-SABR PSA 
1.90ng/ml falling to 0.26, 
0.30 and 0.18ng/ml at 1, 2 
and 3 years. 
For patients not receiving 
androgen deprivation, 
median pre-SABR PSA  
6.31, falling to 0.93ng/ml, 
0.87ng/ml and 0.62ng/ml 
at 1, 2 and 3 years 
PSA bounce in 12% of 
those not receiving 
androgen suppression 
(defined as transient rise 
in PSA), median bounce 
1.08ng/ml after median of 
23 months 
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Table C1 cont. Clinical studies delivering prostate SABR using the Cyberknife™. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Oliai et al 
2013 [78] 
Retrospective 
70 31 months 
(13-51) 
Low 
(majority), 
intermediate 
and high 
Cyberknife™ 
4 fiducials 
MRI fusion 
 
Prostate +/- 
proximal 2cm of SV 
+ 5mm (3mm 
posteriorly) 
PTV: 
V100%: ≥95% 
Rectum: 
V36Gy: <1cc 
50% isodose within 
rectum 
Bladder: 
V37Gy: <10cc 
35Gy- 37.5Gy  in 5 
fractions (198-225) 
35Gy: n=5 
36.25Gy: n=36 
37.5Gy: n=29 
Prescription isodose: 
75-85% 
7-15 days Yes- 33% 
(n=23) 
3 year actuarial freedom 
from biochemical failure 
(Phoenix): for all patients: 
94.5%, for low, 
intermediate and high risk 
patients: 100%, 95% and 
77.1% respectively. 
For low dose patients 
(35Gy and 36.25Gy), 
median nadir to date: 
0.3ng/ml. 
For high dose patients 
(37.5Gy),  median nadir to 
date: 0.2ng/ml. 
PSA bounce in 9% of those 
not receiving androgen 
suppression 
(increase≥0.2ng/ml) at 
median of 19 months. 
Dose response for 
intermediate and high risk 
patients (p=0.0363) with 3 
year freedom from 
biochemical failure of 72% 
and 100% in patients 
receiving low and high 
dose respectively. Trend 
only (p=0.0775) if low risk 
patients included 
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Table C1 cont. Clinical studies delivering prostate SABR using the Cyberknife™. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Tree et al 
2014 [77] 
 
51 15 months Low and 
intermediate 
Cyberknife™ NR NR 36.25Gy in 5 fractions 
(211) 
 Yes- 25% 
(n=13) 
For hormone naïve 
patients: fall in median 
PSA from 7.5ng/ml at 
baseline to median of 
1.9mg/ml at 12 months. 
No biochemical 
recurrences 
Seattle group (some overlap between patient populations): 
Meier et al 
2010 [69] 
Prospective 
phase II 
211 NR Low and 
intermediate 
Cyberknife™  
Fiducials 
MRI fusion 
Prostate  
(+ SV if intermediate 
risk)  
Margins NR 
NR 40Gy in 5 fractions 
36.25Gy in 5 fractions 
to proximal SV if 
intermediate risk 
(253 to prostate, 211 
to SV) 
 
NR No Fall in median PSA from 
5.2 at baseline to 0.9ng/ml 
at 12 months and 0.7ng/ml 
at 18 months.  1 PSA 
failure (Phoenix).  
 
 
Meier et al 
2012 [107] 
Prospective 
phase II 
(Intermediate 
risk patients 
only reported 
- some 
overlap with 
patients from 
Meier et al 
2010) 
129 30 months 
(range 10-
42) 
Intermediate Cyberknife™  
Fiducials 
MRI fusion 
Prostate  
(+ SV if intermediate 
risk)  
Margins NR 
NR 40Gy in 5 fractions 
36.25Gy in 5 fractions 
to seminal vesicles 
Prescription isodose 
NR 
NR No Fall in median PSA from 
5.9 at baseline to 0.8ng/ml 
at 12 months, 0.38 at 24 
months and 0.2ng/ml at 36 
months. 
One biochemical failure at 
3 months (Phoenix).  
3-year biochemical 
progression free survival 
99.2% 
 
 
298 
 
Table C1 cont. Clinical studies delivering prostate SABR using the Cyberknife™. Continued overleaf. 
Study and 
type of study 
(where 
available)  
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Georgetown group (some overlap between patient populations): 
Chen et al 
2013 [76] 
Data 
collection 
prospective, 
review 
retrospective 
including 
studies below 
 
100 28 months 
(17-42) 
Low, 
intermediate 
(majority) 
and high 
Cyberknife™ 
Fiducials 
MRI fusion 
Prostate + proximal 
SV up to split of left 
and right SV +5mm 
(3mm posteriorly) 
PTV: 
V36.25≥95% 
Rectum:  
V50%<50% 
V75%<25% 
V80%<20% 
V90%<10% 
V100%<5%  
V36Gy<1cc 
Bladder:  
V50%<40% 
V100%<10% 
V37Gy<5cc 
Prostatic urethra: 
Dmax≤133% 
Membranous 
urethra: 
V37Gy<50% 
Penile bulb: 
V29.5Gy<50% 
Sigmoid colon: 
V30GY<1cc 
Testicles: 
D20%<2Gy 
 
35 or 36.25Gy in 5 
fractions (198 or 211) 
Prescription isodose 
≥75% 
Consecutive 
or alternate 
(range 5 to 16 
days) 
Yes- 11% 
(n=11) 
Fall in median PSA from 
6.2ng/ml to 0.49ng/ml at 2 
years 
One biochemical failure (in 
high risk patient (Phoenix) 
2-year biochemical RFS 
99% 
PSA bounce (>0.2ng/ml) in 
31% of 0.5ng/ml (median) 
after median of 15 months 
Ju et al 
2013 [89] 
(Intermediate 
risk patients 
only- some 
overlap with 
patients in 
Chen et al 
2013) 
41 21 months 
(13-27.5) 
Intermediate Cyberknife™, 
Fiducials 
MRI fusion 
Prostate + proximal 
SV up to split of left 
and right SV +5mm 
(3mm posteriorly) 
35 or 36.25Gy in 5 
fractions (198 or 211) 
Median prescription 
isodose 77% (75%-
80%) 
Over 1-2 
weeks- 
consecutive 
or alternate 
No Fall in mean baseline PSA 
from 7.67g/ml at baseline 
to mean of 1.35ng/ml at 
12 months and 0.64ng/ml 
at 21 months. 
One biochemical failure 
(Phoenix)  
2-year biochemical RFS 
97.6% 
Obayomi-
Davis et al 
2013 [127] 
(Hormone 
naïve 
patients only, 
some overlap 
with patients 
in Chen et al 
2013) 
97 32.4 
months 
(minimum 
24 months) 
Low, 
intermediate 
(majority) 
and high 
Cyberknife™ 
Fiducials 
MRI fusion 
Prostate + proximal 
SV up to split of left 
and right SV +5mm 
(3mm posteriorly) 
35 or 36.25Gy in 5 
fractions (198 or 211) 
 
Over 1-2 
weeks- 
consecutive 
or alternate 
No Fall in median baseline PSA 
from 5.9ng/ml at baseline 
to median of 0.5ng/ml at 
24 months. 
One biochemical failure 
(Phoenix)  
2-year biochemical RFS 
99% 
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Table C1 cont. Clinical studies delivering prostate SABR using the Cyberknife™. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Georgetown group continued (some overlap between patient populations): 
Bhattasali et 
al 2014 [123] 
Data 
collection 
prospective, 
review 
retrospective 
(Hormone 
naïve 
patients only, 
some overlap 
with patients 
in Chen et al 
2013) 
228 45.6 
months 
Low, 
intermediate 
(majority) 
and high 
Cyberknife™ 
Fiducials 
MRI fusion 
Prostate + proximal 
SV up to split of left 
and right SV +5mm 
(3mm posteriorly) 
PTV: 
V36.25≥95% 
Rectum:  
V50%<50% 
V75%<25% 
V80%<20% 
V90%<10% 
V100%<5%  
V36Gy<1cc 
Bladder:  
V50%<40% 
V100%<10% 
V37Gy<5cc 
Prostatic urethra: 
Dmax≤133% 
Membranous 
urethra: 
V37Gy<50% 
Penile bulb: 
V29.5Gy<50% 
Sigmoid colon: 
V30GY<1cc 
Testicles: 
D20%<2Gy 
35 or 36.25Gy in 5 
fractions (198 or 211) 
Prescription 
isodose≥75% 
Treatment 
delivered 
over 1 to 2 
weeks 
No 6 biochemical failures 
(Phoenix)  
2-year biochemical relapse 
free survival 97.2% 
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Table C1 cont. Clinical studies delivering prostate SABR using the Cyberknife™. Continued overleaf. 
Study and 
type of study 
(where 
available)  
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Flushing Group (some overlap between studies): 
Katz et al 
2013 [75] 
Retrospective 
304 
Group 
1: n=50 
Group 
2: 
n=254 
Group 1: 72 
months (9-
78) 
Group 2: 60 
months (8-
72) 
Low 
(majority), 
intermediate 
and high 
Cyberknife™ 
4 fiducials 
MRI fusion 
Bowel prep 
Rectal 
amifostine 
Low risk: 
Prostate + 5mm 
except 3mm 
posteriorly at 
rectum 
Intermediate risk: 
Prostate + proximal 
half SV + 5mm 
except 3mm 
posteriorly 
High risk: 
Prostate + proximal 
half SV + 5mm 
except 3mm 
posteriorly + 8mm 
on affected side. 
PTV: 
Group 1: 
V35Gy≥96% 
Group 2: 
V36.25Gy≥96% 
 
Group 1: 
35Gy in5 fractions 
(198) 
Group 2: 36.25Gy in 5 
fractions (211) 
 
NR Yes- 19% 
(n=57) 
5-year biochemical recurrence 
free survival (Phoenix): 97% for 
low risk (no difference with dose), 
90.7% for intermediate risk, 
74.1% for high risk.  
Median PSA at 5years: 0.12ng/ml- 
dose had no impact on PSA 
No deaths due to prostate cancer 
PSA bounce in 17% (>0.2ng.ml), 
median time to bounce 30 
months, median bounce 
0.55ng/ml 
 
 
 
 
Katz et al 
2014 [90] 
Retrospective 
(low and 
intermediate 
risk patients 
only, 
differences in 
PTV and 
coverage- 
some overlap 
with patients 
in Katz et al 
above) 
477 
Group 
1: 
n=154 
Group 
2: 
n=323 
72 months 
(0-96) 
Low 
(majority) 
and 
intermediate 
Cyberknife™ 
4 fiducials 
MRI fusion 
Bowel prep 
Rectal 
amifostine 
Prostate + 5mm 
(3mm posteriorly) 
Group 1: 
V35Gy≥95% 
Group 2: 
V36.25Gy≥95% 
Rectum:  
V50%<50% 
V80%<20% 
V90%<10% 
V100%<5%  
Bladder:  
V50%<40% 
V100%<10% 
Femoral heads: 
V40%<5% 
Group 1: 
35Gy in5 fractions 
(198; low and low-
intermediate risk 
patients only)) 
Group 2: 36.25Gy in 5 
fractions (211) 
Prescription isodose: 
83-87% 
NR Yes-11% 
(n=51) 
Fall in baseline mean PSA from 
5.3ng/ml to median of 0.11 at 7 
years 
7-year freedom from biochemical 
failure 93.7% for all, 95.6% in low 
risk, 89.3% in intermediate risk 
No deaths due to prostate cancer 
No impact of dose on biochemical 
outcome for low and low-
intermediate risk patients                               
No impact of androgen 
deprivation on outcome 
PSA bounce in 16% (>0.2ng.ml), 
median time to bounce 36 
months, median bounce 0.5ng/ml 
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Table C1 cont. Clinical studies delivering prostate SABR using the Cyberknife™ 
Study and 
type of study 
(where 
available)  
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV definition Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Pooled data 
King et al 
2013 [121] 
Prospective 
phase II 
POOLED 
DATA from 8 
institutions 
Includes 
patients from 
institutions 
of: 
King et al 
2012, Fuller 
et al 2008, 
Friedland et 
al 2009, 
Bolzicco et al 
2010, Katz et 
al 2010, 
Meier et al 
2010, 
Mcbride et al 
2012, Chen 
et al 2013 
(see above) 
1100 36 months Low 
(majority), 
intermediate 
and high 
Cyberknife™ 
3 or 4 fiducials 
Alpha cradle 
Prostate +5mm 
(3mm posteriorly) 
for homogeneous 
planning, 
Prostate + 2mm 
(0mm posteriorly) 
for heterogeneous 
planning 
For majority: 
Volume receiving 
prescription 
dose≥95% 
Rectum: 
V50%<50% 
V80%<20% 
V90%<10% 
V100%<5% 
Bladder: 
V50%<40% 
V100%<10% 
Femoral heads: 
V40%<5% 
35- 40Gy in 5 fractions 
(homogeneous dose 
distributions in >90%, 
normalised to 90% 
isodose, 
heterogeneous (HDR-
like) in remainder) 
Consecutive 
in >95%, 
alternate day 
in remainder 
Yes -14% (4 
months in 
all) (n=147) 
5-year biochemical relapse 
free survival 93% for all, 
95%, 84% and 81% for low, 
intermediate and high risk 
patients (Phoenix) 
No difference in 
biochemical relapse free 
survival with dose 
No impact of androgen 
deprivation on outcome 
Median nadir 0.2ng/ml at 
3 years 
PSA bounce in 16% (of 
>0.2ng/ml) in 16% after 
median of 18 months, 
median bounce 0.5ng/ml 
 
For patients with ≥5 years 
follow-up, 5-year 
biochemical relapse free 
survival: 99% for low risk 
and 93% for intermediate 
risk. No impact of dose of 
androgen deprivation on 
outcome 
ASTRO: American Society for Radiation Oncology, BED: biologically equivalent dose, CI: confidence interval, Dmax: maximum dose, Dx: Dose 
received by x% or xcc of volume, HDR: high dose rate, IPSS: International Prostatic Symptom Score, MRI: magnetic resonance imaging, NR: not 
reported, PSA: prostate specific antigen, PTV: planning target volume, Vx: volume receiving at least x% of prescription dose or xGy * See Appendix 
A for Phoenix/ASTRO definitions of biochemical failure 
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Table C2 Clinical studies delivering prostate SABR using a linear accelerator. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Pawlicki et al 
2007 [362] 
(NB planning 
study only) 
2 
 
N/A- 
Planning 
study 
NR IMRT 
Fiducials  
kV imaging 
Vacuum bag 
NR Rectum: 
V19.5≤35% 
V31.5≤17% 
1cc≤38.5Gy 
Bladder: 
V19.5≤50% 
V31.5≤25% 
Central PTV 
(urethra): 
Dose≤37Gy 
Femoral heads: 
V22≤1% 
Body: 
Dmax≤40.0Gy 
Peripheral dose: 
≤15Gy for each 
beam angle 
36.25Gy in 5 
fractions 
(211) 
NR NR More homogenous dose using 
IMRT compared to 
Cyberknife™. Improved 
urethral sparing and more 
rapid rectal dose fall-off with 
IMRT compared to 
Cyberknife™. 7 field IMRT plan 
resulted in 40% reduction in 
dose to periphery compared to 
5-field plan 
Pham 
2010  [80] 
and Madsen 
2007 [95] 
Prospective 
phase I/II 
40 60 months 
(range 9-
96) 
Low  Linear accelerator 
Flex prone 
position 
6 non-coplanar 
beams, quasi 
coronal beams 
tangential to the 
rectum, 
3 fiducials, portal 
images 
Low gas diet with 
simethecone 
NR Prostate:5 
D100%≥30.2Gy 
33.5Gy in 5 fractions 
(183) 
Prescribed to 
isocentre 
5 
consecutive 
fractions  
for most 
patients 
NR 5-year biochemical free survival 
93% (Phoenix)  and 71% 
(ASTRO) 
5-year overall survival 75%- no 
known prostate cancer related 
deaths 
Median PSA nadir 0.65 ng/ml, 
median time to nadir 24 
months  
PSA bounce (not defined) in 
22.5% 
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Table C2 cont. Clinical studies delivering prostate SABR using a linear accelerator. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Boike et al 
2011 [83] 
Prospective 
phase I 
45 
Dose 
escalatio
n trial- 15 
patients 
in each 
of 3 dose 
levels 
Group 1: 
30months 
(3-36) 
Group 2: 
18months 
(0-30) 
Group 3: 12 
months (3-
18) 
 
Low to 
intermediate 
Prostate 
volume ≤60cc 
IPSS≤15 
No previous 
TURP 
TomoTherapy® or 
linear accelerator 
based- Trilogy 
system (including 
CBCT). 
Fiducials or 
Calypso® 
electromagnetic 
beacons. Bowel 
prep including 
enema. Rectal 
balloon 
Full bladder 
Catheter at 
simulation 
4mg 
dexamethasone 
each fraction 
 
Prostate 
+3mm 
PTV: 
V100%≥95% 
Rectum: 
Anterior rectal wall 
Dmax 105%,  
Lateral rectal walls 
V90%<3cc 
Posterior rectal wall 
max: ≤45% 
Bladder wall Dmax 
105% and 
D10cc<18.3Gy 
Prostatic urethra 
Dmax ≤105% 
Group 1: 
45Gy in 5 fraction 
(315;n=15) 
Group 2: 
47.5Gy in 5 fractions 
(348;n=15) 
Group 3: 50Gy in 5 
fractions (383; 
n=15) 
One 
fraction at 
least every 
36hours  
Yes- 22% 
(n=10) 
Biochemical failure free survival 
100% (1 patient excluded from 
analysis as subsequently was 
found to have GS9 disease- this 
patient has relapsed; Phoenix) 
 
 
 
 
 
 
 
 
 
 
 
 
Alongi et al 
2013 [84] 
Prospective 
phase I/II 
40 11 months 
(range 5-16 
months) 
Low 
(majority) 
and 
intermediate 
Linear accelerator 
(VMAT 10MV FFF) 
MRI fusion 
Daily CBCT, intra-
prostatic 
calcifications 
identified in all 
patients and used 
as surrogates for 
fiducials 
Rectal-prostate 
spacer in selected 
cases (n=8) 
 
Prostate (+ 
some or all 
SV in higher 
risk) + 3-
5mm 
CTV: 
V95%>99% 
D99%>95% 
Dmax≤105% 
PTV: 
V95%>95% 
D99%>90% 
Dmax≤105% 
Rectum: 
V18Gy<35% 
V28Gy<10% 
V32Gy<5% 
Bladder: 
D1%<35Gy 
35Gy in 5 fractions 
(198) 
Alternate 
day 
Yes  PSA reduction in all patients 
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Table C2 cont. Clinical studies delivering prostate SABR using a linear accelerator. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-
up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Macias et al 
2014 [85] 
Prospective 
17 5 months 
(range 1-
10) 
Low, 
intermediate
(majority) 
and high 
IPSS>20 and 
previous 
history 
urinary 
retention 
excluded 
Helical 
TomoTherapy® 
Laxatives and 
catheter at 
planning 
Enema pre-
treatment, 
drinking 
protocol, low 
gas diet, steroid 
enema each 
night 
CBCT 
Low risk: 
Prostate + 
proximal 1cm of 
SV + 7-9mm 
anteriorly, 5-
6mm laterally 
and 2-4mm 
posteriorly 
Intermediate 
and high risk: 
Prostate + 
whole SV + 7-
9mm anteriorly, 
5-6mm laterally 
and 2-4mm 
posteriorly 
 
CTV: 
V100%≥95% 
PTV: 
V98%>95% 
D98%≥98% 
D2%≤103% 
Rectum: 
V43Gy≤10% 
V40Gy≤15% 
V37Gy≤20% 
V34Gy≤30% 
V28Gy≤40% 
Posterior rectum: 
V37Gy≤2% 
Bladder: 
V43Gy≤20% 
V40Gy≤30% 
V37Gy≤40% 
Femoral heads: 
V28Gy≤5% 
Penile bulb: 
V40Gy≤60% 
V28Gy≤90% 
Low risk: 
43.8Gy in 8 fractions 
(204) 
Intermediate and 
high risk: 
45.2Gy in 8 fractions 
(215) 
 
Alternate 
days 
Yes- 82% Only acute toxicity reported- see 
Table C5 
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Table C2 cont. Clinical studies delivering prostate SABR using a linear accelerator. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-
up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Fort Myers Group (different studies): 
Mantz et al 
2007 [79] 
Prospective 
phase II 
22 NR (18 
patients 
followed-
up for a t 
least 1 
month) 
Low  
Prostate 
volume<60cc 
IPSS<18 
Linear 
Accelerator 
CBCT 
 
Prostate + 3mm Rectum: 
Dmax:=85% 
Bladder: 
Dmax=100% 
Femoral heads: 
Dmax=50% 
36.25Gy in 5 
fractions (211) 
Prescription isodose 
chosen so OAR dose 
maxima not 
exceeded 
Alternate 
days 
NR Only acute toxicity reported- see 
Table C5 
 
 
 
Mantz et al 
2010 [58] 
Prospective 
phase II 
54 26 
months, 
minimum 
follow-up 
12 
months 
Low  Linear 
Accelerator 
CBCT 
Calypso®- 
electromagnetic 
fiducials tracking 
NR NR 40Gy in 5 fractions 
(253) 
Alternate 
days 
NR Fall in median PSA from 6.9ng/ml  
at baseline to 1.0 and 0.3ng/ml at 
12 and 24 months respectively 
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Table C2 cont. Clinical studies delivering prostate SABR using a linear accelerator 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-
up 
(range) 
Risk group 
(see 
Appendix B 
for 
definitions) 
Technique PTV Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Sunnybrook Group (different studies): 
Quon et al 
2011 [81] 
Prospective 
phase I/II 
30 3 months 
(range 1-
6 
months) 
Low and 
intermediate 
Linear 
accelerator 
IMRT 
Fiducials 
Prostate + 
5mm [128] 
NR 40Gy in 5 fractions 
(253) 
Once weekly, 
over 29 days 
NR NR 
Loblaw et al 
2013 [82] 
Prospective 
phase I/II 
84 55 
months 
(13-68) 
Low  
Prostate 
volume 
<60cc 
IPSS≤19 
Linear 
accelerator 6MV 
IMRT 
3 fiducials, 
portal imaging 
Drinking 
protocol,  
Vacuum bag 
Prostate + 4mm  Prostate:  
V35Gy>99%  
PTV 
V33.25Gy>99% 
Dmax≤105% 
Rectum: 
V28Gy≤40% 
V32Gy≤33% 
Bladder: 
V32Gy≤40% 
Penile bulb: 
V20Gy≤90% 
35Gy in 5 fractions 
(198) 
Once weekly 
fractions, over 
29 days 
Yes 5-year biochemical control 98% 
(95% CI: 96-100%; Phoenix). One 
episode of biochemical failure.  
5-year biochemical control  97% 
(95%CI: 93-100%, ASTRO) 
Based on n=83 
Median nadir 0.51ng/ml, median 
time to nadir 12months. PSA 
bounce (>0.2ng/ml) in 42%, median 
time to bounce 18 months 
Repeat biopsy at 36 months in 71, 
4% (n-=3) positive biopsies 
ASTRO: American Society for Radiation Oncology, BED: biologically equivalent dose, CBCT: cone beam computer tomography, CI: confidence interval, Dmax: maximum dose, Dx: 
Dose received by x% or xcc of volume, FFF: flattening filter free, IMRT: intensity modulated radiotherapy, MRI: magnetic resonance imaging, NR: not reported, PSA: prostate specific 
antigen, PTV: planning target volume, TURP: transurethral resection of the prostate, VMAT: volumetric modulated arc therapy, Vx: volume receiving at least x% of prescription dose 
or xGy * See Appendix A for Phoenix/ASTRO definitions of biochemical failure 
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Table C3 Clinical studies delivering prostate SABR as a boost following conventional fractionation. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see Appendix 
B for 
definitions for 
risk groups in 
each study) 
Technique PTV Dose-volume  
objectives/ 
constraints 
Dose, fractionation  
(BED (Gy); α/β=1.5) 
and prescription 
isodose if reported 
Duration Use of 
androgen 
deprivation 
Outcome* 
Katz et al 
2010 [86] 
 
73 33 months 
(22-43) 
Intermediate 
and high 
Cyberknife™ 
4 fiducials 
Bowel prep 
Rectal 
amifostine 
Boost: prostate + 5mm 
except 3mm posteriorly in 
region of the rectum 
PTV:  
V100%=95% 
45Gy in 25 fractions 
conformal + 18- 21Gy 
in 3 fractions (189-
218), 83-87% isodose 
3 consecutive 
days (2 weeks 
after 
conformal 
radiotherapy) 
Yes- 48% 
(n=36) 
3-year 
biochemical 
relapse free 
survival of 89.5% 
for intermediate 
risk and 77.7% for 
high risk.  PSA 
nadir of 0.5ng/ml 
achieved in 72% 
after 24 months 
10 PSA failures 
(Phoenix) at 
median of 15 
months.  
Miralbell et al 
2010 [87] 
50 63 months 
(18-88) 
Low, 
intermediate 
and high 
Linear 
accelerator 
IMRT 
Rectal balloon  
Infra-red 
detected 
surface 
markers 
Empty bladder, 
Catheter at 
planning 
For boost: 
“dominant tumour region 
within prostate” 
(essentially horseshoe 
shape round urethra) +/- 
SV + 3mm margin 
Initial constraints: 
Rectum and bladder: 
V50%< 50% 
V90%<30% 
Dmax=95% 
Urethra: NR but 
priority factor 100% 
 
Conventional EBRT: 64- 
64.4Gy in 1.8 to 2Gy 
fractions 
Stereotactic boost: 
10-16Gy in 2 fractions 
of  5 to 8Gy 
(193-268) 
Boost:1 week 
between 
fractions 
Yes- 66% 
(n=33) 
5-year 
Biochemical 
relapse free 
survival 98% +/- 
1.9% (Phoenix) 
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Table C3 cont. Studies delivering prostate SABR as a boost following conventional fractionation. Continued overleaf. 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see Appendix 
B for 
definitions for 
risk groups in 
each study) 
Technique PTV Dose-volume  
objectives/ 
constraints 
Dose and fractionation  
(BED (Gy); α/β=1.5) 
Duration Use of 
androgen 
deprivation 
Outcome* 
Oermann et 
al 2010 [88] 
 
24 9.3 months 
(6.6-16.9)  
Intermediate 
and high 
Cyberknife™ 
4 fiducials 
Enemas 
Low 
gas/motility 
diet, 
Prostate, regions of 
extracapsular spread, 
proximal SV plus 5mmm 
(3mm posteriorly) 
PTV:  
V100%≥95% 
Rectum: 
V50%<50% 
V80%<20% 
V90%<10% 
V100%<5%          
D1cc< 
≤36Gy 
Bladder: 
D10cc<100% 
Penile bulb: 
V15Gy<50% 
Membranous 
urethra: 
V18Gy<50% 
Dmax:133% 
Bladder:            
D10cc< 19.5Gy 
Sigmoid colon and 
other bowel: 
D1cc<15Gy 
19.5Gy in 3 fraction 
boost, prescription 
isodose ≥75%  then 
50.4Gy in 28 fractions 
IMRT 
(215) 
Consecutive or 
alternate days 
Yes- 42% 
(n=10) 
Fall in median PSA 
from 10.6ng/ml at 
baseline to 
1.5ng/ml at 6 
months in patients 
not receiving 
androgen 
deprivation 
Townsend et 
al 2011 [71] 
Retrospective 
11 11.5 weeks 
(for boost 
and non-
boost 
patients) 
Low (majority), 
intermediate 
and high 
Cyberknife™      
3-4 fiducials 
MRI fusion 
Prostate + 5mm (3mm 
posteriorly) 
PTV:                       
V100%: ≥97%          
Dmax: 115%       
Rectum:       
D1cc<36Gy 
V50%<50Gy    
Bladder:      
D10cc<37Gy 
Boost: 17.6-25Gy in 2-5 
fractions (non-boost 
dose NR)       
Prescription isodose: 
85% 
NR Yes- 25% 
(n=12) 
Fall in mean PSA 
from 9.34ng/ml at 
baseline to 
2.41ng/ml at 
mean of 12 weeks 
(n=28 for this 
analysis, includes 
boost and non-
boost patients) 
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Table C3 cont. Studies delivering prostate SABR as a boost following conventional fractionation 
Study and 
type of study 
(where 
available) 
Patient 
no. 
Follow-up 
(range) 
Risk group 
(see Appendix 
B for 
definitions for 
risk groups in 
each study) 
Technique PTV Dose-volume  
objectives/ 
constraints 
Dose and fractionation  
(BED (Gy); α/β=1.5) 
Duration Use of 
androgen 
deprivation 
Outcome* 
Jabbari et al 
2012 [72] 
 
18 23.5 
months 
(range12.6-
34.5) 
 Intermediate 
and high 
Cyberknife™,  
3 fiducials 
MRI fusion 
Prostate +/- Some or all SV 
on case by case basis, 
0-2mm margin, no overlap 
with rectum 
NR Pelvic IMRT 45-50Gy 
(fraction size NR) 
 19Gy in 2 fraction 
boost (238 to 256 if 
1.8-2Gy fractions for 
non-boost dose) 
 Prescription isodose 
60-80% 
Mostly 2 
consecutive 
days 
Yes Median PSA nadir 
0.10ng/ml, no 
evidence of 
progression 
ASTRO: American Society for Radiation Oncology, BED: biologically equivalent dose, Dmax: maximum dose, Dx: Dose received by x% or xcc of 
volume, IMRT: intensity modulated radiotherapy, MRI: magnetic resonance imaging, NR: not reported, PSA: prostate specific antigen, PTV: planning 
target volume, Vx: volume receiving at least x% of prescription dose or xGy * See Appendix A for Phoenix/ASTRO definitions of biochemical failure 
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Table C4 Toxicity from prostate SABR Cyberknife™ studies. Continued overleaf. 
Study Toxicity 
grading 
system 
BED 
(Gy) to 
acute 
Tissues 
(αβ=10) 
Acute genitourinary/ urinary 
toxicity grade (n) 
(within 3 months unless 
stated) 
Acute gastrointestinal/ rectal 
toxicity grade (n) 
(within 3 months unless 
stated) 
BED 
(Gy) to 
late 
tissues 
(αβ=3) 
Late genitourinary/ urinary 
toxicity grade (n) 
(beyond 3 months unless 
stated) 
Late gastrointestinal/ 
rectal toxicity grade (n) 
(beyond 3 months unless 
stated) 
  1 2 3 4 1 2 3 4  1 2 3 4 1 2 3 4 
Fuller et al 
2008 [57] 
RTOG 74 NR 0 60% 
(6) 
0 158 NR NR 
Friedland 
et al 
2009 [68] 
NR - 6%¤ 
(7) 
1%¤ 
(1) 
0 NR 0  NR 0 NR 1%§ 
(1) 
0 
Kang et al 
2011  [70]
 
CTCAEv
3 
58-68 30% 
(13) 
14% 
(6) 
0 0 16% 
(7) 
9% 
(4) 
0 0 117-144 9% 
(4) 
7% 
(3) 
0 0 2% 
(1) 
11% 
(5) 
0 0 
Townsend 
et al 
2011 [71]¥ 
(SABR 
alone 
patients) 
CTCAEv
3 
60-66 57% 
(21) 
5% 
(2) 
8% 
(3) 
0 14% 
(5) 
0 0 0 117-131 NR NR 
Jabbari et 
al 
2012 [72]† 
CTCAEv
3 
74 NR 45% 
(9) 
0 0 NR 5% 
(1) 
0 0 158 3%‡ 
(1) 
8%‡ 
(3) 
5%‡ 
(2) 
0 5%‡ 
(2) 
3%‡ 
(1) 
0 0 
King et al  
2009 [363] 
(acute) and 
2012 [61] 
(late)
 
RTOG 63 NR 0 NR 0 124 23% 
(13) 
5% 
(3) 
4% 
(2) 
0 14% 
(8) 
2% 
(1) 
0 0 
Lee et al 
2012 [74] 
CTCAEv
4 
60-66 10% 
(3) 
24% 
(7) 
0 0 24% 
(7) 
3% 
(1) 
0 0 117-131 7% 
(2) 
3% 
(1) 
3% 
(1) 
0 3% 
(1) 
0 0 0 
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Table C4 cont. Toxicity from prostate SABR Cyberknife™ studies. Continued overleaf. 
Study Toxicity 
grading 
system 
BED 
(Gy) to 
acute 
Tissues 
(αβ=10) 
Acute genitourinary/ urinary 
toxicity grade (n) 
(within 3 months unless 
stated) 
Acute gastrointestinal/ rectal 
toxicity grade (n) 
(within 3 months unless 
stated) 
BED 
(Gy) to 
late 
tissues 
(αβ=3) 
Late genitourinary/ urinary 
toxicity grade (n) 
(beyond 3 months unless 
stated) 
Late gastrointestinal/ rectal 
toxicity grade (n) 
(beyond 3 months unless 
stated) 
  1 2 3 4 1 2 3 4  1 2 3 4 1 2 3 4 
McBride et 
al 
2012 [73] 
CTCAEv
4 
63-66 59% 
(25) 
19% 
(8) 
0 0 31% 
(13) 
7% 
(3) 
0 0 124-131 17% 
(7) 
17% 
(7) 
2% 
(1) 
0 7% 
(3) 
7% 
(3) 
5% 
(2) 
0 
Aluwini 
2013 et 
al [60]* 
RTOG 74 NR 15% 8% 0 NR 12% 2% 0 158 NR 10% 6% 0 NR 3% 0 0 
Bolzicco et 
al 
2010 [59]† 
RTOG 60 34% 
 
12% 
 
0 0 27% 
 
18% 
 
0 0 117 4% 
 
3% 1% 
 
0 2% 1% 
 
0 0 
Tree et al 
2014 [77] 
RTOG 63 NR 51% 
(26) 
24% 
(12) 
0 0 124 NR NR 2% 
(1) 
0 0 
Seattle Group (some overlap between patient populations) 
Meier et al 
2010 [69]
 
CTCAEv
3  
63-72 NR 20% 
 
0 0 NR 9% 
 
0 0 
 
124-147 
 
NR 6% 
 
0.4
% 
(1) 
0 NR 1% 
 
0 0 
Meier et al 
2012 [107]
 
CTCAEv
3  
63-72 NR 20% 
 
0 0 NR 9% 
 
0 0 
 
124-147 
 
NR 10% 
 
1% 
(1) 
0 NR 2% 
 
0 0 
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Table C4 cont. Toxicity from prostate SABR Cyberknife™ studies. Continued overleaf. 
Study Toxicity 
grading 
system 
BED 
(Gy) to 
acute 
Tissues 
(αβ=10) 
Acute genitourinary/ urinary 
toxicity grade (n) 
(within 3 months unless 
stated) 
Acute gastrointestinal/ rectal 
toxicity grade (n) 
(within 3 months unless 
stated) 
BED 
(Gy) to 
late 
tissues 
(αβ=3) 
Late genitourinary/ urinary 
toxicity grade (n) 
(beyond 3 months unless 
stated) 
Late gastrointestinal/ 
rectal toxicity grade (n) 
(beyond 3 months unless 
stated) 
  1 2 3 4 1 2 3 4  1 2 3 4 1 2 3 4 
Georgetown Group (some overlap between patient populations) 
Chen et al 
2013 [76]** 
CTCAEv
3 
60-63 36% 
(36) 
35% 
(35) 
0 0 35% 
(35) 
5% 
(5) 
0 0 117-124 23% 
(23) 
17% 
(17) 
1% 
(1) 
0 12% 
(12) 
1% 
(1) 
0 0 
Ju et al 
2013 [89]† 
CTCAEv
4 
60-63 NR NR 0 0 NR NR 0 0 117-124 NR 44% 
(18) 
0 0 NR 7% 
(3) 
0 0 
Arscott et al 
2014 [116]†
$ 
CTCAEv
3 
60-63 NR 40% 
 
NR 117-124 NR 41% 
 
NR 
Katz et al (toxicity for each dose level shown separately for 2013 paper, some overlap between patients in 2013 and 2014 papers) 
Katz et al 
2013 [75] 
(35Gy 
group) 
RTOG 60 72% 
(36) 
4% 
(2) 
0 0 76% 
(38) 
4% 
(2) 
0 0 117 6% 
 
4% 
 
0 0 4% 
 
2% 
 
0 0 
Katz et al 
2013 [75] 
(36.25Gy 
group) 
RTOG 63 75% 
(190) 
5% 
(12) 
0 0 74% 
(189) 
4% 
(9) 
0 0 124 8% 
 
9% 
 
2% 
 
0 5% 
 
5% 
 
0 0 
Katz et al 
2014 [90] 
RTOG 60-63 NR NR 0 0 NR NR 0 0 117-124 NR NR 2% 
(9) 
0 NR NR 0 0 
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Table C4 cont. Toxicity from prostate SABR Cyberknife™ studies 
Study Toxicity 
grading 
system 
BED 
(Gy) to 
acute 
Tissues 
(αβ=10) 
Acute genitourinary/ urinary 
toxicity grade (n) 
(within 3 months unless 
stated) 
Acute gastrointestinal/ rectal 
toxicity grade (n) 
(within 3 months unless 
stated) 
BED 
(Gy) to 
late 
tissues 
(αβ=3) 
Late genitourinary/ urinary 
toxicity grade (n) 
(beyond 3 months unless 
stated) 
Late gastrointestinal/ 
rectal toxicity grade (n) 
(beyond 3 months unless 
stated) 
  1 2 3 4 1 2 3 4  1 2 3 4 1 2 3 4 
Oliai et al (toxicity for low dose and high dose groups shown separately) 
Oliai et al 
2013 [78] 
(35 and 
36.25Gy 
group) 
RTOG 60-63 54% 
(22) 
22% 
(9) 
5% 
(2) 
0 20% 
(8) 
7% 
(3) 
0 0 117-124 41% 
(7) 
32% 
(13) 
0 0 10% 
(4) 
10% 
(4) 
0 0 
Oliai et al 
2013 [78] 
(37.5Gy 
group) 
RTOG 66 59% 
(17) 
14% 
(4) 
3% 
(1) 
0 14% 
(4) 
0 0 0 131 48% 
(14) 
24% 
(7) 
7% 
(2) 
0 10% 
(7) 
7% 
(2) 
0 0 
Pooled data 
Freeman 
and King 
2011 [118] 
(pooled) 
RTOG 60-63 NR NR 117-124 25% 
(10) 
7% 
(3) 
3% 
(1) 
0 13% 
(6) 
3% 
(1) 
0 0 
CTCAEvX: Common Terminology Criteria of Adverse Events version X, NR: not reported, RTOG: Radiation Therapy Oncology Group, *Acute toxicity at two weeks 
post treatment and late toxicity at 6 months, ** highest toxicity reported at 1 month and 12 months post-treatment, † acute toxicity considered as within 6 months of 
SABR, and late toxicity thereafter,  ¥ acute toxicity included up to 24 week assessment for some patients, median follow-up to 12 weeks,  ‡ includes 18 additional 
patients treated with SABR as boost following pelvic external beam radiotherapy as well as SABR monotherapy patients; § timing of grade 3 rectal toxicity not 
reported- presumed to be late, $ 2-year cumulative incidence of acute and late urinary obstruction alone reported, ¤urinary retention reported in 7 patients, none of 
whom required catheterisation: judged as grade 1 or 2, one patient required trans-urethral resection of the prostate: judged to be grade 3 
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  Table C5 Toxicity from prostate SABR linear accelerator studies. Continued overleaf. 
Study Toxicity 
grading 
system 
BED (Gy) 
to acute 
Tissues 
(αβ=10) 
Acute genitourinary/ 
urinary toxicity grade (n) 
(within 3 months unless 
stated) 
Acute gastrointestinal/ rectal 
toxicity grade (n) 
(within 3 months unless 
stated) 
BED (Gy) 
to late 
tissues 
(αβ=3) 
Late genitourinary/ urinary 
toxicity grade (n) 
(beyond 3 months unless 
stated) 
Late gastrointestinal/ 
rectal toxicity grade (n) 
(beyond 3 months unless 
stated) 
  1 2 3 4 1 2 3 4  1 2 3 4 1 2 3 4 
Madsen et 
al 
2007 [95] 
and Pham 
et al 
2010 [80]§ 
 
RTOG/CT
CAEv2 
56 28% 
(11) 
21% 
(8) 
3% 
(1) 
0 26% 
(10) 
13% 
(5) 
0 0 
 
108 23% 
(NR) 
13% 
(NR) 
3% 
(NR) 
0 23% 
(NR) 
8% 
(NR) 
0 0 
Alongi  et 
al 
2013 [84]‡ 
CTCAEv4 60 20% 
(8) 
40% 
(16) 
0 0 15% 
(6) 
10% 
(4) 
0 0 117 12% 
(3) 
4% 
(1) 
0 0 0 0 0 0 
Macias et 
al 
2014 [85] 
 68-71 70% 6% 0 0 50% 0 0 0 124-130 NR NR 
Fort Myers group (different studies) 
Mantz et al 
2007 [79]† 
CTCAEv3 63 28% 
(5) 
0 0 0 0 6% 
(1) 
0 0 124 NR NR 
Mantz et al 
2010 [58] 
CTCAEv3 72 NR NR 147 NR 0 NR 0 
Sunnybrook group (different studies) 
Quon  et al 
2011 [81]* 
CTCAEv3 72 57% 13% 0 0 67% 3% 0 0 147 NR NR 
Loblaw et 
al 
2013 [82] 
CTCAEv3 60 71% 19% 1% 0 67% 10% 0 0 117 2% 5% 
(4) 
0 0 35% 7% 0 1% 
(1) 
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Table C5 cont. Toxicity from prostate SABR linear accelerator studies 
Study Toxicity 
grading 
system 
BED (Gy) 
to acute 
Tissues 
(αβ=10) 
Acute genitourinary/ 
urinary toxicity grade (n) 
(within 3 months unless 
stated) 
Acute gastrointestinal/ rectal 
toxicity grade (n) 
(within 3 months unless 
stated) 
BED 
(Gy) to 
late 
tissues 
(αβ=3) 
Late genitourinary/ urinary 
toxicity grade (n) 
(beyond 3 months unless 
stated) 
Late gastrointestinal/ rectal 
toxicity grade (n) 
(beyond 3 months unless 
stated) 
  1 2 3 4 1 2 3 4  1 2 3 4 1 2 3 4 
Boike et al (toxicity for each dose level shown separately) 
Boike et al
 
2011 [83] 
45Gy arm 
CTCAEv3 86 20% 
(3) 
27% 
(4) 
0 0 40% 
(6) 
0 0 0 180 20% 
(3) 
13% 
(2) 
0 0 7% 
(1) 
7% 
(1) 
0 0 
Boike et al 
2011 [83] 
47.5Gy 
arm 
CTCAEv3 93 33% 
(5) 
7% 
(1) 
0 0 13 
(2) 
27% 
(4) 
0 0 198 20% 
(3) 
13% 
(2) 
7%  
(1) 
0 27% 
(4) 
7% 
(1) 
0 0 
Boike et al 
2011 [83] 
and Kim et 
al 
2014 [117] 
¥
 
50Gy arm 
CTCAEv3 100 33% 
(5) 
33% 
(5) 
0 0 47% 
(7) 
7% 
(1) 
0
¥
 0
¥
 217 0 0 7%  
(1) 
0 33% 
(5) 
0 7%
¥
 
(4) 
3%
¥
 
(2) 
CTCAEvX: Common Terminology Criteria of Adverse Events version X, NR: not reported, RTOG: Radiation Therapy Oncology Group,                                                         
§ late toxicity considered as toxicity beyond 1 month; *acute toxicity at 5 weeks (peak in symptoms reported at this time point), 
† 
acute toxicity reported at 1 month 
only, 
‡ 
late toxicity from 6 months, 
¥
Acute and late grade 3 and 4 rectal toxicity for  50Gy in 5 fraction arm from Kim et al [117] which included 15 patients from the 
original phase I trial and 46 additional patients treated within phase II component of the trial. Sufficient detail was provided to allow categorisation of the timing of 
grade 3 and 4 acute and late rectal toxicity to become the same as that reported in the phase I component of the trial (i.e. acute and late toxicity within and beyond 3 
months of radiotherapy). All other data in this row is from original phase I trial with 15 patients. 
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Table C6 Toxicity from prostate studies which delivered conventionally fractionated radiotherapy and a prostate SABR boost 
Study Toxicity 
grading 
system 
BED 
(Gy) to 
acute 
Tissues 
(αβ=10) 
Acute genitourinary/ urinary 
toxicity grade (n if available) 
 
Acute gastrointestinal/ rectal 
toxicity grade (n if available) 
 
BED (Gy) 
to late 
tissues 
(αβ=3) 
Late genitourinary/ urinary 
toxicity grade (n if available) 
 
Late gastrointestinal/ rectal 
toxicity grade (n if available) 
 
  1 2 3 4 1 2 3 4  1 2 3 4 1 2 3 4 
Katz et al 
2010 [86]* 
RTOG 82-89 72% 
(36) 
4% 
(2) 
0 0 75% 
(226) 
5% 
(14) 
0 0 126-142 5% 
(12) 
5% 
(13) 
0.3% 
(1) 
0 5% 
(13) 
2% 
(6) 
0 0 
Miralbell et 
al 
2010 [87]** 
RTOG 91-106 34% 
(17) 
46% 
(23) 
4% 
(2) 
0 28% 
(14) 
8% 
(4) 
0 0 133-179 24% 
(12) 
12% 
(6) 
0 0 38% 
(19) 
10% 
(5) 
10% 
(5) 
0 
Oermann et 
al 2010 [88]† 
CTCAEv
3 
92 75% 
(18) 
13% 
(3) 
0 0 50% 
(12) 
4% 
(1) 
0 0 142 46% 
(11) 
8% 
(2) 
0 0 33% 
(8) 
0 0 0 
Townsend et 
al 2011 [71]¥
 
(Boost 
patients) 
CTCAEv
3 
38-43 + 
convent
ional 
45% 
(5) 
27% 
(3) 
9% 
(1) 
0 0 0 0 0 67-94 + 
conventi
onal 
NR NR 
Jabbari et al 
2012 [72]† 
(Boost 
patients) 
CTCAEv
3 
90-97 NR 39% 
 
0 0 NR 17% 
 
0 0 151-163 3%‡ 
(1) 
8%‡ 
(3) 
5%‡ 
(2) 
0 5%‡ 
(2) 
3%‡ 
(1) 
0 0 
CTCAEvX: Common Terminology Criteria of Adverse Events version X, NR: not reported, RTOG: Radiation Therapy Oncology Group,                                                            
* Acute toxicity considered as occurring and resolving within 5 months, ** Acute toxicity during radiotherapy, late toxicity at 6 months and beyond, † acute toxicity 
considered as within 6 months of SABR, and late toxicity thereafter, ¥ acute toxicity included up to 24 week assessment for some patients, median follow-up 12 
weeks, ‡ includes 18 additional patients treated with SABR as boost following pelvic external beam radiotherapy as well as SABR monotherapy patients 
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Appendix D: Systematic review search strategy 
1  exp Neoplasms, Radiation-Induced/ 
2 exp Neoplasms, Second Primary/ 
3 
second cancer?.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare disease supplementary 
concept, unique identifier] 
4 
second primary cancer?.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
5 
secondary cancer?.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
6 
secondary carcinom*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
7 
second tumo?r?.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare disease supplementary 
concept, unique identifier] 
8 
secondary tumo?r?.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
9 
second malignancy.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
10 
second malignancies.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
11 
secondary malignanc*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
12 
second neoplasm?.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
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supplementary concept, unique identifier] 
13 
secondary neoplasm?.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
14 
integral dose.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare disease supplementary 
concept, unique identifier] 
15 
radiation-induced neoplasm?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
16 
radiation induced neoplasm?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
17 
radiation-induced cancer?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
18 
radiation induced cancer?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
19 
radiation-induced tumo?r?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
20 
radiation induced tumo?r?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
21 
radiation-induced carcinom*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
22 
radiation induced carcinom*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
23 
radiotherapy-induced neoplasm?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
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24 
radiotherapy induced neoplasm?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
25 
radiotherapy-induced cancer.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
26 
radiotherapy induced cancer.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
27 
radiotherapy-induced tumo?r?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
28 
radiotherapy induced tumo?r?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
29 
radiotherapy-induced carcinom*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
30 
radiotherapy induced carcinom*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
31 
radiotherapy-induced cancer?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
32 
radiotherapy induced cancer?.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
33 
radiotherapy-induced second primary cancer?.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary concept, 
rare disease supplementary concept, unique identifier] 
34 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
or 20 0r 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 
35 exp Prostatic Neoplasms/ 
36 prostat* cancer?.mp. [mp=title, abstract, original title, name of substance word, subject heading 
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word, keyword heading word, protocol supplementary concept, rare disease supplementary 
concept, unique identifier] 
37 
prostat* carcinom*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
38 
prostat* neoplasm?.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
39 
prostat* tumo?r?.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
40 
prostat* adenocarcinom*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
41 35 or 36 or 37 or 38 or 39 or 40 
42 
exp Radiotherapy Planning, Computer-Assisted/ or exp Radiotherapy Dosage/ or exp 
Radiotherapy/ or exp Radiotherapy, Conformal/ or exp Radiotherapy, Intensity-Modulated/ or 
exp Radiotherapy, Computer-Assisted/ or exp Radiotherapy, High-Energy/ 
43 exp Brachytherapy/ 
44 
(implant adj6 radiotherapy).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
45 
(interstitial adj6 radiotherapy).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
46 
(seed adj6 radiotherapy).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
47 
(seed adj6 implant).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
48 
(permanent adj6 implant).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
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49 
implant radiation.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
50 
interstitial radiation.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
51 
(implant adj6 radiation).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
52 
(interstitial adj6 radiation).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
53 
3D conformal radiotherapy.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
54 
3D-conformal radiotherapy.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
55 
(2D adj6 radiotherapy).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
56 
intensity modulated radiotherapy.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
57 
intensity-modulated radiotherapy.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
58 
intensity modulated radiation.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
59 
intensity-modulated radiation.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
60 IMRT.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
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keyword heading word, protocol supplementary concept, rare disease supplementary concept, 
unique identifier] 
61 exp Protons/ 
62 
proton radiotherapy.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
63 
proton radiation.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
64 
proton therapy.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare disease supplementary 
concept, unique identifier] 
65 
external beam radiotherapy.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
66 
external-beam radiotherapy.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
67 
EBRT.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept, rare disease supplementary concept, 
unique identifier] 
68 
external beam radiation.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
69 
external-beam radiation.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
70 
tomotherapy.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare disease supplementary 
concept, unique identifier] 
71 
volumetric modulated arc therapy.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
72 VMAT.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
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keyword heading word, protocol supplementary concept, rare disease supplementary concept, 
unique identifier] 
73 
rapidarc.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept, rare disease supplementary concept, 
unique identifier] 
74 
rapid arc.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept, rare disease supplementary concept, 
unique identifier] 
75 
arc therap*.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare disease supplementary 
concept, unique identifier] 
76 
42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 
59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 
77 34 and 41 and 76 
